

## Update tot 30-04-2020

1. **Chloroquine and Hydroxychloroquine for the Prevention or Treatment of Novel Coronavirus Disease (COVID-19) in Africa: Caution for Inappropriate Off-Label Use in Healthcare Settings.** Abena PM, Decloedt EH, Bottieau E, Suleman F, Adejumo P, Sam-Agudu NA, et al. *Am j trop med hyg.* 2020.
2. **Evaluation of Hydroxychloroquine Retinopathy Using Ultra-Widefield Fundus Autofluorescence: Peripheral Findings in the Retinopathy.** Ahn SJ, Joung J, Lee BR. *American journal of ophthalmology.* 2020;209:35-44. <http://dx.doi.org/10.1016/j.ajo.2019.09.008>. Epub 2019 Sep 14.
3. **COVID-19 research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine.** Alexander PE, Debono VB, Mammen MJ, Iorio A, Aryal K, Deng D, et al. *J clin epidemiol.* 2020.
4. **Chloroquine and Hydroxychloroquine in the Era of SARS - CoV2: Caution on Their Cardiac Toxicity.** Bauman JL, Tisdale JE. *Pharmacotherapy.* 2020.
5. **Repositioned chloroquine and hydroxychloroquine as antiviral prophylaxis for COVID-19: A protocol for rapid systematic review of randomized controlled trials.** Chang R, Sun W-Z. *medRxiv.* 2020:2020.04.18.20071167.
6. **Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.** Colson P, Rolain J-M, Lagier J-C, Brouqui P, Raoult D. *Int J Antimicrob Agents.* 2020:105932-.
7. **Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model.** Cui C, Zhang M, Yao X, Tu S, Hou Z, Jie En VS, et al. *Acta Pharmaceutica Sinica B.* 2020.
8. **Hydroxychloroquine; Why It Might Be Successful and Why It Might Not Be Successful in the Treatment of Covid-19 Pneumonia? Could It Be A Prophylactic Drug?** Deniz O. 2020.
9. **Cardiovascular Considerations in Treating Patients with Coronavirus (COVID-19).** Dixon DL, Van Tassell BW, Vecchié A, Bonaventura A, Talasaz A, Kakavand H, et al. *Journal of cardiovascular pharmacology.* 2020.
10. **Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine.** Erhardt DP, Cannon GW, Teng CC, Mikuls TR, Curtis JR, Sauer BC. *Arthritis care & research.* 2019;71(10):1326-35. <http://dx.doi.org/10.1002/acr.23759>. Epub 2019 Aug 30.
11. **Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with Novel Coronavirus Disease (COVID-19).** Falcão MB, Pamplona de Góes Cavalcanti L, Filgueiras Filho NM, Antunes de Brito CA. *The American Journal of Tropical Medicine and Hygiene.* 2020.
12. **Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection.** Fantini J, Di Scala C, Chahinian H, Yahi N. *Int J Antimicrob Agents.* 2020:105960-.
13. **Chloroquine and hydroxychloroquine in covid-19.** Ferner RE, Aronson JK. *BMJ.* 2020;369:m1432-m.
14. **Caution Needed on the Use of Chloroquine and Hydroxychloroquine for Coronavirus Disease 2019.** Fihn SD, Perencevich E, Bradley SM. *JAMA Netw Open.* 2020;3(4):e209035-e.
15. **Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.** Funck-Brentano C, Salem J-E, Nguyen LS, Drici M-D, Roden DM. *Arch Cardiovasc Dis.* 2020.

16. **Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19).** Gao J, Hu S. Bioscience trends (Online). 2020.
17. **Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review.** Gbinigie K, Frie K. 2020.
18. **Could chloroquine /hydroxychloroquine be harmful in Coronavirus Disease 2019 (COVID-19) treatment?** Guastalegname M, Vallone A. Clin infect dis. 2020.
19. **COVID-19 and diabetes: Knowledge in progress.** Hussain A, Bhowmik B, do Vale Moreira NC. Diabetes Research and Clinical Practice. 2020;162.
20. **Hydroxy-CHLOROQUINE: THE CHEMOPROPHYLAXIS OF MALARIA AND COVID-19.** Hussain I.
21. **Drug-induced acute eosinophilic pneumonia due to hydroxychloroquine in a chilblain lupus patient.** Ishiguro Y, Muro Y, Murase C, Takeichi T, Kono M, Adachi R, et al. The Journal of dermatology. 2019;46(10):e356-e7. <http://dx.doi.org/10.1111/1346-8138.14905>. Epub 2019 May 3.
22. **Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus.** Jakhar D, Kaur I. Nat med. 2020.
23. **Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.** Juurlink DN. CMAJ. 2020.
24. **Ultrasonography of articular and periarticular structures as a relapse predictor in patients with clinically remitted rheumatoid arthritis.** Karami M, Mohammadzadeh Z, Ebrahimian S, Moradi M, Zahra S. Indian Journal of Rheumatology. 2020;15(1):17-22.
25. **Myths and Facts: Chloroquine May Be A Potential Supportive/Therapeutic Drug in COVID-19 Treatment.** Kashif M, Aamir M, Minhas S, Tahir R, Jahan S, Afzal N. 2020.
26. **A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19).** Keshtkar-Jahromi M, Bavari S. Am j trop med hyg. 2020.
27. **Safety review of 42 cases of COVID-19 treated with low-dose chloroquine.** Li L, Zhou B, Zhang J, Liu Y, Hong W, Jian F, et al. Journal. 2020(Issue).
28. **Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.** Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Cell discovery. 2020.
29. **Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19.** Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin JW, Sutton SS, et al. medRxiv. 2020:2020.04.16.20065920.
30. **COVID-19 and Chloroquine/Hydroxychloroquine: is there Ophthalmological Concern?** Marmor MF. Am j ophthalmol. 2020.
31. **Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution.** Mégarbane B. Clin Toxicol (Phila). 2020:1-2.
32. **Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin.** Millán-Oñate J, Millan W, Mendoza LA, Sánchez CG, Fernandez-Suarez H, Bonilla-Aldana DK, et al. Annals of Clinical Microbiology and Antimicrobials. 2020;19(1):16.

33. **An algorithm for managing QT prolongation in Coronavirus Disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine.** Mitra RL, Greenstein SA, Epstein LM. *HeartRhythm Case Reports*. 2020.
34. **Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?** Moiseev S, Avdeev S, Brovko M, Novikov P, Fomin V. *Ann rheum dis*. 2020.
35. **International Standards for Neurological Classification of Spinal Cord Injury: factors influencing the frequency, completion and accuracy of documentation of neurology for patients with traumatic spinal cord injuries.** Osunronbi T, Sharma H. *European journal of orthopaedic surgery & traumatology : orthopedie traumatologie*. 2019;29(8):1639-48. <http://dx.doi.org/10.1007/s00590-019-02502-7>. Epub 2019 Jul 19.
36. **The alteration of stress-related physiological parameters after probiotics administration in oral surgeons with different degrees of surgical experience.** Pacifici A, Pacifici L, Nuzzolese M, Cascella G, Ballini A, Santacroce L, et al. *La Clinica terapeutica*. 2020;171(3):e197-e208. <http://dx.doi.org/10.7417/CT.2020.2214>.
37. **Hydroxychloroquine for the Treatment of COVID-19: Evidence, Possible Mode of Action and Industrial Supply of the Drug.** Pagliaro M, Meneguzzo F. 2020.
38. **Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review.** Pereira BB. *J Toxicol Environ Health B Crit Rev*. 2020:1-5.
39. **Chloroquine or hydroxychloroquine for prophylaxis of COVID-19.** Principi N, Esposito S. *The Lancet Infectious Diseases*. 2020.
40. **Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring.** Ramireddy A, Chugh HS, Reinier K, Ebinger J, Park E, Thompson M, et al. *medRxiv*. 2020:2020.04.22.20075671.
41. **Hydroxychloroquine prophylaxis for COVID-19 contacts in India.** Rathi S, Ish P, Kalantri A, Kalantri S. *The Lancet Infectious Diseases*. 2020.
42. **Delirium Cafe: interactive learning to enhance delirium care.** Roitto HM, Aalto UL, Soderling R, Laakkonen ML, Ohman H. *European geriatric medicine*. 2020;11(1):113-6. <http://dx.doi.org/10.1007/s41999-019-00283-0>. Epub 2020 Jan 10.
43. **Review on the global epidemiological situation and the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19.** Saqrane S, El Mhammedi MA. *New Microbes and New Infections*. 2020.
44. **Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.** Sarayani A, Cicali B, Henriksen CH, Brown JD. *Res soc adm pharm*. 2020.
45. **A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in Coronavirus Disease-19 (COVID-19).** Shah S, Das S, Jain A, Misra DP, Negi VS. *Int j rheum dis*. 2020.
46. **Hydroxychloroquine Versus COVID-19: A Rapid Systematic Review and Meta-Analysis.** Shamshirian A, Hessami A, Heydari K, Alizadeh-Navaei R, Ebrahimzadeh MA, Ghasemian R, et al. *medRxiv*. 2020:2020.04.14.20065276.
47. **Chloroquine paradox may cause more damage than help fight COVID-19.** Sharma A. *Microbes and Infection*. 2020.

48. **Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries.** Singh AK, Singh A, Shaikh A, Singh R, Misra A. *Diabetes Metab Syndr.* 2020;14(3):241-6.
49. **Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.** Singh B, Ryan H, Kredon T, Chaplin M, Fletcher T. *Cochrane Database of Systematic Reviews.* 2020(4).
50. **Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties.** Smit C, Peeters MYM, van den Anker JN, Knibbe CAJ. *Clinical pharmacokinetics.* 2020. <http://dx.doi.org/10.1007/s40262-020-00891-1>.
51. **Chloroquine and COVID-19 – a potential game changer?** Sturrock BRH, Chevassut TJT. *Clinical Medicine.* 2020:clinmed.2020-0129.
52. **Hydroxychloroquine for the management of COVID-19: Hope or Hype? A Systematic review of the current evidence.** Suranagi UD, Rehan HS, Goyal N. *medRxiv.* 2020:2020.04.16.20068205.
53. **Risk of drug-induced Long QT Syndrome associated with the use of repurposed COVID-19 drugs: a systematic review.** Turgeon J, Michaud V, Dow P, Al Rihani SR, Deodhar M, Arwood M, et al. *medRxiv.* 2020:2020.04.21.20066761.
54. **Simulation of Urgent Airway Management in a Postthyroidectomy Hematoma.** Wu K, Kim S, Rajasingham SJ, Bruni I, Fung K, Roth KE. *MedEdPORTAL : the journal of teaching and learning resources.* 2019;15:10802. [http://dx.doi.org/10.15766/mep\\_2374-8265.10802](http://dx.doi.org/10.15766/mep_2374-8265.10802).
55. **Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.** Yazdany J, Kim AHJ. *Ann intern med.* 2020.
56. **Chloroquine, arbidol (umifenovir) or lopinavir/ritonavir as the antiviral monotherapy for COVID-19 patients: a retrospective cohort study.** Zhou L, Huang W, Huang H, Guan L, Yang Y, Grange JML, et al. *Journal.* 2020(Issue).

## Literatuuroverzicht tot 23-04-2020

1. **Prostaglandins and schizofrenia - too much or too little?** Journal of Pharmacotherapy. 1978;1(3):64-5.
2. **Is the combination of amphetamine and chloroquine the cause of unexpected psychological symptoms?** Läkartidningen. 1985;82(21):1962.
3. **Malaria prevention July 1990.** Bulletin de la Societe des Sciences Medicales du Grand-Duche de Luxembourg. 1990;127(2):85-7.
4. **Recent advances in the treatment of liver diseases: Round-table discussion.** Drugs. 1990;40:129-38.
5. **Recommendations for the prevention of malaria among travelers.** Journal of the American Medical Association. 1990;263(20):2729-40.
6. **Change of dosing regimen for malaria prophylaxis with mefloquine.** Journal of the American Medical Association. 1991;265(7):849.
7. **The prevention, diagnosis and therapy of malaria.** Fortschritte der Medizin. 1993;111(1):23-5.
8. **A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study.** The American journal of medicine. 1995;98(2):156-68. [http://dx.doi.org/10.1016/s0002-9343\(99\)80399-4](http://dx.doi.org/10.1016/s0002-9343(99)80399-4).
9. **Vietnamese women in education and health care.** Women of Vietnam. 1998(2):9-10, 22.
10. **Interpharm 2000 in Stuttgart: Pharmacotherapy in the elderly.** Deutsche Apotheker Zeitung. 2000;140(15):56-74.
11. **Treatment of rheumatoid arthritis.** Prescrire International. 2001;10(52):55-61.
12. **Temporal variations in school-associated student homicide and suicide events--United States, 1992-1999.** MMWR Morbidity and mortality weekly report. 2001;50(31):657-60.
13. **Cutaneous Drug Reaction Case Reports: From the World Literature.** American Journal of Clinical Dermatology. 2003;4(10):727-31.
14. **The risks and benefits of treatments must be considered when treating or preventing malaria.** Drugs and Therapy Perspectives. 2004;20(12):22-6.
15. **Digoxin: Serious drug interactions.** Prescrire International. 2010;19(106):68-70.
16. National Institute for Health and Care Excellence: Clinical Guidelines. Intravenous fluid therapy in adults in hospital. London: National Institute for Health and Care Excellence (UK) Copyright (c) NICE 2020.; 2013.
17. **Rigid ureteroscopy for ureteral stones: factors associated with intraoperative adverse events.** Abdelrahim AF, Abdelmaguid A, Abuzeid H, Amin M, Mousa el S, Abdelrahim F. J Endourol. 2008;22(2):277-80. <http://dx.doi.org/10.1089/end.2007.0072>.
18. **Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab.** Abdulkader R, Dharmapalaiah C, Rose G, Shand LM, Clunie GP, Watts RA. Journal of Rheumatology. 2014;41(5):858-61.
19. **Diagnosis of drug-induced psoriasis.** Abel EA. Seminars in Dermatology. 1992;11(4):269-74.
20. **Neuropsychiatric lupus.** Abel T, Gladman DD, Urowitz MB. The Journal of rheumatology. 1980;7(3):325-33.

21. **Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and Controls.** Aberle T, Bourn RL, Munroe ME, Chen H, Roberts VC, Guthridge JM, et al. *Arthritis Care and Research*. 2017;69(12):1780-8.
22. **Chloroquine-induced venodilation in human hand veins.** Abiose AK, Grossmann M, Tangphao O, Hoffman BB, Blaschke TF. *Clinical Pharmacology and Therapeutics*. 1997;61(6):677-83.
23. **Malaria: An audit of 56 cases admitted to a hospital.** Abisheganaden J, Rajasoorya C, Tan PK, Ang P, Chew LS. *Singapore Medical Journal*. 1996;37(2):153-6.
24. **Is It the Age at Disease Onset or the Disease Radiological Severity That Affects Cervical Spine Involvement in Patients With Rheumatoid Arthritis?** Abozaid HSM, El-din Hassan RA, Elmadany WA, Ismail MA, Elgendy DS, Elsayed SA, et al. *Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders*. 2018;11.
25. **Toxic tau: The TAU gene polymorphisms associate with concussion history in rugby union players.** Abrahams S, Mc Fie S, Patricios J, Suter J, September AV, Posthumus M. *Journal of science and medicine in sport*. 2019;22(1):22-8. <http://dx.doi.org/10.1016/j.jsams.2018.06.012>. Epub 2018 Jun 21.
26. **Some drugs that cause psychiatric symptoms.** Abramowicz M, Rizack MA, Goodstein D, Faucard A, Hansten PD, Steigbigel NH. *Medical Letter on Drugs and Therapeutics*. 1998;40(1020):21-4.
27. **The appropriateness of referral of medically compromised dental patients to hospital.** Absi EG, Satterthwaite J, Shepherd JP, Thomas DW. *The British journal of oral & maxillofacial surgery*. 1997;35(2):133-6. [http://dx.doi.org/10.1016/s0266-4356\(97\)90690-2](http://dx.doi.org/10.1016/s0266-4356(97)90690-2).
28. **Effect of tocilizumab on fatigue and bone mineral density in patients with rheumatoid arthritis.** Abu-Shakra M, Zisman D, Balbir-Gurman A, Amital H, Levy Y, Langevitz P, et al. *Israel Medical Association Journal*. 2018;20(4):239-44.
29. **Retrospective analysis to describe associations between tumor necrosis factor alpha inhibitors and COPD-related hospitalizations.** Accortt NA, Chung JB, Bonafede M, Limone BL, Mannino DM. *International Journal of COPD*. 2017;12:2085-94.
30. **Pharmacovigilance study of patients receiving treatment at medical ICU of C. U. Shah Medical College & Hospital, Surendranagar.** Acharya T, Trivedi M, Vekariya R, Chhaiya S, Mehta D. *International Journal of Pharmaceutical Sciences and Research*. 2018;9(12):5265-70.
31. **Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania.** Acosta CJ, Galindo CM, Schellenberg D, Aponte JJ, Kahigwa E, Urassa H, et al. *Tropical Medicine and International Health*. 1999;4(5):368-76.
32. **Suicide after treatment of chloroquine-resistant falciparum malaria with quinine.** Adam I, Elbashir MI. *Saudi Medical Journal*. 2004;25(2):248-9.
33. **Quantitative assessment of the 103-hexagon multifocal electroretinogram in detection of hydroxychloroquine retinal toxicity.** Adam MK, Covert DJ, Stepien KE, Han DP. *The British journal of ophthalmology*. 2012;96(5):723-9. <http://dx.doi.org/10.1136/bjophthalmol-2011-300504>. Epub 2012 Feb 10.
34. **Buried legacy? An analysis of psychiatric toxicity of pre-chloroquine anti-malarials.** Adams DP, Mauck DE. *Biological Psychiatry*. 2015;77(9):785-95.
35. **Hydroxychloroquine in the treatment of rheumatoid arthritis.** Adams EM, Yocum DE, Bell CL. *The American journal of medicine*. 1983;75(2):321-6. [http://dx.doi.org/10.1016/0002-9343\(83\)91211-1](http://dx.doi.org/10.1016/0002-9343(83)91211-1).

36. **Inability of short-term, low-dose hydroxychloroquine to resolve vitamin D-mediated hypercalcemia in patients with B-cell lymphoma.** Adams JS, Kantorovich V. *The Journal of clinical endocrinology and metabolism*. 1999;84(2):799-801. <http://dx.doi.org/10.1210/jcem.84.2.5454>.
37. **Decision-Delivery Interval and Perinatal Outcome in Emergency Caesarean Section:A University Teaching Hospital Experience.** Adewunmi AA, Rabiun KA, Tayo TA, Ottun TA, Kehinde OA, Akinlusi FM, et al. *West African journal of medicine*. 2014;33(4):252-7.
38. **The amphiphilic drug-induced tryptophan fluorescence change of ion-transporting ATPases.** Adhikary G, Chandra S, Sikdar R, Sen PC. *Biochimica et Biophysica Acta - Bioenergetics*. 1994;1188(3):220-6.
39. **Association between corrected QT interval and inflammatory cytokines in rheumatoid arthritis.** Adlan AM, Panoulas VF, Smith JP, Fisher JP, Kitis GD. *Journal of Rheumatology*. 2015;42(3):421-8.
40. **Gastric sarcoidosis and review of the literature.** Afshar K, BoydKing A, Sharma OP, Shigemitsu H. *Journal of the National Medical Association*. 2010;102(5):419-22.
41. **Early effect of hydroxychloroquine therapy: relationship between cumulative dose and retinal thickness.** Agarwal P, Wong YH, Dasgupta E, Agarwal R, Livingstone BI, Ramamurthy S, et al. *Cutaneous and ocular toxicology*. 2015;34(3):179-84. <http://dx.doi.org/10.3109/15569527.2014.938751>. Epub 2014 Jul 28.
42. **Pattern of infliximab utilization in rheumatoid arthritis patients at an Academic Medical Center.** Agarwal SK, Maier AL, Chibnik LB, Coblyn JS, Fossel A, Lee R, et al. *Arthritis Care and Research*. 2005;53(6):872-8.
43. **Chloroquine induced psychosis.** Agrawal A, Agrawal R. *Indian Pediatrics*. 1988;25(12):1226-7.
44. **Evaluation and management of a child with suspected malaria.** Agrawal D, Teach SJ. *Pediatric Emergency Care*. 2006;22(2):127-36.
45. **Rate and Risk Factors of Early Ventriculoperitoneal Shunt Revision: A Five-Year Retrospective Analysis of a Referral Center.** Ahmadvand S, Dayyani M, Etemadrezaie H, Ghorbanpour A, Zarei R, Shahriyari A, et al. *World Neurosurg*. 2020;134:e505-e11. <http://dx.doi.org/10.1016/j.wneu.2019.10.108>. Epub 2019 Nov 13.
46. **The HLA-DRB1\*0401 allele and the development of methotrexate-induced accelerated rheumatoid nodulosis: A follow-up study of 79 Caucasian patients with rheumatoid arthritis.** Ahmed SS, Arnett FC, Smith CA, Ahn C, Reveille JD. *Medicine*. 2001;80(4):271-8.
47. **En Face Optical Coherence Tomography Imaging of the Photoreceptor Layers in Hydroxychloroquine Retinopathy.** Ahn SJ, Joung J, Lee BR. *American journal of ophthalmology*. 2019;199:71-81. <http://dx.doi.org/10.1016/j.ajo.2018.11.003>. Epub 2018 Nov 16.
48. **Optical Coherence Tomography Protocols for Screening of Hydroxychloroquine Retinopathy in Asian Patients.** Ahn SJ, Joung J, Lim HW, Lee BR. *American journal of ophthalmology*. 2017;184:11-8. <http://dx.doi.org/10.1016/j.ajo.2017.09.025>. Epub 2017 Sep 28.
49. **Evaluation of Retromode Imaging for Use in Hydroxychloroquine Retinopathy.** Ahn SJ, Lee SU, Lee SH, Lee BR. *American journal of ophthalmology*. 2018;196:44-52. <http://dx.doi.org/10.1016/j.ajo.2018.08.013>. Epub 2018 Aug 15.
50. **Choroidal Thinning Associated With Hydroxychloroquine Retinopathy.** Ahn SJ, Ryu SJ, Joung JY, Lee BR. *American journal of ophthalmology*. 2017;183:56-64. <http://dx.doi.org/10.1016/j.ajo.2017.08.022>. Epub 2017 Sep 8.
51. **Evaluation of macrophage activation syndrome in hospitalised patients with Kikuchi-Fujimoto disease**

**based on the 2016 EULAR/ACR/PRINTO classification criteria.** Ahn SS, Lee B, Kim D, Jung SM, Lee SW, Park MC, et al. *PLoS ONE*. 2019;14(7).

52. **Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease.** Aisen PS, Marin DB, Brickman AM, Santoro J, Fusco M. *Alzheimer Disease and Associated Disorders*. 2001;15(2):96-101.

53. **Junior doctor training in pleural procedures: a quality survey.** Aiyappan V, Munawar A, Thien F. *Internal medicine journal*. 2013;43(1):96-100. <http://dx.doi.org/10.1111/imj.12019>.

54. **Q Fever in Southern California: a Case Series of 20 Patients from a VA Medical Center.** Akamine CM, Perez ML, Lee JH, Ing MB. *The American journal of tropical medicine and hygiene*. 2019;101(1):33-9. <http://dx.doi.org/10.4269/ajtmh.18-0283>.

55. **Neurological complications in patients with plasmodium vivax malaria from Karachi, Pakistan.** Akhlaq A, Ghanchi NK, Usmani B, Shahzad R, Rahim A, Wasay M, et al. *Journal of the Royal College of Physicians of Edinburgh*. 2018;48(3):198-201.

56. **Chloroquine induced mania.** Akhtar S, Mukherjee S. *International Journal of Psychiatry in Medicine*. 1993;23(4):349-56.

57. **Study to assess differences in outcome following open carpal tunnel decompressions performed by surgeons of differing grade.** Akhtar S, Sinha S, Bradley MJ, Burke FD, Wilgis SE, Dubin NH. *Annals of the Royal College of Surgeons of England*. 2007;89(8):785-8. <http://dx.doi.org/10.1308/003588407X232035>.

58. **Incidence of surgical site infection in postoperative patients at a tertiary care centre in India.** Akhter MS, Verma R, Madhukar KP, Vaishampayan AR, Unadkat PC. *Journal of wound care*. 2016;25(4):210-2, 4-7. <http://dx.doi.org/10.12968/jowc.2016.25.4.210>.

59. **The impacts of state and trait anxiety as moderated by perceived social support among Nigerian patients with rheumatoid arthritis.** Akintayo RO, Odunlami GJ, Bamidele OF, Fabiyi EP, Akintayo FC, Bamidele OV, et al. *Reumatologia*. 2018;56(3):155-63.

60. **Severity of episcleritis and systemic disease association.** Akpek EK, Uy HS, Christen W, Gurdal C, Foster CS. *Ophthalmology*. 1999;106(4):729-31.

61. **Substance use in a sample of Turkish medical students.** Akvardar Y, Demiral Y, Ergor G, Ergor A, Bilici M, Akil Ozer O. *Drug and alcohol dependence*. 2003;72(2):117-21. [http://dx.doi.org/10.1016/s0376-8716\(03\)00192-3](http://dx.doi.org/10.1016/s0376-8716(03)00192-3).

62. **Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia.** Al Arfaj AS, Khalil N. *Lupus*. 2009;18(5):465-73.

63. **Optimizing pharmacotherapy of systemic lupus erythematosus: the pharmacist role.** Al Hussaini M, Hammouda EI, Hammouda AE. *International journal of clinical pharmacy*. 2014;36(4):684-92. <http://dx.doi.org/10.1007/s11096-014-9966-1>. Epub 2014 Jul 2.

64. **Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug Interactions.** Alam K, Pahwa S, Wang X, Zhang P, Ding K, Abuznait AH, et al. *Molecular pharmaceutics*. 2016;13(3):839-51. <http://dx.doi.org/10.1021/acs.molpharmaceut.5b00763>. Epub 2016 Feb 1.

65. **Epidemiology of Rheumatoid Arthritis in a tertiary care unit, Karachi, Pakistan.** Alam SM, Kidwai AA, Jafri SR, Qureshi BM, Sami A, Qureshi HH, et al. *Journal of the Pakistan Medical Association*. 2011;61(2):123-6.

66. **Neuropsychiatric adverse events during prophylaxis against malaria by using mefloquine before**



**traveling.** Al-Amer O. *Annals of Tropical Medicine and Public Health*. 2015;8(5):159-63.

67. **Prescribing errors by junior doctors- A comparison of errors with high risk medicines and non-high risk medicines.** Alanazi MA, Tully MP, Lewis PJ. *PLoS One*. 2019;14(1):e0211270. <http://dx.doi.org/10.1371/journal.pone.0211270>. eCollection 2019.
68. **Psychiatric complications of malaria: A case report.** Alao AO, Dewan MJ. *International Journal of Psychiatry in Medicine*. 2001;31(2):217-23.
69. **Can handheld micropower impulse radar technology be used to detect pneumothorax? Initial experience in a European trauma centre.** Albers CE, Haefeli PC, Zimmermann H, de Moya M, Exadaktylos AK. *Injury*. 2013;44(5):650-4. <http://dx.doi.org/10.1016/j.injury.2012.02.001>. Epub 2012 Mar 3.
70. **Side effects of and compliance with malaria prophylaxis in children.** Albright TA, Binns HJ, Katz BZ. *Journal of Travel Medicine*. 2002;9(6):289-92.
71. **Q fever in Spain: Description of a new series, and systematic review.** Alende-Castro V, Macía-Rodríguez C, Novo-Veleiro I, García-Fernández X, Treviño-Castellano M, Rodríguez-Fernández S, et al. *PLoS Neglected Tropical Diseases*. 2018;12(3).
72. **Laboratory testing in rheumatoid arthritis patients taking disease-modifying antirheumatic drugs: Clinical evaluation and cost analysis.** Aletaha D, Smolen JS. *Arthritis Care and Research*. 2002;47(2):181-8.
73. **Surgical nurse assistants in cardiac surgery: a UK trainee's perspective.** Alex J, Rao VP, Cale AR, Griffin SC, Cowen ME, Guvendik L. *European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery*. 2004;25(1):111-5. [http://dx.doi.org/10.1016/s1010-7940\(03\)00578-5](http://dx.doi.org/10.1016/s1010-7940(03)00578-5).
74. **Severe Plasmodium vivax malaria, Brazilian Amazon.** Alexandre MA, Ferreira CO, Siqueira AM, Magalhães BL, Mourão MPG, Lacerda MV, et al. *Emerging Infectious Diseases*. 2010;16(10):1611-4.
75. **Is Sjögren's syndrome a cause for dry eyes and dry mouth in the elderly?** Al-Hashimi I. *Aging Health*. 2009;5(4):535-49.
76. **Scores of awareness and altruism in organ transplantation among Saudi health colleges students-impact of gender, year of study, and field of specialization.** AlHejaili W, Almalik F, Albrahim L, Alkhalidi F, AlHejaili A, Al Sayyari A. *Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia*. 2018;29(5):1028-34. <http://dx.doi.org/10.4103/1319-2442.243947>.
77. **Methotrexate in rheumatoid arthritis: a 2 year experience at a university hospital in Pakistan.** Ali AA, Iqbal MP, Hussain MA, Mehboobali N, Beg JA, Rahbar MH. *JPMA The Journal of the Pakistan Medical Association*. 1998;48(1):3-6.
78. **Late-onset immune-mediated adverse effects after poly-L-lactic acid injection in non-HIV patients: Clinical findings and long-term follow-up.** Alijotas-Reig J, Garcia-Gimenez V, Vilardell-Tarres M. *Dermatology*. 2009;219(4):303-8.
79. **Drug interactions and pharmacogenetic reactions are the basis for chloroquine and mefloquine-induced psychosis.** Alisky JM, Chertkova EL, Iczkowski KA. *Medical Hypotheses*. 2006;67(5):1090-4.
80. **Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: Retrospective analysis of safety and adherence to treatment.** Alivernini S, Mazzotta D, Zoli A, Ferraccioli G. *Drugs and Aging*. 2009;26(5):395-402.
81. **High prevalence of self-medication practices among medical and pharmacy students: a study from**

- Jordan.** Alkhatatbeh MJ, Alefan Q, Alqudah MA. International journal of clinical pharmacology and therapeutics. 2016;54(5):390-8. <http://dx.doi.org/10.5414/CP202451>.
82. **Adherence to Guidelines for Inpatient Pharmacologic Management of Type 2 Diabetes in Adults and Glycemic Outcomes.** Alkhiari R, Alzayer H, Aljazeera J, Vanniyasingam T, Punthakee Z. Canadian journal of diabetes. 2018;42(2):158-62. <http://dx.doi.org/10.1016/j.jcjd.2017.05.003>. Epub 2017 Jun 26.
83. **Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: The BeSt study.** Allaart CF, Geokoop-Ruiterman YPM, de Vries-Bouwstra JK, Breedveld FC, Dijkmans BAC. Clinical and Experimental Rheumatology. 2006;24(6):S77-S82.
84. **Optical Coherence Tomography Minimum Intensity as an Objective Measure for the Detection of Hydroxychloroquine Toxicity.** Allahdina AM, Stetson PF, Vitale S, Wong WT, Chew EY, Ferris FL, III, et al. Investigative ophthalmology & visual science. 2018;59(5):1953-63. <http://dx.doi.org/10.1167/iovs.17-22668>.
85. **New orally active proteasome inhibitors in multiple myeloma.** Allegra A, Alonci A, Gerace D, Russo S, Innao V, Calabrò L, et al. Leukemia Research. 2014;38(1):1-9.
86. **Frequency of high-risk use of QT-prolonging medications.** Allen LaPointe NM, Curtis LH, Chan KA, Kramer JM, Lafata JE, Gurwitz JH, et al. Pharmacoepidemiology and Drug Safety. 2006;15(6):361-8.
87. **Threshold Amsler grid as a screening tool for asymptomatic patients on hydroxychloroquine therapy.** Almony A, Garg S, Peters RK, Mamet R, Tsong J, Shibuya B, et al. The British journal of ophthalmology. 2005;89(5):569-74. <http://dx.doi.org/10.1136/bjo.2004.050120>.
88. **Acute generalized exanthematous pustulosis: clinical characteristics, etiologic associations, treatments, and outcomes in a series of 28 patients at Mayo Clinic, 1996–2013.** Alniemi DT, Wetter DA, Bridges AG, el-Azhary RA, Davis MDP, Camilleri MJ, et al. International Journal of Dermatology. 2017;56(4):405-14.
89. **Risk behaviors and spectrum of diseases among elderly travelers: A comparison of younger and older adults.** Alon D, Shitrit P, Chowers M. Journal of Travel Medicine. 2010;17(4):250-5.
90. **Effects of antirheumatic drug underutilization on rheumatoid arthritis disease activity.** Alqudah MAY, Al-azzam S, Alzoubi K, Alkhatatbeh M, Alawneh K, Alazzeah O, et al. Inflammopharmacology. 2017;25(4):431-8.
91. **Continuity of second-line drug therapy in rheumatological outpatient care.** Alten R, Brauer D, Eggens U, Gromnica-Ihle E, Hagemann D, Listing J, et al. Aktuelle Rheumatologie. 1995;20(3):87-92.
92. **[Acute respiratory distress syndrome (ARDS) as a complication of malaria P.vivax].** Altman A, Gueta I, Grosman T, Schwartz E. Harefuah. 2010;149(9):580-2, 620.
93. **Pharmacological therapies for osteoarthritis of the hand: A review of the evidence.** Altman RD. Drugs and Aging. 2010;27(9):729-45.
94. **Predicting the fear of assault at school and while going to and from school in an adolescent population.** Alvarez A, Bachman R. Violence and victims. 1997;12(1):69-86.
95. **Dynamics of Plasmodium falciparum parasitemia regarding combined treatment regimens for acute uncomplicated malaria, Antioquia, Colombia.** Álvarez G, Tobón A, Piñeros JG, Ríos A, Blair S. American Journal of Tropical Medicine and Hygiene. 2010;83(1):90-6.
96. **Perception of BDS students and fresh graduates about significance of professional ethics in dentistry.** Al-Zain SA, Al-Sadhan SA, Ahmedani MS. JPMA The Journal of the Pakistan Medical Association. 2014;64(2):118-23.

97. **Some behavioural effects of chloroquine in rats suggesting dopaminergic activation.** Amabeoku GJ. Indian Journal of Medical Research. 1994;99:87-94.
98. **Chloroquine remains effective for treating Plasmodium vivax malaria in Pursat Province, western Cambodia.** Amaratunga C, Sreng S, Mao S, Tullo GS, Anderson JM, Chuor CM, et al. Antimicrobial Agents and Chemotherapy. 2014;58(10):6270-2.
99. **Pattern of macular diseases in Nigerians: a preliminary report.** Amoni SS. Annals of ophthalmology. 1983;15(4):384-8.
100. **Diffusion-weighted imaging for the detection of mesenteric small bowel tumours with Magnetic Resonance--enterography.** Amzallag-Bellenger E, Soyer P, Barbe C, Nguyen TL, Amara N, Hoeffel C. Eur Radiol. 2014;24(11):2916-26. <http://dx.doi.org/10.1007/s00330-014-3303-x>. Epub 2014 Aug 12.
101. **Association of Surgeon Age and Experience With Congenital Heart Surgery Outcomes.** Anderson BR, Wallace AS, Hill KD, Gulack BC, Matsouaka R, Jacobs JP, et al. Circulation Cardiovascular quality and outcomes. 2017;10(7). <http://dx.doi.org/10.1161/CIRCOUTCOMES.117.003533>.
102. **Humphrey visual field findings in hydroxychloroquine toxicity.** Anderson C, Blaha GR, Marx JL. Eye (London, England). 2011;25(12):1535-45. <http://dx.doi.org/10.1038/eye.2011.245>. Epub 2011 Nov 18.
103. **Pilot study of ultrasound-guided corticosteroid hip injections by emergency physicians.** Anderson ES, Hodell E, Mantuani D, Fahimi J, Pampalone I, Nagdev A. The western journal of emergency medicine. 2014;15(7):919-24. <http://dx.doi.org/10.5811/westjem.2014.9.20575>. Epub 2014 Oct 29.
104. **Psychosocial Twin Cohort Studies in Japan: The Keio Twin Research Center (KoTReC).** Ando J, Fujisawa KK, Hiraishi K, Shikishima C, Kawamoto T, Nozaki M, et al. Twin research and human genetics : the official journal of the International Society for Twin Studies. 2019;22(6):591-6. <http://dx.doi.org/10.1017/thg.2019.109>. Epub 2020 Jan 15.
105. **Effect of high-intensity interval training on muscle remodeling in rheumatoid arthritis compared to prediabetes.** Andonian BJ, Bartlett DB, Huebner JL, Willis L, Hoselton A, Kraus VB, et al. Arthritis Research and Therapy. 2018;20(1).
106. **Clinical presentation and management of drug-induced agranulocytosis.** Andrès E, Zimmer J, Mecili M, Weitten T, Alt M, Maloisel F. Expert Review of Hematology. 2011;4(2):143-51.
107. **Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis.** Andres M, Sivera F, Pascual E. Journal of Clinical Rheumatology. 2012;18(5):234-6.
108. **The side effects of antimalarial drugs indicates a polyamine involvement in both schizophrenia and depression.** Andrews RCR. Medical Hypotheses. 1985;18(1):11-8.
109. **Resistance of infection by Plasmodium vivax to chloroquine in Bolivia.** Añez A, Moscoso M, Laguna Á, Garnica C, Melgar V, Cuba M, et al. Malaria Journal. 2015;14(1).
110. **Combination antimalarials in the treatment of cutaneous dermatomyositis: A retrospective study.** Ang GC, Werth VP. Archives of Dermatology. 2005;141(7):855-9.
111. **Vitamin D and prolonged treatment with photosensitivity-associated antibiotics.** Angelakis E, Oddoze C, Raoult D. Antimicrob Agents Chemother. 2013;57(12):6409-10. <http://dx.doi.org/10.1128/AAC.01969-13>. Epub 2013 Oct 7.
112. **Travel health advice: Benefits, compliance, and outcome.** Angelin M, Evengård B, Palmgren H.

Scandinavian Journal of Infectious Diseases. 2014;46(6):447-53.

113. **Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis.** Angelis-Stoforidis P, Vajda FJE, Christophidis N. *Clinical and Experimental Rheumatology*. 1999;17(3):313-20.
114. **[Adverse drug reactions (ADRs) to antimalarial drugs. Analysis of spontaneous report from the French pharmacovigilance database (1996-2000)].** Angles A, Bagheri H, Montastruc JL, Magnaval JF. *Presse Med*. 2003;32(3):106-13.
115. **Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies.** Anh-Tu Hoa S, Hudson M. *Seminars in Arthritis and Rheumatism*. 2017;46(4):488-508.
116. **Clinical study of adverse cutaneous drug reactions at a rural based tertiary care centre in Gujarat.** Anjaneyan G, Gupta R, Vora R. *National Journal of Physiology, Pharmacy and Pharmacology*. 2013;3(2):129-36.
117. **Perception of ischaemic heart disease, knowledge of and attitude to reduction of its risk factors.** Ansa VO, Oyo-Ita A, Essien OE. *East Afr Med J*. 2007;84(7):318-23. <http://dx.doi.org/10.4314/eamj.v84i7.9586>.
118. **Diagnosis and therapy for hospitalized imported malaria in adults in Italy.** Antinori S, Cigardi B, Galimberti L, Orlando G, Schifanella L, Milazzo L, et al. *Journal of Travel Medicine*. 2011;18(6):379-85.
119. **Improving prescribing using a rule based prescribing system.** Anton C, Nightingale PG, Adu D, Lipkin G, Ferner RE. *Quality & safety in health care*. 2004;13(3):186-90. <http://dx.doi.org/10.1136/qhc.13.3.186>.
120. **Changing trends in mortality in systemic lupus erythematosus? An analysis of SLE inpatient mortality at University Hospital Coventry and Warwickshire NHS Trust from 2007 to 2016.** Anver H, Dubey S, Fox J. *Rheumatology International*. 2019;39(12):2069-75.
121. **Factors influencing uptake of voluntary counselling and testing services for HIV/AIDS in the Lower Manya Krobo Municipality (LMKM) in the Eastern Region of Ghana: a cross-sectional household survey.** Apanga PA, Akparibo R, Awoonor-Williams JK. *Journal of health, population, and nutrition*. 2015;33:23. <http://dx.doi.org/10.1186/s41043-015-0035-8>.
122. **Antiparasite therapy.** Aparicio P, Rodríguez E, Gárate T, Molina R, Soto A, Alvar J. *Enfermedades Infecciosas y Microbiología Clínica*. 2003;21(10):579-94+604.
123. **Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: Feasibility and results.** Apisarnthanarax N, Donato M, Körbling M, Couriel D, Gajewski J, Giralt S, et al. *Bone Marrow Transplantation*. 2003;31(6):459-65.
124. **Voxel-based morphometry of brain SPECT can detect the presence of active central nervous system involvement in systemic lupus erythematosus.** Appenzeller S, Amorim BJ, Ramos CD, Rio PA, de CEECS, Camargo EE, et al. *Rheumatology*. 2007;46(3):467-72.
125. **Vaginal delivery of the second twin in unengaged cephalic presentation.** Arabin B, Kyvernitakis I, Hamza A, Maul H, Di Tommaso M, van Eyck J, et al. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet*. 2019:1-5. <http://dx.doi.org/10.1080/14767058.2019.1590333>.
126. **Anti-Neutrophil Antibody Associated Vasculitis in Systemic Sclerosis.** Arad U, Balbir-Gurman A, Doenyas-Barak K, Amit-Vazina M, Caspi D, Elkayam O. *Seminars in Arthritis and Rheumatism*. 2011;41(2):223-9.

127. **Factors associated with chloroquine-induced retinopathy in rheumatic diseases.** Araiza-Casillas R, Cardenas F, Morales Y, Cardiel MH. *Lupus*. 2004;13(2):119-24. <http://dx.doi.org/10.1191/0961203304lu514oa>.
128. **[Optical coherence tomography to evaluate peripapillary retinal nerve fiber layer in chloroquine patients].** Arana LA, Arana J, Hasimoto AR, Schirr G, Arana E, Beckhauser AP, et al. *Arquivos brasileiros de oftalmologia*. 2010;73(1):28-32. <http://dx.doi.org/10.1590/s0004-27492010000100005>.
129. **Effect of anti-malarial interventions on trends of malaria cases, hospital admissions and deaths, 2005-2015, Ghana.** Aregawi M, Malm KL, Wahjib M, Kofi O, Allotey NK, Yaw PN, et al. *Malaria Journal*. 2017;16(1).
130. **Needle aspiration of liver abscess under ultrasound guidance.** Arif M. *Journal of the College of Physicians and Surgeons Pakistan*. 2001;11(9):565-8.
131. **Determining the common medical presenting problems to an accident and emergency department.** Armon K, Stephenson T, Gabriel V, MacFaul R, Eccleston P, Werneke U, et al. *Arch Dis Child*. 2001;84(5):390-2. <http://dx.doi.org/10.1136/adsc.84.5.390>.
132. **Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases.** Arnal C, Piette JC, Leone J, Taillan B, Hachulla E, Roudot-Thoraval F, et al. *The Journal of rheumatology*. 2002;29(1):75-83.
133. **Comparison between multifocal ERG and C-Scan SD-OCT ("en face" OCT) in patients with a suspicion of antimalarial retinal toxicity: preliminary results.** Arndt C, Costantini M, Chiquet C, Afriat M, Berthemy S, Vasseur V, et al. *Documenta ophthalmologica Advances in ophthalmology*. 2018;136(2):97-111. <http://dx.doi.org/10.1007/s10633-018-9625-2>. Epub 2018 Mar 13.
134. **Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin.** Arndt U, Kaltwasser JP, Gottschalk R, Hoelzer D, Möller B. *Annals of Hematology*. 2005;84(3):159-66.
135. **Hydroxychloroquine for treatment of SARS-CoV-2 infection? Improving our confidence in a model-based approach to dose selection.** Arnold SLM, Buckner F. *Clinical and Translational Science*. 2020.
136. **The Imperial Stress Assessment Tool (ISAT): a feasible, reliable and valid approach to measuring stress in the operating room.** Arora S, Tierney T, Sevdalis N, Aggarwal R, Nestel D, Woloshynowych M, et al. *World J Surg*. 2010;34(8):1756-63. <http://dx.doi.org/10.1007/s00268-010-0559-4>.
137. **Capsule complication during cataract surgery: Case-control study of preoperative and intraoperative risk factors: Swedish Capsule Rupture Study Group report 2.** Artzen D, Lundstrom M, Behndig A, Stenevi U, Lydahl E, Montan P. *Journal of cataract and refractive surgery*. 2009;35(10):1688-93. <http://dx.doi.org/10.1016/j.jcrs.2009.05.026>.
138. **Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis.** Asanuma Y, Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, et al. *Atherosclerosis*. 2007;195(2):e135-e41.
139. **An evaluation of the resident learning curve in performing laparoscopic supracervical hysterectomies as compared with patient outcome: five-year experience.** Ascher-Walsh CJ, Capes T. *Journal of minimally invasive gynecology*. 2007;14(6):719-23. <http://dx.doi.org/10.1016/j.jmig.2007.07.005>.
140. **Acquired methemoglobinemia: A retrospective series of 138 cases at 2 teaching hospitals.** Ash-Bernal R, Wise R, Wright SM. *Medicine*. 2004;83(5):265-73.
141. **Malaria.** Ashley E, McGready R, Proux S, Nosten F. *Travel Medicine and Infectious Disease*. 2006;4(3):159-73.

142. **[Psoriasis and systemic lupus erythematosus: a rare association with specific therapeutic problems].** Astudillo L, Sailler L, Carreiro M, Dahan S, Ollier S, Arlet P. *Annales de medecine interne.* 2003;154(1):3-6.
143. **Epidemiological applications: a case report of a village epidemic of gastroenteritis.** Asuzu MC, Singh N. *Pacific health dialog.* 2001;8(1):110-4.
144. **Development of a difficulty score for spinal anaesthesia.** Atallah MM, Demian AD, Shorrab AA. *Br J Anaesth.* 2004;92(3):354-60. <http://dx.doi.org/10.1093/bja/ae073>. Epub 2004 Jan 22.
145. **Is there still a place for "old therapies" in the management of immune thrombocytopenia?** Audia S, Godeau B, Bonnotte B. *La Revue de medecine interne.* 2016;37(1):43-9. <http://dx.doi.org/10.1016/j.revmed.2015.08.007>. Epub 2015 Oct 1.
146. **Perioperative outcomes and complications related to teaching residents and fellows in scoliosis surgery.** Auerbach JD, Lonner BS, Antonacci MD, Kean KE. *Spine (Phila Pa 1976).* 2008;33(10):1113-8. <http://dx.doi.org/10.1097/BRS.0b013e31816f69cf>.
147. **Chloroquine levels in blood during chronic treatment of patients with rheumatoid arthritis.** Augustijns P, Geusens P, Verbeke N. *European journal of clinical pharmacology.* 1992;42(4):429-33. <http://dx.doi.org/10.1007/bf00280130>.
148. **Ocular diseases in patients with rheumatic diseases.** Ausayakhun S, Louthrenoo W, Aupapong S. *Journal of the Medical Association of Thailand.* 2002;85(8):855-62.
149. **Prosthetic valve endocarditis due to *Coxiella burnetii*: Six cases.** Auzary C, Pinganaud C, Launay O, Joly V, Cremieux AC, Idatte JM, et al. *Revue de Medecine Interne.* 2001;22(10):948-58.
150. **Changes in psychiatry residents' attitudes towards individuals with substance use disorders over the course of residency training.** Avery J, Han BH, Zerbo E, Wu G, Mauer E, Avery J, et al. *The American journal on addictions.* 2017;26(1):75-9. <http://dx.doi.org/10.1111/ajad.12406>. Epub 2016 Oct 17.
151. **Incidence of myopathy in patients treated with antimalarials. A report of three cases and a review of the literature.** Avina-Zubieta JA, Johnson ES, Suarez-Almazor ME, Russell AS. *British Journal of Rheumatology.* 1995;34(2):166-70.
152. **Chloroquine-primaquine versus chloroquine alone to treat vivax malaria in Afghanistan: An open randomized superiority trial.** Awab GR, Imwong M, Bancone G, Jeeyapant A, Day NPJ, White NJ, et al. *American Journal of Tropical Medicine and Hygiene.* 2017;97(6):1782-7.
153. **Dihydroartemisinin-piperazine versus chloroquine to treat vivax malaria in Afghanistan: An open randomized, non-inferiority, trial.** Awab GR, Pukrittayakamee S, Imwong M, Dondorp AM, Woodrow CJ, Lee SJ, et al. *Malaria Journal.* 2010;9(1).
154. **Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.** Awodele O, Aliu R, Ali I, Oni Y, Adeyeye CM. *Pharmacology Research and Perspectives.* 2018;6(5).
155. **Frequency of depression and anxiety in patients attending a rheumatology clinic.** Azad N, Gondal M, Abbas N. *Journal of the College of Physicians and Surgeons Pakistan.* 2008;18(9):569-73.
156. **Ciprofloxacin-induced chorea (multiple letters) [5].** Azar S, Ramjiani A, Van Gerpen JA, Post B, Koelman JHTM, Tijssen MAJ. *Movement Disorders.* 2005;20(4):513-4.

157. **Predictors of predominant Lupus Low Disease Activity State (LLDAS-50).** Babaoglu H, Li J, Goldman D, Magder LS, Petri M. *Lupus*. 2019;28(14):1648-55.
158. **Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus.** Baca V, Lavalle C, García R, Catalán T, Saucedo JM, Sánchez G, et al. *Journal of Rheumatology*. 1999;26(2):432-9.
159. **Cutaneous sarcoidosis therapy updated.** Badgwell C, Rosen T. *Journal of the American Academy of Dermatology*. 2007;56(1):69-83.
160. **Improved health outcomes with Etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis.** Bae SC, Gun SC, Mok CC, Khandker R, Nab HW, Koenig AS, et al. *BMC Musculoskeletal Disorders*. 2013;14.
161. **Potential drug interactions in patients with rheumatoid arthritis.** Bagatini F, Blatt CR, Maliska G, Trespash GV, Pereira IA, Zimmermann AF, et al. *Revista Brasileira de Reumatologia*. 2011;51(1):20-39.
162. **Radiation exposure of the hands and thyroid gland during percutaneous wiring of wrist and hand procedures.** Bahari S, Morris S, Broe D, Taylor C, Lenehan B, McElwain J. *Acta Orthop Belg*. 2006;72(2):194-8.
163. **Effectiveness of antimalarial drugs.** Baird JK. *New England Journal of Medicine*. 2005;352(15):1565-77+623.
164. **Impact of acute stress on psychomotor bimanual performance during a simulated tumor resection task.** Bajunaid K, Mullah MA, Winkler-Schwartz A, Alotaibi FE, Fares J, Baggiani M, et al. *J Neurosurg*. 2017;126(1):71-80. <http://dx.doi.org/10.3171/2015.5.JNS15558>. Epub 2016 Mar 11.
165. **Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure.** Baker JF, Sauer B, Teng CC, George M, Cannon GW, Ibrahim S, et al. *Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases*. 2018;24(4):203-9. <http://dx.doi.org/10.1097/RHU.0000000000000736>.
166. **Surgical site infections after dermatologic surgery in immunocompromised patients: A single-center experience.** Balakirski G, Kotliar K, Pauly KJ, Krings LK, Rübben A, Baron JM, et al. *Dermatologic Surgery*. 2018;44(12):1525-36.
167. **Scleroderma overlap syndrome.** Balbir-Gurman A, Braun-Moscovici Y. *Israel Medical Association Journal*. 2011;13(1):14-20.
168. **From clinical trials to the bedside: How can we treat patients with rheumatoid arthritis and concurrent morbidities who are generally excluded from randomised controlled clinical trials?** Baldini C, Deel Sedie A, Bombardieri S. *Clinical and Experimental Rheumatology*. 2005;23(6):893-904.
169. **Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies.** Baldini C, Martin Romano P, Voisin AL, Danlos FX, Champiat S, Laghouati S, et al. *European Journal of Cancer*. 2020;129:71-9.
170. **[On clinical features, etiology and treatment of acute lupus erythematosus].** Balevska N. *Dermatologische Wochenschrift*. 1965;151(30):873-6.
171. **Effect of Avemar® - A fermented wheat germ extract - On rheumatoid arthritis. Preliminary data.** Bálint G, Apáthy Á, Gaál M, Telekes A, Resetár Á, Blazsó G, et al. *Clinical and Experimental Rheumatology*. 2006;24(3):325-8.

172. **Prevalence and risk factors associated to pruritus in Plasmodium vivax patients using chloroquine in the Brazilian Amazon.** Ballut PC, Siqueira AM, Orlando AC, Alexandre MA, Alecrim MG, Lacerda MV. Acta tropica. 2013;128(3):504-8. <http://dx.doi.org/10.1016/j.actatropica.2013.07.008>. Epub 2013 Jul 29.
173. **Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis.** Baltzan M, Mehta S, Kirkham TH, Cosio MG. American Journal of Respiratory and Critical Care Medicine. 1999;160(1):192-7.
174. **Benign tertian malaria - a misnomer?** Bammigatti C, Shetty S, Shetty S, Kumar A. Tropical Doctor. 2011;41(3):168-9.
175. **PRO-OSTEO Project (improving osteoporosis management in the acute hospital setting): a pilot single-centre study.** Banakh I. Arch Osteoporos. 2011;6:157-65. <http://dx.doi.org/10.1007/s11657-011-0061-0>. Epub 2011 Aug 10.
176. **Learning Curve in Laparoscopic Inguinal Hernia Repair: Experience at a Tertiary Care Centre.** Bansal VK, Krishna A, Misra MC, Kumar S. The Indian journal of surgery. 2016;78(3):197-202. <http://dx.doi.org/10.1007/s12262-015-1341-5>. Epub 2015 Sep 12.
177. **The clinical pattern and complications of severe malaria in the Gizan region of Saudi Arabia.** Banzal S, Ayoola EA, El Sammani EE, Rahim SI, Subramaniam P, Gadour MOE, et al. Annals of Saudi Medicine. 1999;19(4):378-80.
178. **Bronchoscopic guidance makes percutaneous tracheostomy a safe, cost-effective, and easy-to-teach procedure.** Barba CA, Angood PB, Kauder DR, Latenser B, Martin K, McGonigal MD, et al. Surgery. 1995;118(5):879-83. [http://dx.doi.org/10.1016/s0039-6060\(05\)80279-x](http://dx.doi.org/10.1016/s0039-6060(05)80279-x).
179. **A prospective comparative study of Knowlesi, falciparum, and vivax malaria in sabah, Malaysia: High proportion with severe disease from plasmodium knowlesi and plasmodium vivax but No mortality with early Referral and artesunate therapy.** Barber BE, William T, Grigg MJ, Menon J, Auburn S, Marfurt J, et al. Clinical Infectious Diseases. 2013;56(3):383-97.
180. **Thalidomide: Still an important second-line treatment in refractory cutaneous lupus erythematosus?** Baret I, De Haes P. Journal of Dermatological Treatment. 2015;26(2):173-7.
181. **Impact of litigation on senior clinicians: implications for risk management.** Bark P, Vincent C, Olivieri L, Jones A. Quality in health care : QHC. 1997;6(1):7-13. <http://dx.doi.org/10.1136/qshc.6.1.7>.
182. **Propoxyphene (dextropropoxyphene): A critical review of a weak opioid analgesic that should remain in antiquity.** Barkin RL, Barkin SJ, Barkin DS. American Journal of Therapeutics. 2006;13(6):534-42.
183. **A prospective observational study to assess the impact of operator seniority on outcome following arteriovenous fistula formation.** Barnes R, Smith GE, Chetter IC. The journal of vascular access. 2015;16(5):372-6. <http://dx.doi.org/10.5301/jva.5000401>. Epub 2015 Jul 9.
184. **Intracameral cefuroxime injection at the end of cataract surgery to reduce the incidence of endophthalmitis: French study.** Barreau G, Mounier M, Marin B, Adenis JP, Robert PY. Journal of cataract and refractive surgery. 2012;38(8):1370-5. <http://dx.doi.org/10.1016/j.jcrs.2012.03.024>.
185. **Risk factors for drug-resistant bloodstream infections in patients with systemic lupus erythematosus.** Barrera-Vargas A, Gómez-Martín D, Merayo-Chalico J, Ponce-De-León A, Alcocer-Varela J. Journal of Rheumatology. 2014;41(7):1311-6.
186. **Malaria - Current diagnosis and therapy.** Barreto Miranda I, Löscher T. Medizinische Klinik. 2009;104(7):543-54.



187. **Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: Postal and telephone survey of travellers.** Barrett PJ, Emmins PD, Clarke PD, Bradley DJ. *British Medical Journal*. 1996;313(7056):525-8.
188. **Myasthenic syndrome during a penicillamin treatment.** Barroche G, Briquel F, Presles O. *Annales Medicales de Nancy et de l'Est*. 1980;19:767-70.
189. **Drug-induced neuromuscular blockade and myasthenia gravis.** Barrons RW. *Pharmacotherapy*. 1997;17(6):1220-32.
190. **Visual function and long-term chloroquine treatment.** Bartel PR, Roux P, Robinson E, Anderson IF, Brighton SW, van der Hoven HJ, et al. *South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde*. 1994;84(1):32-4.
191. **Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort.** Bartels CM, Buhr KA, Goldberg JW, Bell CL, Visekruna M, Nekkanti S, et al. *Journal of Rheumatology*. 2014;41(4):680-7.
192. **Cardiovascular disease risk burden in primary Sjögren's syndrome: results of a population-based multicentre cohort study.** Bartoloni E, Baldini C, Schillaci G, Quartuccio L, Priori R, Carubbi F, et al. *Journal of Internal Medicine*. 2015;278(2):185-92.
193. **Differential expression of programmed death 1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis and psoriatic arthritis.** Bartosińska J, Zakrzewska E, Król A, Raczkiewicz D, Purkot J, Majdan M, et al. *Polish Archives of Internal Medicine*. 2017;127(12):815-22.
194. **Molecular epidemiology of malaria in Cameroon. XIX. Quality of antimalarial drugs used for self-medication.** Basco LK. *American Journal of Tropical Medicine and Hygiene*. 2004;70(3):245-50.
195. **Malaria and the traveller.** Batchelor T. *South Pacific Underwater Medicine Society Journal*. 2003;33(1):11-8.
196. **Thromboprophylaxis following cast immobilisation for lower limb injuries--survey of current practice in United Kingdom.** Batra S, Kurup H, Gul A, Andrew JG. *Injury*. 2006;37(9):813-7. <http://dx.doi.org/10.1016/j.injury.2006.03.016>.
197. **[Dyslipidemia and atherogenic risk in patients with rheumatoid arthritis].** Batun Garrido JA, Olan F, Hernandez Nunez E. *Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis*. 2016;28(3):123-31. <http://dx.doi.org/10.1016/j.arteri.2016.02.002>. Epub 2016 Mar 26.
198. **Features of sarcoidosis associated with chronic disease.** Baughman RP, Lower EE. *Sarcoidosis Vasculitis and Diffuse Lung Diseases*. 2014;31(4):275-81.
199. **Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.** Baughman RP, Meyer KC, Nathanson I, Angel L, Bhorade SM, Chan KM, et al. *Chest*. 2012;142(5):e1S-e111S.
200. **Repository corticotropin for Chronic Pulmonary Sarcoidosis.** Baughman RP, Sweiss N, Keijsers R, Birring SS, Shipley R, Saketkoo LA, et al. *Lung*. 2017;195(3):313-22.
201. **Chloroquine and Hydroxychloroquine in the Era of SARS – CoV2: Caution on Their Cardiac Toxicity.** Bauman JL, Tisdale JE. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*. 2020.
202. **Development and validation of a risk calculator to differentiate flares from infections in systemic lupus erythematosus patients with fever.** Beça S, Rodríguez-Pintó I, Alba MA, Cervera R, Espinosa G. *Autoimmunity*

Reviews. 2015;14(7):586-93.

203. **Comparative features and outcomes of malaria at a tertiary care hospital in Karachi, Pakistan.** Beg MA, Sani N, Mehraj V, Jafri W, Khan MA, Malik A, et al. *International Journal of Infectious Diseases*. 2008;12(1):37-42.

204. **Malaria in travellers: Epidemiology and prevention.** Behrens RH, Curtis CF. *British Medical Bulletin*. 1993;49(2):363-81.

205. **Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.** Belkhir R, Le Burel S, Dunogeant L, Marabelle A, Hollebecque A, Besse B, et al. *Annals of the Rheumatic Diseases*. 2017;76(10):1747-50.

206. **Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial.** Belkouz A, de Vos-Geelen J, Mathôt RAA, Eskens FALM, van Gulik TM, van Oijen MGH, et al. *British Journal of Cancer*. 2020;122(5):634-9.

207. **Hydroxychloroquine sulfate in rheumatoid arthritis: long-term response rate and predictive parameters.** Bell CL. *The American journal of medicine*. 1983;75(1):46-51.  
[http://dx.doi.org/10.1016/0002-9343\(83\)91270-6](http://dx.doi.org/10.1016/0002-9343(83)91270-6).

208. **Clinical pharmacology of antiarrhythmic drugs.** Bellet S. *Clinical Pharmacology and Therapeutics*. 1961;2(3):345-58.

209. **Risk analysis and clinical outcomes of intraoperative periprosthetic fractures: a retrospective study of 481 bipolar hemiarthroplasties.** Bellova P, Baecker H, Lotzien S, Brandt M, Schildhauer TA, Gessmann J. *J Orthop Surg Res*. 2019;14(1):432. <http://dx.doi.org/10.1186/s13018-019-1494-1>.

210. **Association of Resident Duty Hour Restrictions, Level of Trainee, and Number of Available Residents with Mortality in the Neonatal Intensive Care Unit.** Beltempo M, Clement K, Lacroix G, Belanger S, Julien AS, Piedboeuf B. *American journal of perinatology*. 2018;35(9):911-8. <http://dx.doi.org/10.1055/s-0038-1627442>. Epub 2018 Feb 8.

211. **Hydroxychloroquine niosomes: A new trend in topical management of oral lichen planus.** Bendas ER, Abdullah H, El-Komy MHM, Kassem MAA. *International Journal of Pharmaceutics*. 2013;458(2):287-95.

212. **Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor  $\alpha$  inhibitor infliximab.** Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. *Arthritis and Rheumatism*. 2006;54(12):3782-9.

213. **Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: Studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus.** Bengtsson AA, Sturfelt G, Lood C, Rönneblom L, Van Vollenhoven RF, Axelsson B, et al. *Arthritis and Rheumatism*. 2012;64(5):1579-88.

214. **Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure.** Bennett AN, Peterson P, Zain A, Grumley J, Panayi G, Kirkham B. *Rheumatology*. 2005;44(8):1026-31.

215. **Antimalarials in dermatology.** Bennett ML. *Current Problems in Dermatology*. 2000;12(6):257-9.

216. **Hydroxychloroquine: From malaria to autoimmunity.** Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. *Clinical Reviews in Allergy and Immunology*. 2012;42(2):145-53.

217. **Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments.** Beretta-Piccoli BT, Mieli-Vergani G, Vergani D. World Journal of Gastroenterology. 2017;23(33):6030-48.
218. **FUNDUS AUTOFLUORESCENCE FINDINGS in EARLY CHLOROQUINE MACULOPATHY.** Bergholz R, Rossel M, Schroeter J, Dutescu RM, Salchow DJ. Retinal Cases and Brief Reports. 2018;12(2):81-6.
219. **Evaluation of risk factors for retinal damage due to chloroquine and hydroxychloroquine.** Bergholz R, Schroeter J, Ruther K. The British journal of ophthalmology. 2010;94(12):1637-42. <http://dx.doi.org/10.1136/bjo.2009.174458>. Epub 2010 Oct 12.
220. **Evaluation of the duration of thromboembolic prophylaxis after high-risk orthopaedic surgery: The ETHOS observational study.** Bergqvist D, Arcelus JJ, Felicissimo P. Thrombosis and Haemostasis. 2012;107(2):270-9.
221. **Toxicity of commonly-used antimalarial drugs.** Berman J. Travel Medicine and Infectious Disease. 2004;2(3):171-84.
222. **Approval of tafenoquine for malaria chemoprophylaxis.** Berman JD. American Journal of Tropical Medicine and Hygiene. 2019;100(6):1301-4.
223. **Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis.** Bernatsky S, Hudson M, Suissa S. Rheumatology. 2005;44(5):677-80.
224. **Adherence to ophthalmologic monitoring for antimalarial toxicity in a lupus cohort.** Bernatsky S, Pineau C, Joseph L, Clarke A. Journal of Rheumatology. 2003;30(8):1756-60.
225. **Ocular safety of hydroxychloroquine.** Bernstein HN. Annals of ophthalmology. 1991;23(8):292-6.
226. **Ocular safety of hydroxychloroquine sulfate (Plaquenil).** Bernstein HN. South Med J. 1992;85(3):274-9. <http://dx.doi.org/10.1097/00007611-199203000-00010>.
227. **Accessory or sublingual salivary gland biopsy to assess systemic disease: a comparative retrospective study.** Berquin K, Mahy P, Weynand B, Reyhler H. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery. 2006;263(3):233-6. <http://dx.doi.org/10.1007/s00405-005-0984-4>. Epub 2005 Dec 24.
228. **The effects of exposure to community violence on Khmer refugee adolescents.** Berthold SM. Journal of traumatic stress. 1999;12(3):455-71. <http://dx.doi.org/10.1023/A:1024715003442>.
229. **Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus.** Bessant R, Hingorani A, Patel L, MacGregor A, Isenberg DA, Rahman A. Rheumatology. 2004;43(7):924-9.
230. **Pharmacotherapy Pearls in Rheumatology for the Care of Older Adult Patients: Focus on Oral Disease-Modifying Antirheumatic Drugs and the Newest Small Molecule Inhibitors.** Betancourt BY, Biehl A, Katz JD, Subedi A. Rheumatic Disease Clinics of North America. 2018;44(3):371-91.
231. **Hydroxychloroquine in patients with systemic lupus erythematosus with end-stage renal disease.** Bethel M, Yang FM, Li S, Nahman NS, Oliver AM, Machua W, et al. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 2016;64(4):908-10. <http://dx.doi.org/10.1136/jim-2016-000065>. Epub 2016 Feb 19.
232. **Leflunomide in rheumatoid arthritis in daily practice: Treatment discontinuation rates in comparison with other DMARDs.** Bettembourg-Brault I, Gossec L, Pham T, Gottenberg JE, Damiano J, Dougados M. Clinical and

Experimental Rheumatology. 2006;24(2):168-71.

233. **An uncommon cause of fever in the elderly: late-onset systemic lupus erythematosus.** Beyan E, Uzuner A, Beyan C. Clin Rheumatol. 2003;22(6):481-3. <http://dx.doi.org/10.1007/s10067-003-0795-1>. Epub 2003 Nov 7.

234. **Efficacy of Chloroquine for the Treatment of Vivax malaria in Northwest Ethiopia.** Beyene HB, Beyene MB, Ebstie YA, Desalegn Z. PLoS One. 2016;11(8):e0161483. <http://dx.doi.org/10.1371/journal.pone.0161483>. eCollection 2016.

235. **Risk perception of prescription drugs: results of a survey among experts in the European regulatory network.** Beyer AR, Fasolo B, Phillips LD, de Graeff PA, Hillege HL. Medical decision making : an international journal of the Society for Medical Decision Making. 2013;33(4):579-92. <http://dx.doi.org/10.1177/0272989X12472397>. Epub 2013 Mar 11.

236. **Palliative and end-of-life care and junior doctors': a systematic review and narrative synthesis.** Bharmal A, Morgan T, Kuhn I, Wee B, Barclay S. BMJ supportive & palliative care. 2019. <http://dx.doi.org/10.1136/bmjspcare-2019-001954>.

237. **Efficacy and safety of an anti-CD20 monoclonal antibody (Reditux™) for the treatment of patients with moderate to severe rheumatoid arthritis following the failure of conventional synthetic disease-modifying anti-rheumatic drugs.** Bhati M, Bandyopadhyay S. Clinical Rheumatology. 2016;35(8):1931-5.

238. **Chloroquine--induced recurrent psychosis (brief report).** Bhatia MS. Indian journal of medical sciences. 1996;50(11):302-4.

239. **Capgras' syndrome in chloroquine induced psychosis.** Bhatia MS, Dhar NK, Singhal PK. Indian Pediatrics. 1988;25(9):905-6.

240. **A case of chloroquine-induced recurrent mania.** Bhatia MS, Jhanjee A, Oberoi A. Primary Care Companion to the Journal of Clinical Psychiatry. 2012;14(3).

241. **Psychiatric complications of cloroquine.** Bhatia MS, Malik SC. Indian Pediatrics. 1995;32(3):351-3.

242. **Prevalence of abuse in mentally ill patients visiting outpatient setting in a tertiary care hospital in India.** Bhatia MS, Srivastava S, Khyati M, Kaushik R. Medicine, science, and the law. 2016;56(2):91-8. <http://dx.doi.org/10.1177/0025802415577811>. Epub 2015 Apr 6.

243. **Subconjunctival sirolimus in the treatment of autoimmune non-necrotizing anterior scleritis: Results of a phase I/II clinical trial.** Bhatt N, Dalal M, Tucker W, Obiyor D, Nussenblatt R, Sen HN. American Journal of Ophthalmology. 2015;159(3):601-6.

244. **Recent advances in malaria drug discovery.** Biamonte MA, Wanner J, Le Roch KG. Bioorganic and Medicinal Chemistry Letters. 2013;23(10):2829-43.

245. **Rheumatoid nodules and postoperative complications.** Bibbo C, Anderson RB, Davis WH, Norton J. Foot and Ankle International. 2003;24(1):40-4.

246. **Lupus erythematosus profundus Kaposi-Irgang.** Biedermann T, Schirren CG, Meurer M, Bieber T. European Journal of Dermatology. 1996;6(7):519-22.

247. **Prediction of survival in patients with acute myocardial infarction. A clinical study on 100 consecutive patients.** Biorck G, Erhardt LR, Lindberg G. Acta medica Scandinavica. 1979;206(3):165-8. <http://dx.doi.org/10.1111/j.0954-6820.1979.tb13488.x>.

248. **Emerging trends in diagnosis and treatment of rheumatoid arthritis.** Birch JT, Bhattacharya S. Primary Care - Clinics in Office Practice. 2010;37(4):779-92.
249. **Obstetric skills drills: evaluation of teaching methods.** Birch L, Jones N, Doyle PM, Green P, McLaughlin A, Champney C, et al. Nurse education today. 2007;27(8):915-22. <http://dx.doi.org/10.1016/j.nedt.2007.01.006>. Epub 2007 Mar 21.
250. **A single-blind comparative study of auranofin and hydroxychloroquine in patients with rheumatoid arthritis.** Bird HA, Le Gallez P, Dixon JS, Surrall KE, Cole DS, Goldman MH, et al. Clin Rheumatol. 1984;3:57-66. <http://dx.doi.org/10.1007/bf03342623>.
251. **Students' self-identified learning needs: a case study of baccalaureate students designing their own death and dying course curriculum.** Birkholz G, Clements PT, Cox R, Gaume A. The Journal of nursing education. 2004;43(1):36-9.
252. **Non-length-dependent and length-dependent small-fiber neuropathies associated with tumor necrosis factor (TNF)-inhibitor therapy in patients with rheumatoid arthritis: Expanding the spectrum of neurological disease associated with TNF-inhibitors.** Birnbaum J, Bingham CO. Seminars in Arthritis and Rheumatism. 2014;43(5):638-47.
253. **Drug-induced mental health disorders.** Bishop S, Lee A. Pharmaceutical Journal. 1998;261(7024):935-9.
254. **Cardiovascular system changes in rheumatoid arthritis patients with continued low disease activity.** Biskup M, Biskup W, Majdan M, Targońska-Stępnik B. Rheumatology International. 2018;38(7):1207-15.
255. **Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness.** Bisser S, N'Siesi FX, Lejon V, Preux PM, Van Nieuwenhove S, Bilenge CMM, et al. Journal of Infectious Diseases. 2007;195(3):322-9.
256. **Psychological sequelae of facial trauma.** Bisson JI, Shepherd JP, Dhutia M. The Journal of trauma. 1997;43(3):496-500. <http://dx.doi.org/10.1097/00005373-199709000-00018>.
257. **Psychosis following chloroquine ingestion: A 10-year comparative study from a malaria-hyperendemic district of India.** Biswas PS, Sen D, Majumdar R. General Hospital Psychiatry. 2014;36(2):181-6.
258. **Treatment of neurosarcoidosis.** Bitoun S, Bouvry D, Borie R, Mahevas M, Sacre K, Haroche J, et al. Neurology. 2016;87(24):2517-21.
259. **Complications and patient-injury after ankle fracture surgery. -A closed claim analysis with data from the Patient Compensation Association in Denmark.** Bjorslev N, Ebskov LB, Merso C, Wong C. Injury. 2018;49(2):430-6. <http://dx.doi.org/10.1016/j.injury.2017.11.025>. Epub 2017 Nov 21.
260. **Half of UK patients with rheumatoid arthritis are prescribed oral glucocorticoid therapy in primary care: A retrospective drug utilisation study.** Black RJ, Joseph RM, Brown B, Movahedi M, Lunt M, Dixon WG. Arthritis Research and Therapy. 2015;17(1).
261. **Gaining consent for carotid surgery: a simulation-based study of vascular surgeons.** Black SA, Nestel D, Tierney T, Amygdalos I, Kneebone R, Wolfe JH. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery. 2009;37(2):134-9. <http://dx.doi.org/10.1016/j.ejvs.2008.11.009>. Epub 2008 Dec 1.
262. **Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone.** Blackburn WD, Jr., Prupas HM, Silverfield JC, Poiley JE,

Caldwell JR, Collins RL, et al. Arthritis and rheumatism. 1995;38(10):1447-56. <http://dx.doi.org/10.1002/art.1780381011>.

263. **A study examining rates of medical staff recognition of pressure ulceration in hospital inpatients.**

Blackman J, Walsgrove J, Gunawardena I. Postgrad Med J. 2013;89(1051):258-61.

<http://dx.doi.org/10.1136/postgradmedj-2012-131411>. Epub 2013 Mar 1.

264. **DCMP as a clinical syndrome: Results of nosological diagnostics with myocardial biopsy and differentiated treatment in virus-positive and virus-negative patients.**

Blagova OV, Nedostup AV, Kogan EA, Sedov VP, Donnikov AE, Kadochnikova VV, et al. Russian Journal of Cardiology. 2016;129(1):7-19.

265. **The perplexity of prescribing and switching of biologic drugs in rheumatoid arthritis: A UK regional audit of practice.**

Blake T, Rao V, Hashmi T, Erb N, O'Reilly SC, Shaffu S, et al. BMC Musculoskeletal Disorders. 2014;15(1).

266. **Patient knowledge, beliefs, and behavior concerning the prevention and treatment of glucocorticoid-induced osteoporosis.**

Blalock SJ, Norton LL, Patel RA, Dooley MA. Arthritis Care and Research. 2005;53(5):732-9.

267. **[Results of laparoscopic hernioplasty. A study of 401 cases in 318 patients].**

Blanc P, Porcheron J, Breton C, Bonnot P, Baccot S, Tiffet O, et al. Chirurgie; memoires de l'Academie de chirurgie. 1999;124(4):412-8.

[http://dx.doi.org/10.1016/s0001-4001\(00\)80014-8](http://dx.doi.org/10.1016/s0001-4001(00)80014-8).

268. **Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine.**

Blanco R, Martínez-Taboada VM, González-Gay MA, Armona J, Fernández-Sueiro JL, González-Vela MC, et al. Arthritis and Rheumatism. 1996;39(6):1016-20.

269. **Socioeconomic class and universal healthcare: Analysis of stroke cost and outcomes in US military healthcare.**

Blattner M, Price J, Holtkamp MD. J Neurol Sci. 2018;386:64-8. <http://dx.doi.org/10.1016/j.jns.2018.01.018>.

270. **Malaria primer for clinicians in the United States.**

Bledsoe GH. Southern Medical Journal. 2005;98(12):1197-204.

271. **Discordance of the pediatric surgeon's intraoperative assessment of pediatric appendicitis with the pathologists report.**

Bliss D, McKee J, Cho D, Krishnaswami S, Zallen G, Harrison M, et al. J Pediatr Surg. 2010;45(7):1398-403. <http://dx.doi.org/10.1016/j.jpedsurg.2010.02.048>.

272. **Malaria chemoprophylaxis regimens: a descriptive drug utilization study.**

Bloechliger M, Schlagenhauf P, Toovey S, Schnetzler G, Tatt I, Tomianovic D, et al. Travel Med Infect Dis. 2014;12(6):718-25.

<http://dx.doi.org/10.1016/j.tmaid.2014.05.006>. Epub 2014 Jun 2.

273. **Rheumatoid arthritis and the incidence of influenza and influenza-related complications: A retrospective cohort study.**

Blumentals WA, Arreglado A, Napalkov P, Toovey S. BMC Musculoskeletal Disorders. 2012;13.

274. **Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature.**

Boddaert J, Huong DL, Amoura Z, Wechsler B, Godeau P, Piette JC. Medicine (Baltimore). 2004;83(6):348-59. <http://dx.doi.org/10.1097/01.md.0000147737.57861.7c>.

275. **Work-related health complaints in surgical residents and the influence of social support and job-related autonomy.**

Boerjan M, Bluysen SJ, Bleichrodt RP, van Weel-Baumgarten EM, van Goor H. Medical education. 2010;44(8):835-44. <http://dx.doi.org/10.1111/j.1365-2923.2010.03724.x>.

276. **Psychiatric adverse effects of chloroquine.**

Bogaczewicz A, Sobów T. Psychiatria i Psychologia Kliniczna. 2017;17(2):111-4.

277. **Chloroquine-induced subacute paranoid-like disorder as a complication of dermatological treatment.** Bogaczewicz A, Sobow T, Bogaczewicz J, Bienkowski P, Kowalski J, Wozniacka A. *International Journal of Dermatology*. 2016;55(12):1378-80.
278. **Exacerbations of bipolar disorder triggered by chloroquine in systemic lupus erythematosus - A case report.** Bogaczewicz J, Sobów T, Bogaczewicz A, Robak E, Bienkowski P, Sysa-Jędrzejowska A, et al. *Lupus*. 2014;23(2):188-93.
279. **Genetic variation in the SLC19A1 gene and methotrexate toxicity in rheumatoid arthritis patients.** Bohanec Grabar P, Leandro-García LJ, Inglada-Pérez L, Logar D, Rodríguez-Antona C, Dolžan V. *Pharmacogenomics*. 2012;13(14):1583-94.
280. **Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients.** Bohanec Grabar P, Rozman B, Tomšič M, Šuput D, Logar D, Dolžan V. *European Journal of Clinical Pharmacology*. 2008;64(9):871-6.
281. **Navy Hearing Conservation Program: threshold shifts in enlisted personnel, 1995-1999.** Bohnker BK, Page JC, Rovig G, Betts LS, Sack DM. *Mil Med*. 2002;167(1):48-52.
282. **Initial experience with a dual-console robotic-assisted platform for training in colorectal surgery.** Bolger JC, Broe MP, Zarog MA, Looney A, McKeivitt K, Walsh D, et al. *Tech Coloproctol*. 2017;21(9):721-7. <http://dx.doi.org/10.1007/s10151-017-1687-8>. Epub 2017 Sep 19.
283. **Chloroquine psychosis.** Bomb BS, Bedi HK, Bhatnagar LK. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1975;69(5):523.
284. **Letter: Chloroquine psychosis.** Bomb BS, Bedi HK, Bhatnagar LK. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1975;69(5):523.
285. **Etanercept-Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis.** Bonafede M, Johnson BH, Tang DH, Shah N, Harrison DJ, Collier DH. *Arthritis care & research*. 2015;67(12):1656-63. <http://dx.doi.org/10.1002/acr.22638>.
286. **Preliminary results of laparoscopic colorectal resections: does surgeon's age influences outcomes?** Boni L, Di Giuseppe M, Bertoglio C, Benevento A, Dionigi G, Rovera F, et al. *Surgical oncology*. 2007;16:S57-60. <http://dx.doi.org/10.1016/j.suronc.2007.10.005>. Epub 2007 Nov 26.
287. **Disease activity and disability but probably not glucocorticoid treatment predicts loss in bone mineral density in women with early rheumatoid arthritis.** Book C, Karlsson M, Åkesson K, Jacobsson L. *Scandinavian Journal of Rheumatology*. 2008;37(4):248-54.
288. **Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma.** Boone BA, Bahary N, Zureikat AH, Moser AJ, Normolle DP, Wu WC, et al. *Annals of surgical oncology*. 2015;22(13):4402-10. <http://dx.doi.org/10.1245/s10434-015-4566-4>. Epub 2015 Apr 24.
289. **Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study).** Borba M, Val FdA, Sampaio VS, Alexandre MA, Melo GC, Brito M, et al. *medRxiv*. 2020:2020.04.07.20056424.
290. **Lipid-lowering agent-triggered dermatomyositis and polymyositis: a case series and literature review.** Borges IBP, Silva MG, Misse RG, Shinjo SK. *Rheumatology International*. 2018;38(2):293-301.

291. **Pharmacotherapy in systemic lupus erythematosus.** Borham LE. *Current Rheumatology Reviews*. 2012;8(3):166-79.
292. **Laparoscopic appendicectomy: a trainee's perspective.** Botha AJ, Elton C, Moore EE, Sauven P. *Annals of the Royal College of Surgeons of England*. 1995;77(4):259-62.
293. **Recent Advances in Anti-Infectious Chemotherapy: Ertapenem, Voriconazole, Malarone (Second of two parts).** Botta GA. *Journal of the Bahrain Medical Society*. 2003;15(4):240-6.
294. **Cutaneous lesions of the digits in systemic lupus erythematosus: 50 cases.** Bouaziz JD, Barete S, Le Pelletier F, Amoura Z, Piette JC, Frances C. *Lupus*. 2007;16(3):163-7. <http://dx.doi.org/10.1177/0961203306075792>.
295. **Impact of a chest-pain guideline on clinical decision-making.** Boufous S, Kelleher PW, Pain CH, Dann LM, Ieraci S, Jalaludin BB, et al. *The Medical journal of Australia*. 2003;178(8):375-80.
296. **[Assessing beliefs and attitudes of relatives of patients with schizophrenia: a study in a Tunisian sample].** Bouhrel S, Ben Haouala S, Klibi A, Ghaouar M, Chennoufi L, Melki W, et al. *Encephale*. 2013;39(3):165-73. <http://dx.doi.org/10.1016/j.encep.2012.06.012>. Epub 2012 Jul 12.
297. **Etiologies and prognostic factors of leukocytoclastic vasculitis with skin involvement: A retrospective study in 112 patients.** Bouiller K, Audia S, Devilliers H, Collet E, Aubriot MH, Leguy-Seguine V, et al. *Medicine (United States)*. 2016;95(28).
298. **Determinants of sit-to-stand tasks in individuals with hemiparesis post stroke: A review.** Boukadida A, Piotte F, Dehail P, Nadeau S. *Annals of physical and rehabilitation medicine*. 2015;58(3):167-72. <http://dx.doi.org/10.1016/j.rehab.2015.04.007>. Epub 2015 May 23.
299. **Calcinosis in rheumatic diseases.** Boulman N, Slobodin G, Rozenbaum M, Rosner I. *Seminars in Arthritis and Rheumatism*. 2005;34(6):805-12.
300. **Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease.** Bounfour T, Bouaziz JD, Bézier M, Cordoliani F, Saussine A, Petit A, et al. *Journal of the European Academy of Dermatology and Venereology*. 2014;28(9):1150-7.
301. **Interobserver agreement on endoscopic diagnosis of bleeding peptic ulcers.** Bour B, Person B, Cales P, Blanchi A, Burtin P, Oberti F, et al. *Gastrointest Endosc*. 1997;46(1):27-32. [http://dx.doi.org/10.1016/s0016-5107\(97\)70205-0](http://dx.doi.org/10.1016/s0016-5107(97)70205-0).
302. **Current treatment of malaria.** Bourée P. *Antibiotiques*. 2003;5(4):198-207.
303. **How common—and how serious— is clostridium difficile colitis after geriatric hip fracture? Findings from the NSQIP dataset.** Bovonratwet P, Bohl DD, Russo GS, Ondeck NT, Nam D, Della Valle CJ, et al. *Clinical Orthopaedics and Related Research*. 2018;476(3):453-62.
304. **Antisynthetase syndrome with refractory lung involvement and myositis successfully treated with double filtration plasmapheresis.** Bozkirli DE, Kozanoglu I, Bozkirli E, Yucel E. *Journal of clinical apheresis*. 2013;28(6):422-5. <http://dx.doi.org/10.1002/jca.21285>. Epub 2013 Jul 3.
305. **Malaria prophylaxis: Guidelines for travellers from Britain.** Bradley DJ, Warhurst DC. *British Medical Journal*. 1995;310(6981):709-14.
306. **A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A 2, in the treatment of rheumatoid arthritis.** Bradley JD, Dmitrienko AA, Kivitz



- AJ, Gluck OS, Weaver AL, Wiesenhutter C, et al. *Journal of Rheumatology*. 2005;32(3):417-23.
307. **The effectiveness of intermittent plantar venous compression in prevention of deep venous thrombosis after total hip arthroplasty.** Bradley JG, Krugener GH, Jager HJ. *The Journal of arthroplasty*. 1993;8(1):57-61. [http://dx.doi.org/10.1016/s0883-5403\(06\)80108-7](http://dx.doi.org/10.1016/s0883-5403(06)80108-7).
308. **The effect of training level on complications after free flap surgery of the head and neck.** Brady JS, Crippen MM, Filimonov A, Nadpara NV, Eloy JA, Baredes S, et al. *American journal of otolaryngology*. 2017;38(5):560-4. <http://dx.doi.org/10.1016/j.amjoto.2017.06.001>. Epub 2017 Jun 2.
309. **Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial.** Brahe CH, Østergaard M, Johansen JS, Defranoux N, Wang X, Bolce R, et al. *Scandinavian Journal of Rheumatology*. 2019;48(1):9-16.
310. **Evidence and experience: what is the balance in surgeons' training?** Brandt CT. *Acta chirurgica brasileira*. 2007;22(4):239-42. <http://dx.doi.org/10.1590/s0102-86502007000400002>.
311. **Pulsed Doppler sonography for the guidance of vein puncture: a prospective study.** Branger B, Dauzat M, Zabadani B, Vecina F, Lefranc JY. *Artificial organs*. 1995;19(9):933-8. <http://dx.doi.org/10.1111/j.1525-1594.1995.tb02454.x>.
312. **[Continuous guidance for venous punctures using a new pulsed Doppler probe: efficiency, safety].** Branger B, Zabadani B, Vecina F, Juan JM, Dauzat M. *Nephrologie*. 1994;15(2):137-40.
313. **Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.** Braun J, McHugh N, Singh A, Wajdula JS, Sato R. *Rheumatology*. 2007;46(6):999-1004.
314. **An update on methotrexate.** Braun J, Rau R. *Current Opinion in Rheumatology*. 2009;21(3):216-23.
315. **Update on management of connective tissue panniculitides.** Braunstein I, Werth VP. *Dermatologic Therapy*. 2012;25(2):173-82.
316. **Chloroquine and hydroxychloroquine for the treatment of COVID-19: A living systematic review protocol.** Bravo Jeria R, Rojas Reyes MX, Franco JV, Acuna MP, Torres Lopez LA, Rada Gr. medRxiv. 2020:2020.04.03.20052530.
317. **Clinical strategies to aim an adequate safety profile for patients and effective training for surgical residents: The laparoscopic cholecystectomy model.** Bresadola V, Pravisani R, Pighin M, Seriau L, Cherchi V, Giuseppe S, et al. *Annals of medicine and surgery* (2012). 2016;11:58-61. <http://dx.doi.org/10.1016/j.amsu.2016.09.006>. eCollection 2016 Nov.
318. **Therapy of noninfectious granulomatous skin diseases with fumaric acid esters.** Breuer K, Gutzmer R, Völker B, Kapp A, Werfel T. *British Journal of Dermatology*. 2005;152(6):1290-5.
319. **Rabies vaccination: Protecting vulnerable travelers.** Briggs DJ. *Infections in Medicine*. 2002;19(12):561-5.
320. **Long-term course of chloroquine retinopathy after cessation of medication.** Brinkley JR, Jr., Dubois EL, Ryan SJ. *American journal of ophthalmology*. 1979;88(1):1-11. [http://dx.doi.org/10.1016/0002-9394\(79\)90743-8](http://dx.doi.org/10.1016/0002-9394(79)90743-8).
321. **Chloroquine psychosis.** Brookes DB. *British medical journal*. 1966;1(5493):983.
322. **Problems of antiarthritic therapy in the elderly.** Brooks PM, Kean WF, Kassam Y, Buchanan WW. *Journal of*

the American Geriatrics Society. 1984;32(3):229-34. <http://dx.doi.org/10.1111/j.1532-5415.1984.tb02007.x>.

323. **Vascular complications and surgical interventions after world's largest Q fever outbreak.** Broos PPHL, Hagenars JCJP, Kampschreur LM, Wever PC, Bleeker-Rovers CP, Koning OHJ, et al. *Journal of Vascular Surgery*. 2015;62(5):1273-80.

324. **DMARD non-use in low-income, elderly rheumatoid arthritis patients: Results of 86 structured interviews.** Brown EM, Garneau KL, Tsao H, Solomon DH. *Arthritis Research and Therapy*. 2014;16(1).

325. **A survey-based cross-sectional study of doctors' expectations and experiences of non-technical skills for Out of Hours work.** Brown M, Shaw D, Sharples S, Jeune IL, Blakey J. *BMJ Open*. 2015;5(2):e006102. <http://dx.doi.org/10.1136/bmjopen-2014-006102>.

326. **Recent developments in the discovery of melanin-concentrating hormone antagonists: Novel antiobesity agents.** Browning A. *Expert Opinion on Therapeutic Patents*. 2004;14(3):313-25.

327. **Hydroxychloroquine and chloroquine retinopathy: Screening for drug toxicity.** Browning DJ. *American Journal of Ophthalmology*. 2002;133(5):649-56.

328. **Impact of the revised american academy of ophthalmology guidelines regarding hydroxychloroquine screening on actual practice.** Browning DJ. *American Journal of Ophthalmology*. 2013;155(3):418-28.

329. **Scotoma analysis of 10–2 visual field testing with a red target in screening for hydroxychloroquine retinopathy.** Browning DJ, Lee C. *Clinical Ophthalmology*. 2015;9:1499-509.

330. **Therapy for recurrent acute pericarditis: A rheumatological solution?** Brucato A, Brambilla G, Adler Y, Spodick DH, Canesi B. *Clinical and Experimental Rheumatology*. 2006;24(1):45-50.

331. **Hyperglycemia, Hydroxychloroquine, and the COVID-19 Epidemic.** Brufsky A. *Journal of Medical Virology*. 2020.

332. **[Follow-up and immunologic findings in drug-induced myasthenia].** Bruggemann W, Herath H, Ferbert A. *Medizinische Klinik (Munich, Germany)*. 1996;91(5):268-71.

333. **Prospective evaluation of 100 robotic-assisted unilateral adrenalectomies.** Brunaud L, Ayav A, Zarnegar R, Rouers A, Klein M, Boissel P, et al. *Surgery*. 2008;144(6):995-1001; discussion <http://dx.doi.org/10.1016/j.surg.2008.08.032>.

334. **Remitting Seronegative Symmetrical Synovitis With Pitting Edema Syndrome in a Rural Tertiary Care Practice: A Retrospective Analysis.** Bucaloiu ID, Olenginski TP, Harrington TM. *Mayo Clinic Proceedings*. 2007;82(12):1510-5.

335. **[Stress at work and well-being in junior residents].** Buddeberg-Fischer B, Klaghofer R, Buddeberg C. *Zeitschrift für Psychosomatische Medizin und Psychotherapie*. 2005;51(2):163-78. <http://dx.doi.org/10.13109/zptm.2005.51.2.163>.

336. **Factors associated with hypertension in Nigerian civil servants.** Bunker CH, Ukoli FA, Nwankwo MU, Omene JA, Currier GW, Holifield-Kennedy L, et al. *Preventive medicine*. 1992;21(6):710-22. [http://dx.doi.org/10.1016/0091-7435\(92\)90078-v](http://dx.doi.org/10.1016/0091-7435(92)90078-v).

337. **[Recommendations for prevention of malaria in patients with epilepsy].** Burchard GD, Bauer J. *Der Nervenarzt*. 2001;72(6):460-5. <http://dx.doi.org/10.1007/s001150050781>.

338. **Treatment of tropical diseases in travelers.** Burchard GD, Sudeck H. *Internist*. 2003;44(5):633-42.

339. **The Influence of Preoperative Radiographic Patellofemoral Degenerative Changes and Malalignment on Patellofemoral-Specific Outcome Scores Following Fixed-Bearing Medial Unicompartmental Knee Arthroplasty.** Burger JA, Kleeblad LJ, Laas N, Pearle AD. *J Bone Joint Surg Am.* 2019;101(18):1662-9. <http://dx.doi.org/10.2106/JBJS.18.01385>.
340. **Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies.** Burgos-Vargas R, Cardiel M, Xibillé D, Pacheco-Tena C, Pascual-Ramos V, Abud-Mendoza C, et al. *Reumatologia Clinica.* 2019;15(1):43-53.
341. **Mefloquine [28].** Burke BM. *Lancet.* 1993;341(8860):1605-6.
342. **Clinical practice with anti-dementia drugs: A consensus statement from British Association for Psychopharmacology.** Burns A, O'Brien J. *Journal of Psychopharmacology.* 2006;20(6):732-55.
343. **Evaluation of warfarin dosing by pharmacists for elderly medical in-patients.** Burns N. *Pharmacy world & science : PWS.* 2004;26(4):232-7. <http://dx.doi.org/10.1023/b:phar.0000035885.00408.9e>.
344. **Cardiac sarcoidosis: Diagnosis and management.** Bussinguer M, Danielian A, Sharma OP. *Current Treatment Options in Cardiovascular Medicine.* 2012;14(6):652-64.
345. **Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: Retrospective analysis of 27 cases.** Bussone G, Ribeiro E, Dechartres A, Viillard JF, Bonnotte B, Fain O, et al. *American Journal of Hematology.* 2009;84(3):153-7.
346. **The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial.** Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. *Annals of Internal Medicine.* 2005;142(12):953-62+I-22.
347. **Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice.** Bykerk VP, Östör AJK, Alvaro-Gracia J, Pavelka K, Román Ivorra JA, Nurmohamed MT, et al. *Clinical Rheumatology.* 2019;38(9):2411-21.
348. **Recalcitrant symptomatic vulvar lichen planus: Response to topical tacrolimus.** Byrd JA, Davis MDP, Rogers IRS. *Archives of Dermatology.* 2004;140(6):715-20.
349. **Clinical correlates, outcomes, and predictors of inflammatory ocular disease associated with rheumatoid arthritis in the biologic era.** Caimmi C, Crowson CS, Smith WM, Matteson EL, Makol A. *Journal of Rheumatology.* 2018;45(5):595-603.
350. **Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice.** Calderón-Goercke M, Loricera J, Aldasoro V, Castañeda S, Villa I, Humbría A, et al. *Seminars in Arthritis and Rheumatism.* 2019;49(1):126-35.
351. **Chronic cutaneous lupus erythematosus. Clinical, laboratory, therapeutic, and prognostic examination of 62 patients.** Callen JP. *Arch Dermatol.* 1982;118(6):412-6. <http://dx.doi.org/10.1001/archderm.118.6.412>.
352. **Management of skin disease in patients with lupus erythematosus.** Callen JP. *Best Practice and Research: Clinical Rheumatology.* 2002;16(2):245-64.
353. **Management of 'refractory' skin disease in patients with lupus erythematosus.** Callen JP. *Best Practice and Research: Clinical Rheumatology.* 2005;19(5):767-84.

354. **Cutaneous lupus erythematosus: A personal approach to management.** Callen JP. *Australasian Journal of Dermatology*. 2006;47(1):13-27.
355. **Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients.** Calvo-Alén J, Toloza SMA, Fernández M, Bastian HM, Fessler BJ, Roseman JM, et al. *Arthritis and Rheumatism*. 2005;52(7):2060-8.
356. **Ziprasidone and the corrected QT interval: A comprehensive summary of clinical data.** Camm AJ, Karayal ON, Meltzer H, Kolluri S, O'Gorman C, Miceli J, et al. *CNS Drugs*. 2012;26(4):351-65.
357. **Factors influencing the early outcome of major lower limb amputation for vascular disease.** Campbell WB, Marriott S, Eve R, Mapson E, Sexton S, Thompson JF. *Annals of the Royal College of Surgeons of England*. 2001;83(5):309-14.
358. **Severe and complicated malaria.** Canfield CJ, Chongsuphajaisiddhi T, Danis M, Gillis CHM, Krogstad DJ, Molyneux ME, et al. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1990;84:1-65.
359. **Treatment of generalized granuloma annulare with hydroxychloroquine.** Cannistraci C, Lesnoni La Parola I, Falchi M, Picardo M. *Dermatology*. 2005;211(2):167-8. <http://dx.doi.org/10.1159/000086452>.
360. **Prospective 5-year followup of recombinant interferon- $\gamma$  in rheumatoid arthritis.** Cannon GW, Emkey RD, Denes A, Cohen SA, Saway PA, Wolfe F, et al. *Journal of Rheumatology*. 1993;20(11):1867-73.
361. **Adverse events with disease modifying antirheumatic drugs (DMARD): A cohort study of leflunomide compared with other DMARD.** Cannon GW, Holden WL, Juhaeri J, Dai W, Scarazzini L, Stang P. *Journal of Rheumatology*. 2004;31(10):1906-11.
362. **Amyopathic dermatomyositis or dermatomyositis-like skin disease: Retrospective review of 16 cases with amyopathic dermatomyositis.** Cao H, Parikh TN, Zheng J. *Clinical Rheumatology*. 2009;28(8):979-84.
363. **Rituximab in the Treatment of Refractory Noninfectious Scleritis.** Cao JH, Oray M, Cocho L, Foster CS. *American Journal of Ophthalmology*. 2016;164:22-8.
364. **Implementing a 48 h EWTD-compliant rota for junior doctors in the UK does not compromise patients' safety: assessor-blind pilot comparison.** Cappuccio FP, Bakewell A, Taggart FM, Ward G, Ji C, Sullivan JP, et al. *Qjm*. 2009;102(4):271-82. <http://dx.doi.org/10.1093/qjmed/hcp004>. Epub 2009 Jan 27.
365. **Malaria in the Colombian regions of Uraba and Bajo Cauca, Province of Antioquia: An overview to interpret the antimalarial therapeutic failure.** Carmona-Fonseca J. *Iatreia*. 2004;17(1):34-53.
366. **A case of urinary incontinence by hydroxychloroquine in a geriatric patient.** Carnovale C, Perrone V, Borsadoli C, Mambrini A, Speziali A, Froidi G, et al. *J Clin Pharm Ther*. 2013;38(2):169-71. <http://dx.doi.org/10.1111/jcpt.12024>. Epub 2012 Nov 29.
367. **Evaluation of a theoretically based AIDS/STD peer education program on postponing sexual intercourse and on condom use among adolescents attending high school.** Caron F, Godin G, Otis J, Lambert LD. *Health education research*. 2004;19(2):185-97. <http://dx.doi.org/10.1093/her/cyg017>.
368. **Relationships between emotional disorders, personality dimensions, and binge eating disorder in French obese adolescents.** Carriere C, Michel G, Feart C, Pellay H, Onorato O, Barat P, et al. *Archives de pediatrie : organe officiel de la Societe francaise de pediatrie*. 2019;26(3):138-44. <http://dx.doi.org/10.1016/j.arcped.2019.02.008>. Epub 2019 Mar 18.

369. **Attributional theory applied to a baccalaureate nursing community experience.** Carroll MC, Carter SV, Hayes ER. *The Journal of nursing education*. 1993;32(4):163-9.
370. **Evaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic Lupus erythematosus.** Cartella S, Cavazzana I, Ceribelli A, Inverardi F, Tincani A, Franceschini F. *Autoimmunity*. 2013;46(6):363-8.
371. **Control of rheumatoid arthritis with conventional disease-modifying antirheumatic drugs in a tertiary hospital in central South Africa.** Carter RMN, Jansen Van Rensburg BJ, Joubert G. *South African Medical Journal*. 2020;110(1):27-31.
372. **[Treatment of recurrent oral aphthae. A double-blind clinical trial with Ercoquin].** Caspersen I. *Tandlaegebladet*. 1970;74(5):498-505.
373. **Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?** Cassone G, Sebastiani M, Vacchi C, Cerri S, Salvarani C, Manfredi A. *Respiratory Medicine Case Reports*. 2020;30.
374. **Malaria prophylaxis: A comprehensive review.** Castelli F, Odolini S, Autino B, Foca E, Russo R. *Pharmaceuticals*. 2010;3(10):3212-39.
375. **Isoniazid toxicity and TB development during biological therapy of patients with psoriasis in Colombia.** Cataño J, Morales M. *Journal of Dermatological Treatment*. 2016;27(5):414-7.
376. **Late-onset systemic lupus erythematosus in Latin Americans: A distinct subgroup?** Catoggio LJ, Soriano ER, Imamura PM, Wojdyla D, Jacobelli S, Massardo L, et al. *Lupus*. 2015;24(8):788-95.
377. **[Early electroretinographic changes in elderly RA patients treated with hydroxychloroquine].** Cavagna L, Rossi P, Bogliolo L, Antoniazzi E, Gelmi C, Caporali R, et al. *Reumatismo*. 2002;54(3):226-31. <http://dx.doi.org/10.4081/reumatismo.2002.226>.
378. **Chemoprophylaxis use and the risk of malaria in travelers to Nepal.** Cave W, Pandey P, Osrin D, Shlim DR. *Journal of Travel Medicine*. 2003;10(2):100-5.
379. **Stepwise Training in Laparoscopic Surgery for Complex Ileocolonic Crohn's Disease: Analysis of 127 Training Episodes.** Celentano V, Flashman KG. *Journal of surgical education*. 2019;76(5):1364-9. <http://dx.doi.org/10.1016/j.jsurg.2019.03.009>. Epub 2019 Mar 28.
380. **Annals On Call - COVID-19: Is Chloroquine the Answer?** Centor RM, Kim AH, Sparks JA. *Annals of Internal Medicine*. 2020.
381. **Pet studies of TSPO in schizophrenia-understanding initial findings.** Cervenka S. *Neuropsychopharmacology*. 2017;43:S102-S3.
382. **Management of peritonsillar abscess (quinsy) at Harare Central Hospital.** Cg TB. *The Central African journal of medicine*. 1990;36(8):187-90.
383. **The role of Abrams percutaneous pleural biopsy in the investigation of exudative pleural effusions.** Chakrabarti B, Ryland I, Sheard J, Warburton CJ, Earis JE. *Chest*. 2006;129(6):1549-55. <http://dx.doi.org/10.1378/chest.129.6.1549>.
384. **Why do patients with systemic lupus erythematosus take or fail to take their prescribed medications? A qualitative study in a UK cohort.** Chambers SA, Raine R, Rahman A, Isenberg D. *Rheumatology*. 2009;48(3):266-71.

385. **FARES method for reduction without medication of first episode of traumatic anterior shoulder dislocation.** Chamseddine AH, Haidar IM, El Hajj OM, Zein HK, Bazzal AM, Alasiry AA, et al. *Int Orthop*. 2019;43(5):1165-70. <http://dx.doi.org/10.1007/s00264-018-4131-4>. Epub 2018 Aug 29.
386. **Risk of tuberculosis comparison in new users of antitumour necrosis factor- $\alpha$  and with existing disease-modifying antirheumatic drug therapy.** Chan MJ, Wen YH, Huang YB, Chuang HY, Tain YL, Lily Wang YC, et al. *Journal of Clinical Pharmacy and Therapeutics*. 2018;43(2):256-64.
387. **Incidence of infection other than tuberculosis in patients with autoimmune rheumatic diseases treated with bDMARDs: a real-time clinical experience from India.** Chandrashekar S, Shobha V, Rao V, Desai A, Jois R, Dharmanand BG, et al. *Rheumatology International*. 2019;39(3):497-507.
388. **Dapsone in rheumatoid arthritis.** Chang DJ, Lamothe M, Stevens RM, Sigal LH. *Seminars in Arthritis and Rheumatism*. 1996;25(6):390-403.
389. **The effect of physician experience on costs and clinical outcomes of laparoscopic-assisted vaginal hysterectomy: a multivariate analysis.** Chang WC, Li TC, Lin CC. *The Journal of the American Association of Gynecologic Laparoscopists*. 2003;10(3):356-9. [http://dx.doi.org/10.1016/s1074-3804\(05\)60261-7](http://dx.doi.org/10.1016/s1074-3804(05)60261-7).
390. **A novel method for screening the multifocal electroretinogram in patients using hydroxychloroquine.** Chang WH, Katz BJ, Warner JE, Vitale AT, Creel D, Digre KB. *Retina*. 2008;28(10):1478-86. <http://dx.doi.org/10.1097/IAE.0b013e318181445b>.
391. **Racial disparities in surgical outcomes: Does the level of resident surgeon play a role?** Changoor NR, Ortega G, Ekladios M, Zogg CK, Cornwell EE, 3rd, Haider AH. *Surgery*. 2015;158(2):547-55. <http://dx.doi.org/10.1016/j.surg.2015.03.046>. Epub 2015 May 21.
392. **Benchmarking rectal cancer care: institutional compliance with a longitudinal checklist.** Chapman WC, Jr., Choi P, Hawkins AT, Hunt SR, Silviera ML, Wise PE, et al. *The Journal of surgical research*. 2018;225:142-7. <http://dx.doi.org/10.1016/j.jss.2018.01.006>. Epub 2018 Feb 21.
393. **Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma.** Charous BL, Halpern EF, Steven GC. *The Journal of allergy and clinical immunology*. 1998;102(2):198-203. [http://dx.doi.org/10.1016/s0091-6749\(98\)70086-7](http://dx.doi.org/10.1016/s0091-6749(98)70086-7).
394. **The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.** Chasset F, Arnaud L, Costedoat-Chalumeau N, Zahr N, Bessis D, Frances C. *J Am Acad Dermatol*. 2016;74(4):693-9.e3. <http://dx.doi.org/10.1016/j.jaad.2015.09.064>. Epub 2016 Feb 3.
395. **Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study.** Chasset F, Arnaud L, Jachiet M, Monfort JB, Bouaziz JD, Cordoliani F, et al. *J Am Acad Dermatol*. 2018;78(1):107-14.e1. <http://dx.doi.org/10.1016/j.jaad.2017.08.045>. Epub 2017 Oct 20.
396. **Resident and Fellow Participation in Breast Surgery: An American College of Surgeons NSQIP Clinical Outcomes Analysis.** Chatterjee A, Pyfer B, Chen L, Czerniecki B, Tchou J, Fisher C. *Journal of the American College of Surgeons*. 2015;221(5):988-94. <http://dx.doi.org/10.1016/j.jamcollsurg.2015.08.008>. Epub 2015 Aug 20.
397. **Assessment of safety of the major antimalarial drugs.** Chattopadhyay R, Mahajan B, Kumar S. *Expert Opinion on Drug Safety*. 2007;6(5):505-21.
398. **Improving stress echocardiography accuracy for detecting left circumflex artery stenosis: a new echocardiographic sign?** Chauvel C, Abergel E, Renault L, Chatellier G, Cohen I, Attane C, et al. *Arch Cardiovasc Dis*.

2012;105(4):196-202. <http://dx.doi.org/10.1016/j.acvd.2012.02.008>. Epub 2012 Apr 17.

399. **Risk factors for mortality from imported falciparum malaria in the United Kingdom over 20 years: An observational study.** Checkley AM, Smith A, Smith V, Blaze M, Bradley D, Chiodini PL, et al. *BMJ (Online)*. 2012;344(7854).
400. **Variations in consenting practice for laparoscopic cholecystectomy.** Chen AM, Leff DR, Simpson J, Chadwick SJ, McDonald PJ. *Annals of the Royal College of Surgeons of England*. 2006;88(5):482-5. <http://dx.doi.org/10.1308/003588406X114857>.
401. **Autoimmune hemolytic anemia in hospitalized patients: 450 patients and their red blood cell transfusions.** Chen C, Wang L, Han B, Qin L, Ying B. *Medicine (United States)*. 2020;99(2).
402. **Determinants of preference for home death among terminally ill patients with cancer in Taiwan: a cross-sectional survey study.** Chen CH, Lin YC, Liu LN, Tang ST. *J Nurs Res*. 2014;22(1):37-44. <http://dx.doi.org/10.1097/jnr.000000000000016>.
403. **Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.** Chen CY, Wang FL, Lin CC. *Clinical toxicology (Philadelphia, Pa)*. 2006;44(2):173-5. <http://dx.doi.org/10.1080/15563650500514558>.
404. **Herpes zoster in patients with systemic lupus erythematosus: Clinical features, complications and risk factors.** Chen D, Li H, Xie J, Zhan Z, Liang L, Yang X. *Experimental and Therapeutic Medicine*. 2017;14(6):6222-8.
405. **Incidence and predictive factors for malignancies with dermatomyositis: A cohort from southern China.** Chen D, Yuan S, Wu X, Li H, Qiu Q, Zhan Z, et al. *Clinical and Experimental Rheumatology*. 2014;32(5):615-21.
406. **Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis.** Chen DY, Chou SJ, Hsieh TY, Chen YH, Chen HH, Hsieh CW, et al. *Journal of the Formosan Medical Association*. 2009;108(4):310-9.
407. **Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNF $\alpha$  inhibitors: The utility of IFN $\gamma$  assay.** Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL. *Annals of the Rheumatic Diseases*. 2012;71(2):231-7.
408. **Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the "flying saucer" sign).** Chen E, Brown DM, Benz MS, Fish RH, Wong TP, Kim RY, et al. *Journal*. 2010;4(Issue):1151-8.
409. **Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: A comparative and prospective study.** Chen F, Lu X, Shu X, Peng Q, Tian X, Wang G. *Internal Medicine Journal*. 2015;45(6):641-7.
410. **An illustrated clinical update on Necrobiosis lipidica.** Chen G, Lee S. *Hong Kong Journal of Dermatology and Venereology*. 2014;22(4):175-82.
411. **Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease.** Chen GL, Carpenter PA, Broady R, Gregory TK, Johnston LJ, Storer BE, et al. *Biology of Blood and Marrow Transplantation*. 2018;24(2):373-80.
412. **Time delay in seeking treatment for first-episode schizophrenia: a retrospective study.** Chen H, Wang T, Wang D, Gao X. *Early intervention in psychiatry*. 2019:e12879. <http://dx.doi.org/10.1111/eip.12879>.

413. **Indirect effect of parental depression on school victimization through adolescent depression.** Chen JK, Wu C, Chang CW, Wei HS. *J Affect Disord.* 2020;263:396-404. <http://dx.doi.org/10.1016/j.jad.2019.11.126>. Epub 2019 Nov 30.
414. **Controversies and misconceptions in malaria chemoprophylaxis for travelers.** Chen LH, Wilson ME, Schlagenhauf P. *Journal of the American Medical Association.* 2007;297(20):2251-63.
415. **A preliminary study of the Six-Item Screener in detecting cognitive impairment.** Chen MR, Guo QH, Cao XY, Hong Z, Liu XH. *Neuroscience bulletin.* 2010;26(4):317-21. <http://dx.doi.org/10.1007/s12264-010-0106-1>.
416. **DNA damage-inducible transcript 4 (DDIT4) mediates methamphetamine-induced autophagy and apoptosis through mTOR signaling pathway in cardiomyocytes.** Chen R, Wang B, Chen L, Cai D, Li B, Chen C, et al. *Toxicology and Applied Pharmacology.* 2016;295:1-11.
417. **Heart failure risk in systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients.** Chen SK, Barbhuiya M, Fischer MA, Guan H, Yoshida K, Feldman CH, et al. *Seminars in Arthritis and Rheumatism.* 2019;49(3):389-95.
418. **A 10-year follow-up study on suicidal mortality after 1999 Taiwan earthquake.** Chen SL, Lee CS, Yen AM, Chen HH, Chan CC, Chiu SY, et al. *Journal of psychiatric research.* 2016;79:42-9. <http://dx.doi.org/10.1016/j.jpsychires.2016.04.007>. Epub 2016 Apr 25.
419. **Hydroxychloroquine was associated with reduced risk of new-onset diabetes mellitus in patients with Sjogren syndrome.** Chen TH, Lai TY, Wang YH, Chiou JY, Hung YM, Wei JC. *Qjm.* 2019;112(10):757-62. <http://dx.doi.org/10.1093/qjmed/hcz112>.
420. **Gender differences in the predictors of physical activity among assisted living residents.** Chen YM, Li YP, Yen ML. *Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing.* 2015;47(3):211-8. <http://dx.doi.org/10.1111/jnu.12132>. Epub 2015 Mar 18.
421. **[The knowledge and attitude of cancer prevention among junior high school teachers].** Cheng CH, Chou P. *Zhonghua yi xue za zhi = Chinese medical journal; Free China ed.* 1994;53(6):1-8.
422. **[Investigation of the cognition and behavior on drug safety in Beijing middle school students].** Cheng YC, Pan YP, Zhang Y, Pan YT, Ding CY, Cao Y, et al. *Beijing da xue xue bao Yi xue ban = Journal of Peking University Health sciences.* 2017;49(6):1038-43.
423. **[Influencing factors of anxiety and depression in asthmatics].** Cheng Z, Li R, Dai L, Liu Y, Wang X, Jiang T, et al. *Zhonghua yi xue za zhi.* 2014;94(4):280-3.
424. **Development of imported malaria since 1984 in the west of France. A multicentric investigation.** Chennebault JM, Chabasse D, Achard J, Breux JP, Brillet P, Kanoun F, et al. *Medecine et Maladies Infectieuses.* 1992;22(6):670-3.
425. **Etiology of chronic urticaria: The Ecuadorian experience.** Cherrez Ojeda I, Vanegas E, Felix M, Mata V, Cherrez S, Simancas-Racines D, et al. *World Allergy Organization Journal.* 2018;11(1).
426. **Chart review of acute myocardial infarction at a district hospital in KwaZulu-Natal, South Africa.** Chetty R, Ross A. *African journal of primary health care & family medicine.* 2016;8(1):e1-5. <http://dx.doi.org/10.4102/phcfm.v8i1.1012>.
427. **An unusual cutaneous manifestation with mefloquine.** Chew HC, Ponampalam R. *American Journal of Emergency Medicine.* 2006;24(5):634-6.



428. **Retinal Findings on OCT in Systemic Conditions.** Chhablani PP, Ambiya V, Nair AG, Bondalapati S, Chhablani J. *Seminars in Ophthalmology*. 2018;33(4):525-46.
429. **Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus.** Chi Chiu M, Chak Sing L, Wong RWS. *Journal of Rheumatology*. 2001;28(4):766-71.
430. **Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: A pilot safety and effectiveness analysis in a small patient cohort.** Chi KH, Ko HL, Yang KL, Lee CY, Chi MS, Kao SJ. *Oncotarget*. 2015;6(18):16735-45.
431. **Double autophagy modulators reduce 2-deoxyglucose uptake in sarcoma patients.** Chi MS, Lee CY, Huang SC, Yang KL, Ko HL, Chen YK, et al. *Oncotarget*. 2015;6(30):29808-17.
432. **Seasonal variations of systemic lupus erythematosus flares in southern France.** Chiche L, Jourde N, Ulmann C, Mancini J, Darque A, Bardin N, et al. *European Journal of Internal Medicine*. 2012;23(3):250-4.
433. **Prevalence and risk factors for chloroquine maculopathy and role of plasma chloroquine and desethylchloroquine concentrations in predicting chloroquine maculopathy.** Chiowchanwisawakit P, Nilganuwong S, Srinonprasert V, Boonprasert R, Chandranipapongse W, Chatsiricharoenkul S, et al. *International journal of rheumatic diseases*. 2013;16(1):47-55. <http://dx.doi.org/10.1111/1756-185X.12029>. Epub 2013 Jan 18.
434. **[At the Savar center, primary health care (PHC) evolves with the health conditions].** Chirac P. *Developpement et sante : revue de perfectionnement medical et sanitaire en pays tropical*. 1989(82):28-30.
435. **Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections.** Chiu YM, Lai MS, Arnold Chan K. *PLoS ONE*. 2018;13(4).
436. **Management of systemic lupus erythematosus in the coming decade: Potentials and challenges.** Chng HH. *APLAR Journal of Rheumatology*. 2006;9(4):419-24.
437. **Korean Red Ginseng exhibits no significant adverse effect on disease activity in patients with rheumatoid arthritis: a randomized, double-blind, crossover study.** Cho SK, Kim D, Yoo D, Jang EJ, Jun JB, Sung YK. *Journal of Ginseng Research*. 2018;42(2):144-8.
438. **Visualizing cellular stress: A hypothesis-driven confocal laboratory exercise to identify compounds that activate heat shock factor binding at Hsp70 loci.** Choi A, Wang M, Hrizo S, Buckley MS. *Biochemistry and molecular biology education : a bimonthly publication of the International Union of Biochemistry and Molecular Biology*. 2018;46(5):445-52. <http://dx.doi.org/10.1002/bmb.21163>. Epub 2018 Sep 11.
439. **Mortality, disability, and healthcare expenditure of patients with seropositive rheumatoid arthritis in Korea: A nationwide population-based study.** Choi IA, Lee JS, Song YW, Lee EY. *PLoS ONE*. 2019;14(1).
440. **Inhibitory properties of nerve-specific human glutamate dehydrogenase isozyme by chloroquine.** Choi MM, Kim EA, Soo YC, Tae UK, Cho SW, Yang SJ. *Journal of Biochemistry and Molecular Biology*. 2007;40(6):1077-82.
441. **Dyslipidaemia in patients with lupus nephritis.** Chong YB, Yap DY, Tang CS, Chan TM. *Nephrology*. 2011;16(5):511-7.
442. **Comparable efficacy of standardized Ayurveda formulation and hydroxychloroquine sulfate (HCQS) in the treatment of rheumatoid arthritis (RA): a randomized investigator-blind controlled study.** Chopra A, Saluja M, Tillu G, Venugopalan A, Narsimulu G, Handa R, et al. *Clin Rheumatol*. 2012;31(2):259-69. <http://dx.doi.org/10.1007/s10067-011-1809-z>. Epub 2011 Jul 20.
443. **Psychosocial determinants of physicians' acceptance of recommendations by antibiotic computerised**

**decision support systems: A mixed methods study.** Chow A, Lye DC, Arah OA. International journal of antimicrobial agents. 2015;45(3):295-304. <http://dx.doi.org/10.1016/j.ijantimicag.2014.10.009>. Epub 2014 Nov 13.

444. **High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: Careful selection of patients gives an excellent outcome.** Chow S, Galvis V, Pillai M, Leach R, Keene E, Spencer-Shaw A, et al. Journal for ImmunoTherapy of Cancer. 2016;4(1).

445. **Smokeless tobacco usage: a growing and menacing addiction among Hoosier children and young adults.** Christen AG. Indiana medicine : the journal of the Indiana State Medical Association. 1996;89(2):176-80.

446. **Preparing children for travel to tropical and developing regions.** Christenson JC. Pediatric Annals. 2004;33(10):676-84.

447. **[Complications after third molar extractions: retrospective analysis of 1,213 teeth].** Christiaens I, Reychler H. Revue de stomatologie et de chirurgie maxillo-faciale. 2002;103(5):269-74.

448. **Extreme BMI predicts higher asthma prevalence and is associated with lung function impairment in school-aged children.** Chu YT, Chen WY, Wang TN, Tseng HI, Wu JR, Ko YC. Pediatr Pulmonol. 2009;44(5):472-9. <http://dx.doi.org/10.1002/ppul.21023>.

449. **Increased coronary-artery atherosclerosis in rheumatoid arthritis: Relationship to disease duration and cardiovascular risk factors.** Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T, et al. Arthritis and Rheumatism. 2005;52(10):3045-53.

450. **Clinical experience of 17 cases of imported malaria at a Taiwan university hospital, 1999-2005.** Chung HC, Wang JT, Sun HY, Wang JL, Lo YC, Sheng WH, et al. Journal of Microbiology, Immunology and Infection. 2007;40(3):209-15.

451. **A pilot trial of rituximab in the treatment of patients with dermatomyositis.** Chung L, Genovese MC, Fiorentino DF. Archives of Dermatology. 2007;143(6):763-7.

452. **Sulfasalazine-related hypersensitivity reactions in patients with rheumatic diseases.** Cildag S, Senturk T. Journal of Clinical Rheumatology. 2017;23(2):77-9.

453. **Impact of the implementation of the AAN epilepsy quality measures on the medical records in a university hospital.** Cisneros-Franco JM, Diaz-Torres MA, Rodriguez-Castaneda JB, Martinez-Silva A, Gutierrez-Herrera MA, San-Juan D. BMC neurology. 2013;13:112. <http://dx.doi.org/10.1186/1471-2377-13-112>.

454. **Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine.** Clarke JB, Neftel K, Kitteringham NR, Park BK. International archives of allergy and applied immunology. 1991;95(4):369-75. <http://dx.doi.org/10.1159/000235475>.

455. **Mood disorders in the general hospital setting.** Cleare AJ. Psychiatry. 2006;5(4):134-7.

456. **Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine.** Clegg DO, Dietz F, Duffy J, Willkens RF, Hurd E, Germain BF, et al. The Journal of rheumatology. 1997;24(10):1896-902.

457. **Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis.** Cleland LG, Caughey GE, James MJ, Proudman SM. The Journal of rheumatology. 2006;33(10):1973-9.

458. **Hypokalaemia related to acute chloroquine ingestion.** Clemessy JL, Favier C, Borron SW, Hantson PE, Vicaut E, Baud FJ. Lancet. 1995;346(8979):877-80.

459. **Recording of patients with colorectal cancer on a database: results and advantages.** Clemmesen T, Sprechler M. *The European journal of surgery = Acta chirurgica.* 1994;160(3):175-8.
460. **Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.** Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, et al. *Arthritis and Rheumatism.* 2008;58(5):1299-309.
461. **Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.** Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. *Arthritis and Rheumatism.* 2006;54(9):2793-806.
462. **Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: Integrated analysis of data from the global clinical trials.** Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, et al. *Annals of the Rheumatic Diseases.* 2017;76(7):1253-62.
463. **Transoesophageal echocardiography current practice in France: A multicentre study.** Coisne A, Dreyfus J, Bohbot Y, Pelletier V, Collette E, Cescau A, et al. *Arch Cardiovasc Dis.* 2018;111(12):730-8. <http://dx.doi.org/10.1016/j.acvd.2018.03.014>. Epub 2018 Jul 4.
464. **The efficacy and safety of simvastatin in patients with rheumatoid arthritis.** Cojocar L, Rusali A, Craiu E, Şuța M. *Archives of the Balkan Medical Union.* 2010;45(1):49-53.
465. **When should we treat pulmonary sarcoidosis, and how?** Coker RK. *Minerva Pneumologica.* 2008;47(1):39-48.
466. **Autoantibodies to estrogen receptor  $\alpha$  interfere with T lymphocyte homeostasis and are associated with disease activity in systemic lupus erythematosus.** Colasanti T, Maselli A, Conti F, Sanchez M, Alessandri C, Barbati C, et al. *Arthritis and Rheumatism.* 2012;64(3):778-87.
467. **The soluble tumor necrosis factor receptor etanercept: A new strategy for the treatment of autoimmune rheumatic disease.** Cole P, Rabasseda X. *Drugs of Today.* 2004;40(4):281-324.
468. **Cardiac tamponade caused by central venous catheter perforation of the heart: a preventable complication.** Collier PE, Goodman GB. *Journal of the American College of Surgeons.* 1995;181(5):459-63.
469. **Chloroquine psychosis masquerading as PCP: A case report.** Collins GB, McAllister MS. *Journal of Psychoactive Drugs.* 2008;40(2):211-4.
470. **Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis.** Combe B, Didry C, Gutierrez M, Anaya JM, Sany J. *European Journal of Medicine.* 1993;2(3):153-6.
471. **Central nervous system involvement in whipple disease: Clinical study of 18 patients and long-term follow-up.** Compain C, Sacre K, Puéchal X, Klein I, Vital-Durand D, Houeto JL, et al. *Medicine (United States).* 2013;92(6):324-30.
472. **Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.** Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M, et al. *Annals of the Rheumatic Diseases.* 2013;72(8):1280-6.
473. **In vivo sensitivity monitoring of chloroquine for the treatment of uncomplicated vivax malaria in four bordered provinces of Thailand during 2009-2010.** Congpuong K, Satimai W, Sujariyakul A, Intanakom S, Harnpitakpong W, Pranuth Y, et al. *Journal of Vector Borne Diseases.* 2011;48(4):190-6.

474. **Photoscratch testing in systemic drug-induced photosensitivity.** Conilleau V, Dompmartin A, Michel M, Verneuil L, Leroy D. *Photodermatology Photoimmunology and Photomedicine*. 2000;16(2):62-6.
475. **The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: Results from a monocentric cohort.** Conti F, Ceccarelli F, Perricone C, Leccese I, Massaro L, Pacucci VA, et al. *Lupus*. 2015;25(7):719-26.
476. **Differential outcomes among immunosuppressed patients with merkel cell carcinoma.** Cook M, Baker K, Redman M, Lachance K, Nguyen MH, Parvathaneni U, et al. *American Journal of Clinical Oncology: Cancer Clinical Trials*. 2019;42(1):82-8.
477. **Outcomes in transplant patients undergoing brachytherapy for prostate cancer.** Coombs CC, Hertzfeld K, Barrett W. *American Journal of Clinical Oncology: Cancer Clinical Trials*. 2012;35(1):40-4.
478. **Revisiting the "July Effect" in Plastic Surgery: New Data to Support Resident Autonomy.** Coombs DM, Ascha MS, Ascha M, Gatherwright J, Knackstedt R, Gurunluoglu R. *Ann Plast Surg*. 2020;84(1):95-9. <http://dx.doi.org/10.1097/SAP.0000000000001999>.
479. **Chloroquine should be used with care in mental health disorders.** Cooper RG. *Indian Journal of Physiology and Pharmacology*. 2008;52(1):97-8.
480. **Controlled therapeutic trials in polymorphic light eruption.** Corbett MF, Hawk JL, Herxheimer A, Magnus IA. *The British journal of dermatology*. 1982;107(5):571-81. <http://dx.doi.org/10.1111/j.1365-2133.1982.tb00409.x>.
481. **Atovaquone-proguanil in the treatment of imported uncomplicated Plasmodium falciparum malaria: A prospective observational study of 553 cases.** Cordel H, Cailhol J, Matheron S, Bloch M, Godineau N, Consigny PH, et al. *Malaria Journal*. 2013;12(1).
482. **[Adverse effects associated with antimalarial chemoprophylaxis].** Corominas N, Gascon J, Mejias T, Caparros F, Quinto L, Codina C, et al. *Medicina clinica*. 1997;108(20):772-5.
483. **Adverse drug reactions associated to the antimalarial chemoprophylaxis.** Corominas N, Gascón J, Mejías T, Caparrós F, Quintó L, Codina C, et al. *Medicina Clinica*. 1997;108(20):772-5.
484. **Surgical experience and supervision may influence the quality of lower limb amputation.** Cosgrove CM, Thornberry DJ, Wilkins DC, Ashley S. *Annals of the Royal College of Surgeons of England*. 2002;84(5):344-7. <http://dx.doi.org/10.1308/003588402760452691>.
485. **[Forecast of physician workforce in the 22 French regions (1998-2013)].** Coste E, Doan BD. *Cahiers de sociologie et de demographie medicales*. 2003;43(1):5-70.
486. **Heart conduction disorders related to antimalarials toxicity: An analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases.** Costedoat-Chalumeau N, Hulot JS, Amoura Z, Leroux G, Lechat P, Funck-Brentano C, et al. *Rheumatology*. 2007;46(5):808-10.
487. **Resident physician's knowledge of risk factors for upper gastrointestinal complications from NSAIDs.** Cote GA, Siqueira F, Rice JP, Howden CW. *Am J Ther*. 2009;16(5):404-11. <http://dx.doi.org/10.1097/MJT.0b013e31818fa106>.
488. **Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD.** Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B, et al. *Blood*. 2006;107(8):3074-80.
489. **Concerns of nursing students beginning clinical courses: A descriptive study.** Cowen KJ, Hubbard LJ,

- Hancock DC. Nurse education today. 2016;43:64-8. <http://dx.doi.org/10.1016/j.nedt.2016.05.001>. Epub 2016 May 12.
490. **Acute lower respiratory tract infections in patients with rheumatoid arthritis.** Coyne P, Hamilton J, Heycock C, Saravanan V, Coulson E, Kelly CA. *Journal of Rheumatology*. 2007;34(9):1832-6.
491. **Inappropriate utilization of intravenous proton pump inhibitors in hospital practice--a prospective study of the extent of the problem and predictive factors.** Craig DG, Thimappa R, Anand V, Sebastian S. *Qjm*. 2010;103(5):327-35. <http://dx.doi.org/10.1093/qjmed/hcq019>. Epub 2010 Mar 7.
492. **Screening of antigen cross-presentation potentiating drugs for vaccine development.** Crespo MI, Guantay ML, Pascual MM, Harman MF, Dho N, Pistoresi MC, et al. *Biocell*. 2019;43:149.
493. **"To Err Is Human" but Disclosure Must be Taught: A Simulation-Based Assessment Study.** Crimmins AC, Wong AH, Bonz JW, Tsyrlunik A, Jubanyik K, Dziura JD, et al. *Simulation in healthcare : journal of the Society for Simulation in Healthcare*. 2018;13(2):107-16. <http://dx.doi.org/10.1097/SIH.0000000000000273>.
494. **Hospital management of the dermatologic patient: The porphyrias.** Cripps DJ. *Seminars in Dermatology*. 1986;5(1):55-68.
495. **Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis.** Crnkic Kapetanovic M, Saxne T, Jönsson G, Truedsson L, Geborek P. *Arthritis Research and Therapy*. 2013;15(5).
496. **An extended role for CT in the emergency diagnosis of malignant spinal cord compression.** Crocker M, Anthanathananjit R, Jones TL, Shoeb M, Joshi Y, Papadopoulos MC, et al. *Clinical radiology*. 2011;66(10):922-7. <http://dx.doi.org/10.1016/j.crad.2010.12.017>. Epub 2011 Jul 23.
497. **Adverse effects of the antimalaria drug, mefloquine: Due to primary liverdamage with secondary thyroid involvement?** Croft AM, Herxheimer A. *BMC Public Health*. 2002;2:1-8.
498. **Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab.** Crommelin HA, Van Der Burg LM, Vorselaars ADM, Drent M, Van Moorsel CHM, Rijkers GT, et al. *Respiratory Medicine*. 2016;115:72-7.
499. **The benefit of smart phone usage in liver organ procurement.** Croome KP, Shum J, Al-Basheer MA, Kamei H, Bloch M, Quan D, et al. *Journal of telemedicine and telecare*. 2011;17(3):158-60. <http://dx.doi.org/10.1258/jtt.2010.100907>. Epub 2011 Jan 26.
500. **B lymphocytes are resistant to death receptor 5-induced apoptosis.** Crowder RN, Zhao H, Chatham WW, Zhou T, Carter RH. *Clinical Immunology*. 2011;139(1):21-31.
501. **Introduction of a Venous Thromboembolism Prophylaxis Protocol for Older Adult Psychiatric Patients.** Croxford A, Clare A, McCurdy K. *BMJ quality improvement reports*. 2015;4(1). <http://dx.doi.org/10.1136/bmjquality.u205852.w3226>. eCollection 2015.
502. **The effect of clinical history on accuracy of electrocardiograph interpretation among doctors working in emergency departments.** Cruz MF, Edwards J, Dinh MM, Barnes EH. *The Medical journal of Australia*. 2012;197(3):161-5. <http://dx.doi.org/10.5694/mja11.11598>.
503. **Epigenetic side-effects of common pharmaceuticals: A potential new field in medicine and pharmacology.** Csoka AB, Szyf M. *Medical Hypotheses*. 2009;73(5):770-80.
504. **Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine. A follow-up study.** Csuka M, Carrera GF, McCarty DJ. *Jama*. 1986;255(17):2315-9.

505. **Subjective and objective screening tests for hydroxychloroquine toxicity.** Cukras C, Huynh N, Vitale S, Wong WT, Ferris FL, 3rd, Sieving PA. *Ophthalmology*. 2015;122(2):356-66. <http://dx.doi.org/10.1016/j.ophtha.2014.07.056>. Epub 2014 Oct 14.
506. **Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.** Cummins L, Katikireddi VS, Shankaranarayana S, Su KY, Duggan E, Videm V, et al. *Internal medicine journal*. 2015;45(12):1266-73. <http://dx.doi.org/10.1111/imj.12896>.
507. **Hydroxychloroquine blood concentration in lupus nephritis: a determinant of disease outcome?** Cunha C, Alexander S, Ashby D, Lee J, Chusney G, Cairns TD, et al. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2018;33(9):1604-10.
508. **Outcomes of screening Parkinson's patients for QTc prolongation.** Cunnington AL, Hood K, White L. *Parkinsonism and Related Disorders*. 2013;19(11):1000-3.
509. **Introduction of nurse led DC cardioversion service in day surgery unit: prospective audit.** Currie MP, Karwatowski SP, Perera J, Langford EJ. *Bmj*. 2004;329(7471):892-4. <http://dx.doi.org/10.1136/bmj.329.7471.892>.
510. **Sarar cohort: Disease activity, functional capacity, and radiological damage in rheumatoid arthritis patients undergoing total hip and knee arthroplasty.** da Cunha BM, de Oliveira SB, dos Santos-Neto LL. *Revista Brasileira de Reumatologia*. 2015;55(5):420-6.
511. **Consensus guidelines for the management of inflammatory bowel disease.** Da Pontte ACA, Damião AOMC, Rosa AM, Da Silva AN, Fachin AV, Cortecazzi Jr A, et al. *Arquivos de Gastroenterologia*. 2010;47(3):313-25.
512. **Tardive dyskinesia: Epidemiology.** D'Abreu A, Akbar U, Friedman JH. *Journal of the Neurological Sciences*. 2018;389:17-20.
513. **Efficacy and safety of artemisinin-based combination therapy and chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: an open label randomized clinical trial.** Daher A, Pereira D, Lacerda MVG, Alexandre MAA, Nascimento CT, Alves de Lima ESJC, et al. *Malar J*. 2018;17(1):45. <http://dx.doi.org/10.1186/s12936-018-2192-x>.
514. **Existing antimalarial agents and malaria-treatment strategies.** D'Alessandro U. *Expert Opinion on Pharmacotherapy*. 2009;10(8):1291-306.
515. **Systemic lupus erythematosus and ocular involvement: an overview.** Dammacco R. *Clinical and Experimental Medicine*. 2018;18(2):135-49.
516. **Ocular Involvement in Systemic Lupus Erythematosus: The Experience of Two Tertiary Referral Centers.** Dammacco R, Procaccio P, Racanelli V, Vacca A, Dammacco F. *Ocular immunology and inflammation*. 2018;26(8):1154-65. <http://dx.doi.org/10.1080/09273948.2018.1501495>. Epub 2018 Aug 10.
517. **Clinical and laboratory features of human Plasmodium knowlesi infection.** Daneshvar C, Davis TME, Cox-Singh J, Rafa'ee MZ, Zakaria SK, Divis PCS, et al. *Clinical Infectious Diseases*. 2009;49(6):852-60.
518. **Open-label study on treatment with 20 % subcutaneous IgG administration in polymyositis and dermatomyositis.** Danieli MG, Moretti R, Gambini S, Paolini L, Gabrielli A. *Clinical Rheumatology*. 2014;33(4):531-6.
519. **LC3 and p62 as diagnostic markers of drug-induced autophagic vacuolar cardiomyopathy: a study of 3 cases.** Daniels BH, McComb RD, Mobley BC, Gultekin SH, Lee HS, Margeta M. *The American journal of surgical pathology*. 2013;37(7):1014-21. <http://dx.doi.org/10.1097/PAS.0b013e3182863fa8>.

520. **Drug reactions and interactions.** D'Arcy PF. *Journal de Pharmacie de Belgique*. 1986;41(2):118-24.
521. **Clinical and immunological aspects and outcome of a Brazilian cohort of 414 patients with systemic lupus erythematosus (SLE): Comparison between childhood-onset, adult-onset, and late-onset SLE.** Das Chagas Medeiros MM, Campos Bezerra M, Holanda Ferreira Braga FN, Melo Da Justa Feijão MR, Rodrigues Gois AC, Do Rosário Rebouças VC, et al. *Lupus*. 2016;25(4):355-63.
522. **Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: A cross-sectional study.** Davaine AC, Saraux A, Prigent S, Kupfer-Bessaguet I, Roswag D, Plantin P, et al. *Journal of the European Academy of Dermatology and Venereology*. 2008;22(12):1471-7.
523. **[Evaluation of a practical use of synthetic antimalarials in the treatment of rheumatoid polyarthritis].** David-Chausse J, David-Chausse F, Picot C, Laporte G, Lagoarde J, Dehais J. *Revue du rhumatisme et des maladies osteo-articulaires*. 1971;38(11):681-90.
524. **Variations in guideline use and practice relating to diagnosis and management of infection in paediatric burns services in England and Wales: A national survey.** Davies A, Spickett-Jones F, Brock P, Coy K, Young A. *Burns : journal of the International Society for Burn Injuries*. 2017;43(1):215-22.  
<http://dx.doi.org/10.1016/j.burns.2016.07.032>. Epub 2016 Sep 3.
525. **Idiopathic pulmonary fibrosis: Current and future treatment options.** Davies HR, Richeldi L. *American Journal of Respiratory Medicine*. 2002;1(3):211-24.
526. **Recombinant Human Tumor Necrosis Factor Receptor (Etanercept) for Treating Ankylosing Spondylitis: A Randomized, Controlled Trial.** Davis Jr JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. *Arthritis and Rheumatism*. 2003;48(11):3230-6.
527. **Prevention and treatment of malaria in pregnancy.** Davis TME, Mueller I, Rogerson SJ. *Future Microbiology*. 2010;5(10):1599-613.
528. **Diagnoses not to be missed. Toxic psychosis.** Davison K. *British Journal of Hospital Medicine*. 1981;26(5):530-7.
529. **Valproic acid may exerts its cytotoxic effect through rassf1a expression induction in acute myeloid leukemia.** Davood ZA, Shamsi S, Ghaedi H, Sahand RI, Mojtaba G, Mahdi T, et al. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2016;37(8):11001-6.  
<http://dx.doi.org/10.1007/s13277-016-4985-2>. Epub 2016 Feb 19.
530. **Dermatomyositis: A dermatology-based case series.** Dawkins MA, Jorizzo JL, Walker FO, Albertson D, Sinal SH, Hinds A. *Journal of the American Academy of Dermatology*. 1998;38(3):397-404.
531. **The spectrum of oculocutaneous disease: Part II. Neoplastic and drug-related causes of oculocutaneous disease.** Day A, Abramson AK, Patel M, Warren RB, Menter MA. *Journal of the American Academy of Dermatology*. 2014;70(5):821.e1-.e19.
532. **Initial experience using a femtosecond laser cataract surgery system at a UK National Health Service cataract surgery day care centre.** Day AC, Dhallu SK, Maurino V, Wilkins MR. *BMJ Open*. 2016;6(7):e012078.  
<http://dx.doi.org/10.1136/bmjopen-2016-012078>.
533. **Atovaquone and proguanil for the treatment of malaria in Brazil.** De Alencar FEC, Cerutti Jr C, Durlacher RR, Boulos M, Alves FP, Milhous W, et al. *Journal of Infectious Diseases*. 1997;175(6):1544-7.
534. **Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review.** de Boysson H, Boutemy J, Creveuil C, Ollivier Y, Letellier P, Pagnoux C, et al. *Seminars in Arthritis*

and Rheumatism. 2013;43(1):105-12.

535. **The psychophysiological stress response in psoriasis and rheumatoid arthritis.** De Brouwer SJM, Van Middendorp H, Stormink C, Kraaijaat FW, Sweep FCGJ, De Jong EMGJ, et al. *British Journal of Dermatology*. 2014;170(4):824-31.
536. **Predicting cardiac arrhythmias and sudden death in diabetic users of proarrhythmic drugs.** De Bruin ML, Van Staa TP, Belitser SV, Leufkens HGM, Hoes AW. *Diabetes Care*. 2005;28(2):440-2.
537. **Can Surgical Registrars Accurately Identify the Urgent from the Non-Urgent Patient Presenting with Acute Abdominal Pain?** de Burlet KJ, Lam ABM, Harper SJ, Larsen PD, Dennett ER. *European surgical research Europäische chirurgische Forschung Recherches chirurgicales europeennes*. 2019;60(1):24-30. <http://dx.doi.org/10.1159/000496021>. Epub 2019 Feb 6.
538. **Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial.** de Jong PH, Hazes JM, Han HK, Huisman M, van Zeben D, van der Lubbe PA, et al. *Ann Rheum Dis*. 2014;73(7):1331-9. <http://dx.doi.org/10.1136/annrheumdis-2013-204788>. Epub 2014 May 1.
539. **On chikungunya acute infection and chloroquine treatment.** De Lamballerie X, Boisson V, Reynier JC, Enault S, Charrel RN, Flahault A, et al. *Vector-Borne and Zoonotic Diseases*. 2008;8(6):837-9.
540. **Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate.** De Rotte MCFJ, De Jong PHP, Pluijm SMF, Čalasan MB, Barendregt PJ, Van Zeben D, et al. *Arthritis and Rheumatism*. 2013;65(11):2803-13.
541. **Complex prosthetic joint infections due to carbapenemase-producing *Klebsiella pneumoniae*: A unique challenge in the era of untreatable infections.** de Sanctis J, Teixeira L, van Duin D, Odio C, Hall G, Tomford JW, et al. *International Journal of Infectious Diseases*. 2014;25:73-8.
542. **In vitro diagnosis of drug allergy. Assessment of the chromatin activation test (CAT).** De Sousa Pinto JM, Babo MJ. *Pharmacoepidemiology and Drug Safety*. 1997;6:S61-S9.
543. **Systemic lupus erythematosus with muscle weakness due to myasthenia gravis.** de Sousa Studart SA, Rodrigues CL, Soares CB, Callado MRM, Vieira WP. *Revista Brasileira de Reumatologia*. 2011;51(3):289-94.
544. **Adult dermatomyositis: Experience of a Brazilian tertiary care center.** de Souza FHC, Barros TBM, Levy-Neto M, Shinjo SK. *Revista Brasileira de Reumatologia*. 2012;52(6):897-902.
545. **Patient Safety Risks of Basic Urological Procedures Performed by Junior and Senior Residents.** de Vries AH, Boute MC, Kuppen MC, van Merriënboer JJ, Koldewijn EL, Pelger RC, et al. *Journal of surgical education*. 2015;72(5):918-26. <http://dx.doi.org/10.1016/j.jsurg.2015.04.014>. Epub 2015 Jun 24.
546. **High educational impact of a national simulation-based urological curriculum including technical and non-technical skills.** de Vries AH, Schout BM, van Merriënboer JJ, Pelger RC, Koldewijn EL, Muijtjens AM, et al. *Surgical endoscopy*. 2017;31(2):928-36. <http://dx.doi.org/10.1007/s00464-016-5060-1>. Epub 2016 Jul 7.
547. **A case of giant cell arteritis associated with culture-proven *Coxiella burnetii* aortitis.** de Worm S, Giot JB, Courtoy C, Gillet E, Amrane S, Huynen P, et al. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2018;69:50-4. <http://dx.doi.org/10.1016/j.ijid.2018.01.028>. Epub 2018 Mar 2.
548. **Non-thromboembolic risk in systemic lupus erythematosus associated with antiphospholipid syndrome.** Deák M, Bocskai M, Burcsár S, Dányi O, Fekete Z, Kovács L. *Lupus*. 2014;23(9):913-8.



549. **Neuroimmune interactions in Sjögren's syndrome: Relationship of exocrine gland dysfunction with autoantibodies to muscarinic acetylcholine receptor-3 and mental health status parameters.** Deák M, Szvetnik A, Balog A, Sohár N, Varga R, Pokorny G, et al. *NeuroImmunoModulation*. 2013;20(2):79-86.
550. **Clinical pearls and therapeutic challenges in connective tissue disease.** Dean RJ, Fivenson DP. *Dermatologic Therapy*. 2001;14(2):126-33.
551. **Mentored Trainees have Similar Short-Term Outcomes to a Consultant Trainer Following Laparoscopic Colorectal Resection.** De'Ath HD, Devoto L, Mehta C, Bromilow J, Qureshi T. *World J Surg*. 2017;41(7):1896-902. <http://dx.doi.org/10.1007/s00268-017-3925-7>.
552. **Tumor necrosis factor inhibitor therapy and the risk for depression among working-age adults with rheumatoid arthritis.** Deb A, Dwibedi N, Lemasters T, Hornsby JA, Wei W, Sambamoorthi U. *American Health and Drug Benefits*. 2019;12(1):30-8.
553. **The attitude of the pharmacist towards eye problems in the pharmacy: Referral or OTC?** Decorte E, Delaey C, Van De Voorde J, Boussery K. *Farmaceutisch Tijdschrift voor België*. 2006;83(1):3-12.
554. **Therapy of uncomplicated malaria in children: A review of treatment principles, essential drugs and current recommendations.** Deen JL, Von Seidlein L, Dondorp A. *Tropical Medicine and International Health*. 2008;13(9):1111-30.
555. **Polymyalgia rheumatica and giant cell arteritis: Management of two diseases of the elderly.** Dejaco C, Duftner C, Dasgupta B, Matteson EL, Schirmer M. *Aging Health*. 2011;7(4):633-45.
556. **Topical sodium metabisulfite for the treatment of calcinosis cutis: a promising new therapy.** del Barrio-Díaz P, Moll-Manzur C, Álvarez-Veliz S, Vera-Kellet C. *British Journal of Dermatology*. 2016;175(3):608-11.
557. **Using community health workers for malaria control: Experience in Zaire.** Delacollette C, Van Der Stuyft P, Molima K. *Bulletin of the World Health Organization*. 1996;74(4):423-30.
558. **Therapy of rheumatoid arthritis.** Delgado JN, Isaacson EI, Cosgrove FP. *Pharmindex*. 1984;26(2):11-5.
559. **The prognostic value of baseline 18F-FDG PET/CT in steroid-naïve large-vessel vasculitis: introduction of volume-based parameters.** Dellavedova L, Carletto M, Faggioli P, Sciascera A, Del Sole A, Mazzone A, et al. *European Journal of Nuclear Medicine and Molecular Imaging*. 2016;43(2):340-8.
560. **Could combinations of new and old drugs enhance tumor cell death?** Delou JMA, Hajdu KL, Borges HL. *Future Oncology*. 2018;14(23):2319-22.
561. **Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: A large retrospective study.** Den Broeder AA, Creemers MCW, Fransen J, De Jong E, De Rooij DJR, Wymenga A, et al. *Journal of Rheumatology*. 2007;34(4):689-95.
562. **Risk factors for mesh erosion after female pelvic floor reconstructive surgery: a systematic review and meta-analysis.** Deng T, Liao B, Luo D, Shen H, Wang K. *BJU international*. 2016;117(2):323-43. <http://dx.doi.org/10.1111/bju.13158>. Epub 2015 Jun 11.
563. **Controlled trial of hydroxychloroquine in schizophrenia.** Desta M, Tadesse A, Gebre N, Barci BM, Torrey EF, Knable MB. *Journal of Clinical Psychopharmacology*. 2002;22(5):507-10.
564. **Inguinal herniorrhaphy. Reduced morbidity by service standardization.** Deysine M, Grimson RC, Soroff

HS. Archives of surgery (Chicago, Ill : 1960). 1991;126(5):628-30.  
<http://dx.doi.org/10.1001/archsurg.1991.01410290106020>.

565. **Burst-forming unit-erythroid assays to distinguish cellular bone marrow failure disorders.** DeZern AE, Pu J, McDevitt MA, Jones RJ, Brodsky RA. Experimental Hematology. 2013;41(9):808-16.

566. **Randomized controlled trial comparing 2 different starting doses of methotrexate in rheumatoid arthritis.** Dhir V, Singla M, Gupta N, Goyal P, Sagar V, Sharma A, et al. Clinical Therapeutics. 2014;36(7):1005-15.

567. **Frequency of thrombophilia determinant factors in patients with livedoid vasculopathy and treatment with anticoagulant drugs - A prospective study.** Di Giacomo TB, Hussein TP, Souza DG, Criado PR. Journal of the European Academy of Dermatology and Venereology. 2010;24(11):1340-6.

568. **Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis.** Díaz-Borjón A. Drugs and Aging. 2009;26(4):273-93.

569. **Monitoring of failure of chloroquine treatment for Plasmodium vivax using polymerase chain reaction in Sanliurfa province, Turkey.** Dilmeç F, Ali Kurcer M, Akkafa F, Simsek Z. Parasitology Research. 2010;106(4):783-8.

570. **Hydroxychloroquine-related retinal toxicity.** Ding HJ, Denniston AK, Rao VK, Gordon C. Rheumatology (Oxford, England). 2016;55(6):957-67. <http://dx.doi.org/10.1093/rheumatology/kev357>. Epub 2015 Oct 1.

571. **Defining the learning curve for video-assisted thyroidectomy.** Dionigi G, Boni L, Rovera F, Annoni M, Villa F, Dionigi R. International journal of surgery (London, England). 2008;6:S1-3.  
<http://dx.doi.org/10.1016/j.ijsu.2008.12.004>. Epub 2008 Dec 10.

572. **Safety and efficacy of atovaquone and proguanil hydrochloride for the prophylaxis of Plasmodium falciparum malaria in South Africa.** Dirk van der Berg J, Duvenage CSJ, Roskell NS, Scott TR. Clinical Therapeutics. 1999;21(4):741-9.

573. **Falciparum malaria in the north of Laos: the occurrence and implications of the Plasmodium falciparum chloroquine resistance transporter (pfcr1) gene haplotype SVMNT.** Dittrich S, Alifrangis M, Stohrer JM, Thongpaseuth V, Vanisaveth V, Phetsouvanh R, et al. Tropical medicine & international health : TM & IH. 2005;10(12):1267-70. <http://dx.doi.org/10.1111/j.1365-3156.2005.01514.x>.

574. **The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: A nested case-control study.** Dixon WG, Kezouh A, Bernatsky S, Suissa S. Annals of the Rheumatic Diseases. 2011;70(6):956-60.

575. **[Annular elastolytic giant cell granuloma].** Djilali-Bouzina F, Grange F, Krzisch S, Schnebelen MP, Grosshans E, Guillaume JC. Ann Dermatol Venereol. 2010;137(8):536-40.  
<http://dx.doi.org/10.1016/j.annder.2010.06.004>. Epub 2010 Aug 19.

576. **Autoimmune disorders due to double antiviral therapy with peginterferon and ribavirin in patients with hepatitis C virus infection.** Docea AO, Gofita E, Calina D, Ioan ZS, Valcea DI, Mitrut P. Farmacia. 2016;64(4):605-11.

577. **Evidence-based therapy for cutaneous sarcoidosis.** Doherty CB, Rosen T. Drugs. 2008;68(10):1361-83.

578. **Immunosuppression is an independent prognostic factor associated with aggressive tumor behavior in cutaneous melanoma.** Donahue T, Lee CY, Sanghvi A, Obregon R, Sidiropoulos M, Cooper C, et al. Journal of the American Academy of Dermatology. 2015;73(3):461-6.

579. **Death certification in fractured neck of femur.** Donaldson LJ, Parsons L, Cook AJ. Public Health. 1989;103(4):237-43. [http://dx.doi.org/10.1016/s0033-3506\(89\)80036-8](http://dx.doi.org/10.1016/s0033-3506(89)80036-8).
580. **Macrolide therapy of chronic Lyme Disease.** Donta ST. Medical Science Monitor. 2003;9(11):PI136-PI42.
581. **IX 207-887 in rheumatoid arthritis: A double-blind placebo-controlled study.** Dougados M, Combe B, Beveridge T, Bourdeix I, Lallemand A, Amor B, et al. Arthritis and Rheumatism. 1992;35(9):999-1006.
582. **Cutaneous abnormalities in rheumatoid arthritis compared with non-inflammatory rheumatic conditions.** Douglas KMJ, Ladoyanni E, Treharne GJ, Hale ED, Erb N, Kitas GD. Annals of the Rheumatic Diseases. 2006;65(10):1341-5.
583. **The antimalarial potential of 4-quinolinecarbinolamines may be limited due to neurotoxicity and cross-resistance in mefloquine-resistant Plasmodium falciparum strains.** Dow GS, Koenig ML, Wolf L, Gerena L, Lopez-Sanchez M, Hudson TH, et al. Antimicrobial Agents and Chemotherapy. 2004;48(7):2624-32.
584. **The Senior Psychiatrist Survey II: experience and psychiatric practice.** Draper B, Luscombe G, Winfield S. The Australian and New Zealand journal of psychiatry. 1999;33(5):709-16. <http://dx.doi.org/10.1080/j.1440-1614.1999.00623.x>.
585. **Prevention of Torsade de Pointes in Hospital Settings. A Scientific Statement From the American Heart Association and the American College of Cardiology Foundation Endorsed by the American Association of Critical-Care Nurses and the International Society for Computerized Electrocardiology.** Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, et al. Journal of the American College of Cardiology. 2010;55(9):934-47.
586. **[Interest of surgical companionship during the training period of robot-assisted radical prostatectomy].** du Pouget L, Nouhaud FX, Blah M, Defortescu G, Ndangang M, Grise P, et al. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 2017;27(5):297-304. <http://dx.doi.org/10.1016/j.purol.2017.01.005>. Epub 2017 Mar 1.
587. **Antifibrotics in interstitial lung disease related to connective tissue diseases - a paradigm shift in treatment and outcome.** Duarte AC, Vinagre F, Soares J, Cordeiro A. Acta reumatologica portuguesa. 2019;44(2):161-2.
588. **Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria.** Duarte EC, Pang LW, Ribeiro LC, Fontes CJ. The American journal of tropical medicine and hygiene. 2001;65(5):471-6. <http://dx.doi.org/10.4269/ajtmh.2001.65.471>.
589. **Acute tricyclic antidepressant overdose. Study of the effects of concomitant ingestion of benzodiazepines.** Dubien PY, Theurey O, Roux H, Bresson V, Petit P. Reanimation Soins Intensifs Medecine d'Urgence. 1996;12(2):57-62.
590. **An open study of the anti-TNF alpha agent pentoxifylline in the treatment of rheumatoid arthritis.** Dubost JJ, Soubrier M, Ristori JM, Beaujon G, Oualid T, Bussiere JL, et al. Revue du Rhumatisme (English Edition). 1997;64(12):789-93.
591. **Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies.** Dugar M, Cox S, Limaye V, Blumbergs P, Roberts-Thomson PJ. Internal Medicine Journal. 2011;41(9):674-9.
592. **A double-blind, randomized study of azithromycin compared to chloroquine for the treatment of Plasmodium vivax malaria in India.** Dunne MW, Singh N, Shukla M, Valecha N, Bhattacharyya PC, Patel K, et al. The American journal of tropical medicine and hygiene. 2005;73(6):1108-11.

593. **Problems in prescribing malaria chemoprophylaxis for travelers.** Dupouy-Camet J, Yera H, Tourte-Schaeffer C. *Fundamental and Clinical Pharmacology*. 2003;17(2):161-9.
594. **Prevent to enjoy your vacation.** Duquet N. *Journal de Pharmacie de Belgique*. 2007;62(2):X52-60.
595. **Impact of increasing overnight intensive care unit registrar staffing on duration of intubation of elective cardiac surgery patients.** Durie ML, Darvall JN, Rechnitzer T, Tacey MA. *Anaesthesia and intensive care*. 2015;43(5):600-7. <http://dx.doi.org/10.1177/0310057X1504300508>.
596. **[Complications of colonic diverticular disease during rheumatoid polyarthritis: 7 cases].** Durieux S, Rozenberg S, Bourgeois P. *La Revue de medecine interne*. 1999;20(1):50-3. [http://dx.doi.org/10.1016/s0248-8663\(99\)83008-2](http://dx.doi.org/10.1016/s0248-8663(99)83008-2).
597. **Efficacy of combination therapy with artesunate plus amodiaquine compared to monotherapy with chloroquine, amodiaquine or sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum in Afghanistan.** Durrani N, Leslie T, Rahim S, Graham K, Ahmad F, Rowland M. *Tropical medicine & international health : TM & IH*. 2005;10(6):521-9. <http://dx.doi.org/10.1111/j.1365-3156.2005.01429.x>.
598. **One year outcomes of a mentoring scheme for female academics: a pilot study at the Institute of Psychiatry, King's College London.** Dutta R, Hawkes SL, Kuipers E, Guest D, Fear NT, Iversen AC. *BMC medical education*. 2011;11:13. <http://dx.doi.org/10.1186/1472-6920-11-13>.
599. **The Success of Hip Arthroscopy in an Active Duty Population.** Dutton JR, Kusnezov NA, Lanzi JT, Garcia EJ, Pallis MP. *Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association*. 2016;32(11):2251-8. <http://dx.doi.org/10.1016/j.arthro.2016.05.042>. Epub 2016 Aug 23.
600. **Personality status of wrestlers of varying abilities as measured by a sport specific version of a personality inventory.** Dwyer JJ, Carron AV. *Canadian journal of applied sport sciences Journal canadien des sciences appliquees au sport*. 1986;11(1):19-30.
601. **Characterization of lymphocyte  $\beta$ -adrenoceptor activity and G(s)-protein inpatients with rheumatic heart valvular disease.** Dzimiri N, Hussain S, Moorji A, Prabhakar G, Bakr S, Kumar M, et al. *Fundamental and Clinical Pharmacology*. 1995;9(4):372-80.
602. **Fear of failure: are we doing too many trials of instrumental delivery in theatre?** Ebulue V, Vadalkar J, Cely S, Dopwell F, Yoong W. *Acta Obstet Gynecol Scand*. 2008;87(11):1234-8. <http://dx.doi.org/10.1080/00016340802443848>.
603. **Persistence of DNA in a cured patient and positive culture in cases with low antibody levels bring into question diagnosis of Q fever endocarditis.** Edouard S, Million M, Lepidi H, Rolain JM, Fournier PE, La Scola B, et al. *Journal of Clinical Microbiology*. 2013;51(9):3012-7.
604. **Distal targeting device for long Gamma nail((R)). Monocentric observational study.** Ehlinger M, Dillman G, Czekaj J, Adam P, Taglang G, Brinkert D, et al. *Orthopaedics & traumatology, surgery & research : OTSR*. 2013;99(7):799-804. <http://dx.doi.org/10.1016/j.otsr.2013.06.006>. Epub 2013 Oct 4.
605. **Severe malaria in native adult in tropical area, Abidjan (Côte d'Ivoire).** Eholié SP, Ehui E, Adou-Bryn K, Kouamé KE, Tanon A, Kakou A, et al. *Bulletin de la Societe de Pathologie Exotique*. 2004;97(5):340-4.
606. **Therapeutic efficacy of artemether-lumefantrine for Plasmodium vivax infections in a prospective study in Guyana.** Eibach D, Ceron N, Krishnalall K, Carter K, Bonnot G, Bienvenu AL, et al. *Malaria Journal*. 2012;11.
607. **[Localization of scotomas in AMD by reading test : Random series of words in standardized format].**

Eisenbarth W, Pado U, Schriever S, Schotschel D, Feucht N, MacKeben M. *Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft*. 2016;113(9):754-62. <http://dx.doi.org/10.1007/s00347-016-0252-6>.

608. **Laser therapy for refractory discoid lupus erythematosus when everything else has failed.** Ekbäck MP, Troilius A. *Journal of Cosmetic and Laser Therapy*. 2013;15(5):260-5.

609. **Increased risk of tuberculosis in patients treated with antitumor necrosis factor alpha.** Elbek O, Uyar M, Aydin N, Börekçi S, Bayram N, Bayram H, et al. *Clinical Rheumatology*. 2009;28(4):421-6.

610. **Sirolimus and Autophagy Inhibition in Lymphangiomyomatosis: Results of a Phase I Clinical Trial.** El-Chemaly S, Taveira-Dasilva A, Goldberg HJ, Peters E, Haughey M, Bienfang D, et al. *Chest*. 2017;151(6):1302-10. <http://dx.doi.org/10.1016/j.chest.2017.01.033>. Epub 2017 Feb 10.

611. **Early paracentral visual field loss in patients taking hydroxychloroquine.** Elder M, Rahman AM, McLay J. *Archives of ophthalmology (Chicago, Ill : 1960)*. 2006;124(12):1729-33. <http://dx.doi.org/10.1001/archophth.124.12.1729>.

612. **Treatment and prophylactic strategy for coxiella burnetii infection of aneurysms and vascular grafts a retrospective cohort study.** Eldin C, Mailhe M, Lions C, Carrieri P, Safi H, Brouqui P, et al. *Medicine (United States)*. 2016;95(12).

613. **Drugs used in incident systemic lupus erythematosus - results from the Finnish nationwide register 2000-2007.** Elfving P, Puolakka K, Kautiainen H, Virta LJ, Pohjolainen T, Kaipainen-Seppänen O. *Lupus*. 2016;25(6):666-70. <http://dx.doi.org/10.1177/0961203316628998>. Epub 2016 Jan 27.

614. **The efficacy of artemether in the treatment of Plasmodium falciparum malaria in Sudan.** Elhassan IM, Satti GHM, Ali AE, Fadul I, Elkhalifa AA, Abedeirahim M, et al. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1993;87(6):685-6.

615. **Functional and patient-reported outcomes of the Swanson metacarpo-phalangeal arthroplasty in the rheumatoid hand.** Elherik FK, Dolan S, Antrum J, Unglaub F, Howie CR, Breusch SJ. *Archives of Orthopaedic and Trauma Surgery*. 2017;137(5):725-31.

616. **The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.** Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, et al. *Seminars in Arthritis and Rheumatism*. 2010;39(6):442-7.

617. **Toxicity profile of dual methotrexate combinations with gold, hydroxychloroquine, sulphasalazine and minocycline in rheumatoid arthritis patients.** Elkayam O, Yaron M, Zhukovsky G, Segal R, Caspi D. *Rheumatology International*. 1997;17(2):49-53.

618. **Single fascia iliaca compartment block for pain relief in patients with fractured neck of femur in the emergency department: a pilot study.** Elkhodair S, Mortazavi J, Chester A, Pereira M. *European journal of emergency medicine : official journal of the European Society for Emergency Medicine*. 2011;18(6):340-3. <http://dx.doi.org/10.1097/MEJ.0b013e32834533dd>.

619. **Efficacy of 12 months' misoprostol as prophylaxis against NSAID-induced gastric ulcers.** Elliott SL, Yeomans ND, Buchanan RRC, Smallwood RA. *Scandinavian Journal of Rheumatology*. 1994;23(4):171-6.

620. **Prevention and treatment of malaria.** Ellis CJ. *Current Opinion in Infectious Diseases*. 1991;4(6):834-7.

621. **[Frontal fibrosing alopecia: A prospective study of 20 cases].** Elloudi S, Gallouj S, Meziane M, Mernissi FZ, Rimani M. *Ann Dermatol Venereol*. 2017;144(6):409-14. <http://dx.doi.org/10.1016/j.annder.2017.01.014>. Epub 2017 Mar 1.

622. **Cardiac risk indices of staff of Federal University Of Technology Owerri, Imo State, Nigeria.** Emerole CO, Aguwa EN, Onwasigwe CN, Nwakoby BA. Tanzania health research bulletin. 2007;9(2):132-5. <http://dx.doi.org/10.4314/thrb.v9i2.14316>.
623. **Golimumab, a human anti-tumor necrosis factor  $\alpha$  monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.** Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Arthritis and Rheumatism. 2009;60(8):2272-83.
624. **Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin  $\alpha$ : Results of a phase I randomized, placebo-controlled trial.** Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, et al. Arthritis Research and Therapy. 2012;14(1).
625. **Cause-Specific Mortality in Male US Veterans with Rheumatoid Arthritis.** England BR, Sayles H, Michaud K, Caplan L, Davis LA, Cannon GW, et al. Arthritis Care and Research. 2016;68(1):36-45.
626. **Obstetric accidents: a review of 64 cases.** Ennis M, Vincent CA. Bmj. 1990;300(6736):1365-7. <http://dx.doi.org/10.1136/bmj.300.6736.1365>.
627. **Frequency and Clinical Characteristics of Hydroxychloroquine Retinopathy in Korean Patients with Rheumatologic Diseases.** Eo DR, Lee MG, Ham DI, Kang SW, Lee J, Cha HS, et al. Journal of Korean medical science. 2017;32(3):522-7. <http://dx.doi.org/10.3346/jkms.2017.32.3.522>.
628. **Chest tube drainage of pleural effusions--an audit of current practice and complications at Hutt Hospital.** Epstein E, Jayathissa S, Dee S. The New Zealand medical journal. 2012;125(1354):26-35.
629. **The evaluation of the risk factors for capsular complications in phacoemulsification.** Ergun SB, Kocamis SI, Cakmak HB, Cagil N. International ophthalmology. 2018;38(5):1851-61. <http://dx.doi.org/10.1007/s10792-017-0667-3>. Epub 2017 Aug 29.
630. **Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.** Eriksson JK, Karlsson JA, Bratt J, Petersson IF, van Vollenhoven RF, Ernestam S, et al. Ann Rheum Dis. 2015;74(6):1094-101. <http://dx.doi.org/10.1136/annrheumdis-2013-205060>. Epub 2014 Apr 15.
631. **Clinical experience of sirolimus regarding efficacy and safety in systemic lupus erythematosus.** Eriksson P, Wallin P, Sjöwall C. Frontiers in Pharmacology. 2019;10.
632. **A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients.** Erkan D, Willis R, Murthy VL, Basra G, Vega J, Ruiz-Limón P, et al. Annals of the Rheumatic Diseases. 2014;73(6):1176-80.
633. **Idiopathic inflammatory myopathies: Current trends in pathogenesis, clinical features, and up-to-date treatment recommendations.** Ernste FC, Reed AM. Mayo Clinic Proceedings. 2013;88(1):83-105.
634. **Giardiasis: The ever-present threat of a neglected disease.** Escobedo AA, Almirall P, Robertson LJ, Franco RMB, Hanevik K, Mørch K, et al. Infectious Disorders - Drug Targets. 2010;10(5):329-48.
635. **Giardiasis: A pharmacotherapy review.** Escobedo AA, Cimerman S. Expert Opinion on Pharmacotherapy. 2007;8(12):1885-902.
636. **Effects of the disease characteristics and the treatment on psychological status in patients with**

- rheumatoid arthritis and ankylosing spondylitis.** Esen SA, Karabulut Y, Esen İ, Atmiş V. *Current Rheumatology Reviews*. 2018;14(3):271-8.
637. **Malaria in paradise: Characterization of imported cases in Gran Canaria Island (1993-2006).** Espinosa-Vega E, Martín-Sánchez AM, Elcuaz-Romano R, Hernández-Febles M, Molina-Cabrillana J, Pérez-Arellano JL. *Journal of Travel Medicine*. 2011;18(3):165-72.
638. **A two-stage retention débridement protocol for acute periprosthetic joint infections.** Estes CS, Beauchamp CP, Clarke HD, Spangehl MJ. *Clinical Orthopaedics and Related Research*. 2010;468(8):2029-38.
639. **Efficacy and safety of dapsone as second line therapy for adult immune thrombocytopenia: A retrospective study of 42 patients.** Estève C, Samson M, Guilhem A, Nicolas B, Leguy-Seguin V, Berthier S, et al. *PLoS ONE*. 2017;12(10).
640. **Vision screening for correctable visual acuity deficits in school-age children and adolescents.** Evans JR, Morjaria P, Powell C. *The Cochrane database of systematic reviews*. 2018;2:Cd005023. <http://dx.doi.org/10.1002/14651858.CD005023.pub3>.
641. **Psychological effects caused by drugs in overdose.** Evans L. *Drugs*. 1980;19(3):220-42.
642. **Antimalarial psychosis revisited.** Evans RL, Khalid S, Kinney JL. *Archives of Dermatology*. 1984;120(6):765-7.
643. **Stress-vulnerability factors as long-term predictors of disease activity in early rheumatoid arthritis.** Evers AWM, Kraaimaat FW, Geenen R, Jacobs JWG, Bijlsma JWJ. *Journal of Psychosomatic Research*. 2003;55(4):293-302.
644. **Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial.** Faarvang KL, Egsmose C, Kryger P, Podenphant J, Ingeman-Nielsen M, Hansen TM. *Ann Rheum Dis*. 1993;52(10):711-5. <http://dx.doi.org/10.1136/ard.52.10.711>.
645. **Hepatitis C virus infection and arthritis: A clinico-serological investigation of arthritis in patients with or without cryoglobulinemic syndrome.** Fadda P, La Civita L, Zignego AL, Ferri C. *Reumatismo*. 2002;54(4):316-23.
646. **Pattern of postoperative pyrexia in Khartoum.** Fadl Alla AI, Fahal AH, Ahmed ME, Hassan MA. *East African Medical Journal*. 1996;73(1):78-80.
647. **Bortezomib and dexamethasone, an original approach for treating multi-refractory warm autoimmune haemolytic anaemia.** Fadlallah J, Michel M, Crickx E, Limal N, Costedoat N, Malphettes M, et al. *British Journal of Haematology*. 2019;187(1):124-8.
648. **Hydroxychloroquine toxicity despite normal dose therapy.** Falcone PM, Paolini L, Lou PL. *Annals of ophthalmology*. 1993;25(10):385-8.
649. **Safety and efficacy of diagnostic peritoneal lavage performed by supervised surgical and emergency medicine residents.** Falcone RE, Thomas B, Hrutkay L. *European journal of emergency medicine : official journal of the European Society for Emergency Medicine*. 1997;4(3):150-5. <http://dx.doi.org/10.1097/00063110-199709000-00007>.
650. **Teaching senior oncologists communication skills: results from phase I of a comprehensive longitudinal program in the United Kingdom.** Fallowfield L, Lipkin M, Hall A. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 1998;16(5):1961-8. <http://dx.doi.org/10.1200/JCO.1998.16.5.1961>.
651. **Community-based evaluation of etanercept in patients with rheumatoid arthritis.** Farahani P, Levine M,

Gaebel K, Wang ECY, Khalidi N. *Journal of Rheumatology*. 2006;33(4):665-70.

652. **Effects of chronic exposure of hydroxychloroquine/chloroquine on the risk of cancer, metastasis, and death: A population-based cohort study on patients with connective tissue diseases.** Fardet L, Nazareth I, Petersen I. *Clinical Epidemiology*. 2017;9:545-54.

653. **Synthetic antimalarials.** Fardet L, Revuz J. *Annales de Dermatologie et de Venereologie*. 2005;132(8):665-74.

654. **Fever and acute brief psychosis in developing countries [4].** Farooq S, Khawaja MY. *British Journal of Psychiatry*. 1999;175:586.

655. **Inhibitors of brain phospholipase A2 activity: Their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders.** Farooqui AA, Ong WY, Horrocks LA. *Pharmacological Reviews*. 2006;58(3):591-620.

656. **Prolonged remission is associated with a reduced risk of cardiovascular disease in patients with systemic lupus erythematosus: a GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study.** Fasano S, Margiotta DPE, Pierro L, Navarini L, Riccardi A, Afeltra A, et al. *Clinical Rheumatology*. 2019;38(2):457-63.

657. **Does the surgeon's experience impact on radiocephalic fistula patency rates?** Fassiadis N, Morsy M, Siva M, Marsh JE, Makanjuola AD, Chemla ES. *Seminars in dialysis*. 2007;20(5):455-7.  
<http://dx.doi.org/10.1111/j.1525-139X.2007.00310.x>.

658. **Venous thromboembolism. Prophylaxis on a Saturday morning in a district hospital.** Fassiadis N, Stavrianakis C, Moghraby OS, Gandhi P, Smedley FH. *International angiology : a journal of the International Union of Angiology*. 2002;21(4):330-2.

659. **Causes of suboptimal corrected visual acuity following phacoemulsification in a teaching university hospital.** Fathallah M, Eltanamly RM, Saadeldin H, Elnahry GH. *European journal of ophthalmology*. 2017;27(2):169-73.  
<http://dx.doi.org/10.5301/ejo.5000824>. Epub 2016 Jul 11.

660. **Serum and lymphocytic neurotrophins profiles in systemic lupus erythematosus: A case-control study.** Fauchais AL, Lise MC, Marget P, Lapeybie FX, Bezanahary H, Martel C, et al. *PLoS ONE*. 2013;8(11).

661. **Articular manifestations in primary Sjogren's syndrome: clinical significance and prognosis of 188 patients.** Fauchais AL, Ouattara B, Gondran G, Lalloue F, Petit D, Ly K, et al. *Rheumatology (Oxford, England)*. 2010;49(6):1164-72. <http://dx.doi.org/10.1093/rheumatology/keq047>. Epub 2010 Mar 18.

662. **Psychosis related to malaria prophylaxis.** Fauman BJ. *Seminars in Neurology*. 2012;32(5):528-30.

663. **Low complication rate after stoma closure. Consultants attended 90% of the operations.** Fauno L, Rasmussen C, Sloth KK, Sloth AM, Tottrup A. *Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland*. 2012;14(8):e499-505. <http://dx.doi.org/10.1111/j.1463-1318.2012.02991.x>.

664. **Adolescent psychic entropy: a response to unacknowledged fears.** Faupel KC. *Adolescence*. 1989;24(94):375-9.

665. **Short-term exposure to air pollution might exacerbate autoimmune diseases.** Faustini A, Renzi M, Kirchmayer U, Balducci M, Davoli M, Forastiere F. *Environmental Epidemiology*. 2018;2(3).

666. **Tumour necrosis factor  $\alpha$  blocking agents in refractory adult Still's disease: An observational study of 20 cases.** Fautrel B, Sibilia J, Mariette X, Combe B. *Annals of the Rheumatic Diseases*. 2005;64(2):262-6.



667. **Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritis.** Favarato MH, Mease P, Gonçalves CR, Gonçalves Saad C, Sampaio-Barros PD, Goldenstein-Schainberg C. *Clinical and Experimental Rheumatology*. 2014;32(2):182-7.
668. **Postoperative Bleeding Following Dental Extractions in Patients Anticoagulated With Warfarin.** Febbo A, Cheng A, Stein B, Goss A, Sambrook P. *Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons*. 2016;74(8):1518-23. <http://dx.doi.org/10.1016/j.joms.2016.04.007>. Epub 2016 Apr 22.
669. **Resident and fellow participation in Thyroid and Parathyroid surgery: an ACS-NSQIP clinical outcomes analysis.** Feeney T, Price LL, Chen L, Graham R, Chatterjee A. *The Journal of surgical research*. 2017;220:346-52. <http://dx.doi.org/10.1016/j.jss.2017.07.030>. Epub 2017 Aug 21.
670. **Impact of the surgeon's experience on the postoperative outcome--a retrospective analysis of non-melanoma skin cancers of the head and neck region.** Felcht M, Faulhaber J, Linder AS, Goerdts S, Koenen W. *Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG*. 2010;8(3):167-73. <http://dx.doi.org/10.1111/j.1610-0387.2009.07218.x>. Epub 2009 Oct 9.
671. **Sex Differences in Health Care Utilization, End-Stage Renal Disease, and Mortality Among Medicaid Beneficiaries With Incident Lupus Nephritis.** Feldman CH, Broder A, Guan H, Yazdany J, Costenbader KH. *Arthritis and Rheumatology*. 2018;70(3):417-26.
672. **The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus.** Feldmann R, Salomon D, Saurat JH. *Dermatology*. 1994;189(4):425-7.
673. **Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center.** Femia AN, Eastham AB, Lam C, Merola JF, Qureshi AA, Vleugels RA. *J Am Acad Dermatol*. 2013;69(4):654-7. <http://dx.doi.org/10.1016/j.jaad.2013.06.007>.
674. **Relationship between spinal morphology and function and adolescent non-specific back pain: A cross-sectional study.** Feng Q, Jiang C, Zhou Y, Huang Y, Zhang M. *Journal of back and musculoskeletal rehabilitation*. 2017;30(3):625-33. <http://dx.doi.org/10.3233/BMR-160544>.
675. **Prognostic indicators of hospitalized patients with systemic lupus erythematosus: A large retrospective multicenter study in China.** Feng X, Zou Y, Pan W, Wang X, Wu M, Zhang M, et al. *Journal of Rheumatology*. 2011;38(7):1289-95.
676. **Risks factors and prevention of Q fever endocarditis.** Fenollar F, Fournier PE, Carrieri MP, Habib G, Messana T, Raoult D. *Clinical Infectious Diseases*. 2001;33(3):312-6.
677. **Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature.** Fernández RR, Rubio JLC, Cano DS, Moreno JAS, Centeno NO. *Clinical and Experimental Rheumatology*. 2009;27(6):1009-16.
678. **Hallucinations during treatment with hydrochloroquine.** Ferraro V, Mantoux F, Denis K, Lay-Macagno MA, Ortonne JP, Lacour JP. *Annales de Dermatologie et de Venereologie*. 2004;131(5):471-3.
679. **The immune reconstitution inflammatory syndrome in Whipple disease: A cohort study.** Feurle GE, Moos V, Schinnerling K, Geelhaar A, Allers K, Biagi F, et al. *Annals of Internal Medicine*. 2010;153(11):710-7.
680. **Maintenance and tolerability of infliximab in a cohort of 152 patients with rheumatoid arthritis.** Figueiredo IT, Morel J, Sany J, Combe B. *Clinical and Experimental Rheumatology*. 2008;26(1):18-23.

681. **Chemical cardiomyopathies: The negative effects of medications and nonprescribed drugs on the heart.** Figueredo VM. *American Journal of Medicine*. 2011;124(6):480-8.
682. **Side effects of basic drugs in patients with rheumatoid arthritis.** Filipowicz-Sosnowska A, Rell-Bakalarska M, Werynska-Przybylska J, Maczynska-Rusiniak B. *Reumatologia*. 1992;30(1):3-10.
683. **Anti-TNF  $\alpha$  agents in elderly patients with rheumatoid arthritis: A study of a group of 105 over sixty five years old patients.** Filippini M, Bazzani C, Zingarelli S, Ziglioli T, Nuzzo M, Vianelli M, et al. *Reumatismo*. 2008;60(1):41-9.
684. **Muscle pain in mitochondrial diseases: a picture from the Italian network.** Filosto M, Cotti Piccinelli S, Lamperti C, Mongini T, Servidei S, Musumeci O, et al. *Journal of Neurology*. 2019;266(4):953-9.
685. **Safety attitudes and beliefs of junior Australian football players.** Finch C, Donohue S, Garnham A. *Injury prevention : journal of the International Society for Child and Adolescent Injury Prevention*. 2002;8(2):151-4. <http://dx.doi.org/10.1136/ip.8.2.151>.
686. **Ward-based rather than team-based junior surgical doctors reduce mortality for patients with a fracture of the proximal femur: results from a two-year observational study.** Findlay JM, Keogh MJ, Boulton C, Forward DP, Moran CG. *The Journal of bone and joint surgery British volume*. 2011;93(3):393-8. <http://dx.doi.org/10.1302/0301-620X.93B3.25730>.
687. **The safety and effectiveness of the LVIS stent system for the treatment of wide-necked cerebral aneurysms: final results of the pivotal US LVIS trial.** Fiorella D, Boulos A, Turk AS, Siddiqui AH, Arthur AS, Diaz O, et al. *Journal of neurointerventional surgery*. 2019;11(4):357-61. <http://dx.doi.org/10.1136/neurintsurg-2018-014309>. Epub 2018 Oct 8.
688. **The impact of surgical resident participation in breast reduction surgery--outcome analysis from the 2005-2011 ACS-NSQIP datasets.** Fischer JP, Wes AM, Kovach SJ. *Journal of plastic surgery and hand surgery*. 2014;48(5):315-21. <http://dx.doi.org/10.3109/2000656X.2014.882345>. Epub 2014 Jan 30.
689. **Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: A prospective observational study.** Fischer-Betz R, Chehab G, Sander O, Vordenbäumen S, Voiculescu A, Brinks R, et al. *Journal of Rheumatology*. 2012;39(11):2111-7.
690. **Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: An open-label trial.** Flagg SD, Meador R, Hsia E, Kitumnuaypong T, Schumacher Jr HR. *Arthritis Care and Research*. 2005;53(4):613-7.
691. **Anakinra, a recombinant human interleukin-1 receptor antagonist (r-methHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial.** Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, et al. *Arthritis and Rheumatism*. 2003;48(4):927-34.
692. **Supporting doctors as healthcare quality and safety advocates: Recommendations from the Association of Surgeons in Training (ASiT).** Fleming CA, Humm G, Wild JR, Mohan HM, Hornby ST, Harries RL, et al. *International journal of surgery (London, England)*. 2018;52:349-54. <http://dx.doi.org/10.1016/j.ijssu.2018.02.002>. Epub 2018 Feb 9.
693. **The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study.** Flendrie M, Creemers MCW, Welsing PMJ, van Riel PLCM. *Rheumatology*. 2005;44(4):472-8.
694. **Surgery and Medicine Residents' Perspectives of Morbidity and Mortality Conference: An**

**Interdisciplinary Approach to Improve ACGME Core Competency Compliance.** Flynn-O'Brien KT, Mandell SP, Eaton EV, Schleyer AM, McIntyre LK. *Journal of surgical education*. 2015;72(6):e258-66. <http://dx.doi.org/10.1016/j.j Surg.2015.05.015>. Epub 2015 Jul 2.

695. **Human deaths from drug overdoses with carfentanyl involvement-new rising problem in forensic medicine A STROBE-compliant retrospective study.** Fomin D, Baranauskaitė V, Usaviciene E, Sumkovskaja A, Laima S, Jasulaitis A, et al. *Medicine (United States)*. 2018;97(48).

696. **A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation.** Fong T, Trinkaus K, Adkins D, Vij R, Devine SM, Tomasson M, et al. *Biology of Blood and Marrow Transplantation*. 2007;13(10):1201-6.

697. **Walking Speed, Risk Factors, and Cardiovascular Events in Older Adults-Systematic Review.** Fonseca Alves DJ, Bartholomeu-Neto J, Junior ER, Ribeiro Zarricueta BS, Nobrega OT, Cordova C. *Journal of strength and conditioning research*. 2017;31(11):3235-44. <http://dx.doi.org/10.1519/JSC.0000000000002182>.

698. **Stroke, dementia, and drug delivery.** Ford GA, Bryant CA, Mangoni AA, Jackson SHD. *British Journal of Clinical Pharmacology*. 2004;57(1):15-26.

699. **Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients.** Foreman C, Russo P, Davies N, Hissaria P, Proudman S, Hughes T, et al. *Internal Medicine Journal*. 2017;47(1):112-5.

700. **Structured training program in colorectal surgery: the robotic surgeon as a new paradigm.** Formisano G, Esposito S, Coratti F, Giuliani G, Salaj A, Bianchi PP. *Minerva chirurgica*. 2019;74(2):170-5. <http://dx.doi.org/10.23736/S0026-4733.18.07951-8>. Epub 2018 Nov 21.

701. **Physical activity and cardiovascular risk factors in a developing population.** Forrest KY, Bunker CH, Kriska AM, Ukoli FA, Huston SL, Markovic N. *Medicine and science in sports and exercise*. 2001;33(9):1598-604. <http://dx.doi.org/10.1097/00005768-200109000-00025>.

702. **Cranial nerve injuries after carotid artery surgery. A prospective study of 663 operations.** Forssell C, Kitzing P, Bergqvist D. *European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery*. 1995;10(4):445-9. [http://dx.doi.org/10.1016/s1078-5884\(05\)80167-4](http://dx.doi.org/10.1016/s1078-5884(05)80167-4).

703. **Effect of Structured Touch and Guided Imagery for Pain and Anxiety in Elective Joint Replacement Patients--A Randomized Controlled Trial: M-TIJRP.** Forward JB, Greuter NE, Crisall SJ, Lester HF. *The Permanente journal*. 2015;19(4):18-28. <http://dx.doi.org/10.7812/TPP/14-236>. Epub 2015 Jul 24.

704. **Malaria.** Foucault C, Delmont J, Brouqui P. *Revue du Praticien*. 2002;52(9):1009-15.

705. **Awareness, acceptability and application of paracetamol overdose management guidelines in a New Zealand emergency department.** Fountain JS, Hawwari H, Kerr K, Holt A, Reith D. *The New Zealand medical journal*. 2014;127(1402):20-9.

706. **Treatment of primary Sjogren's syndrome with hydroxychloroquine: a retrospective, open-label study.** Fox RI, Dixon R, Guarrasi V, Krubel S. *Lupus*. 1996;5:S31-6.

707. **Tnf blockers show distinct patterns of immune response to the pandemic influenza a h1n1 vaccine in inflammatory arthritis patients.** França ILA, Ribeiro ACM, Aikawa NE, Saad CGS, Moraes JCB, Goldstein-schainberg C, et al. *Rheumatology (United Kingdom)*. 2012;51(11):2091-8.

708. **Candidemia in a Brazilian tertiary care hospital: Incidence, frequency of different species, risk factors and antifungal susceptibility.** França JCB, Ribeiro CEL, De Queiroz-Telles F. *Revista da Sociedade Brasileira de Medicina Tropical*. 2008;41(1):23-8.

709. **Epidemiology and clinical features of imported malaria in East London.** Francis BC, Gonzalo X, Duggineni S, Thomas JM, NicFhogartaigh C, Babiker ZOE. *Journal of Travel Medicine*. 2016;23(6).
710. **Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance.** Francis D, Nsohya SL, Talisuna A, Yeka A, Kanya MR, Machekano R, et al. *The Journal of infectious diseases*. 2006;193(7):978-86. <http://dx.doi.org/10.1086/500951>. Epub 2006 Mar 1.
711. **Neurosyphilis, malaria, and the discovery of antipsychotic agents.** Frankenburg FR, Baldessarini RJ. *Harvard Review of Psychiatry*. 2008;16(5):299-307.
712. **Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: A multicentre, cluster randomised controlled trial.** Fransen J, Moens HB, Speyer I, Van Riel PLCM. *Annals of the Rheumatic Diseases*. 2005;64(9):1294-8.
713. **Factors associated with adverse events resulting from medical errors in the emergency department: two work better than one.** Freund Y, Goulet H, Bokobza J, Ghanem A, Carreira S, Madec D, et al. *The Journal of emergency medicine*. 2013;45(2):157-62. <http://dx.doi.org/10.1016/j.jemermed.2012.11.061>. Epub 2013 Feb 21.
714. **Chloroquine serum concentration and side effects: Evidence for dose-dependent kinetics.** Frisk-Holmberg M, Bergkvist Y, Domeij-Nyberg B, Hellstrom L, Jansson F. *Clinical Pharmacology and Therapeutics*. 1979;25(3):345-50.
715. **Quetiapine: Support for the adoption of a new atypical antipsychotic and suggestions for the official guidelines at Brazilian public health services.** Frota LH, Brasil MAA, Bueno JR, Da Silva Filho JF. *Jornal Brasileiro de Psiquiatria*. 2002;51(5):299-312.
716. **TOAST criteria applied in acute ischemic stroke.** Fure B, Wyller TB, Thommessen B. *Acta Neurol Scand*. 2005;112(4):254-8. <http://dx.doi.org/10.1111/j.1600-0404.2005.00470.x>.
717. **Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: A phase I trial in patients with systemic lupus erythematosus.** Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, et al. *Arthritis Research and Therapy*. 2008;10(5).
718. **Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: A 12 week multicenter, double blind, dose response study versus placebo and diclofenac.** Furst DE, Kolba KS, Fleischmann R, Silverfield J, Greenwald M, Roth S, et al. *Journal of Rheumatology*. 2002;29(3):436-46.
719. **Adalimumab, a Fully Human Anti-Tumor Necrosis Factor- $\alpha$  Monoclonal Antibody, and Concomitant Standard Antirheumatic Therapy for the Treatment of Rheumatoid Arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).** Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. *Journal of Rheumatology*. 2003;30(12):2563-71.
720. **Patients with preexisting psychiatric disorders admitted to ICU: a descriptive and retrospective cohort study.** Gacouin A, Maamar A, Fillatre P, Sylvestre E, Dolan M, Le Tulzo Y, et al. *Annals of Intensive Care*. 2017;7(1).
721. **Risk factors for tibial implant malpositioning in total knee arthroplasty-consecutive series of one thousand, four hundred and seventeen cases.** Gaillard R, Cerciello S, Lustig S, Servien E, Neyret P. *Int Orthop*. 2017;41(4):749-56. <http://dx.doi.org/10.1007/s00264-016-3307-z>. Epub 2016 Oct 13.
722. **Importance of low serum DNase I activity and polyspecific anti-neutrophil cytoplasmic antibodies in propylthiouracil-induced lupus-like syndrome.** Gajic-Veljcic M, Bonaci-Nikolic B, Lekic B, Skiljevic D, Ciric J, Zoric S, et al. *Rheumatology (United Kingdom)*. 2015;54(11):2061-70.

723. **Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy.** Galarraga B, Belch JF, Pullar T, Ogston S, Khan F. *Journal of Rheumatology*. 2010;37(3):521-8.
724. **Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population.** Gale SL, Trinh H, Mathew N, Jahreis A, Lin CJF, Sarsour K. *Rheumatology and Therapy*. 2020;7(1):89-99.
725. **A placebo controlled study of the efficacy and tolerability of a nonsteroidal anti-inflammatory drug, DHEP plaster, in inflammatory peri- and extra-articular rheumatological diseases.** Galeazzi M, Marcolongo R. *Drugs under Experimental and Clinical Research*. 1993;19(3):107-15.
726. **Ecstasy and related substances.** Galliot-Guilley M, Sueur C, Lebeau B, Fompeydie D, Benezech A, Bazard JP. *Presse Medicale*. 1999;28(7):358-62.
727. **Psoas abscess and chronic Q fever: A contiguous or hematogenous complication? A case report and literature review.** Galy A, Decousser JW, El-Anbassi S, Nebbad B, Belzunce C, Cochenec F, et al. *Infectious Diseases*. 2016;48(8):626-31.
728. **A ten-year retrospective study on livedo vasculopathy in Asian patients.** Gan EY, Tang MBY, Tan SH, Chua SH, Tan AWH. *Annals of the Academy of Medicine Singapore*. 2012;41(9):400-6.
729. **Post-chikungunya chronic arthritis--our experience with DMARDs over two year follow up.** Ganu MA, Ganu AS. *The Journal of the Association of Physicians of India*. 2011;59:83-6.
730. **[Impact of psychosocial factors on suicide attempts in high school and college students, data from eight cities of China].** Gao R, Tao FB, Hu CL, Su PY, Hao JH, Wan YH. *Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi*. 2010;31(1):9-13.
731. **Malaria.** Garcia LS. *Clinics in Laboratory Medicine*. 2010;30(1):93-129.
732. **Tropheryma whipplei endocarditis in Spain.** García-Álvarez L, Sanz MM, Marín M, Fariñas M, Montejo M, Goikoetxea J, et al. *Medicine (United States)*. 2016;95(26).
733. **Toxic psychosis due to chloroquine.** Garg P, Mody P, Lall KB. *Indian Journal of Pediatrics*. 1990;57(1):133-4.
734. **Neurological manifestations of malaria : An update.** Garg RK, Karak B, Misra S. *Neurology India*. 1999;47(2):85-91.
735. **Novel mutations in the antifolate drug resistance marker genes among Plasmodium vivax isolates exhibiting severe manifestations.** Garg S, Saxena V, Lumb V, Pakalapati D, Boopathi PA, Subudhi AK, et al. *Experimental parasitology*. 2012;132(4):410-6. <http://dx.doi.org/10.1016/j.exppara.2012.09.018>. Epub 2012 Oct 5.
736. **Reproducibility and factors influencing the assessment of the SYNTAX score in the left main Xience study.** Garot P, Tafflet M, Kumar S, Salvatella N, Darremont O, Jouven X, et al. *Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions*. 2012;80(2):231-7. <http://dx.doi.org/10.1002/ccd.23443>. Epub 2012 Apr 17.
737. **Triaging patients to the ICU: a pilot study of factors influencing admission decisions and patient outcomes.** Garrouste-Orgeas M, Montuclard L, Timsit JF, Misset B, Christias M, Carlet J. *Intensive Care Med*. 2003;29(5):774-81. <http://dx.doi.org/10.1007/s00134-003-1709-z>. Epub 2003 Apr 2.
738. **The latroref study: medical errors are associated with symptoms of depression in ICU staff but not**

**burnout or safety culture.** Garrouste-Orgeas M, Perrin M, Soufir L, Vesin A, Blot F, Maxime V, et al. *Intensive Care Med.* 2015;41(2):273-84. <http://dx.doi.org/10.1007/s00134-014-3601-4>. Epub 2015 Jan 10.

739. Garstang J, Duncan JR, Byard RW. *Parental Perspectives. SIDS Sudden Infant and Early Childhood Death: The Past, the Present and the Future.* Adelaide (AU): University of Adelaide Press (c) 2018 The Contributors, with the exception of which is by Federal United States employees and is therefore in the public domain.; 2018.

740. **Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial.** Gautret P, Lagier JC, Parola P, Hoang VT, Medded L, Mailhe M, et al. *Journal.* 2020(Issue).

741. **Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients.** Gavand PE, Serio I, Arnaud L, Costedoat-Chalumeau N, Carvelli J, Dossier A, et al. *Autoimmunity Reviews.* 2017;16(7):743-9.

742. **Accuracy and inter-operator variability of small bowel length measurement at laparoscopy.** Gazer B, Rosin D, Bar-Zakai B, Willenz U, Doron O, Gutman M, et al. *Surgical endoscopy.* 2017;31(11):4697-704. <http://dx.doi.org/10.1007/s00464-017-5538-5>. Epub 2017 Apr 13.

743. **Opportunities and barriers to implementing antibiotic stewardship in low and middle-income countries: Lessons from a mixed-methods study in a tertiary care hospital in Ethiopia.** Gebretekle GB, Haile Mariam D, Abebe W, Amogne W, Tenna A, Fenta TG, et al. *PLoS One.* 2018;13(12):e0208447. <http://dx.doi.org/10.1371/journal.pone.0208447>. eCollection 2018.

744. **Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.** Genovese MC, Greenwald M, Codding C, Zubrzycka-Sienkiewicz A, Kivitz AJ, Wang A, et al. *Arthritis & rheumatology (Hoboken, NJ).* 2017;69(5):932-42. <http://dx.doi.org/10.1002/art.40054>.

745. **Results from a phase IIA parallel group study of JNJ-40346527, an oral CSF-1R inhibitor, in patients with active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy.** Genovese MC, Hsia E, Belkowski SM, Chien C, Masterson T, Thurmond RL, et al. *Journal of Rheumatology.* 2015;42(10):1752-60.

746. **Effect of Filgotinib vs Placebo on Clinical Response in Patients with Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.** Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, et al. *JAMA - Journal of the American Medical Association.* 2019;322(4):315-25.

747. **LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study.** Genovese MC, Van Den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, et al. *Arthritis and Rheumatism.* 2010;62(4):929-39.

748. **An analysis of the dermatological uses of mycophenolate mofetil in a tertiary hospital.** George L, Hamann I, Chen K, Choi J, Fernandez-Peñas P. *Journal of Dermatological Treatment.* 2015;26(1):63-6.

749. **Biologic and glucocorticoid use after methotrexate initiation in patients with rheumatoid arthritis.** George MD, Sauer BC, Teng CC, Cannon GW, England BR, Kerr GS, et al. *Journal of Rheumatology.* 2019;46(4):343-50.

750. **Transnasal Humidified Rapid Insufflation Ventilatory Exchange in children requiring emergent intubation (Kids THRIVE): a protocol for a randomised controlled trial.** George S, Humphreys S, Williams T, Gelbart B, Chavan A, Rasmussen K, et al. *BMJ Open.* 2019;9(2):e025997. <http://dx.doi.org/10.1136/bmjopen-2018-025997>.

751. **Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort.** Geraldino-Pardilla L, Perel-Winkler A, Miceli J, Neville K, Danias G, Nguyen S, et al. *Lupus*. 2019;28(7):862-7. <http://dx.doi.org/10.1177/0961203319851558>. Epub 2019 May 24.
752. **Adult-onset still disease: Manifestations, treatment, outcome, and prognostic factors in 57 patients.** Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I, et al. *Medicine (United States)*. 2014;93(2):91-9.
753. **Cardiovascular disease mortality in relation to physical activity during adolescence and adulthood in Japan: Does school-based sport club participation matter?** Gero K, Iso H, Kitamura A, Yamagishi K, Yatsuya H, Tamakoshi A. *Preventive medicine*. 2018;113:102-8. <http://dx.doi.org/10.1016/j.ypmed.2018.05.012>. Epub 2018 May 16.
754. **An audit of the management of malignant hypercalcaemia.** Gerrard GE, Dodwell DJ, Vail A, Watters J, Overend MA. *Clinical oncology (Royal College of Radiologists (Great Britain))*. 1996;8(1):39-42. [http://dx.doi.org/10.1016/s0936-6555\(05\)80037-8](http://dx.doi.org/10.1016/s0936-6555(05)80037-8).
755. **The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonyleureas-a randomized trial.** Gerstein HC, Thorpe KE, Wayne Taylor D, Brian Haynes R. *Diabetes Research and Clinical Practice*. 2002;55(3):209-19.
756. **Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia.** Getachew S, Thriemer K, Auburn S, Abera A, Gadisa E, Aseffa A, et al. *Malar J*. 2015;14:525. <http://dx.doi.org/10.1186/s12936-015-1041-4>.
757. **Percutaneous CT-guided lung biopsy: sequential versus spiral scanning. A randomized prospective study.** Ghaye B, Dondelinger RF, Dewe W. *Eur Radiol*. 1999;9(7):1317-20. <http://dx.doi.org/10.1007/s003300050839>.
758. **How are we treating our systemic patients with primary Sjogren syndrome? Analysis of 1120 patients.** Gheitasi H, Kostov B, Solans R, Fraile G, Suarez-Cuervo C, Casanovas A, et al. *International immunopharmacology*. 2015;27(2):194-9. <http://dx.doi.org/10.1016/j.intimp.2015.03.027>. Epub 2015 Apr 18.
759. **A Case Series and Literature Review of Merkel Cell Carcinoma Metastasizing to Pancreas.** Ghouri YA, Krishna SG, Kundu UR, Butani MS, Lee JH, Ross WA. *Digestive Diseases and Sciences*. 2015;60(6):1805-12.
760. **Digestive-tract sarcoidosis French nationwide case-control study of 25 cases.** Ghrenassia E, Mekinian A, Chapelon-Albric C, Levy P, Cosnes J, Sève P, et al. *Medicine (United States)*. 2016;95(29).
761. **Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety.** Gianfrancesco MA, Schmajuk G, Haserodt S, Trupin L, Izadi Z, Jafri K, et al. *Rheumatology International*. 2017;37(10):1611-8.
762. **Efficacy and safety of anti-TNF- $\alpha$  therapy combined with cyclosporine a in patients with rheumatoid arthritis and concomitant hepatitis C virus infection.** Giannitti C, Benucci M, Caporali R, Manganelli S, Bellisai F, Sebastiani GD, et al. *International Journal of Immunopathology and Pharmacology*. 2009;22(2):543-6.
763. **Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma.** Giglio P, Dhamne M, Hess KR, Gilbert MR, Groves MD, Levin VA, et al. *Cancer*. 2012;118(14):3599-606.
764. **Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review.** Gil B, Merav L, Pnina L, Chagai G. *Clinical Rheumatology*. 2016;35(8):2125-30.
765. **Ocular myasthenia gravis.** Gilbert ME, Savino PJ. *International Ophthalmology Clinics*. 2007;47(4):93-103.

766. **Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis.** Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V, et al. *Arthritis Care and Research.* 2006;55(2):333-7.
767. **Mefloquine.** Giraldo C, Blair S. *Iatreia.* 2003;16(1):19-31.
768. **Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany.** Gissel C, Götz G, Repp H. *Zeitschrift für Rheumatologie.* 2016;75(10):1006-15.
769. **Inflammaging as a prodrome to Alzheimer's disease.** Giunta B, Fernandez F, Nikolic WV, Obregon D, Rapo E, Town T, et al. *Journal of Neuroinflammation.* 2008;5.
770. **Association between surgical resident involvement and blood use in noncardiac surgery.** Glance LG, Mukamel DB, Blumberg N, Fleming FJ, Hohmann SF, Dick AW. *Transfusion.* 2014;54(3):691-700. <http://dx.doi.org/10.1111/trf.12350>. Epub 2013 Jul 25.
771. **Coping strategies and psychological distress: prospective analyses of early and middle adolescents.** Glyshaw K, Cohen LH, Towbes LC. *American journal of community psychology.* 1989;17(5):607-23. <http://dx.doi.org/10.1007/bf00922638>.
772. **Endoscopic treatment of Zenker's diverticulum with the stag beetle knife (sb knife) - feasibility and follow-up.** Goelder SK, Brueckner J, Messmann H. *Scandinavian journal of gastroenterology.* 2016;51(10):1155-8. <http://dx.doi.org/10.1080/00365521.2016.1186729>. Epub 2016 May 24.
773. **Safety of immunomodulatory therapy in patients with bronchiectasis associated with rheumatic disease and IBD: A retrospective and cohort analysis.** Goeminne PC, Verschuere P, Scheers H, Dupont LJ. *Clinical Rheumatology.* 2012;31(2):367-73.
774. **Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria.** Gogtay N, Kannan S, Thatte UM, Olliaro PL, Sinclair D. *Cochrane Database of Systematic Reviews.* 2013;2013(10).
775. **A randomized, parallel-group study in Mumbai (Bombay), comparing chloroquine with chloroquine plus sulfadoxine-pyrimethamine in the treatment of adults with acute, uncomplicated, Plasmodium falciparum malaria.** Gogtay NJ, Desai S, Kadam VS, Kamtekar KD, Dalvi SS, Kshirsagar NA. *Annals of Tropical Medicine and Parasitology.* 2000;94(4):309-12.
776. **The Validity of Optical Coherence Tomography Angiography as a Screening Test for the Early Detection of Retinal Changes in Patients with Hydroxychloroquine Therapy.** Goker YS, Ucgul Atilgan C, Tekin K, Kiziltoprak H, Yetkin E, Yesil Karahan N, et al. *Current Eye Research.* 2019;44(3):311-5.
777. **A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.** Goldberg SB, Supko JG, Neal JW, Muzikansky A, Digumarthy S, Fidias P, et al. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.* 2012;7(10):1602-8. <http://dx.doi.org/10.1097/JTO.0b013e318262de4a>.
778. **Serious infections in British patients with systemic lupus erythematosus: Hospitalisations and mortality.** Goldblatt F, Chambers S, Rahman A, Isenberg DA. *Lupus.* 2009;18(8):682-9.
779. **Seronegative autoimmune autonomic neuropathy: a distinct clinical entity.** Golden EP, Bryarly MA, Vernino S. *Clinical Autonomic Research.* 2018;28(1):115-23.
780. **Can a "novice" do aneurysm surgery? Surgical outcomes in a low-volume, non-specialised neurosurgical unit.** Goldschlager T, Selvanathan S, Walker DG. *Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia.* 2007;14(11):1055-61. <http://dx.doi.org/10.1016/j.jocn.2006.12.002>. Epub 2007



Aug 15.

781. **Surgical complications of bedside tracheotomy in an otolaryngology residency program.** Goldstein SI, Breda SD, Schneider KL. *The Laryngoscope*. 1987;97(12):1407-9. <http://dx.doi.org/10.1288/00005537-198712000-00006>.
782. **Antiphospholipid Antibodies Associated with Malignancies: Clinical and Pathological Characteristics of 120 Patients.** Gómez-Puerta JA, Cervera R, Espinosa G, Aguiló S, Bucciarelli S, Ramos-Casals M, et al. *Seminars in Arthritis and Rheumatism*. 2006;35(5):322-32.
783. **Adverse cutaneous drug reactions with antimalarials in cutaneous lupus and dermatomyositis: A retrospective cohort study.** Gonzalez CD, Hansen C, Clarke JT. *J Am Acad Dermatol*. 2019;81(3):859-60. <http://dx.doi.org/10.1016/j.jaad.2019.04.068>. Epub 2019 May 11.
784. **Time to neuropsychiatric damage occurrence in LUMINA (LXVI): A multi-ethnic lupus cohort.** González LA, Pons-Estel GJ, Zhang J, Vilá LM, Reveille JD, Alarcón GS. *Lupus*. 2009;18(9):822-30.
785. **Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort.** González-Echavarri C, Capdevila O, Espinosa G, Suárez S, Marín-Ballvé A, González-León R, et al. *Lupus*. 2018;27(14):2253-61.
786. **HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis.** Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, Piñeiro A, Garcia-Porrua C, Miranda-Filloo JA, et al. *Arthritis Care and Research*. 2007;57(1):125-32.
787. **Behavioral toxicity and equivocal suicide associated with chloroquine and its derivatives.** Good MI, Shader RI. *American Journal of Psychiatry*. 1977;134(7):798-801.
788. **Lethality and behavioral side effects of chloroquine.** Good MI, Shader RI. *Journal of Clinical Psychopharmacology*. 1982;2(1):40-7.
789. **Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: Results from a primary care based inception cohort of patients.** Goodson NJ, Brookhart AM, Symmons DPM, Silman AJ, Solomon DH. *Annals of the Rheumatic Diseases*. 2009;68(3):367-72.
790. **Effect of surgical training on outcome and hospital costs in coronary surgery.** Goodwin AT, Birdi I, Ramesh TP, Taylor GJ, Nashef SA, Dunning JJ, et al. *Heart*. 2001;85(4):454-7. <http://dx.doi.org/10.1136/heart.85.4.454>.
791. **Chloroquine induced psychosis in a child [3].** Goraya JS, Ghosh D, Singhi P. *Neurology India*. 1998;46(3):252-3.
792. **A role for Toll-like receptor 3 variants in host susceptibility to enteroviral myocarditis and dilated cardiomyopathy.** Gorbea C, Makar KA, Pauschinger M, Pratt G, Bersola JL, Varela J, et al. *The Journal of biological chemistry*. 2010;285(30):23208-23. <http://dx.doi.org/10.1074/jbc.M109.047464>. Epub 2010 May 14.
793. **Definition and treatment of lupus flares measured by the BILAG index.** Gordon C, Sutcliffe N, Skan J, Stoll T, Isenberg DA. *Rheumatology*. 2003;42(11):1372-9.
794. **A 10 year prospective followup of patients with rheumatoid arthritis 1986-96.** Gordon P, West J, Jones H, Gibson T. *Journal of Rheumatology*. 2001;28(11):2409-15.
795. **Predictors of tobacco control among nursing students.** Gorin SS. *Patient education and counseling*. 2001;44(3):251-62. [http://dx.doi.org/10.1016/s0738-3991\(00\)00205-6](http://dx.doi.org/10.1016/s0738-3991(00)00205-6).

796. **Simulation of carotid artery stenting reduces training procedure and fluoroscopy times.** Gosling AF, Kendrick DE, Kim AH, Nagavalli A, Kimball ES, Liu NT, et al. *J Vasc Surg.* 2017;66(1):298-306. <http://dx.doi.org/10.1016/j.jvs.2016.11.066>. Epub 2017 May 19.
797. **Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis.** Gossage DL, Cieslarová B, Ap S, Zheng H, Xin Y, Lal P, et al. *Clinical Therapeutics.* 2018;40(1):156-65.e5.
798. **Induction of clinical autoimmune disease by therapeutic interferon- $\alpha$ .** Gota C, Calabrese L. *Autoimmunity.* 2003;36(8):511-8.
799. **Life events and personality factors in children and adolescents with obsessive-compulsive disorder and other anxiety disorders.** Gothelf D, Aharonovsky O, Horesh N, Carty T, Apter A. *Comprehensive psychiatry.* 2004;45(3):192-8. <http://dx.doi.org/10.1016/j.comppsy.2004.02.010>.
800. **Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome: the JOQUER randomized clinical trial.** Gottenberg JE, Ravaud P, Puechal X, Le Guern V, Sibilia J, Goeb V, et al. *Jama.* 2014;312(3):249-58. <http://dx.doi.org/10.1001/jama.2014.7682>.
801. **[Prognosis of treated temporal arteritis. Retrospective study of 87 cases].** Gouet D, Marechaud R, Le Berre D, Alcalay M, Becq-Giraudon B, Boissonnot L, et al. *Presse Med.* 1986;15(13):603-6.
802. **Accuracy and reproducibility of the peritoneal cancer index in advanced ovarian cancer during laparoscopy and laparotomy.** Gouy S, Belghiti J, Uzan C, Canlorbe G, Gauthier T, Morice P. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.* 2013;23(9):1699-703. <http://dx.doi.org/10.1097/IGC.0b013e3182a616a7>.
803. **Grief reactions and impact of patient death on pediatric oncologists.** Granek L, Bartels U, Scheinemann K, Labrecque M, Barrera M. *Pediatric blood & cancer.* 2015;62(1):134-42. <http://dx.doi.org/10.1002/pbc.25228>. Epub 2014 Sep 11.
804. **Common synonymous variants in ABCA4 are protective for chloroquine induced maculopathy (toxic maculopathy).** Grassmann F, Bergholz R, Mandl J, Jagle H, Ruether K, Weber BH. *BMC ophthalmology.* 2015;15:18. <http://dx.doi.org/10.1186/s12886-015-0008-0>.
805. **Validation of the colour difference plot scoring system analysis of the 103 hexagon multifocal electroretinogram in the evaluation of hydroxychloroquine retinal toxicity.** Graves GS, Adam MK, Stepien KE, Han DP. *Acta ophthalmologica.* 2014;92(5):e377-81. <http://dx.doi.org/10.1111/aos.12353>. Epub 2014 Feb 7.
806. **Definitive emergency treatment of perforated duodenal ulcer.** Gray JG, Roberts AK. *Surgery, gynecology & obstetrics.* 1976;143(6):890-4.
807. **A comparison of structural and functional changes in patients screened for hydroxychloroquine retinopathy.** Greenstein VC, Amaro-Quireza L, Abraham ES, Ramachandran R, Tsang SH, Hood DC. *Documenta ophthalmologica Advances in ophthalmology.* 2015;130(1):13-23. <http://dx.doi.org/10.1007/s10633-014-9474-6>. Epub 2014 Dec 12.
808. **The clinical frailty scale predicts functional decline and mortality when used by junior medical staff: a prospective cohort study.** Gregorevic KJ, Hubbard RE, Lim WK, Katz B. *BMC geriatrics.* 2016;16:117. <http://dx.doi.org/10.1186/s12877-016-0292-4>.
809. **Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery.** Grennan DM, Gray J, Loudon J, Fear S. *Annals of the Rheumatic Diseases.*

2001;60(3):214-7.

810. **Antimalarial therapy for granuloma annulare: Results of a retrospective analysis.** Grewal SK, Rubin C, Rosenbach M. *J Am Acad Dermatol.* 2017;76(4):765-7. <http://dx.doi.org/10.1016/j.jaad.2016.11.044>.

811. **Hydroxychloroquine and visual screening in a rheumatology outpatient clinic.** Grierson DJ. *Annals of the Rheumatic Diseases.* 1997;56(3):188-90.

812. **Validity and efficacy of a pediatric airway foreign body training course in resident education.** Griffin GR, Hoesli R, Thorne MC. *The Annals of otology, rhinology, and laryngology.* 2011;120(10):635-40. <http://dx.doi.org/10.1177/000348941112001002>.

813. **Does pediatric housestaff experience influence tests ordered for infants in the neonatal intensive care unit?** Griffith CH, 3rd, Wilson JF, Desai NS, Rich EC. *Critical care medicine.* 1997;25(4):704-9. <http://dx.doi.org/10.1097/00003246-199704000-00024>.

814. **Artemether-Lumefantrine Versus Chloroquine for the Treatment of Uncomplicated Plasmodium knowlesi Malaria: An Open-Label Randomized Controlled Trial CAN KNOW.** Grigg MJ, William T, Barber BE, Rajahram GS, Menon J, Schimann E, et al. *Clin Infect Dis.* 2018;66(2):229-36. <http://dx.doi.org/10.1093/cid/cix779>.

815. **Efficacy of artesunate-mefloquine for chloroquine-resistant plasmodium vivax malaria in Malaysia: An open-label, randomized, controlled trial.** Grigg MJ, William T, Menon J, Barber BE, Wilkes CS, Rajahram GS, et al. *Clinical Infectious Diseases.* 2016;62(11):1403-11.

816. **Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial.** Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. *Lancet.* 2004;364(9430):263-9.

817. **Improving inappropriate medication and information transfer at hospital discharge: study protocol for a cluster RCT.** Grischott T, Zechmann S, Rachamin Y, Markun S, Chmiel C, Senn O, et al. *Implementation science : IS.* 2018;13(1):155. <http://dx.doi.org/10.1186/s13012-018-0839-1>.

818. **Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.** Groot N, Shaikhani D, Teng YKO, de Leeuw K, Bijl M, Dolhain R, et al. *Arthritis & rheumatology (Hoboken, NJ).* 2019;71(2):290-301. <http://dx.doi.org/10.1002/art.40697>.

819. **Treatment of wide-necked aneurysms with the Low-profile Visualized Intraluminal Support (LVIS Jr) device: a multicenter experience.** Grossberg JA, Hanel RA, Dabus G, Keigher K, Haussen DC, Sauvageau E, et al. *Journal of neurointerventional surgery.* 2017;9(11):1098-102. <http://dx.doi.org/10.1136/neurintsurg-2016-012687>. Epub 2016 Oct 27.

820. **Porphyria cutanea tarda. Clinical features and laboratory findings in 40 patients.** Grossman ME, Bickers DR, Poh-Fitzpatrick MB, Deleo VA, Harber LC. *The American journal of medicine.* 1979;67(2):277-86. [http://dx.doi.org/10.1016/0002-9343\(79\)90403-0](http://dx.doi.org/10.1016/0002-9343(79)90403-0).

821. **Tropheryma whipplei bivalvular endocarditis and polyarthralgia: a case report.** Gruber JR, Sarro R, Delaloye J, Surmely JF, Siniscalchi G, Tozzi P, et al. *Journal of medical case reports.* 2015;9:259. <http://dx.doi.org/10.1186/s13256-015-0746-x>.

822. **Prevalence and outcome of secondary hemophagocytic lymphohistiocytosis among sirs patients: Results from a prospective cohort study.** Gualdoni GA, Hofmann GA, Wohlfarth P, Winkler HM, Winkler S, Haslacher H, et al. *Journal of Clinical Medicine.* 2019;8(4).

823. **Methadone for persistent pain in the older patient.** Guay DRP. *Aging Health.* 2006;2(2):313-24.

824. **[Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis]**. Gubar EE, Bochkova AG, Bunchuk NV. *Terapevticheskii arkhiv*. 2008;80(5):25-30.
825. **Fibre-optic intubation teaching in sedated patients with anticipated difficult intubation**. Gueret G, Billard V, Bourgain JL. *European journal of anaesthesiology*. 2007;24(3):239-44. <http://dx.doi.org/10.1017/S0265021506001475>. Epub 2006 Nov 7.
826. **Sulfasalazine plus chloroquine-induced mood disorder in a patient with rheumatoid arthritis**. Gulec G, Yenilmez C, Ayranci U. *Iranian Journal of Medical Sciences*. 2009;34(1):72-5.
827. **Comparison of articular manifestations of mixed connective tissue disease and systemic lupus erythematosus on clinical examination and musculoskeletal ultrasound**. Gunashekar S, Prakash M, Minz RW, Sharma A, Sharma S, Dhir V. *Lupus*. 2018;27(13):2086-92.
828. **Resuscitation skills of pediatric residents and effects of Neonatal Resuscitation Program training**. Gunay I, Agin H, Devrim I, Apa H, Tezel B, Ozbas S. *Pediatrics international : official journal of the Japan Pediatric Society*. 2013;55(4):477-80. <http://dx.doi.org/10.1111/ped.12081>. Epub 2013 Jun 10.
829. **The acute abdomen: the role of computer-assisted diagnosis**. Gunn AA. *Bailliere's clinical gastroenterology*. 1991;5(3):639-65. [http://dx.doi.org/10.1016/0950-3528\(91\)90046-4](http://dx.doi.org/10.1016/0950-3528(91)90046-4).
830. **Alcohol use and alcohol-related problems among adolescents in China: A large-scale cross-sectional study**. Guo L, Deng J, He Y, Deng X, Huang J, Huang G, et al. *Medicine (Baltimore)*. 2016;95(38):e4533. <http://dx.doi.org/10.1097/MD.0000000000004533>.
831. **[A cross-sectional study on the status of tobacco use among junior middle school students in Shaanxi province]**. Guo Y, Wang AH, Liu CY, Mu CN, Wang B. *Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi*. 2018;39(2):184-7. <http://dx.doi.org/10.3760/cma.j.issn.0254-6450.2018.02.009>.
832. **[Survival analysis on HIV/AIDS patients who began receiving antiretroviral therapy from 2005 to 2015 in Tianjin]**. Guo Y, Zhou N, Zhao FN, Liu ZQ, Li L, Yu MH. *Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi*. 2019;40(8):936-40. <http://dx.doi.org/10.3760/cma.j.issn.0254-6450.2019.08.012>.
833. **Real-world clinical effectiveness and tolerability of hydroxychloroquine 400 mg in uncontrolled type 2 diabetes subjects who are not willing to initiate insulin therapy (HYQ-real-world study)**. Gupta A. *Current Diabetes Reviews*. 2019;15(6):510-9.
834. **Task shifting in surgery: Lessons from an Indian Heart Hospital**. Gupta B, Huckman RS, Khanna T. *Healthcare (Amsterdam, Netherlands)*. 2015;3(4):245-50. <http://dx.doi.org/10.1016/j.hjdsi.2015.08.005>. Epub 2015 Sep 9.
835. **A prospective 2-year study of 75 patients with adult-onset septic arthritis**. Gupta MN, Sturrock RD, Field M. *Rheumatology*. 2001;40(1):24-30.
836. **Occurrence of chloroquine-induced psychotic manifestations in children with malaria**. Gupte S. *Annals of tropical paediatrics*. 1992;12(2):229.
837. **Psychotic symptoms related to hydroxychloroquine**. Gurbuz-Ozgun B, Aslan-Kunt D, Sevincok L. *Klinik Psikofarmakoloji Bulteni*. 2014;24:S160.
838. **Can Total Thyroidectomy Be Safely Performed by Residents?: A Comparative Retrospective Multicenter Study**. Gurrado A, Bellantone R, Cavallaro G, Citton M, Constantinides V, Conzo G, et al. *Medicine*

(Baltimore). 2016;95(14):e3241. <http://dx.doi.org/10.1097/MD.0000000000003241>.

839. **Risk of QT prolonged and torsade de pointes induced by antipsychotics.** Gury C, Advenier E, Canceil O, Iaria P. *Journal de Pharmacie Clinique*. 2002;21(1):47-55.
840. **Can the experienced ICU physician predict ICU length of stay and outcome better than less experienced colleagues?** Gusmao Vicente F, Polito Lomar F, Melot C, Vincent JL. *Intensive Care Med*. 2004;30(4):655-9. <http://dx.doi.org/10.1007/s00134-003-2139-7>. Epub 2004 Jan 21.
841. **A double-blind comparative study of hydroxychloroquine and dapsone, alone and in combination, in rheumatoid arthritis.** Haar D, Solvkjaer M, Unger B, Rasmussen KJ, Christensen L, Hansen TM. *Scand J Rheumatol*. 1993;22(3):113-8. <http://dx.doi.org/10.3109/03009749309099254>.
842. **Autophagy inhibition to augment mTOR inhibition: A phase I/II trial of everolimus and hydroxychloroquine in patients with previously treated renal cell carcinoma.** Haas NB, Appleman LJ, Stein M, Redlinger M, Wilks M, Xu X, et al. *Clinical Cancer Research*. 2019;25(7):2080-7.
843. **Complications of cholecystectomy in district general hospitals.** Habib NA, Foo CL, el-Masry R, Gouli O, Cox S, Salem R, et al. *The British journal of clinical practice*. 1990;44(5):189-92.
844. **Post-tonsillectomy haemorrhage: a prospective, randomized, controlled clinical trial of cold dissection versus bipolar diathermy dissection.** Haddow K, Montague ML, Hussain SS. *The Journal of laryngology and otology*. 2006;120(6):450-4. <http://dx.doi.org/10.1017/S0022215106000120>. Epub 2006 Jan 27.
845. **Juvenile idiopathic arthritis. An old disease with a new name.** Häfner R. *Padiatrische Praxis*. 2006;68(1):127-48.
846. **Totally extraperitoneal (TEP) approach for inguinal hernia: the favorable learning curve for trainees.** Haidenberg J, Kendrick ML, Meile T, Farley DR. *Current surgery*. 2003;60(1):65-8. [http://dx.doi.org/10.1016/S0149-7944\(02\)00657-8](http://dx.doi.org/10.1016/S0149-7944(02)00657-8).
847. **Sarcoidosis: A comprehensive review and update for the dermatologist: Part I. Cutaneous disease.** Haimovic A, Sanchez M, Judson MA, Prystowsky S. *Journal of the American Academy of Dermatology*. 2012;66(5):699.e1-.e18+717-8.
848. **Antimalarials - are they effective and safe in rheumatic diseases?** Haładyj E, Sikora M, Felis-Giemza A, Olesinska M. *Reumatologia*. 2018;56(3):164-73.
849. **Chloroquine psychosis.** Halder D, Nagpauli, Patwari AK, Mullink DN. *Indian Journal of Pediatrics*. 1988;55(6):983-5.
850. **Development and evaluation of a simulation-based resuscitation scenario assessment tool for emergency medicine residents.** Hall AK, Pickett W, Dagnone JD. *Cjem*. 2012;14(3):139-46. <http://dx.doi.org/10.2310/8000.2012.110385>.
851. **Association of psychosis with antiphospholipid antibody syndrome: A systematic review of clinical studies.** Hallab A, Naveed S, Altibi A, Abdelkhalek M, Ngo HT, Le TP, et al. *General Hospital Psychiatry*. 2018;50:137-47.
852. **Drug related illness as a cause of admission to a department of respiratory medicine.** Hallas J, Davidson O, Grodum E, Damsbo N, Gram LF. *Respiration*. 1992;59(1):30-4.
853. **A nephrotic syndrome of tropical origin: Case report and short review of the aetiology.** Halleux D, Moerman F, Gavage P, Carpentier M, Van Esbroeck M, Craenen S, et al. *Acta Clinica Belgica*. 2014;69(5):379-81.

854. **Metabolic syndrome in systemic lupus erythematosus patients: Relationship to disease activity and neuropsychiatric lupus.** Hammam N, Rashad SM, Mohamed AAA. *Zeitschrift fur Rheumatologie*. 2018;77(10):938-45.
855. **Successful treatment of massive ascites due to lupus peritonitis with hydroxychloroquine in old-onset lupus erythematosus.** Hammami S, Bdioui F, Ouaz A, Loghmari H, Mahjoub S, Saffar H. *The Pan African medical journal*. 2014;18:165. <http://dx.doi.org/10.11604/pamj.2014.18.165.2080>. eCollection 2014.
856. **Accuracy and safety of ward based pleural ultrasound in the Australian healthcare system.** Hammerschlag G, Denton M, Wallbridge P, Irving L, Hew M, Steinfort D. *Respirology*. 2017;22(3):508-12. <http://dx.doi.org/10.1111/resp.12932>. Epub 2016 Nov 2.
857. **Is seniority of emergency physician associated with the weekend mortality effect? An exploratory analysis of electronic health records in the UK.** Han L, Fine J, Robinson SM, Boyle AA, Freeman M, Scholtes S. *Emergency medicine journal : EMJ*. 2019;36(12):708-15. <http://dx.doi.org/10.1136/emered-2018-208114>. Epub 2019 Oct 30.
858. **Management of rheumatoid arthritis.** Handa R. *National Medical Journal of India*. 2004;17(3):143-51.
859. **Systemic lupus erythematosus: Clinical recognition & overview of present day management.** Handa R, Wali JP. *Journal International Medical Sciences Academy*. 2002;15(1):28-34.
860. **Intralesional Versus Oral Chloroquine in Cutaneous Leishmaniasis: Comparison of Outcome, Duration of Treatment and Total Dose of Drug.** Hanif MM, Akram K, Mustafa G. *Journal of the College of Physicians and Surgeons--Pakistan : JCPSP*. 2016;26(4):260-2. <http://dx.doi.org/2287>.
861. **Retinal toxicity secondary to Plaquenil therapy.** Hanna B, Holdeman NR, Tang RA, Schiffman JS. *Optometry (St Louis, Mo)*. 2008;79(2):90-4. <http://dx.doi.org/10.1016/j.optm.2007.08.017>.
862. **Connective tissue panniculitis: Lupus panniculitis, dermatomyositis, morphea/scleroderma.** Hansen CB, Callen JP. *Dermatologic Therapy*. 2010;23(4):341-9.
863. **Cutaneous lupus erythematosus.** Hansen CB, Dahle KW. *Dermatologic Therapy*. 2012;25(2):99-111.
864. **Hydroxychloroquine sulphate in prevention of deep venous thrombosis following fracture of the hip, pelvis, or thoracolumbar spine.** Hansen EH, Jessing P, Lindewald H, Ostergaard P, Olesen T, Malver EI. *J Bone Joint Surg Am*. 1976;58(8):1089-93.
865.  **$\alpha/\beta$ -Arteether-induced mania in a predisposed adolescent.** Haq MZU, Mishra BR, Goyal N, Sinha VK. *General Hospital Psychiatry*. 2009;31(4):391-3.
866. **Risk factors for clinical coronary heart disease in systemic lupus erythematosus: The Lupus and Atherosclerosis Evaluation of Risk (LASER) study.** Haque S, Gordon C, Isenberg D, Rahman A, Lanyon P, Bell A, et al. *Journal of Rheumatology*. 2010;37(2):322-9.
867. **Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study.** Haraoui B, Cividino A, Stewart J, Guérette B, Keystone EC. *BMC Musculoskeletal Disorders*. 2011;12.
868. **The relationship between educational level and mortality. The Reykjavik Study.** Hardarson T, Gardarsdottir M, Gudmundsson KT, Thorgeirsson G, Sigvaldason H, Sigfusson N. *Journal of internal medicine*. 2001;249(6):495-502. <http://dx.doi.org/10.1046/j.1365-2796.2001.00834.x>.
869. **"Short report" staffing in practice: five years' experience of a consultant based service in obstetrics**

**and neonatal paediatrics.** Hare MJ, Miles RN, Lattimore CR, Southern JP. *Bmj*. 1990;300(6728):857-9.  
<http://dx.doi.org/10.1136/bmj.300.6728.857>.

870. **Malaria in Wisconsin 1981-1989: A review of cases and update on chemoprophylaxis.** Hargarten SW, McKinney WP. *Wisconsin Medical Journal*. 1991;90(5):215-7.

871. **A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand.** Harinasuta T, Bunnag D, Wernsdorfer WH. *Bulletin of the World Health Organization*. 1983;61(2):299-305.

872. **Chemokine blockade and chronic inflammatory disease: Proof of concept in patients with rheumatoid arthritis.** Haringman JJ, Kraan MC, Smeets TJM, Zwinderman KH, Tak PP. *Annals of the Rheumatic Diseases*. 2003;62(8):715-21.

873. **Suboptimal identification of patient-specific risk factors for poor wound healing can be improved by simple interventions.** Harris LS, Luck JE, Atherton RR. *International wound journal*. 2017;14(1):138-41.  
<http://dx.doi.org/10.1111/iwj.12573>. Epub 2016 Mar 22.

874. **Does age bias the aggressive treatment of elderly patients with rheumatoid arthritis?** Harrison MJ, Kim CA, Silverberg M, Paget SA. *Journal of Rheumatology*. 2005;32(7):1243-8.

875. **Suicidal behavior in dermatology.** Harth W, Hillert A, Hermes B, Seikowski K, Niemeier V, Freudenmann RW. *Hautarzt*. 2008;59(4):289-96.

876. **Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: A randomised controlled trial.** Hartkamp A, Geenen R, Godaert GLR, Bijl M, Bijlsma JWJ, Derksen RHW. *Annals of the Rheumatic Diseases*. 2010;69(6):1144-7.

877. **Laparoscopic left lateral sectionectomy as a training procedure for surgeons learning laparoscopic hepatectomy.** Hasegawa Y, Nitta H, Sasaki A, Takahara T, Ito N, Fujita T, et al. *Journal of hepato-biliary-pancreatic sciences*. 2013;20(5):525-30. <http://dx.doi.org/10.1007/s00534-012-0591-x>.

878. **QT dispersion and prognostication of the outcome in acute cardiotoxicities: A comparison with SAPS II and APACHE II scoring systems.** Hassanian-Moghaddam H, Amiri H, Zamani N, Rahimi M, Shadnia S, Taherkhani M. *Cardiovascular Toxicology*. 2014;14(2):129-33.

879. **Effect of imipramine on the rheumatoid factor titre of psychotic patients with depressive symptomatology.** Haydu GG, Goldschmidt L, Drymiotis AD. *Annals of the Rheumatic Diseases*. 1974;33(3):273-5.

880. **Interventions for enhancing medication adherence.** Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. *Cochrane Database of Systematic Reviews*. 2008(2).

881. **Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: A randomised, double-blind, placebo-controlled trial.** He J, Zhang R, Shao M, Zhao X, Miao M, Chen J, et al. *Annals of the Rheumatic Diseases*. 2020;79(1):141-9.

882. **'All by myself': interns' reports of their experiences taking consent in Irish hospitals.** Heaney RM, Murray M, Heaney AM, Doherty EM. *Irish journal of medical science*. 2019;188(1):259-63.  
<http://dx.doi.org/10.1007/s11845-018-1782-5>. Epub 2018 Mar 9.

883. **Health-related quality of life and functional ability in patients with early arthritis during remission steered treatment: results of the IMPROVED study.** Heimans L, Wevers-de Boer KV, Koudijs KK, Visser K, Goekoop-Ruiterman YP, Harbers JB, et al. *Arthritis research & therapy*. 2013;15(5):R173.  
<http://dx.doi.org/10.1186/ar4361>.

884. **[Burnout in anesthesiology and intensive care : is there a problem in Germany?]**. Heinke W, Dunkel P, Brahler E, Nubling M, Riedel-Heller S, Kaisers UX. *Der Anaesthesist*. 2011;60(12):1109-18. <http://dx.doi.org/10.1007/s00101-011-1947-3>. Epub 2011 Nov 11.
885. **Does hydroxychloroquine prevent the transmission of covid-19?** Heldwein FL, Calado A. *Annals of the Rheumatic Diseases*. 2020:annrheumdis-2020-217501.
886. **Ethnic differences in responses to disease modifying drugs.** Helliwell PS, Ibrahim G. *Rheumatology*. 2003;42(10):1197-201.
887. **Infectious diseases and therapeutic strategies. Report of the 24th Seminar Congress of the German Federal pharmacist's Chamber at Westerland/Sylt.** Hellwig B, Rall B. *Deutsche Apotheker Zeitung*. 1998;138(39):99-121.
888. **Frontal Fibrosing Alopecia: A Retrospective Analysis of 72 Patients from a German Academic Center.** Heppt MV, Letulé V, Laniauskaite I, Reinholz M, Tietze JK, Wolff H, et al. *Facial plastic surgery : FPS*. 2018;34(1):88-94.
889. **(Hydroxy)-chloroquine retinal toxicity: two case reports and safety guidelines.** Herman K, Leys A, Spileers W. *Bulletin de la Societe belge d'ophtalmologie*. 2002(284):21-9.
890. **[Influenceable surgical and anesthesiological risk factors for the development of cardiac and pulmonary complications in laparoscopic surgery of the colon]**. Hermeneit S, Muller M, Terzic A, Rodehorst A, Schamberger M, Bottger T. *Zentralblatt fur Chirurgie*. 2008;133(2):156-63. <http://dx.doi.org/10.1055/s-2008-1004739>.
891. **Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.** Hernández-Cruz B, Márquez-Saavedra E, Caliz-Caliz R, Navarro-Sarabia F. *Arthritis Research and Therapy*. 2016;18(1).
892. **Risk factors associated with mortality in systemic lupus erythematosus. A case-control study in a tertiary care center in Mexico City.** Hernández-Cruz B, Tapia N, Villa-Romero AR, Reyes E, Cardiel MH. *Clinical and Experimental Rheumatology*. 2001;19(4):395-401.
893. **Outcome of knee revisions for osteoarthritis and inflammatory arthritis with postero-stabilized arthroplasties: a mean ten-year follow-up with 90 knee revisions.** Hernigou P, Dubory A, Potage D, Roubineau F, Flouzat-Lachaniette CH. *International Orthopaedics*. 2017;41(4):757-63.
894. **Does the surgeon's experience influence the outcome of laparoscopic treatment of common bile duct stones?** Herrero A, Philippe C, Guillon F, Millat B, Borie F. *Surgical endoscopy*. 2013;27(1):176-80. <http://dx.doi.org/10.1007/s00464-012-2416-z>. Epub 2012 Jun 27.
895. **Differences in long-term disease activity and treatment of adult patients with childhood and adult-onset systemic lupus erythematosus.** Hersh AO, Von Scheven E, Yazdany J, Panopalis P, Trupin L, Julian L, et al. *Arthritis Care and Research*. 2009;61(1):13-20.
896. **Malaria chemoprophylaxis and self-treatment of malaria: Problems and current solutions.** Heusser R, Steffen R, Machler R, Fuchs E. *Schweizerische Rundschau fur Medizin/Praxis*. 1991;80(4):49-52.
897. **Medical disorders in psychiatric patients part I: Epidemiology, common diseases.** Hewer W, Fieß H. *Fortschritte der Neurologie Psychiatrie*. 2009;77(12):720-37.
898. **Laparoscopic pyloromyotomy can be performed safely by senior pediatric surgery trainees without supervision at high volume centers.** Heye P, Russell KW, Laje P. *J Pediatr Surg*. 2019.



<http://dx.doi.org/10.1016/j.jpedsurg.2019.11.023>.

899. **Systemic lupus erythematosus: A therapeutic update.** Heyneman CA. *Journal of Pharmacy Practice*. 2009;22(1):29-52.
900. **The new digit tourniquet ForgetMeNot((R)).** Hidalgo Diaz JJ, Muresan L, Touchal S, Bahlouli N, Liverneaux P, Facca S. *Orthopaedics & traumatology, surgery & research : OTSR*. 2018;104(1):133-6. <http://dx.doi.org/10.1016/j.otsr.2017.10.011>. Epub 2017 Dec 9.
901. **The effect of social support on educational outcomes.** Hilbert GA, Allen LR. *The Journal of nursing education*. 1985;24(2):48-52.
902. **Methotrexate in the treatment of rheumatoid arthritis.** Hilliquin P, Laoussadi S, Menkes CJ. *Revue du Rhumatisme et des Maladies Osteo-Articulaires*. 1991;58(6):419-26.
903. **Reported illness and compliance in US travelers attending an immunization facility.** Hilton E, Edwards B, Singer C. *Arch Intern Med*. 1989;149(1):178-9.
904. **Myopathies.** Hilton-Jones D. *Reviews in Clinical Gerontology*. 2001;11(2):131-47.
905. **Can laparoscopic appendectomy be safely performed by surgical residents without prior experience of open appendectomy?** Hiramatsu K, Toda S, Tate T, Fukui Y, Tomizawa K, Hanaoka Y, et al. *Asian journal of surgery*. 2018;41(3):270-3. <http://dx.doi.org/10.1016/j.asjsur.2016.12.003>. Epub 2017 Jan 27.
906. **Hydroxychloroquine for subglottic stenosis: a novel therapy in the battle for air.** Hirshoren N, Eliashar R, Weinberger JM. *The Laryngoscope*. 2010;120(4):743-4. <http://dx.doi.org/10.1002/lary.20848>.
907. **Cardiac Tamponade and Complete Heart Block During Transcatheter Aortic Valve Implantation: A Simulation Scenario for Anesthesia Providers.** Hitchcock R, Obr CJ, Subramani S. *MedEdPORTAL : the journal of teaching and learning resources*. 2018;14:10779. [http://dx.doi.org/10.15766/mep\\_2374-8265.10779](http://dx.doi.org/10.15766/mep_2374-8265.10779).
908. **A single sub-anaesthetic dose of propofol to reduce patient recall of peribulbar block.** Hocking G, Balmer HG. *Journal of the Royal Army Medical Corps*. 2000;146(3):196-8. <http://dx.doi.org/10.1136/jramc-146-03-08>.
909. **Functional disability and health-related quality of life in South Africans with early rheumatoid arthritis.** Hodkinson B, Musenge E, Ally M, Meyer PWA, Anderson R, Tikly M. *Scandinavian Journal of Rheumatology*. 2012;41(5):366-74.
910. **Impact of tutorial assistance in laparoscopic sigmoidectomy for acute recurrent diverticulitis.** Hoffmann H, Dell-Kuster S, Genstorfer J, Heizmann O, Kettelhack C, Langer I, et al. *Surgery today*. 2014;44(10):1869-78. <http://dx.doi.org/10.1007/s00595-013-0790-3>. Epub 2013 Nov 27.
911. **Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team.** Høgh B, Clarke PD, Camus D, Nothdurft HD, Overbosch D, Gunther M, et al. *Lancet*. 2000;356(9245):1888-94. [http://dx.doi.org/10.1016/s0140-6736\(00\)03260-8](http://dx.doi.org/10.1016/s0140-6736(00)03260-8).
912. **Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: A randomised, double-blind study.** Høgh B, Clarke PD, Camus D, Nothdurft HD, Overbosch D, Günther M, et al. *Lancet*. 2000;356(9245):1888-94.
913. **Neurosarcoidosis: A clinical dilemma.** Hoitsma E, Faber CG, Drent M, Sharma OP. *Lancet Neurology*. 2004;3(7):397-407.

914. **Comparison of bupivacaine and prilocaine used in Bier block--a double blind trial.** Hollingworth A, Wallace WA, Dabir R, Ellis SJ, Smith AF. *Injury*. 1982;13(4):331-6. [http://dx.doi.org/10.1016/0020-1383\(82\)90331-x](http://dx.doi.org/10.1016/0020-1383(82)90331-x).
915. **Adverse drug reactions in psychiatry.** Hollweg M, Krupinski M, Steinwachs A. *Medizinische Monatsschrift fur Pharmazeuten*. 1997;20(2):36-43.
916. **Psychoses induced by mefloquine - Problems of causality in two case reports.** Hollweg M, Soyka M, Greil W. *Psychiatrische Praxis*. 1995;22(1):33-6.
917. **[Outpatient laparoscopic cholecystectomy. Experience with the first 300 operations].** Holme JB, Skarderud F, Ahlburg P, Funch-Jensen PM. *Ugeskrift for laeger*. 2005;167(24):2638-40.
918. **Comparison of 2 cricothyrotomy techniques: standard method versus rapid 4-step technique.** Holmes JF, Panacek EA, Sakles JC, Brofeldt BT. *Annals of emergency medicine*. 1998;32(4):442-6. [http://dx.doi.org/10.1016/s0196-0644\(98\)70173-8](http://dx.doi.org/10.1016/s0196-0644(98)70173-8).
919. **Toxidromes.** Holstege CP, Borek HA. *Critical Care Clinics*. 2012;28(4):479-98.
920. **Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease.** Holvast B, Huckriede A, Wilschut J, Horst G, De Vries JJC, Benne CA, et al. *Annals of the Rheumatic Diseases*. 2006;65(7):913-8.
921. **Anesthesia crisis resource management: real-life simulation training in operating room crises.** Holzman RS, Cooper JB, Gaba DM, Philip JH, Small SD, Feinstein D. *Journal of clinical anesthesia*. 1995;7(8):675-87. [http://dx.doi.org/10.1016/0952-8180\(95\)00146-8](http://dx.doi.org/10.1016/0952-8180(95)00146-8).
922. **Experienced trauma team leaders save the lives of multiple-trauma patients with severe head injuries.** Hong ZJ, Chen CJ, Chan DC, Chen TW, Yu JC, Hsu SD. *Surgery today*. 2019;49(3):261-7. <http://dx.doi.org/10.1007/s00595-018-1723-y>. Epub 2018 Oct 9.
923. **Epilepsy in systemic lupus erythematosus: prevalence and risk factors.** Hopia L, Andersson M, Svenungsson E, Khademi M, Piehl F, Tomson T. *European Journal of Neurology*. 2020;27(2):297-307.
924. **Rheumatoid arthritis in the elderly: A distinct clinical entity?** Hopkins A, Lozada CJ. *Clinical Geriatrics*. 2008;16(1):40-8.
925. **The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity.** Hopkins AM, O'Doherty CE, Foster DJR, Suppiah V, Upton RN, Spargo LD, et al. *Journal of Clinical Pharmacy and Therapeutics*. 2014;39(5):555-60.
926. **Whipple's disease diagnosed during biological treatment for joint disease.** Hoppe E, Masson C, Audran M, Drillon M, Andreu M, Saraux A, et al. *Joint Bone Spine*. 2010;77(4):335-9. <http://dx.doi.org/10.1016/j.jbspin.2010.03.015>. Epub 2010 May 14.
927. **The use of anti-tumour necrosis factor- $\alpha$  therapies for rheumatoid arthritis in Singapore.** Hor BTY, Vasoo S, Koh ET. *APLAR Journal of Rheumatology*. 2006;9(2):157-60.
928. **Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic - Data from the ATTRA registry.** Horák P, Skácelová M, Hejduk K, Smržová A, Pavelka K. *Clinical Rheumatology*. 2013;32(10):1451-8.
929. **Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: An investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled Trial.** Hørslev-Petersen K,

Hetland ML, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, et al. *Annals of the Rheumatic Diseases*. 2014;73(4):654-61.

930. **Distal intestinal obstruction syndrome: an important differential diagnosis for abdominal pain in patients with cystic fibrosis.** Hort A, Hameed A, Middleton PG, Pleass HC. *ANZ J Surg*. 2019. <http://dx.doi.org/10.1111/ans.15357>.

931. **Clinical experience with halofantrine in the treatment of malaria.** Horton RJ, Parr SN, Bokor LC. *Drugs under Experimental and Clinical Research*. 1990;16(10):497-503.

932. **Meteorological conditions and sports deaths at school in Japan, 1993-1998.** Hoshi A, Inaba Y. *International journal of biometeorology*. 2005;49(4):224-31. <http://dx.doi.org/10.1007/s00484-004-0238-y>. Epub 2004 Dec 21.

933. **Reactive hemophagocytic syndrome in adult-onset still disease: Clinical features and long-term outcome: A case-control study of 8 patients.** Hot A, Toh ML, Coppéré B, Perard L, Girard Madoux MH, Mausservey C, et al. *Medicine*. 2010;89(1):37-46.

934. **Systemic involvement of acute generalized exanthematous pustulosis: A retrospective study on 58 patients.** Hotz C, Valeyrie-Allanore L, Haddad C, Bouvresse S, Ortonne N, Duong TA, et al. *British Journal of Dermatology*. 2013;169(6):1223-32.

935. **Systemic lupus erythematosus in Tunisia: Demographic and clinical analysis of 100 patients.** Houman MH, Smiti-Khanfir M, Ghorbell IB, Miled M. *Lupus*. 2004;13(3):204-11.

936. **Selected acute phase proteins and interleukin-6 in systemic lupus erythematosus patients treated with low doses of quinagolide.** Hrycek A, Pochopien-Kenig G, Scieszka J. *Autoimmunity*. 2007;40(3):217-22.

937. **Strategies to prevent acute diarrhea and upper respiratory tract infection among disaster relief workers.** Hsu IL, Chuang CC, Chi CH, Lin CH, Tsai MC. *Journal of Acute Medicine*. 2017;7(3):101-6.

938. **Prognostic profile of systemic sclerosis: Analysis of the clinical EUSTAR cohort in China.** Hu S, Hou Y, Wang Q, Li M, Xu D, Zeng X. *Arthritis Research and Therapy*. 2018;20(1).

939. **Chikungunya Virus-Associated Disease.** Hua C, Combe B. *Current Rheumatology Reports*. 2017;19(11).

940. **Retrospective cohort study on risk of hearing loss in patients with rheumatoid arthritis using claims data.** Huang CM, Chen HJ, Huang PH, Tsay GJ, Lan JL, Sung FC. *BMJ Open*. 2018;8(1).

941. **[Psychiatric disorders in pharyngitis patients and its associated factor analysis].** Huang H, He H, Wu X. *Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery*. 2015;29(17):1541-4.

942. **Factors associated with acceptability of circumcision among male drug users in western China: a cross-sectional study.** Huang J, Jiang J, Abdullah AS, Yang X, Wei B, Deng W, et al. *International journal of STD & AIDS*. 2013;24(7):541-7. <http://dx.doi.org/10.1177/0956462412473893>. Epub 2013 Jul 19.

943. **Repurposing psychiatric drugs as anti-cancer agents.** Huang J, Zhao D, Liu Z, Liu F. *Cancer Letters*. 2018;419:257-65.

944. **Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.** Huang K, Vinik O, Shojania K, Yeung J, Shupak R, Nimmo M, et al. *Rheumatology International*. 2019;39(11):1971-81.

945. **Radiological manifestations of pulmonary tuberculosis in patients subjected to anti-TNF-treatment.** Huang LK, Wu MH, Chang SC. *International Journal of Tuberculosis and Lung Disease*. 2014;18(1):95-101.
946. **A case-oriented web-based training system for breast cancer diagnosis.** Huang Q, Huang X, Liu L, Lin Y, Long X, Li X. *Computer methods and programs in biomedicine*. 2018;156:73-83. <http://dx.doi.org/10.1016/j.cmpb.2017.12.028>. Epub 2017 Dec 23.
947. **"What do you know?"--knowledge among village doctors of lead poisoning in children in rural China.** Huang R, Ning H, Baum CR, Chen L, Hsiao A. *BMC Public Health*. 2017;17(1):895. <http://dx.doi.org/10.1186/s12889-017-4895-2>.
948. **Patterns of inpatient dermatology referral and predictors of diagnostic accuracy in non-dermatologists in a Northern District hospital in Singapore.** Huang W, Chong WS. *Int J Dermatol*. 2016;55(5):546-52. <http://dx.doi.org/10.1111/ijd.12815>. Epub 2015 Jul 31.
949. **Incidence and risk factors of osteomyelitis in adult and pediatric systemic lupus erythematosus: a nationwide, population-based cohort study.** Huang YF, Chang YS, Chen WS, Tsao YP, Wang WH, Liao HT, et al. *Lupus*. 2019;28(1):19-26.
950. **Simplified cardioversion service with intravenous midazolam.** Hubner PJ, Gupta S, McClellan I. *Heart*. 2004;90(12):1447-9. <http://dx.doi.org/10.1136/hrt.2003.033050>.
951. **Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis.** Huizinga TWJ, Batalov A, Stoilov R, Lloyd E, Wagner T, Saurigny D, et al. *Arthritis Research and Therapy*. 2017;19(1).
952. **Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: Results of a pilot study.** Humbert M, Sanchez O, Fartoukh M, Jagot JL, Le Gall C, Sitbon O, et al. *European Respiratory Journal*. 1999;13(6):1351-6.
953. **Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial.** Humrich JY, von Spee-Mayer C, Siegert E, Bertolo M, Rose A, Abdirama D, et al. *The Lancet Rheumatology*. 2019;1(1):e44-e54.
954. **Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: A nationwide population-based cohort study.** Hung YM, Wang YH, Lin L, Wang PYP, Chiou JY, Wei JC. *Int J Clin Pract*. 2018;72(5):e13095. <http://dx.doi.org/10.1111/ijcp.13095>. Epub 2018 Apr 24.
955. **Education level and outcomes after acute myocardial infarction in China.** Huo X, Khera R, Zhang L, Herrin J, Bai X, Wang Q, et al. *Heart*. 2019;105(12):946-52. <http://dx.doi.org/10.1136/heartjnl-2018-313752>. Epub 2019 Jan 19.
956. **In Vivo Efficacy of Artemether-Lumefantrine and Chloroquine against Plasmodium vivax: A Randomized Open Label Trial in Central Ethiopia.** Hwang J, Alemayehu BH, Reithinger R, Tekleyohannes SG, Takele T, Birhanu SG, et al. *PLoS ONE*. 2013;8(5).
957. **Review of malaria risk and prevention for use in corporate travel.** Hymel P, Yang W. *Journal of Occupational and Environmental Medicine*. 2008;50(8):951-9.
958. **Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register.** Hyrich KL, Symmons DPM, Watson KD, Silman AJ. *Arthritis and Rheumatism*. 2006;54(6):1786-94.

959. **Perioperative complications and adverse events after lumbar spinal surgery: evaluation of 1012 operations at a single center.** Imagama S, Kawakami N, Tsuji T, Ohara T, Matsubara Y, Kanemura T, et al. *Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association*. 2011;16(5):510-5. <http://dx.doi.org/10.1007/s00776-011-0123-6>. Epub 2011 Jul 2.
960. **Pathological rupture of the spleen in malaria: Analysis of 55 cases (1958-2008).** Imbert P, Rapp C, Buffet PA. *Travel Medicine and Infectious Disease*. 2009;7(3):147-59.
961. **Malaria, mefloquine and the mind.** Ingram RJH, Ellis-Pegler RB. *New Zealand Medical Journal*. 1997;110(1042):137-8.
962. **Comparative Analysis of the Reconstruction of Individual Hip Anatomy Using 3 Different Cementless Stem Designs in Patients With Primary Hip Osteoarthritis.** Innmann MM, Spier K, Streit MR, Aldinger PR, Bruckner T, Gotterbarm T, et al. *The Journal of arthroplasty*. 2018;33(4):1126-32. <http://dx.doi.org/10.1016/j.arth.2017.11.026>. Epub 2017 Nov 21.
963. **Taurine's health influence on Japanese high school girls.** Ishikawa M, Arai S, Takano M, Hamada A, Kunimasa K, Mori M. *Journal of biomedical science*. 2010;17:S47. <http://dx.doi.org/10.1186/1423-0127-17-S1-S47>.
964. **Triple DMARD combination for rheumatoid arthritis resistant to methotrexate and steroid combination: A single-center experience.** Isik M, Halacli B, Atmaca O, Etgül S, Doğan I, Kiliç L, et al. *Rheumatology International*. 2013;33(6):1425-7.
965. **Longitudinal survey of Plasmodium falciparum infection in Vietnam: Characteristics of antimalarial resistance and their associated factors.** Isozumi R, Uemura H, Dao LD, Van Hanh T, Giang ND, Vien HV, et al. *Journal of Clinical Microbiology*. 2010;48(1):70-7.
966. **Abdominal wall hernia repair with a composite ePTFE/polypropylene mesh: clinical outcome and quality of life in 152 patients.** Iversen E, Lykke A, Hensler M, Jorgensen LN. *Hernia : the journal of hernias and abdominal wall surgery*. 2010;14(6):555-60. <http://dx.doi.org/10.1007/s10029-010-0729-1>. Epub 2010 Sep 21.
967. **Clinical practice and risk factors for immediate complications of endotracheal intubation in the intensive care unit: a prospective, multiple-center study.** Jaber S, Amraoui J, Lefrant JY, Arich C, Cohendy R, Landreau L, et al. *Critical care medicine*. 2006;34(9):2355-61. <http://dx.doi.org/10.1097/01.CCM.0000233879.58720.87>.
968. **The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1.** Jacobson JM, Bosinger SE, Kang M, Belaunzaran-Zamudio P, Matining RM, Wilson CC, et al. *AIDS research and human retroviruses*. 2016;32(7):636-47. <http://dx.doi.org/10.1089/AID.2015.0336>. Epub 2016 Apr 19.
969. **Clinical features and management of poisoning due to antimalarial drugs.** Jaeger A, Sauder P, Kopferschmitt J, Flesch F. *Medical Toxicology and Adverse Drug Experience*. 1987;2(4):242-73.
970. **Emergence and clinical insights into the pathology of Chikungunya virus infection.** Jaffar-Bandjee MC, Ramful D, Gauzere BA, Hoarau JJ, Krejbich-Trotot P, Robin S, et al. *Expert Review of Anti-Infective Therapy*. 2010;8(9):987-96.
971. **Comparison of clinical judgment and diagnostic ultrasonography in the diagnosis of acute appendicitis: experience with a score-aided diagnosis.** Jahn H, Mathiesen FK, Neckelmann K, Hovendal CP, Bellstrom T, Gottrup F. *The European journal of surgery = Acta chirurgica*. 1997;163(6):433-43.
972. **Influence of steroids and methotrexate on wound complications after elective rheumatoid hand and wrist surgery.** Jain A, Witbreuk M, Ball C, Nanchahal J. *Journal of Hand Surgery*. 2002;27(3):449-55.
973. **Comparative testing of reliability and audit utility of ordinal objective calculus complexity scores. Can**

- we make an informed choice yet?** Jaipuria J, Suryavanshi M, Sen TK. *BJU international*. 2016;118(6):958-68. <http://dx.doi.org/10.1111/bju.13597>. Epub 2016 Aug 17.
974. **Weekly dose of leflunomide for the treatment of refractory rheumatoid arthritis: An open pilot comparative study.** Jakez-Ocampo J, Richaud-Patin Y, Abraham Simón J, Llorente L. *Joint Bone Spine*. 2002;69(3):307-11.
975. **Imported malaria: a retrospective study in University Hospital, Kuala Lumpur, a ten-year experience.** Jamaiah I, Anuar AK, Najib NA, Zurainee MN. *The Medical journal of Malaysia*. 1998;53(1):6-9.
976. **Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.** James HM, Gillis D, Hissaria P, Lester S, Somogyi AA, Cleland LG, et al. *Journal of Rheumatology*. 2008;35(4):562-71.
977. **Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro.** Janowsky A, Eshleman AJ, Johnson RA, Wolfrum KM, Hinrichs DJ, Yang J, et al. *Psychopharmacology*. 2014;231(14):2771-83.
978. **One stage functional end-to-end stapled intestinal anastomosis and resection performed by nonexpert surgeons for the treatment of small intestinal obstruction in 30 dogs.** Jardel N, Hidalgo A, Leperlier D, Manassero M, Gomes A, Bedu AS, et al. *Veterinary surgery : VS*. 2011;40(2):216-22. <http://dx.doi.org/10.1111/j.1532-950X.2010.00784.x>. Epub 2011 Jan 11.
979. **[Clinical evaluation of the new screening procedures for hydroxychloroquine retinopathy, according to the American Academy of Ophthalmology guidelines. Prospective study of 184 patients].** Jaumouille S, Espargilliere D, Mouriaux F, Mortemousque B. *Journal francais d'ophtalmologie*. 2015;38(5):377-87. <http://dx.doi.org/10.1016/j.jfo.2015.01.005>. Epub 2015 Apr 24.
980. **Comparison of metronidazole with emetine & chloroquine in the treatment of hepatic amoebiasis--A controlled double blind study.** Jayawickrema US, Lionel ND. *The Ceylon medical journal*. 1975;20(2):99-102.
981. **Clinical picture of late-onset systemic lupus erythematosus in a group of Polish patients.** Jeleniewicz R, Suszek D, Majdan M. *Polskie Archiwum Medycyny Wewnetrznej*. 2015;125(7):538-44.
982. **Increasing delirium skills at the front door: results from a repeated survey on delirium knowledge and attitudes.** Jenkin RP, Al-Attar A, Richardson S, Myint PK, MacLulich AM, Davis DH. *Age and ageing*. 2016;45(4):517-22. <http://dx.doi.org/10.1093/ageing/afw066>. Epub 2016 Apr 26.
983. **Low frequency of complications in imported falciparum malaria: A review of 222 cases in south-eastern Norway.** Jensenius M, Rønning EJ, Blystad H, Bjørneklett A, Hellum KB, Bucher A, et al. *Scandinavian Journal of Infectious Diseases*. 1999;31(1):73-8.
984. **Clinical manifestations of autoimmune disease-related non-Hodgkin lymphoma: A Korean single-center, retrospective clinical study.** Jeon YW, Yoon JH, Lee SE, Eom KS, Kim YJ, Kim HJ, et al. *Korean Journal of Internal Medicine*. 2016;31(5):944-52.
985. **Surgical experience, workload and learning curve vs postoperative outcome.** Jerjes W, Hopper C. *European journal of oral implantology*. 2018;11:S167-s78.
986. **Third molar surgery: the patient's and the clinician's perspective.** Jerjes W, Upile T, Kafas P, Abbas S, Rob J, McCarthy E, et al. *International archives of medicine*. 2009;2(1):32. <http://dx.doi.org/10.1186/1755-7682-2-32>.
987. **A long-term five-year randomized controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis.** Jessop JD, O'Sullivan MM,

- Lewis PA, Williams LA, Camilleri JP, Plant MJ, et al. *British journal of rheumatology*. 1998;37(9):992-1002. <http://dx.doi.org/10.1093/rheumatology/37.9.992>.
988. **Psychosocial correlates of marijuana use and problem drinking in a national sample of adolescents.** Jessor R, Chase JA, Donovan JE. *American journal of public health*. 1980;70(6):604-13. <http://dx.doi.org/10.2105/ajph.70.6.604>.
989. **Adolescent development and the onset of drinking. A longitudinal study.** Jessor R, Jessor SL. *Journal of studies on alcohol*. 1975;36(1):27-51. <http://dx.doi.org/10.15288/jsa.1975.36.27>.
990. **Methotrexate versus azathioprine in the treatment of rheumatoid arthritis: A forty-eight-week randomized, double-blind trial.** Jeurissen MEC, Boerbooms AMT, Van de Putte LBA, Doesburg WH, Mulder J, Rasker JJ, et al. *Arthritis and Rheumatism*. 1991;34(8):961-72.
991. **Incidence rates and risk factors for injury events in high school students in Lijin County, China.** Jia C, Zhao Z, Bo Q, Zhang Y, Liu Z. *Journal of safety research*. 2005;36(2):133-7. <http://dx.doi.org/10.1016/j.jsr.2004.12.006>.
992. **The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease: A multicentre, randomized, double-blind, placebo-controlled trial.** Jia J, Wei C, Liang J, Zhou A, Zuo X, Song H, et al. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2016;12(2):89-99. <http://dx.doi.org/10.1016/j.jalz.2015.04.010>. Epub 2015 Jun 15.
993. **Efficacy and safety of rituximab in systemic lupus erythematosus and sjögren syndrome patients with refractory thrombocytopenia: A retrospective study of 21 cases.** Jiang B, Li T, Guo L, Shen H, Ye S, Chen S. *Journal of Clinical Rheumatology*. 2015;21(5):244-50.
994. **[Analysis of poisoning cases from Chinese National Injury Surveillance System, 2006 - 2008].** Jiang W, Wu CM, Deng X, Duan LL. *Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi*. 2010;31(9):1009-12.
995. **Preparing active patients for international travel.** Jiménez CE. *Physician and Sportsmedicine*. 2003;31(10):27-35.
996. **The abbreviated mental test: its use and validity.** Jitapunkul S, Pillay I, Ebrahim S. *Age and ageing*. 1991;20(5):332-6. <http://dx.doi.org/10.1093/ageing/20.5.332>.
997. **Microperimetric sensitivity in patients on hydroxychloroquine (Plaquenil) therapy.** Jivrajka RV, Genead MA, McAnany JJ, Chow CC, Mieler WF. *Eye (London, England)*. 2013;27(9):1044-52. <http://dx.doi.org/10.1038/eye.2013.112>. Epub 2013 Jun 14.
998. **Relationship between the in vitro radiosensitivity of skin fibroblasts and the expression of subcutaneous fibrosis, telangiectasia, and skin erythema after radiotherapy.** Johansen J, Bentzen SM, Overgaard J, Overgaard M. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*. 1996;40(2):101-9. [http://dx.doi.org/10.1016/0167-8140\(96\)01777-x](http://dx.doi.org/10.1016/0167-8140(96)01777-x).
999. **Effects of e-mails containing ADR information and a current case report on ADR reporting rate and quality of reports.** Johansson ML, Brunlöf G, Edward C, Wallerstedt SM. *European Journal of Clinical Pharmacology*. 2009;65(5):511-4.
1000. **Prevention of malaria in travelers.** Johnson BA, Kalra MG. *American Family Physician*. 2012;85(10):973-7.
1001. **Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.** Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, et al. *JAMA oncology*. 2016;2(2):234-40.
1002. **Improving the Quality of Ward-based Surgical Care With a Human Factors Intervention Bundle.**

- Johnston MJ, Arora S, King D, Darzi A. *Annals of surgery*. 2018;267(1):73-80. <http://dx.doi.org/10.1097/SLA.0000000000002089>.
1003. **The effect of hydroxychloroquine on symptoms of knee osteoarthritis: A double-blind randomized controlled clinical trial.** Jokar M, Mirfeizi Z, Keyvanpajouh K. *Iranian Journal of Medical Sciences*. 2013;38(3):221-6.
1004. **Introduction of a rapid response system: why we are glad we MET.** Jones D, Bellomo R. *Crit Care*. 2006;10(1):121. <http://dx.doi.org/10.1186/cc4841>.
1005. **Human-factors training for surgical trainees.** Jones M, Howells N, Mitchell S, Burnand H, Mutimer J, Longman R. *The clinical teacher*. 2014;11(3):165-9. <http://dx.doi.org/10.1111/tct.12147>.
1006. **Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines.** Jorge AM, Melles RB, Zhang Y, Lu N, Rai SK, Young LH, et al. *Arthritis research & therapy*. 2018;20(1):133. <http://dx.doi.org/10.1186/s13075-018-1634-8>.
1007. **Stress among surgical attending physicians and trainees: A quantitative assessment during trauma activation and emergency surgeries.** Joseph B, Parvaneh S, Swartz T, Haider AA, Hassan A, Kulvatunyong N, et al. *The journal of trauma and acute care surgery*. 2016;81(4):723-8. <http://dx.doi.org/10.1097/TA.0000000000001162>.
1008. **Association of prognostic factors and immunosuppressive treatment with long-term outcomes in neurosarcoidosis.** Joubert B, Chapelon-Abric C, Biard L, Saadoun D, Demeret S, Dormont D, et al. *JAMA Neurology*. 2017;74(11):1336-44.
1009. **Suicide by skull stab wounds: a case of drug-induced psychosis.** Jousset N, Rougé-Maillart C, Turcant A, Guilleux M, Le Bouil A, Tracqui A. *The American journal of forensic medicine and pathology*. 2010;31(4):378-81.
1010. **Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: Long-term follow-up and review of the literature.** Jovancevic B, Lindholm C, Pullerits R. *Lupus*. 2013;22(7):664-74.
1011. **Survival, Causes of Death, and Risk Factors Associated With Mortality in Spanish Systemic Sclerosis Patients: Results From a Single University Hospital.** Joven BE, Almodovar R, Carmona L, Carreira PE. *Seminars in Arthritis and Rheumatism*. 2010;39(4):285-93.
1012. **Long-term use of antimalarial drugs in rheumatic diseases.** Jover JA, Leon L, Pato E, Loza E, Rosales Z, Matias MA, et al. *Clinical and experimental rheumatology*. 2012;30(3):380-7.
1013. **Risk of Parkinson disease in Sjogren syndrome administered ineffective immunosuppressant therapies: A nationwide population-based study.** Ju UH, Liu FC, Lin CS, Huang WY, Lin TY, Shen CH, et al. *Medicine (Baltimore)*. 2019;98(14):e14984. <http://dx.doi.org/10.1097/MD.00000000000014984>.
1014. **Insect avoidance and malaria chemoprophylaxis.** Juckett RG. *Clinics in Family Practice*. 2005;7(4):653-73.
1015. **The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus.** Jung H, Bobba R, Su J, Shariati-Sarabi Z, Gladman DD, Urowitz M, et al. *Arthritis and rheumatism*. 2010;62(3):863-8. <http://dx.doi.org/10.1002/art.27289>.
1016. **Evaluation of do not resuscitate orders (DNR) in a Swiss community hospital.** Junod Perron N, Morabia A, De Torrente A. *Journal of medical ethics*. 2002;28(6):364-7. <http://dx.doi.org/10.1136/jme.28.6.364>.
1017. **Atrioventricular conduction time in rheumatoid arthritis.** Jurik AG, Moller P. *Rheumatology international*. 1985;5(5):205-7. <http://dx.doi.org/10.1007/bf00541337>.
1018. **Evolutive aspects of systemic lupus erythematosus in Dakar. Apropos of 30 cases.** Ka MM, Diouf B,



- Mbengue M, Kane A, Wade B, Diallo S, et al. Bulletin de la Société de pathologie exotique (1990). 1998;91(4):306-8.
1019. **Chloroquine psychosis.** Kabir SM. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1969;63(4):549.
1020. **Health professional perspectives on systems failures in transitional care for patients with dementia and their carers: a qualitative descriptive study.** Kable A, Chenoweth L, Pond D, Hullick C. BMC health services research. 2015;15:567. <http://dx.doi.org/10.1186/s12913-015-1227-z>.
1021. **Adherence to antimalarial combination therapy with sulfadoxine- pyrimethamine and artesunate in rural Tanzania.** Kachur SP, Khatib RA, Kaizer E, Fox SS, Abdulla SM, Bloland PB. American Journal of Tropical Medicine and Hygiene. 2004;71(6):715-22.
1022. **Visual results and complications of temporal incision phacoemulsification performed with the non-dominant left hand by junior ophthalmologists.** Kageyama T, Yaguchi S, Metori Y, Chida M, Koizumi K, Onishi T, et al. The British journal of ophthalmology. 2002;86(11):1222-4. <http://dx.doi.org/10.1136/bjo.86.11.1222>.
1023. **ON THE SIDE EFFECT OF CHLOROQUINE THERAPY IN RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS.** Kahan A, Bencze G, Olah M, Lakatos L. Orvosi hetilap. 1964;105:883-8.
1024. **Spectral-domain optical coherence tomography as a screening technique for chloroquine and hydroxychloroquine retinal toxicity.** Kahn JB, Haberman ID, Reddy S. Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye. 2011;42(6):493-7. <http://dx.doi.org/10.3928/15428877-20110804-02>. Epub 2011 Aug 11.
1025. **Antimalarial chemotherapy in the age of drug resistance.** Kain KC. Current Opinion in Infectious Diseases. 1993;6(6):803-11.
1026. **Prophylactic drugs for malaria: Why do we need another one?** Kain KC. Journal of Travel Medicine. 1999;6:S2-S7.
1027. **Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens.** Kain KC, Shanks GD, Keystone JS. Clinical Infectious Diseases. 2001;33(2):226-34.
1028. **Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab.** Kaine JL, Kivitz AJ, Birbara C, Luo AY. Journal of Rheumatology. 2007;34(2):272-9.
1029. **Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort.** Kaiser R, Cleveland CM, Criswell LA. Ann Rheum Dis. 2009;68(2):238-41. <http://dx.doi.org/10.1136/ard.2008.093013>. Epub 2008 Sep 9.
1030. **Adherence to hand hygiene protocol by clinicians and medical students at Queen Elizabeth Central Hospital, Blantyre-Malawi.** Kalata NL, Kamange L, Muula AS. Malawi medical journal : the journal of Medical Association of Malawi. 2013;25(2):50-2.
1031. **New concepts in antimalarial use and mode of action in dermatology.** Kalia S, Dutz JP. Dermatologic Therapy. 2007;20(4):160-74.
1032. **Therapeutic options in neurosarcoidosis.** Kaliszky Z, Walker A, Tyor WR. Expert Review of Neurotherapeutics. 2002;2(5):703-8.
1033. **Rheumatoid arthritis: Clinical guideline 2003.** Kalla AA, Stanwix A, Gotlieb D, Asherson RA, Mody GM. South African Medical Journal. 2003;93(12):991-1011.

1034. **Long-term follow-up of patients with idiopathic inflammatory myopathy at Waitemata District Health Board.** Kalluru R, Hart H, Corkill M, Ng KP. *New Zealand Medical Journal.* 2016;129(1429):50-6.
1035. **Current and future role of methotrexate in the therapeutic armamentarium for rheumatoid arthritis.** Kaltsonoudis E, Papagoras C, Drosos AA. *International Journal of Clinical Rheumatology.* 2012;7(2):179-89.
1036. **New directions in the treatment of systemic lupus erythematosus.** Kalunian K, Merrill JT. *Current Medical Research and Opinion.* 2009;25(6):1501-14.
1037. **Malaria: 30 Years of experience at a New York City teaching hospital.** Kambili C, Murray HW, Golightly LM. *American Journal of Tropical Medicine and Hygiene.* 2004;70(4):408-11.
1038. **An intensive monitoring of adverse drug reactions among elderly patients hospitalized in medical wards of a tertiary care hospital.** Kamejaliya DZ, Kapadia JD, Desai CK, Desai MK. *Journal of Young Pharmacists.* 2017;9(4):598-604.
1039. **A controlled trial to assess the effect of quinine, chloroquine, amodiaquine, and artesunate on Loa loa microfilaremia.** Kamgno J, Djomo PN, Pion SD, Thylefors B, Boussinesq M. *The American journal of tropical medicine and hygiene.* 2010;82(3):379-85. <http://dx.doi.org/10.4269/ajtmh.2010.09-0573>.
1040. **Treatment of cutaneous lupus erythematosus.** Kamoun MR, Fazaa B, Kharfi M. *Annales de Dermatologie et de Venereologie.* 2001;128(8):951-4.
1041. **Macular ganglion cell-inner plexiform layer thickness for detection of early retinal toxicity of hydroxychloroquine.** Kan E, Yakar K, Demirag MD, Gok M. *International ophthalmology.* 2018;38(4):1635-40. <http://dx.doi.org/10.1007/s10792-017-0635-y>. Epub 2017 Jul 10.
1042. **The liver is a common non-exocrine target in primary Sjögren's syndrome: A retrospective review.** Kaplan MJ, Ike RW. *BMC Gastroenterology.* 2002;2.
1043. **Mental health services, suicide and 7-day working.** Kapur N, Ibrahim S, Hunt IM, Turnbull P, Shaw J, Appleby L. *The British journal of psychiatry : the journal of mental science.* 2016;209(4):334-9. <http://dx.doi.org/10.1192/bjp.bp.116.184788>. Epub 2016 Jul 7.
1044. **Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial.** Karasic TB, O'Hara MH, Loaiza-Bonilla A, Reiss KA, Teitelbaum UR, Borazanci E, et al. *JAMA oncology.* 2019;5(7):993-8. <http://dx.doi.org/10.1001/jamaoncol.2019.0684>.
1045. **[Treatment of chronic polyarthritis with low-dose methotrexate].** Karger T, Rau R. *Deutsche medizinische Wochenschrift (1946).* 1988;113(21):839-46. <http://dx.doi.org/10.1055/s-2008-1067731>.
1046. **Kidney disease in RA patients: Prevalence and implication on RA-related drugs management: The MATRIX study.** Karie S, Gandjbakhch F, Janus N, Launay-Vacher V, Rozenberg S, Mai Ba CU, et al. *Rheumatology.* 2008;47(3):350-4.
1047. **Assessment of aortic stiffness among patients with systemic lupus erythematosus and rheumatoid arthritis by magnetic resonance imaging.** Karp G, Wolak A, Baumfeld Y, Bar-Am N, Novack V, Wolak T, et al. *International Journal of Cardiovascular Imaging.* 2016;32(6):935-44.
1048. **Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial.** Karstila KL, Rantalaiho VM, Mustonen JT, Mottonen TT, Hannonen PJ, Leirisalo-Repo M, et al. *Clinical and experimental rheumatology.* 2010;28(1):73-8.

1049. **Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: A retrospective study of 29 cases.** Kasitanon N, Petri M, Haas M, Magder LS, Fine DM. *Lupus*. 2008;17(1):40-5.
1050. **Trainee-associated outcomes in laparoscopic colectomy for cancer: propensity score analysis accounting for operative time, procedure complexity and patient comorbidity.** Kasten KR, Celio AC, Trakimas L, Manwaring ML, Spaniolas K. *Surgical endoscopy*. 2018;32(2):702-11. <http://dx.doi.org/10.1007/s00464-017-5726-3>. Epub 2017 Jul 19.
1051. **[Lessons learned from tuberculosis outbreak cases].** Kato S, Kuwabara K. *Kekkaku* : [Tuberculosis]. 2014;89(2):77-88.
1052. **Influenza immunisation of doctors at an Australian tertiary hospital: immunisation rate and factors contributing to uptake.** Kaufman J, Davis J, Krause V. *Communicable diseases intelligence quarterly report*. 2008;32(4):443-8.
1053. **Non-acute congestive heart failure with and without primary sodium retention: Evaluation of laboratory and clinical parameters following treatment with furosemide and potassium chloride.** Kaufman R, Goldberg SW, Bendavit GG, Campos CD, Thomé M, Oliveira L, et al. *Revista Brasileira de Medicina*. 2008;65(6):186-91.
1054. **Comparative efficacy of thalidomide and prednisolone in the treatment of moderate to severe erythema nodosum leprosum: A randomized study.** Kaur I, Dogra S, Narang T, De D. *Australasian Journal of Dermatology*. 2009;50(3):181-5.
1055. **Influence of resident and attending surgeon seniority on operative performance in laparoscopic cholecystectomy.** Kauvar DS, Braswell A, Brown BD, Harnisch M. *The Journal of surgical research*. 2006;132(2):159-63. <http://dx.doi.org/10.1016/j.jss.2005.11.578>. Epub 2006 Jan 18.
1056. **Allele and antigen-specific treatment of rheumatoid arthritis: A double blind, placebo controlled phase trial.** Kavanaugh A, Genovese M, Baughman J, Kivitz A, Bulpitt K, Olsen N, et al. *Journal of Rheumatology*. 2003;30(3):449-54.
1057. **Changes in cotherapies after initiation of disease - Modifying antirheumatic drug therapy in patients with rheumatoid arthritis.** Kawai VK, Grijalva CG, Arbogast PG, Curtis JR, Solomon DH, Delzell E, et al. *Arthritis Care and Research*. 2011;63(10):1415-24.
1058. **Teenagers' oral health attitudes and behavior in Japan: comparison by sex and age group.** Kawamura M, Takase N, Sasahara H, Okada M. *Journal of oral science*. 2008;50(2):167-74. <http://dx.doi.org/10.2334/josnusd.50.167>.
1059. **The frequency of cutaneous vasculitis is not increased in patients with rheumatoid arthritis treated with methotrexate.** Kaye O, Beckers CC, Paquet P, Arrese JE, Piérard GE, Malaise MG. *Journal of Rheumatology*. 1996;23(2):253-7.
1060. **Medication safety at the interface: evaluating risks associated with discharge prescriptions from mental health hospitals.** Keers RN, Williams SD, Vattakatuchery JJ, Brown P, Miller J, Prescott L, et al. *J Clin Pharm Ther*. 2015;40(6):645-54. <http://dx.doi.org/10.1111/jcpt.12328>. Epub 2015 Nov 3.
1061. **Survey of paediatric intravenous fluid prescription: are we safe in what we know and what we do?** Keijzers G, McGrath M, Bell C. *Emergency medicine Australasia : EMA*. 2012;24(1):86-97. <http://dx.doi.org/10.1111/j.1742-6723.2011.01503.x>. Epub 2011 Oct 24.
1062. **Doctors' knowledge of patient radiation exposure from diagnostic imaging requested in the**

**emergency department.** Keijzers GB, Britton CJ. *The Medical journal of Australia.* 2010;193(8):450-3.

1063. **Hospital Medicine (Part 1): what is wrong with acute hospital care?** Kellett J. *European journal of internal medicine.* 2009;20(5):462-4. <http://dx.doi.org/10.1016/j.ejim.2008.12.007>. Epub 2009 Jan 26.

1064. **Cystoid macular oedema and epiretinal membrane formation during progression of chloroquine retinopathy after drug cessation.** Kellner S, Weinitz S, Farmand G, Kellner U. *The British journal of ophthalmology.* 2014;98(2):200-6. <http://dx.doi.org/10.1136/bjophthalmol-2013-303897>. Epub 2013 Nov 1.

1065. **Pulmonary manifestations of Q fever: Analysis of 38 patients.** Kelm DJ, White DB, Fadel HJ, Ryu JH, Maldonado F, Baqir M. *Journal of Thoracic Disease.* 2017;9(10):3973-8.

1066. **Native joint septic arthritis: Epidemiology, clinical features, and microbiological causes in a New Zealand population.** Kennedy N, Chambers ST, Nolan I, Gallagher K, Werno A, Browne M, et al. *Journal of Rheumatology.* 2015;42(12):2392-7.

1067. **Priorities of undergraduate dental education: what do students think?** Kent GG, Croucher R. *Medical education.* 1992;26(5):372-7. <http://dx.doi.org/10.1111/j.1365-2923.1992.tb00189.x>.

1068. **Pharmacogenetics of antimalarial drugs: effect on metabolism and transport.** Kerb R, Fux R, Mörike K, Kreamsner PG, Gil JP, Gleiter CH, et al. *The Lancet Infectious Diseases.* 2009;9(12):760-74.

1069. **PLA2 gene expression in first episode drug naive patients.** Kerr DS, Serpa M, Talib LL, Van De Bilt MT, Alcantara J, Chaim T, et al. *Schizophrenia Research.* 2014;153:S139.

1070. **[Prevalence of anxiety disorders and depression among junior doctors and their links with their work].** Kerrien M, Pougnet R, Garlantezec R, Pougnet L, Le Galudec M, Lodde B, et al. *Presse Med.* 2015;44(4):e84-91. <http://dx.doi.org/10.1016/j.lpm.2014.06.042>. Epub 2015 Jan 29.

1071. **Radiation exposure of eyes, thyroid gland and hands in orthopaedic staff: a systematic review.** Kesavachandran CN, Haamann F, Nienhaus A. *European journal of medical research.* 2012;17:28. <http://dx.doi.org/10.1186/2047-783X-17-28>.

1072. **Increased levels of stress and burnout are related to decreased physician experience and to interventional gastroenterology career choice: findings from a US survey of endoscopists.** Keswani RN, Taft TH, Cote GA, Keefer L. *The American journal of gastroenterology.* 2011;106(10):1734-40. <http://dx.doi.org/10.1038/ajg.2011.148>.

1073. **Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.** Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, et al. *Annals of the Rheumatic Diseases.* 2015;74(2):333-40.

1074. **Antiinfective agents affecting cognition: A review.** Khalifa A. *Journal of Chemotherapy.* 2007;19(6):620-31.

1075. **Working Collaboratively: Outcomes of Geriatrician Input in Older Patients Undergoing Emergency Laparotomy in a District General Hospital.** Khan KA, Subramanian T, Richters M, Mubarak A, Saad Abdalla Al-Zawi A, Thorn CC, et al. *Cureus.* 2020;12(2):e7069. <http://dx.doi.org/10.7759/cureus.7069>.

1076. **Hyaluronic Acid-Hydroxychloroquine Conjugate Proposed for Treatment of COVID-19.** Khan R, Aroulmoji V.

1077. **Human antiprotozoal therapy: Past, present, and future.** Khaw M, Panosian CB. *Clinical Microbiology Reviews.* 1995;8(3):427-39.

1078. **New-onset refractory status epilepticus (NORSE) - The potential role for immunotherapy.** Khawaja AM, DeWolfe JL, Miller DW, Szaflarski JP. *Epilepsy and Behavior*. 2015;47:17-23.
1079. **[Sclerodermatous changes in porphyria cutanea tarda: six cases].** Khayat R, Dupuy A, Panse I, Bagot M, Cordoliani F. *Ann Dermatol Venereol*. 2013;140(10):589-97. <http://dx.doi.org/10.1016/j.annder.2013.04.092>. Epub 2013 May 31.
1080. **Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts.** Khraishi M, MacDonald D, Rampakakis E, Vaillancourt J, Sampalis JS. *Clinical Rheumatology*. 2011;30(7):877-85.
1081. **Semiquantified noncalcified coronary plaque in systemic lupus erythematosus.** Kiani AN, Vogel-Claussen J, Arbab-Zadeh A, Magder LS, Lima J, Petri M. *Journal of Rheumatology*. 2012;39(12):2286-93.
1082. **Predicting postoperative urinary retention after lower limb arthroplasty.** Kieffer WK, Kane TP. *Annals of the Royal College of Surgeons of England*. 2012;94(5):356-8. <http://dx.doi.org/10.1308/003588412X13171221591691>.
1083. **Infliximab and leflunomide combination therapy in rheumatoid arthritis: An open-label study.** Kiely PDW, Johnson DM. *Rheumatology*. 2002;41(6):631-7.
1084. **Rituximab therapy in renal amyloidosis secondary to rheumatoid arthritis.** Kilic L, Erden A, Sener YZ, Armagan B, Sari A, Kalyoncu U, et al. *Biomolecules*. 2018;8(4).
1085. **Impact of interstitial lung disease on mortality of patients with rheumatoid arthritis.** Kim D, Cho SK, Choi CB, Choe JY, Chung WT, Hong SJ, et al. *Rheumatology International*. 2017;37(10):1735-45.
1086. **Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: The APPEAL trial.** Kim HY, Hsu PN, Barba M, Sulaiman W, Robertson D, Vlahos B, et al. *International Journal of Rheumatic Diseases*. 2012;15(2):188-96.
1087. **Bile duct reconstruction by a young surgeon in living donor liver transplantation using right liver graft.** Kim JM, Cho W, Kwon CH, Joh JW, Park JB, Ko JS, et al. *Medicine (Baltimore)*. 2014;93(14):e84. <http://dx.doi.org/10.1097/MD.0000000000000084>.
1088. **Risk of Retinal Toxicity in Longterm Users of Hydroxychloroquine.** Kim JW, Kim YY, Lee H, Park SH, Kim SK, Choe JY. *The Journal of rheumatology*. 2017;44(11):1674-9. <http://dx.doi.org/10.3899/jrheum.170158>. Epub 2017 Sep 1.
1089. **Utility of Low-Profile Visualized Intraluminal Support Junior Stent as a Rescue Therapy for Treating Ruptured Intracranial Aneurysms During Complicated Coil Embolization.** Kim SS, Park H, Lee KH, Jung S, Yoon CH, Kim SK, et al. *World Neurosurg*. 2020;135:e710-e5. <http://dx.doi.org/10.1016/j.wneu.2019.12.110>. Epub 2019 Dec 27.
1090. **The treatment of inflammatory arthritis with methotrexate in clinical practice: Treatment duration and incidence of adverse drug reactions.** Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF. *Rheumatology*. 2005;44(1):61-6.
1091. **Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience.** Kindle SA, Wetter DA, Davis MDP, Pittelkow MR, Sciallis GF. *International Journal of Dermatology*. 2016;55(8):e431-e9.
1092. **Drug-induced psychiatric syndromes.** King DJ. *Prescribers' Journal*. 1986;26(3):50-8.
1093. **Systemic lupus erythematosus: modern strategies for management - a moving target.** King JK, Hahn BH. *Best Practice and Research in Clinical Rheumatology*. 2007;21(6):971-87.

1094. **[Persistent tachypnea in infants: possibly due to interstitial pneumonitis].** Kingma ML, van Krieken JH, de Nef JJ, Merth IT. *Ned Tijdschr Geneeskd.* 2002;146(24):1113-7.
1095. **Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis a randomized trial.** Kingsbury SR, Tharmanathan P, Keding A, Ronaldson SJ, Grainger A, Wakefield RJ, et al. *Annals of Internal Medicine.* 2018;168(6):385-95.
1096. **Prospective randomized trial comparing the Shouldice technique and plication darn for inguinal hernia.** Kingsnorth AN, Gray MR, Nott DM. *Br J Surg.* 1992;79(10):1068-70. <http://dx.doi.org/10.1002/bjs.1800791026>.
1097. **Attitudes of doctors and nurses towards incident reporting: a qualitative analysis.** Kingston MJ, Evans SM, Smith BJ, Berry JG. *The Medical journal of Australia.* 2004;181(1):36-9.
1098. **Systemic lupus erythematosus.** Kiriakidou M, Editors S, Cotton D, Taichman D, Williams S. *Annals of Internal Medicine.* 2013;159(7):ITC4.1-ITC4.16.
1099. **Computer calculated dose in paediatric prescribing.** Kirk RC, Li-Meng Goh D, Packia J, Min Kam H, Ong BK. *Drug Saf.* 2005;28(9):817-24. <http://dx.doi.org/10.2165/00002018-200528090-00006>.
1100. **Safety and patient response as indicated by biomarker changes to binding immunoglobulin protein in the phase I/IIA RAGULA clinical trial in rheumatoid arthritis.** Kirkham B, Chaabo K, Hall C, Garrood T, Mant T, Allen E, et al. *Rheumatology (United Kingdom).* 2016;55(11):1993-2000.
1101. **Increased mortality associated with cerebral contusions following trauma in the elderly: bad patients or bad management?** Kirkman MA, Jenks T, Bouamra O, Edwards A, Yates D, Wilson MH. *J Neurotrauma.* 2013;30(16):1385-90. <http://dx.doi.org/10.1089/neu.2013.2881>. Epub 2013 Jul 17.
1102. **Therapeutic efficacy and adverse events of hydroxychloroquine administration in Japanese systemic/cutaneous lupus erythematosus patients.** Kishi C, Motegi SI, Yasuda M, Ishikawa O. *Journal of Dermatology.* 2018;45(8):1020-2.
1103. **Follow-up study of the arrhythmic graduates from the schools under the heart disease program for students in Osaka.** Kitada M, Uheda K, Nakagawa T, Yamaguchi Y. *Japanese circulation journal.* 1984;48(12):1388-92. <http://dx.doi.org/10.1253/jcj.48.1388>.
1104. **Follow-up study into early adulthood of patients with congenital heart diseases.** Kitada M, Uheda K, Nakagawa T, Yamaguchi Y. *Japanese circulation journal.* 1987;51(12):1409-14. <http://dx.doi.org/10.1253/jcj.51.1409>.
1105. **The problems in controlling heart disease among elementary, junior and senior high school students--an analysis of fatal cases.** Kitada M, Uheda K, Yasutake K, Nakagawa T, Yamaguchi Y. *Japanese circulation journal.* 1983;47(11):1340-6. <http://dx.doi.org/10.1253/jcj.47.1340>.
1106. **Appetite loss as a potential predictor of suicidal ideation and self-harm in adolescents: A school-based study.** Kitagawa Y, Ando S, Yamasaki S, Foo JC, Okazaki Y, Shimodera S, et al. *Appetite.* 2017;111:7-11. <http://dx.doi.org/10.1016/j.appet.2016.12.026>. Epub 2016 Dec 21.
1107. **Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis.** Kitahara K, Kawai S. *Current Opinion in Rheumatology.* 2007;19(3):238-45.
1108. **Clinical characteristics and risk factors for low dose methotrexate toxicity: A cohort of 28 patients.** Kivity S, Zafirir Y, Loebstein R, Puzner R, Mouallem M, Mayan H. *Autoimmunity Reviews.* 2014;13(11):1109-13.
1109. **Dental students' self-assessed competence in geriatric dentistry.** Kiyak HA, Brudvik J. *Journal of dental education.* 1992;56(11):728-34.

1110. **Dapsone as Second-Line Treatment for Cutaneous Lupus Erythematosus? A Retrospective Analysis of 34 Patients and a Review of the Literature.** Klebes M, Wutte N, Aberer E. *Dermatology*. 2016;232(1):91-6.
1111. **Implementation of a paediatric peripheral intravenous catheter care bundle: A quality improvement initiative.** Kleidon TM, Cattanach P, Mihala G, Ullman AJ. *J Paediatr Child Health*. 2019;55(10):1214-23. <http://dx.doi.org/10.1111/jpc.14384>. Epub 2019 Jan 31.
1112. **Peripheral ulcerative keratitis and corneal melt: A 10-year single center review with historical comparison.** Knox Cartwright NE, Tole DM, Georgoudis P, Cook SD. *Cornea*. 2014;33(1):27-31.
1113. **Occupational driving as a risk factor for low back pain in active-duty military service members.** Knox JB, Orchowski JR, Scher DL, Owens BD, Burks R, Belmont PJ, Jr. *The spine journal : official journal of the North American Spine Society*. 2014;14(4):592-7. <http://dx.doi.org/10.1016/j.spinee.2013.06.029>. Epub 2013 Aug 27.
1114. **Retinopathy due to antimalarial drugs in patients with connective tissue diseases: Are they so innocent? A single center retrospective study.** Kobak S, Deveci H. *International Journal of Rheumatic Diseases*. 2010;13(3):e11-e5.
1115. **Infection Incidence Associated with External Ventriculostomy Placement: A Comparison of Outcomes in the Emergency Department, Intensive Care Unit, and Operating Room.** Kohli G, Singh R, Herschman Y, Mammis A. *World Neurosurg*. 2018;110:e135-e40. <http://dx.doi.org/10.1016/j.wneu.2017.10.129>. Epub 2017 Oct 31.
1116. **Participation of surgical residents does not adversely affect the outcome of inguinal hernia repair in an integrated teaching program.** Koizumi M, Sata N, Taguchi M, Kasahara N, Morishima K, Kaneda Y, et al. *Journal of surgical education*. 2012;69(5):605-10. <http://dx.doi.org/10.1016/j.j Surg.2012.05.015>. Epub 2012 Jul 2.
1117. **Ill-considered change of difficult drugs and treatments?** Kojda G, Hafner D. *Pharmazeutische Zeitung*. 2008;153(25):58-62.
1118. **Ototoxicity in Nigeria: Why it persists.** Kokong DD, Bakari A, Ahmad BM. *Ear, Nose and Throat Journal*. 2014;93(7):256-64.
1119. **Bone and joint diseases in the elderly.** Kolodny AL, Klipper AR. *Hospital Practice*. 1976;11(11):91-101.
1120. **Prevalence of Hypertension and Associated Risk Factors among Rural Bapedi Women in Sekhukhune Area, Limpopo Province, South Africa.** Koma MP, Lebelo SL. *Ecology of food and nutrition*. 2017;56(1):31-44. <http://dx.doi.org/10.1080/03670244.2016.1247702>. Epub 2016 Nov 14.
1121. **Monoarticular corticosteroid injection versus systemic administration in the treatment of rheumatoid arthritis patients: A randomized double-blind controlled study.** Konai MS, Furtado RNV, Santos MFD, Natour J. *Clinical and Experimental Rheumatology*. 2009;27(2):214-21.
1122. **An audit of the complications of intercostal chest drain insertion in a high volume trauma service in South Africa.** Kong VY, Oosthuizen GV, Sartorius B, Keene C, Clarke DL. *Annals of the Royal College of Surgeons of England*. 2014;96(8):609-13. <http://dx.doi.org/10.1308/003588414X14055925058599>.
1123. **Compatibility of clozapine and chloroquine [13].** Konig P, Kunz A. *Lancet*. 1991;338(8772):948.
1124. **Biological treatment in rheumatic diseases: Results from a longitudinal surveillance: Adverse events.** Kontinen L, Honkanen V, Uotila T, Pöllänen J, Waahtera M, Romu M, et al. *Rheumatology International*. 2006;26(10):916-22.
1125. **Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an**

- anti-tumor necrosis factor agent.** Koo BS, Hong S, Kim YJ, Kim YG, Lee CK, Yoo B. *Korean Journal of Internal Medicine*. 2015;30(1):104-9.
1126. **How long do we need teaching in the operating room? The true costs of achieving surgical routine.** Koperna T. *Langenbecks Arch Surg*. 2004;389(3):204-8. <http://dx.doi.org/10.1007/s00423-003-0421-3>. Epub 2003 Oct 14.
1127. **Diabetes-related avoidable hospitalizations in Taiwan.** Kornelius E, Huang CN, Yang YS, Lu YL, Peng CH, Chiou JY. *Primary care diabetes*. 2014;8(4):330-7. <http://dx.doi.org/10.1016/j.pcd.2014.02.001>. Epub 2014 Mar 4.
1128. **Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: A single center preliminary study.** Kotb R, Pinganaud C, Trichet C, Lambotte O, Dreyfus M, Delfraissy JF, et al. *European Journal of Haematology*. 2005;75(1):60-4.
1129. **Severe malaria in expatriates in an intensive care unit in Abidjan (Ivory Coast).** Kouamé K, Brouh Y, Soro L, Bissagnéné E, Eholié S, Amonkou A. *Annales Francaises d'Anesthesie et de Reanimation*. 2002;21(5):359-64.
1130. **Hydroxychloroquine retinal toxicity in two patients with dermatological conditions.** Kowalski T, Baker C, Mack HG. *The Australasian journal of dermatology*. 2018;59(4):e266-e8. <http://dx.doi.org/10.1111/ajd.12827>. Epub 2018 May 2.
1131. **Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis.** Krause D, Schleusser B, Herborn G, Rau R. *Arthritis and Rheumatism*. 2000;43(1):14-21.
1132. **Non-dermatological challenges of chronic itch.** Kremer AE, Mettang T, Weisshaar E. *Acta Dermato-Venereologica*. 2020;100(1):22-7.
1133. **Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial.** Kremer JM, Dougados M, Emery P, Durez P, Sibilía J, Shergy W, et al. *Arthritis and Rheumatism*. 2005;52(8):2263-71.
1134. **Therapeutic strategies in rheumatoid arthritis over a 40-year period.** Kremers HM, Nicola P, Crowson CS, O'Fallon WM, Gabriel SE. *Journal of Rheumatology*. 2004;31(12):2366-73.
1135. **Comparison of micronized halofantrine with chloroquine-antibiotic combinations for treating Plasmodium falciparum malaria in adults from Gabon.** Kreamsner PG, Wildling E, Jenne L, Graninger W, Bienzle U. *The American journal of tropical medicine and hygiene*. 1994;50(6):790-5. <http://dx.doi.org/10.4269/ajtmh.1994.50.790>.
1136. **Curing of chloroquine-resistant malaria with clindamycin.** Kreamsner PG, Winkler S, Brandts C, Graninger W, Bienzle U. *The American journal of tropical medicine and hygiene*. 1993;49(5):650-4. <http://dx.doi.org/10.4269/ajtmh.1993.49.650>.
1137. **Lupus erythematosus tumidus response to antimalarial treatment in 36 patients with emphasis on smoking.** Kreuter A, Gaifullina R, Tigges C, Kirschke J, Altmeyer P, Gambichler T. *Archives of Dermatology*. 2009;145(3):244-8.
1138. **Silent microemboli related to diagnostic cerebral angiography: a matter of operator's experience and patient's disease.** Krings T, Willmes K, Becker R, Meister IG, Hans FJ, Reinges MH, et al. *Neuroradiology*. 2006;48(6):387-93. <http://dx.doi.org/10.1007/s00234-006-0074-3>. Epub 2006 Apr 4.
1139. **The safety, efficacy, and quality of life of methotrexate with hydroxychloroquine as a combination versus methotrexate as monotherapy in rheumatoid arthritis: A comparative single-blinded prospective study.** Krishnamurthi J, Praveen D, Chowdary PR, Aanandhi MV. *Drug Invention Today*. 2019;12(11):2690-3.



1140. **[Comparative evaluation of the therapeutic effectiveness of small and regular doses of delagil in porphyria cutanea tarda].** Krivosheev BN. Vestnik dermatologii i venerologii. 1981(9):50-4.
1141. **Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF- $\alpha$  therapy.** Kroesen S, Widmer AF, Tyndall A, Hasler P. Rheumatology. 2003;42(5):617-21.
1142. **[The Czech Republic Register of Injuries (URCR)--experience with the database management in the Brno Faculty Hospital].** Krticka M, Planka L, Ira D, Masek M, Gal P. Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti. 2009;88(12):716-9.
1143. **Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand.** Krudsood S, Tangpukdee N, Muangnoicharoen S, Thanachartwet V, Luplertlop N, Srivilairit S, et al. The Korean journal of parasitology. 2007;45(2):111-4. <http://dx.doi.org/10.3347/kjp.2007.45.2.111>.
1144. **Hydroxychloroquine treatment for primary Sjogren's syndrome: a two year double blind crossover trial.** Kruize AA, Hene RJ, Kallenberg CG, van Bijsterveld OP, van der Heide A, Kater L, et al. Ann Rheum Dis. 1993;52(5):360-4. <http://dx.doi.org/10.1136/ard.52.5.360>.
1145. **A randomized, double-blind, parallel-group, comparative safety, and efficacy trial of oral co-artemether versus oral chloroquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in adults in India.** Kshirsagar NA, Gogtay NJ, Moorthy NS, Garg MR, Dalvi SS, Chogle AR, et al. The American journal of tropical medicine and hygiene. 2000;62(3):402-8. <http://dx.doi.org/10.4269/ajtmh.2000.62.402>.
1146. **Emergency unscheduled returns: can we do better?** Kuan WS, Mahadevan M. Singapore Med J. 2009;50(11):1068-71.
1147. **The potential role of the educational system in addressing the effect of inadequate knowledge of mosquitoes on use of insecticide-treated nets in Ghana.** Kudom AA, Mensah BA. Malar J. 2010;9:256. <http://dx.doi.org/10.1186/1475-2875-9-256>.
1148. **Chronic lupus erythematosus treatment.** Kuenzli S, Saurat JH. Nouvelles Dermatologiques. 2003;22(4):17-20.
1149. **Cutaneous lupus erythematosus: Update of therapeutic options: Part i.** Kuhn A, Ruland V, Bonsmann G. Journal of the American Academy of Dermatology. 2011;65(6):e179-e93.
1150. **Side-effects of frequently used drugs during holidays and travelling.** Kuhn M, Hartmann K, Gartmann J. Schweizerische Apotheker Zeitung. 1992;130(13):396-9.
1151. **Malaria chemoprophylaxis - A survey on drug-related adverse events.** Kühner S, Dräger-Hoppe HS, Dreesman J. Medizinische Welt. 2005;56(1):51-5.
1152. **Effectiveness and safety of hydroxychloroquine compared to teneligliptin in uncontrolled T2DM patients as add-on therapy.** Kumar A, Prakash AS. Journal of the ASEAN Federation of Endocrine Societies. 2019;34(1):87-91.
1153. **Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996-2013.** Kumar AB, Blixt EK, Drage LA, El-Azhary RA, Wetter DA. J Am Acad Dermatol. 2019;80(6):1658-63. <http://dx.doi.org/10.1016/j.jaad.2019.01.040>. Epub 2019 Jan 29.
1154. **Therapeutic assessment of primaquine for radical cure of plasmodium vivax malaria at primary and tertiary care centres in Southwestern India.** Kumar R, Guddattu V, Saravu K. Korean Journal of Parasitology. 2016;54(6):733-42.

1155. **Screening for chloroquine maculopathy in populations with uncertain reliability in outcomes of automatic visual field testing.** Kunavisarut P, Chavengsaksongkram P, Rothova A, Pathanapitoon K. Indian journal of ophthalmology. 2016;64(10):710-4. <http://dx.doi.org/10.4103/0301-4738.195018>.
1156. **Association between Knowledge about Comprehensive Food Education and Increase in Dental Caries in Japanese University Students: A Prospective Cohort Study.** Kunitomo M, Ekuni D, Mizutani S, Tomofuji T, Irie K, Azuma T, et al. Nutrients. 2016;8(3):114. <http://dx.doi.org/10.3390/nu8030114>.
1157. **Efficacy of chloroquine in the treatment of Plasmodium vivax malaria in Turkey.** Kurcer MA, Simsek Z, Zeyrek FY, Atay S, Celik H, Kat I, et al. Ann Trop Med Parasitol. 2004;98(5):447-51. <http://dx.doi.org/10.1179/000349804225021343>.
1158. **Pyogenic and amebic liver abscesses.** Kurland JE, Brann OS. Current Gastroenterology Reports. 2004;6(4):273-9.
1159. **Impact of team familiarity in the operating room on surgical complications.** Kurmann A, Keller S, Tschan-Semmer F, Seelandt J, Semmer NK, Candinas D, et al. World J Surg. 2014;38(12):3047-52. <http://dx.doi.org/10.1007/s00268-014-2680-2>.
1160. **Origin of DSS: to present the plan.** Kurtzke JF. Multiple sclerosis (Houndmills, Basingstoke, England). 2007;13(1):120-3. <http://dx.doi.org/10.1177/1352458506071584>.
1161. **The association between socioeconomic status and reactions to radiation exposure: a cross-sectional study after the Fukushima Daiichi nuclear power station accident.** Kusama T, Aida J, Tsuboya T, Sugiyama K, Yamamoto T, Igarashi A, et al. PLoS One. 2018;13(10):e0205531. <http://dx.doi.org/10.1371/journal.pone.0205531>. eCollection 2018.
1162. **Chloroquine-associated psychosis mimicking very late-onset schizophrenia: Case Report.** Kwak YT, Yang Y, Park SY. Geriatrics & gerontology international. 2015;15(8):1096-7. <http://dx.doi.org/10.1111/ggi.12490>.
1163. **Tight control early rheumatoid arthritis clinic in Hong Kong: A pilot study.** Kwok KY, Leung MH. Hong Kong Medical Journal. 2012;18(2):108-14.
1164. **Hydroxychloroquine-induced myopathy.** Kwon JB, Kleiner A, Ishida K, Godown J, Cialfoni E, Looney RJ. Journal of Clinical Rheumatology. 2010;16(1):28-31.
1165. **Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment.** Laas K, Peltomaa R, Kautiainen H, Puolakka K, Leirisalo-Repo M. Annals of the Rheumatic Diseases. 2006;65(7):924-8.
1166. **Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.** Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. Journal of Microbiology, Immunology and Infection. 2020.
1167. **An evaluation of health-related quality of life in patients with systemic lupus erythematosus using PROMIS and Neuro-QoL.** Lai JS, Beaumont JL, Jensen SE, Kaiser K, Van Brunt DL, Kao AH, et al. Clinical Rheumatology. 2017;36(3):555-62.
1168. **Real-world database examining the association between hydroxychloroquine and retinopathy in Taiwan.** Lai SW, Lin CL, Liao KF. The British journal of dermatology. 2019;180(3):670-1. <http://dx.doi.org/10.1111/bjd.17264>. Epub 2018 Nov 13.
1169. **Visual field and multifocal electroretinography and their correlations in patients on**

- hydroxychloroquine therapy.** Lai TY, Ngai JW, Chan WM, Lam DS. Documenta ophthalmologica Advances in ophthalmology. 2006;112(3):177-87. <http://dx.doi.org/10.1007/s10633-006-9006-0>. Epub 2006 Jun 28.
1170. **Status and Perspectives of Clinical Modes in Surgical Patients With Lung Cancer: A Retrospective Study.** Lai Y, Du H, Wang X, Shen C, Huang J, Li W, et al. Medicine (Baltimore). 2016;95(2):e2429. <http://dx.doi.org/10.1097/MD.0000000000002429>.
1171. **The immunogenicity of seasonal and pandemic influenza vaccination in autoimmune inflammatory rheumatic patients—a 6-month follow-up prospective study.** Lakota K, Perdan-Pirkmajer K, Sodin-Šemrl S, Čučnik S, Šubelj V, Prosenč K, et al. Clinical Rheumatology. 2019;38(5):1277-92.
1172. **Factors associated with low bone mineral density in female patients with systemic lupus erythematosus.** Lakshminarayanan S, Walsh S, Mohanraj M, Rothfield N. The Journal of rheumatology. 2001;28(1):102-8.
1173. **Clinical features and prognosis of late-onset systemic lupus erythematosus: Results from the 1000 faces of lupus study.** Lalani S, Pope J, De Leon F, Peschken C. Journal of Rheumatology. 2010;37(1):38-44.
1174. **Does ultrasonic advanced energy reduce lymphocele incidence in laparoscopic para-aortic lymphadenectomy?** Lamblin G, Chauvy L, Rannou C, Mathevet P, Chabert P, Mellier G, et al. European journal of obstetrics, gynecology, and reproductive biology. 2015;185:53-8. <http://dx.doi.org/10.1016/j.ejogrb.2014.11.030>. Epub 2014 Dec 2.
1175. **Late-onset, seropositive, erosive rheumatoid arthritis.** Lance NJ, Curran JJ. Seminars in Arthritis and Rheumatism. 1993;23(3):177-82.
1176. **A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis.** Landewe RB, Goei The HS, van Rijthoven AW, Breedveld FC, Dijkmans BA. Arthritis and rheumatism. 1994;37(5):637-43. <http://dx.doi.org/10.1002/art.1780370506>.
1177. **Antimalarial drug induced decrease in creatinine clearance.** Landewe RB, Vergouwen MS, Goei The SG, Van Rijthoven AW, Breedveld FC, Dijkmans BA. The Journal of rheumatology. 1995;22(1):34-7.
1178. **Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study.** Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul H, et al. medRxiv. 2020:2020.04.08.20054551.
1179. **[Effect of smoking on the effectiveness of antimalarial drugs for cutaneous lesions of patients with lupus: assessment in a prospective study].** Lardet D, Martin S, Truchetet F, Cuny JF, Virion JM, Schmutz JL. La Revue de medecine interne. 2004;25(11):786-91. <http://dx.doi.org/10.1016/j.revmed.2004.07.005>.
1180. **Is informed consent in cardiac surgery and percutaneous coronary intervention achievable?** Larobina ME, Merry CJ, Negri JC, Pick AW. ANZ J Surg. 2007;77(7):530-4. <http://dx.doi.org/10.1111/j.1445-2197.2007.04143.x>.
1181. **Hydroxychloroquine retinopathy: an emerging problem.** Latasiewicz M, Gourrier H, Yusuf IH, Luqmani R, Sharma SM, Downes SM. Eye (London, England). 2017;31(6):972-6. <http://dx.doi.org/10.1038/eye.2016.297>. Epub 2017 Feb 10.
1182. **Acute generalized exanthematous pustulosis and toxic epidermal necrolysis induced by hydroxychloroquine.** Lateef A, Tan KB, Lau TC. Clin Rheumatol. 2009;28(12):1449-52. <http://dx.doi.org/10.1007/s10067-009-1262-4>. Epub 2009 Aug 30.
1183. **Occurrence of serious infection in patients with rheumatoid arthritis treated with biologics and denosumab observed in a clinical setting.** Lau AN, Wong-Pack M, Rodjanapiches R, Ioannidis G, Wade S, Spangler

L, et al. *Journal of Rheumatology*. 2018;45(2):170-6.

1184. **Control of humoral immunity and auto-immunity by the CXCR4/CXCL12 axis in lupus patients following influenza vaccine.** Launay O, Paul S, Servettaz A, Roguet G, Rozenberg F, Lucht F, et al. *Vaccine*. 2013;31(35):3492-501.

1185. **Steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT): Characteristics, treatment and outcome in 251 cases from the literature.** Laurent C, Capron J, Quillerou B, Thomas G, Alamowitch S, Fain O, et al. *Autoimmunity Reviews*. 2016;15(12):1129-33.

1186. **Consultation with a child before departure for a developing country.** Laurent C, Sorge F. *Medecine Therapeutique Pediatrie*. 2003;6(4):240-51.

1187. **Drug-induced cutaneous lupus erythematosus: 88 new cases.** Laurinaviciene R, Sandholdt LH, Bygum A. *European Journal of Dermatology*. 2017;27(1):28-33.

1188. **Knowledge of malaria, risk perception, and compliance with prophylaxis and personal and environmental preventive measures in travelers exiting Zimbabwe from Harare and Victoria Falls International airport.** Laver SM, Wetzels J, Behrens RH. *Journal of Travel Medicine*. 2001;8(6):298-303.

1189. **Travelers' compliance to prophylactic measures and behavior during stay abroad: Results of a retrospective study of subjects returning to a travel medicine center in Italy.** Laverone E, Boccalini S, Bechini A, Belli S, Santini MG, Baretta S, et al. *Journal of Travel Medicine*. 2006;13(6):338-44.

1190. **Advancement of global health: key messages from the Disease Control Priorities Project.** Laxminarayan R, Mills AJ, Breman JG, Measham AR, Alleyne S, Claeson M, et al. *Lancet*. 2006;367(9517):1193-208.

1191. **Elderly-onset systemic lupus erythematosus: Prevalence, clinical course and treatment.** Lazaro D. *Drugs and Aging*. 2007;24(9):701-15.

1192. **Incidence of cancer in a cohort of patients with primary Sjögren's syndrome.** Lazarus MN, Robinson D, Mak V, Møller H, Isenberg DA. *Rheumatology*. 2006;45(8):1012-5.

1193. **Management of giant cell arteritis value of synthetic antimalarial agents. A retrospective study of thirty six patients.** Le Guennec P, Dromer C, Sixou L, Marc V, Coustals P, Fournie B. *Revue du Rhumatisme (English Edition)*. 1994;61(7):423-8.

1194. **Treatment of Horton disease. Value of synthetic antimalarials. Apropos of a retrospective study of 36 patients.** Le Guennec P, Dromer C, Sixou L, Marc V, Coustals P, Fournie B. *Revue du rhumatisme (Ed française : 1993)*. 1994;61(7):485-90.

1195. **Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: Evidence from the OMEGA trial.** Le Loët X, Nordström D, Rodriguez M, Rubbert A, Sarzi-Puttini P, Wouters JMGW, et al. *Journal of Rheumatology*. 2008;35(8):1538-44.

1196. **First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma.** Le Tourneau C, Dreno B, Kirova Y, Grob JJ, Jouary T, Dutriaux C, et al. *British Journal of Cancer*. 2016;114(11):1199-205.

1197. **Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.** Leandro MJ, Edwards JCW, Cambridge G. *Annals of the Rheumatic Diseases*. 2002;61(10):883-8.

1198. **Senior student smoking at school, student characteristics, and smoking onset among junior students:**

- a multilevel analysis.** Leatherdale ST, Cameron R, Brown KS, McDonald PW. Preventive medicine. 2005;40(6):853-9. <http://dx.doi.org/10.1016/j.ypmed.2004.09.033>.
1199. **Neuropsychiatric side effects with mefloquine chemoprophylaxis: Two case reports.** Lebain P, Juliard C, Davy JP, Dollfus S. Encephale. 2000;26(4):67-70.
1200. **Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients.** Lebeaux D, Frances C, Barete S, Wechsler B, Dubourg O, Renoux J, et al. Rheumatology (Oxford, England). 2012;51(3):557-61. <http://dx.doi.org/10.1093/rheumatology/ker366>. Epub 2011 Nov 25.
1201. **Q fever and Mediterranean spotted fever associated with hemophagocytic syndrome: Case study and literature review.** Lecronier M, Prendki V, Gerin M, Schneerson M, Renvoisé A, Larroche C, et al. International Journal of Infectious Diseases. 2013;17(8):e629-e33.
1202. **[Effect of graduate education on complication rate and costs of hip prosthesis implantation].** Lederer M, Muller RT. Der Unfallchirurg. 2001;104(7):577-82. <http://dx.doi.org/10.1007/s001130170088>.
1203. **Impact of operator expertise on collection of the APACHE II score and on the derived risk of death and standardized mortality ratio.** Ledoux D, Finfer S, McKinley S. Anaesthesia and intensive care. 2005;33(5):585-90. <http://dx.doi.org/10.1177/0310057X0503300506>.
1204. **Previous Intravitreal Therapy Is Associated with Increased Risk of Posterior Capsule Rupture during Cataract Surgery.** Lee AY, Day AC, Egan C, Bailey C, Johnston RL, Tsaloumas MD, et al. Ophthalmology. 2016;123(6):1252-6. <http://dx.doi.org/10.1016/j.ophtha.2016.02.014>. Epub 2016 Mar 18.
1205. **Pericentral hydroxychloroquine retinopathy in Korean patients.** Lee DH, Melles RB, Joe SG, Lee JY, Kim JG, Lee CK, et al. Ophthalmology. 2015;122(6):1252-6.
1206. **Height and shape of the skull base as risk factors for skull base penetration during endoscopic sinus surgery.** Lee JC, Song YJ, Chung YS, Lee BJ, Jang YJ. The Annals of otology, rhinology, and laryngology. 2007;116(3):199-205. <http://dx.doi.org/10.1177/000348940711600307>.
1207. **Cervical Pedicle Screw Placement Using Medial Funnel Technique.** Lee JH, Choi BK, Han IH, Choi WG, Nam KH, Kim HS. Korean Journal of Spine. 2017;14(3):84-8. <http://dx.doi.org/10.14245/kjs.2017.14.3.84>. Epub 2017 Sep 30.
1208. **Learning curve for total gastrectomy with D2 lymph node dissection: cumulative sum analysis for qualified surgery.** Lee JH, Ryu KW, Lee JH, Park SR, Kim CG, Kook MC, et al. Annals of surgical oncology. 2006;13(9):1175-81. <http://dx.doi.org/10.1245/s10434-006-9050-8>. Epub 2006 Sep 1.
1209. **Predictors of switching anti-tumor necrosis factor therapy in patients with ankylosing spondylitis.** Lee JW, Kang JH, Yim YR, Kim JE, Wen L, Lee KE, et al. PLoS ONE. 2015;10(7).
1210. **A cross-sectional retrospective assessment of anti-arthritis drugs in patients with arthritis in Korea.** Lee MC, Lee S, Suh DC, Kim J, Kong SX. Current Medical Research and Opinion. 2003;19(7):597-602.
1211. **Mortality rates under the care of junior and senior surgery residents in a surgical intensive care unit/neurologic intensive care unit: a 5-year retrospective cohort study at Taoyuan Armed Forces General Hospital.** Lee MT, Hu P, Hsi SC, Liu KY, Chao HM, Chen YQ. J Crit Care. 2008;23(4):550-5. <http://dx.doi.org/10.1016/j.jcrc.2008.03.039>. Epub 2008 Jul 21.
1212. **Germes on a plane - Infectious issues and the pediatric international traveler: What pediatricians should know.** Lee PJ, Krilov LR. Pediatric Annals. 2007;36(6):344-51.

1213. **Asthma Control and Prior Medical Care of Patients Presenting with Acute Asthma at the Emergency Department.** Lee PY, Khoo EM. Medical Journal of Malaysia. 2003;58(4):482-9.
1214. **Compliance and persistence with hydroxychloroquine in South Korean patients with systemic lupus erythematosus.** Lee SG, Park EK, Park JH, Kweon SM, Kim YK, Kim GT. Lupus. 2018;27(5):753-61. <http://dx.doi.org/10.1177/0961203317742712>. Epub 2017 Nov 20.
1215. **New approaches for preventing and treating chronic graft-versus-host disease.** Lee SJ. Blood. 2005;105(11):4200-6.
1216. **The role of antimalarial agents in the treatment of SLE and lupus nephritis.** Lee SJ, Silverman E, Bargman JM. Nature Reviews Nephrology. 2011;7(12):718-29.
1217. **Cost of illness and quality of life of patients with rheumatoid arthritis in South Korea.** Lee TJ, Park BH, Son HK, Song R, Shin KC, Lee EB, et al. Value in Health. 2012;15(1):S43-S9.
1218. **The direct medical cost of rheumatoid arthritis in Hong Kong.** Lee VWY, Chan CW, Chan LH, Ng TS, Tam LS, Li EKM, et al. Journal of Medical Economics. 2007;10(4):443-53.
1219. **Using Audience Response Systems for Real-Time Learning Assessments During Surgical Morbidity and Mortality Conference.** Leeds IL, DiBrito SR, Jones CD, Higgins RSD, Haut ER. Journal of surgical education. 2018;75(6):1535-43. <http://dx.doi.org/10.1016/j.jsurg.2018.05.010>. Epub 2018 Jul 4.
1220. **Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease.** Leffler J, Martin M, Gullstrand B, Tydén H, Lood C, Truedsson L, et al. Journal of Immunology. 2012;188(7):3522-31.
1221. **Malaria prophylaxis prescribed for travellers from New Zealand.** Leggat PA, Heydon JL, Menon A. The New Zealand medical journal. 1997;110(1050):319-21.
1222. **Role of primary prophylaxis for pneumocystis pneumonia in patients treated with systemic corticosteroids or other immunosuppressive agents for immune-mediated dermatologic conditions.** Lehman JS, Kalaaji AN. Journal of the American Academy of Dermatology. 2010;63(5):815-23.
1223. **PCR analysis is superior to histology for diagnosis of Whipple's disease mimicking seronegative rheumatic diseases.** Lehmann P, Ehrenstein B, Hartung W, Dragonas C, Reischl U, Fleck M. Scandinavian Journal of Rheumatology. 2017;46(2):138-42.
1224. **Efficacy and safety of meloxicam in patients with rheumatoid arthritis.** Lemmel EM, Bolten W, Burgos-Vargas R, Platt P, Nissilä M, Sahlberg D, et al. Journal of Rheumatology. 1997;24(2):282-90.
1225. **Orthopedic surgery in rheumatoid arthritis in the era of biologic therapy.** Leon L, Abasolo L, Carmona L, Rodriguez-Rodriguez L, Lamas JR, Hernandez-Garcia C, et al. Journal of Rheumatology. 2013;40(11):1850-5.
1226. **Variable compliance with clinical practice guidelines identified in a 1-day audit at 66 French adult intensive care units.** Leone M, Ragonnet B, Alonso S, Allaouchiche B, Constantin JM, Jaber S, et al. Critical care medicine. 2012;40(12):3189-95. <http://dx.doi.org/10.1097/CCM.0b013e31826571f2>.
1227. **The hyper-reactive malarial splenomegaly: A systematic review of the literature.** Leoni S, Buonfrate D, Angheben A, Gobbi F, Bisoffi Z. Malaria Journal. 2015;14(1).
1228. **Length of exposure to antiphospholipid antibodies, rather than age, is a risk factor for thrombosis: a retrospective single-centre observational study.** Les I, Parraza N, Anaut P, Eguiluz S, Sánchez C, Preciado ME, et al. Rheumatology International. 2018;38(2):229-38.

1229. **Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: A randomized controlled trial.** Leslie T, Mayan MI, Hasan MA, Safi MH, Klinkenberg E, Whitty CJM, et al. *Journal of the American Medical Association*. 2007;297(20):2201-9.
1230. **Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.** Leung LS, Neal JW, Wakelee HA, Sequist LV, Marmor MF. *American journal of ophthalmology*. 2015;160(4):799-805.e1. <http://dx.doi.org/10.1016/j.ajo.2015.07.012>. Epub 2015 Jul 17.
1231. **Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: Adverse events and other reasons leading to discontinuation of the treatment.** Levälampi T, Korpela M, Vuolteenaho K, Moilanen E. *Rheumatology International*. 2008;28(3):261-9.
1232. **Systemic Lupus Erythematosus in Children and Adolescents.** Levy DM, Kamphuis S. *Pediatric Clinics of North America*. 2012;59(2):345-64.
1233. **Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice.** Levy GD, Munz SJ, Paschal J, Cohen HB, Pince KJ, Peterson T. *Arthritis and rheumatism*. 1997;40(8):1482-6. <http://dx.doi.org/10.1002/art.1780400817>.
1234. **Drug interactions with antimalarial medications in older travelers: A clinical guide.** Lewis J, Gregorian T, Portillo I, Goad J. *Journal of Travel Medicine*. 2020;27(1).
1235. **Exploring the causes of junior doctors' prescribing mistakes: a qualitative study.** Lewis PJ, Ashcroft DM, Dornan T, Taylor D, Wass V, Tully MP. *British journal of clinical pharmacology*. 2014;78(2):310-9. <http://dx.doi.org/10.1111/bcp.12332>.
1236. **G6PD deficiency and antimalarial efficacy for uncomplicated malaria in Bangladesh: A prospective observational study.** Ley B, Alam MS, Thriemer K, Hossain MS, Kibria MG, Auburn S, et al. *PLoS ONE*. 2016;11(4).
1237. **Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China.** Li C, Wang XR, Ji HJ, Zhang XY, Li XF, Wang LZ, et al. *Clinical Rheumatology*. 2017;36(5):1023-9.
1238. **Pulmonary thromboendarterectomy is a curative resolution for chronic thromboembolic pulmonary hypertension associated with antiphospholipid syndrome: a retrospective cohort study.** Li C, Zhao J, Liu S, Song W, Zhu J, Hua L, et al. *Lupus*. 2018;27(14):2206-14.
1239. **Seniority of Emergency Physician, Patient Disposition and Outcome Following Disposition.** Li CJ, Syue YJ, Kung CT, Hung SC, Lee CH, Wu KH. *The American journal of the medical sciences*. 2016;351(6):582-8. <http://dx.doi.org/10.1016/j.amjms.2016.02.041>. Epub 2016 Mar 31.
1240. **The Impact of Emergency Physician Seniority on Clinical Efficiency, Emergency Department Resource Use, Patient Outcomes, and Disposition Accuracy.** Li CJ, Syue YJ, Tsai TC, Wu KH, Lee CH, Lin YR. *Medicine (Baltimore)*. 2016;95(6):e2706. <http://dx.doi.org/10.1097/MD.0000000000002706>.
1241. **[Study on the current situation and influential factors of anxiety sensitivity among middle school students in Chongqing].** Li QQ, Zhang DJ, Guo LT, Feng ZZ, Wu MX. *Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi*. 2007;28(9):868-71.
1242. **Clinical analysis of pulmonary nocardiosis in patients with autoimmune disease.** Li S, Song XY, Zhao YY, Xu K, Bi YL, Huang H, et al. *Medicine (United States)*. 2015;94(39):e1561.
1243. **Risk of severe herpes simplex virus infection in systemic lupus erythematosus: Analysis of**

**epidemiology and risk factors analysis in Taiwan.** Li TH, Lai CC, Wang WH, Chen WS, Tsao YP, Tsai CY, et al. *Annals of the Rheumatic Diseases*. 2019;78(7):941-6.

1244. **Clinical and laboratory profiles of primary Sjogren's syndrome in a Chinese population: A retrospective analysis of 315 patients.** Li X, Xu B, Ma Y, Li X, Cheng Q, Wang X, et al. *International Journal of Rheumatic Diseases*. 2015;18(4):439-46.

1245. **Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.** Li Z, An Y, Su H, Li X, Xu J, Zheng Y, et al. *International Journal of Rheumatic Diseases*. 2018;21(2):402-14.

1246. **Risk factors of perioperative complications and transfusion following total hip arthroplasty in systemic lupus erythematosus patients.** Li Z, Du Y, Xiang S, Feng B, Bian Y, Qian W, et al. *Lupus*. 2019;28(9):1134-40.

1247. **Causes and factors associated with frequent hospitalization in Chinese patients with systemic lupus erythematosus: An ambispective cohort study.** Liang H, Pan HF, Tao JH, Ye DQ. *Medical Science Monitor*. 2019;25:8061-8.

1248. **Providing instrumental social support is more beneficial to reduce mortality risk among the elderly with low educational level in Taiwan: a 12-year follow-up national longitudinal study.** Liao CC, Yeh CJ, Lee SH, Liao WC, Liao MY, Lee MC. *The journal of nutrition, health & aging*. 2015;19(4):447-53. <http://dx.doi.org/10.1007/s12603-014-0545-x>.

1249. **Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: A case-control study in Asia.** Liao TL, Chen YM, Liu HJ, Chen DY. *BMJ Open*. 2017;7(1).

1250. **Assessment of the "July Effect": outcomes after early resident transition in adult neurosurgery.** Lieber BA, Appelboom G, Taylor BE, Malone H, Agarwal N, Connolly ES, Jr. *J Neurosurg*. 2016;125(1):213-21. <http://dx.doi.org/10.3171/2015.4.JNS142149>. Epub 2015 Dec 15.

1251. **Sleep Disturbance and Depression Symptoms Mediate Relationship Between Pain and Cognitive Dysfunction in Lupus.** Lillis TA, Tirone V, Gandhi N, Weinberg S, Nika A, Sequeira W, et al. *Arthritis Care and Research*. 2019;71(3):406-12.

1252. **One-year tuberculosis risk in rheumatoid arthritis patients starting their first tumor necrosis factor inhibitor therapy from 2008 to 2012 in Taiwan: A nationwide population-based cohort study.** Lim CH, Lin CH, Chen DY, Chen YM, Chao WC, Liao TL, et al. *PLoS ONE*. 2016;11(11).

1253. **Chronic actinic dermatitis: results of patch and photopatch tests with Compositae, fragrances, and pesticides.** Lim HW, Cohen D, Soter NA. *J Am Acad Dermatol*. 1998;38(1):108-11. [http://dx.doi.org/10.1016/s0190-9622\(98\)70549-3](http://dx.doi.org/10.1016/s0190-9622(98)70549-3).

1254. **Laparoscopic cholecystectomy: an audit of our training programme.** Lim SH, Salleh I, Poh BK, Tay KH. *ANZ J Surg*. 2005;75(4):231-3. <http://dx.doi.org/10.1111/j.1445-2197.2005.03370.x>.

1255. **Idiopathic inflammatory myositis is associated with a high incidence of hypertension and diabetes mellitus.** Limaye VS, Lester S, Blumbergs P, Roberts-Thomson PJ. *International Journal of Rheumatic Diseases*. 2010;13(2):132-7.

1256. **Tumor necrosis factor-alpha antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study.** Lin KM, Cheng TT, Lin JC, Chen CJ. *Clin Rheumatol*. 2015;34(6):1039-46. <http://dx.doi.org/10.1007/s10067-015-2962-6>. Epub 2015 May 5.



1257. **Association of early-onset dementia with activities of daily living (ADL) in middle-aged adults with intellectual disabilities: the caregiver's perspective.** Lin LP, Hsu SW, Hsia YC, Wu CL, Chu C, Lin JD. *Res Dev Disabil.* 2014;35(3):626-31. <http://dx.doi.org/10.1016/j.ridd.2013.12.015>. Epub 2014 Jan 24.
1258. **Comparison of warfarin therapy clinical outcomes following implementation of an automated mobile phone-based critical laboratory value text alert system.** Lin SW, Kang WY, Lin DT, Lee J, Wu FL, Chen CL, et al. *BMC medical genomics.* 2014;7:S13. <http://dx.doi.org/10.1186/1755-8794-7-S1-S13>. Epub 2014 May 8.
1259. **Rheumatoid arthritis patients with hip fracture: a nationwide study.** Lin YC, Li YH, Chang CH, Hu CC, Chen DW, Hsieh PH, et al. *Osteoporosis International.* 2014;26(2):811-7.
1260. **Dapsone in the treatment of cutaneous lupus erythematosus.** Lindskov R, Reymann F. *Dermatologica.* 1986;172(4):214-7. <http://dx.doi.org/10.1159/000249338>.
1261. **Etanercept reduces synovitis as measured by magnetic resonance imaging in patients with active rheumatoid arthritis after only 6 weeks.** Lisbona MP, Maymo J, Perich J, Almirall M, Pérez-García C, Carbonell J. *Journal of Rheumatology.* 2008;35(3):394-7.
1262. **Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis.** Liu D, Li X, Zhang Y, Kwong JS, Li L, Zhang Y, et al. *Drug design, development and therapy.* 2018;12:1685-95. <http://dx.doi.org/10.2147/DDDT.S166893>. eCollection 2018.
1263. **Artemisinin-naphthoquine combination versus chloroquine-primaquine to treat vivax malaria: an open-label randomized and non-inferiority trial in Yunnan Province, China.** Liu H, Yang HL, Xu JW, Wang JZ, Nie RH, Li CF. *Malar J.* 2013;12:409. <http://dx.doi.org/10.1186/1475-2875-12-409>.
1264. **Combined Patterns Of Physical Activity And Screen-Related Sedentary Behavior Among Chinese Adolescents And Their Correlations With Depression, Anxiety And Self-Injurious Behaviors.** Liu M, Zhang J, Hu E, Yang H, Cheng C, Yao S. *Psychology research and behavior management.* 2019;12:1041-50. <http://dx.doi.org/10.2147/PRBM.S220075>. eCollection 2019.
1265. **Prevalence of Posttraumatic Stress Disorder (PTSD) and Its Correlates Among Junior High School Students at 53 Months After Experiencing an Earthquake.** Liu Q, Jiang M, Yang Y, Zhou H, Zhou Y, Yang M, et al. *Disaster medicine and public health preparedness.* 2019;13(3):414-8. <http://dx.doi.org/10.1017/dmp.2018.76>. Epub 2018 Sep 12.
1266. **[Sulphasalazine in patients with rheumatoid arthritis in China: a cross-sectional study].** Liu T, Wang XR, An Y, Zhou YS, Zhang XY, Duan TJ, et al. *Beijing da xue xue bao Yi xue ban = Journal of Peking University Health sciences.* 2012;44(2):188-94.
1267. **Effect of chinese herbs in enhancing prednisone for treatment of refractory rheumatoid arthritis.** Liu W, Liu XY, Wang Y. *Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban.* 2007;27(8):742-4.
1268. **Clinical features and prognosis of adult-onset still's disease: 75 cases from China.** Liu Z, Lv X, Tang G. *International Journal of Clinical and Experimental Medicine.* 2015;8(9):16634-9.
1269. **Atovaquone and proguani hydrochloride compared with chloroquine or pyrimethamine/sulfadoxine for treatment of acute Plasmodium falciparum malaria in Peru.** Llanos-Cuentas A, Campos P, Clendenes M, Canfield CJ, Hutchinson DB. *The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.* 2001;5(2):67-72.
1270. **Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria**

- (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.** Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, et al. *Lancet*. 2014;383(9922):1049-58. [http://dx.doi.org/10.1016/S0140-6736\(13\)62568-4](http://dx.doi.org/10.1016/S0140-6736(13)62568-4). Epub 2013 Dec 19.
1271. **Analysis of presenting symptoms and diagnoses made at Middlemore Hospital: an audit carried out between Monday 1 August and Sunday 7 August 2016.** Lock A, Wright M. *The New Zealand medical journal*. 2019;132(1495):30-41.
1272. **Investigating ward nurses' responses to deteriorating patients.** Loftus NW, Smith D. *Nursing standard (Royal College of Nursing (Great Britain))* : 1987). 2018. <http://dx.doi.org/10.7748/ns.2018.e11020>.
1273. **Left ventricular function in treatment-naive early rheumatoid arthritis.** Løgstrup BB, Deibjerg LK, Hedemann-Andersen A, Ellingsen T. *American Journal of Cardiovascular Disease*. 2014;4(2):79-86.
1274. **Impact of a spreading epidemic on medical students.** Loh LC, Ali AM, Ang TH, Chelliah A. *The Malaysian journal of medical sciences : MJMS*. 2006;13(2):30-6.
1275. **Impact of Residency Training Level on the Surgical Quality Following General Surgery Procedures.** Loiero D, Slankamenac M, Clavien PA, Slankamenac K. *World J Surg*. 2017;41(11):2652-66. <http://dx.doi.org/10.1007/s00268-017-4092-6>.
1276. **The accuracy and interobserver agreement in detecting the 'gallop sounds' by cardiac auscultation.** Lok CE, Morgan CD, Ranganathan N. *Chest*. 1998;114(5):1283-8. <http://dx.doi.org/10.1378/chest.114.5.1283>.
1277. **Risk factors for intra-operative complications during phacoemulsification performed by residents.** Lomi N, Sharma R, Khokhar S, Dada T, Vanathi M, Agarwal T. *International ophthalmology*. 2016;36(3):401-6. <http://dx.doi.org/10.1007/s10792-015-0146-7>. Epub 2015 Oct 22.
1278. **Study of clinical profile of acute respiratory distress syndrome and acute lung injury in Plasmodium vivax malaria.** Londhe C, Ganeriwal A, Desouza R. *Journal of Vector Borne Diseases*. 2014;51(4):339-42.
1279. **Malaria, mefloquine, madness, and mosquito nets [6].** Lonergan G, Pickering AH, Lobel HO, Lackritz EM, Campbell CC. *Journal of the American Medical Association*. 1991;265(21):2808-9.
1280. **Decreased platelet size is associated with platelet activation and anti-phospholipid syndrome in systemic lupus erythematosus.** Lood C, Tydén H, Gullstrand B, Nielsen CT, Heegaard NHH, Linge P, et al. *Rheumatology (United Kingdom)*. 2017;56(3):408-16.
1281. **Comparison between intra-articular ozone and placebo in the treatment of knee osteoarthritis: A randomized, double-blinded, placebo-controlled study.** Lopes De Jesus CC, Dos Santos FC, De Jesus LMOB, Monteiro I, Sant'Ana MSSC, Trevisani VFM. *PLoS ONE*. 2017;12(7).
1282. **Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort.** Lopez R, Davidson JE, Beeby MD, Egger PJ, Isenberg DA. *Rheumatology*. 2012;51(3):491-8.
1283. **Malaria prevention in international travel.** López-Vélez R. *Enfermedades Infecciosas y Microbiología Clínica*. 2003;21(5):248-60.
1284. **Clinicoepidemiological study of imported malaria in travelers and immigrants to Madrid.** López-Vélez R, Viana A, Pérez-Casas C, Martín-Aresti J, Turrientes MC, García-Camacho A. *Journal of Travel Medicine*. 1999;6(2):81-6.
1285. **Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: An open-label dose escalation study.** Lorenz HM, Schmitt WH, Tesar V, Müller-Ladner U, Tarner I, Hauser IA, et al.

Arthritis Research and Therapy. 2010;13(2).

1286. **Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: Twelve-year outcomes.** Lorenzi AR, Clarke AM, Wooldridge T, Waldmann H, Hale G, Symmons D, et al. *Arthritis and Rheumatism*. 2008;58(2):370-5.
1287. **Urticarial vasculitis in Northern Spain: Clinical study of 21 cases.** Loricera J, Calvo-Río V, Mata C, Ortiz-Sanjuán F, González-López MA, Alvarez L, et al. *Medicine (United States)*. 2014;93(1):53-60.
1288. **Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.** Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al. *Arthritis and Rheumatism*. 2008;58(5):1496-504.
1289. **Non-Traumatic corneal perforations: Aetiology, treatment and outcomes.** Loya-Garcia D, Serna-Ojeda JC, Pedro-Aguilar L, Jimenez-Corona A, Olivo-Payne A, Graue-Hernandez EO. *British Journal of Ophthalmology*. 2017;101(5):634-9.
1290. **Suppression of Myocardial 18F-FDG Uptake Through Prolonged High-Fat, High-Protein, and Very-Low-Carbohydrate Diet before FDG-PET/CT for Evaluation of Patients with Suspected Cardiac Sarcoidosis.** Lu Y, Grant C, Xie K, Sweiss NJ. *Clinical Nuclear Medicine*. 2017;42(2):88-94.
1291. **Mortality prediction in systemic lupus erythematosus patients with pulmonary infection.** Lu Z, Li J, Ji J, Gu Z, Da Z. *International Journal of Rheumatic Diseases*. 2019;22(6):1077-83.
1292. **Rational use of chloroquine and hydroxychloroquine in times of COVID-19.** Lucchetta RC, de Carvalho Mastroianni P. *Journal of Basic and Applied Pharmaceutical Sciences*. 2019.
1293. **Association of systemic lupus erythematosus with uranium exposure in a community living near a uranium-processing plant: a nested case-control study.** Lu-Fritts PY, Kottyan LC, James JA, Xie C, Buckholz JM, Pinney SM, et al. *Arthritis & rheumatology (Hoboken, NJ)*. 2014;66(11):3105-12. <http://dx.doi.org/10.1002/art.38786>.
1294. **Lichen planus and lichenoid reactions as a systemic disease.** Lukács J, Schliemann S, Elsner P. *Clinics in Dermatology*. 2015;33(5):512-9.
1295. **Dual diagnosis: prevalence, risk factors, and relationship with suicide risk in a nationwide sample of French prisoners.** Lukasiewicz M, Blecha L, Falissard B, Neveu X, Benyamina A, Reynaud M, et al. *Alcoholism, clinical and experimental research*. 2009;33(1):160-8. <http://dx.doi.org/10.1111/j.1530-0277.2008.00819.x>. Epub 2008 Oct 31.
1296. **Association of health-risk behaviors and depressive symptoms and anxiety symptoms: a school-based sample of Chinese adolescents.** Luo X, Zhou Y, Zheng R, Li X, Dai Y, Narayan A, et al. *Journal of public health (Oxford, England)*. 2019. <http://dx.doi.org/10.1093/pubmed/fdz115>.
1297. **A Systematic Review of the Clinical Value and Applications of Three-Dimensional Printing in Renal Surgery.** Lupulescu C, Sun Z. *Journal of clinical medicine*. 2019;8(7). <http://dx.doi.org/10.3390/jcm8070990>.
1298. **Acute leg ischaemia--a case for the junior surgeon?** Luther M, Alback A. *Annales chirurgiae et gynaecologiae*. 1995;84(4):373-8.
1299. **Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria.** Lwin KM, Phyo AP, Tarning J, Hanpithakpong W, Ashley EA, Lee SJ, et al. *Antimicrobial Agents and Chemotherapy*. 2012;56(3):1571-7.
1300. **A review of the use of methadone for the treatment of chronic noncancer pain.** Lynch ME. *Pain Research and Management*. 2005;10(3):133-44.

1301. **Coronary risk profile of young soldiers with coronary heart disease.** Lynch P. Journal of the Royal Army Medical Corps. 1985;131(1):38-41. <http://dx.doi.org/10.1136/jramc-131-01-09>.
1302. **Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography.** Lyons JS, Severns ML. American journal of ophthalmology. 2007;143(5):801-9. <http://dx.doi.org/10.1016/j.ajo.2006.12.042>. Epub 2007 Mar 6.
1303. **Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: A review.** Lyons JS, Severns ML. Documenta Ophthalmologica. 2009;118(1):29-36.
1304. **Retinal nerve fiber layer alteration in chronic users of chloroquine.** Lyra Antunes DDA, Dantas Cavalcanti H, Leal D, Viana Santana H, Vieira Santos RA, Ferreira Santos LP. Arquivos Brasileiros de Oftalmologia. 2005;68(2):195-7.
1305. **Management of hydrocephalus associated with autoimmune diseases: a series of 19 cases.** Ma B, Wu H, Yin H, Chang J, Wang L, Wang R, et al. Autoimmunity. 2017;50(7):422-7.
1306. **Episiotomy: What angle do you cut to the midline?** Ma K, Byrd L. European journal of obstetrics, gynecology, and reproductive biology. 2017;213:102-6. <http://dx.doi.org/10.1016/j.ejogrb.2017.04.006>. Epub 2017 Apr 11.
1307. **Drug-related problems in patients with rheumatoid arthritis.** Ma SN, Huri HZ, Yahya F. Therapeutics and Clinical Risk Management. 2019;15:505-24.
1308. **Chloroquine keratopathy of rheumatoid arthritis patients detected by in vivo confocal microscopy.** Ma X, He L, He D, Xu J. Current eye research. 2012;37(4):293-9. <http://dx.doi.org/10.3109/02713683.2011.631719>.
1309. **The causal ordering of mathematics anxiety and mathematics achievement: a longitudinal panel analysis.** Ma X, Xu J. Journal of adolescence. 2004;27(2):165-79. <http://dx.doi.org/10.1016/j.adolescence.2003.11.003>.
1310. **Prospective audit of discharge summary errors.** Macaulay EM, Cooper GG, Engeset J, Naylor AR. Br J Surg. 1996;83(6):788-90. <http://dx.doi.org/10.1002/bjs.1800830619>.
1311. **A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperazine in adults and children with uncomplicated Plasmodium falciparum malaria.** Macintyre F, Adoke Y, Tiono AB, Duong TT, Mombo-Ngoma G, Bouyou-Akotet M, et al. BMC Medicine. 2017;15(1).
1312. **A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma.** Mackean MJ, Kerr D, Lesko M, Svedberg A, Hansson F, Jodrell D, et al. British Journal of Cancer. 1998;78(12):1620-3.
1313. **The Impact of Different Postgraduate Year Training in Neurosurgery Residency on 30-Day Return to Operating Room: A National Surgical Quality Improvement Program Study.** Macki M, Fakhri M, Kandagatla P, Rubinfeld I, Chang V. World Neurosurg. 2018;114:e70-e6. <http://dx.doi.org/10.1016/j.wneu.2018.02.068>. Epub 2018 Feb 21.
1314. **The Impact of Different Postgraduate Year Training in Neurosurgery Residency on 30-Day Postoperative Outcomes.** Macki M, Fakhri M, Rubinfeld I, Chang V, Walters BC. Neurosurgery. 2019;84(3):778-87. <http://dx.doi.org/10.1093/neuros/nyy277>.
1315. **Value of a modified early obstetric warning system (MEOWS) in managing maternal complications in the peripartum period: an ethnographic study.** Mackintosh N, Watson K, Rance S, Sandall J. BMJ quality & safety.

- 2014;23(1):26-34. <http://dx.doi.org/10.1136/bmjqs-2012-001781>. Epub 2013 Jul 18.
1316. **Treatment and management of pseudogout: Insights for the clinician.** MacMullan P, McCarthy G. *Therapeutic Advances in Musculoskeletal Disease*. 2012;4(2):121-31.
1317. **Structured assessment tool to evaluate patient suitability for cataract surgery under local anaesthesia.** MacPherson R. *Br J Anaesth*. 2004;93(4):521-4. <http://dx.doi.org/10.1093/bja/ae243>. Epub 2004 Aug 20.
1318. **[Amsler grid and visual field on screening for chloroquine retinopathy].** Madalena BV, Oshima A, Serracarbassa PD. *Arquivos brasileiros de oftalmologia*. 2012;75(3):170-3. <http://dx.doi.org/10.1590/s0004-27492012000300004>.
1319. **Efficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: A cohort study.** Madan V, August PJ, Chalmers RJG. *Clinical and Experimental Dermatology*. 2010;35(1):27-30.
1320. **Tofacitinib in the treatment of active rheumatoid arthritis - Single-centre experience.** Madej M, Woytala P, Frankowski M, Lubiński L, Sokolik R, Sebastian A, et al. *Reumatologia*. 2019;57(4):192-8.
1321. **The prevention of malaria.** Magill AJ. *Primary Care - Clinics in Office Practice*. 2002;29(4):815-42.
1322. **Improving Outcomes Defending Patient Safety: The Learning Journey in Robotic Liver Resections.** Magistri P, Guerrini GP, Ballarin R, Assirati G, Tarantino G, Di Benedetto F. *Biomed Res Int*. 2019;2019:1835085. <http://dx.doi.org/10.1155/2019/1835085>. eCollection 2019.
1323. **Combined autophagy and HDAC inhibition: A phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.** Mahalingam D, Mita M, Sarantopoulos J, Wood L, Amaravadi RK, Davis LE, et al. *Autophagy*. 2014;10(8):1403-14.
1324. **Safety and feasibility of the teaching assistant role of senior surgical residents: a prospective randomized study.** Mahmoud A, Ward C, Padmesh H, Daher M. *Journal of surgical education*. 2012;69(2):249-52. <http://dx.doi.org/10.1016/j.jsurg.2011.11.002>.
1325. **Immunosuppressive therapy in Whipple's disease patients is associated with the appearance of gastrointestinal manifestations.** Mahnel R, Kalt A, Ring S, Stallmach A, Strober W, Marth T. *American Journal of Gastroenterology*. 2005;100(5):1167-73.
1326. **[Coxiella burnetti endocarditis on bioprosthesis. Apropos of a case].** Maillet JM, Ben Hamda K, Fouchard J. *Archives des maladies du coeur et des vaisseaux*. 1996;89(1):95-7.
1327. **Azithromycin and the risk of cardiovascular complications.** Maisch NM, Kochupurackal JG, Sin J. *Journal of Pharmacy Practice*. 2014;27(5):496-500.
1328. **Results of laparoscopic colorectal surgery from a national training center.** Maitra RK, Acheson AG, Gornall C, Scholefield JH, Williams JP, Maxwell-Armstrong CA. *Asian journal of surgery*. 2014;37(1):1-7. <http://dx.doi.org/10.1016/j.asjsur.2013.07.005>. Epub 2013 Aug 27.
1329. **Etanercept in a therapeutic program for the treatment of rheumatoid arthritis and ankylosing spondylitis-7 years' personal experience.** Majdan M, Kiełbik Z, Seweryn R. *Reumatologia*. 2013;51(1):15-9.
1330. **Effect of hydroxychloroquine on treatment and recurrence of acute brucellosis: a single-blind, randomized clinical trial.** Majzoobi MM, Hashemi SH, Mamani M, Keramat F, Poorolajal J, Ghasemi Basir HR. *International journal of antimicrobial agents*. 2018;51(3):365-9. <http://dx.doi.org/10.1016/j.ijantimicag.2017.08.009>.

Epub 2017 Aug 4.

1331. **Effects of antimalarial agents on plasma levels of chlorpromazine and its metabolites in schizophrenic patients.** Makanjuola ROA, Dixon PAF, Oforah E. *Tropical and Geographical Medicine*. 1988;40(1):31-3.
1332. **Frequency, presentation, and outcome of Takayasu arteritis in Western Australia.** Makin K, Isbel M, Nossent J. *Modern Rheumatology*. 2017;27(6):1019-23.
1333. **Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor- $\alpha$  inhibitors in India - An audit report.** Malaviya AN, Kapoor S, Garg S, Rawat R, Shankar S, Nagpal S, et al. *Journal of Rheumatology*. 2009;36(7):1414-20.
1334. **Examining psychosocial correlates of physical activity and sedentary behavior in youth with and without HIV.** Malete L, Tladi DM, Etnier JL, Makhanda J, Anabwani GM. *PLoS One*. 2019;14(12):e0225890. <http://dx.doi.org/10.1371/journal.pone.0225890>. eCollection 2019.
1335. **Phase Ib/II study of hydroxychloroquine in combination with chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC).** Malhotra J, Jabbour S, Orlick M, Riedlinger G, Guo Y, White E, et al. *Cancer Treatment and Research Communications*. 2019;21.
1336. **Comparing the Efficacy of Oral Chloroquine versus Oral Tetracycline in the Treatment of Cutaneous Leishmaniasis.** Malik F, Hanif MM, Mustafa G. *Journal of the College of Physicians and Surgeons--Pakistan : JCPSP*. 2019;29(5):403-5. <http://dx.doi.org/10.29271/jcpsp.2019.05.403>.
1337. **Anal involvement in pemphigus vulgaris.** Malik M, El Tal AEK, Ahmed AR. *Diseases of the Colon and Rectum*. 2006;49(4):500-6.
1338. **Low-dose prednisolone in rheumatoid arthritis: Adverse effects of various disease modifying antirheumatic drugs.** Malysheva OA, Wahle M, Wagner U, Pierer M, Arnold S, Häntzschel H, et al. *Journal of Rheumatology*. 2008;35(6):979-85.
1339. **Skin manifestations of sarcoidosis.** Mañá J, Marcoval J. *Presse Medicale*. 2012;41(6):e355-e74.
1340. **Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso.** Mandi G, Witte S, Meissner P, Coulibaly B, Mansmann U, Rengelshausen J, et al. *Tropical Medicine and International Health*. 2005;10(1):32-8.
1341. **Perspectives of clinical handover processes: a multi-site survey across different health professionals.** Manias E, Geddes F, Watson B, Jones D, Della P. *Journal of clinical nursing*. 2016;25(1):80-91. <http://dx.doi.org/10.1111/jocn.12986>. Epub 2015 Sep 28.
1342. **Should laparoscopic cholecystectomy be practiced in the developing world?: the experience of the first training program in Afghanistan.** Manning RG, Aziz AQ. *Annals of surgery*. 2009;249(5):794-8. <http://dx.doi.org/10.1097/SLA.0b013e3181a3eaa9>.
1343. **Antimalarials - Are they effective and safe in rheumatic disease? Focus on the neuropsychiatric side effects.** Manzo C. *Reumatologia*. 2018;56(5):333-4.
1344. **Consultation with the specialist: Malaria prophylaxis in children.** Maples HD, Schutze GE. *Pediatrics in Review*. 2006;27(9):346-50.
1345. **Cardiovascular death in rheumatoid arthritis: A population-based study.** Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. *Arthritis and Rheumatism*. 2005;52(3):722-32.

1346. **The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.** Marco H, Smith RM, Jones RB, Guerry MJ, Catapano F, Burns S, et al. BMC Musculoskeletal Disorders. 2014;15(1).
1347. **Plasmodium falciparum resistance to anti-malarial drugs in Papua New Guinea: evaluation of a community-based approach for the molecular monitoring of resistance.** Marfurt J, Smith TA, Hastings IM, Muller I, Sie A, Oa O, et al. Malar J. 2010;9:8. <http://dx.doi.org/10.1186/1475-2875-9-8>.
1348. **Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis.** Marguerie L, Flipo RM, Grardel B, Beaurain D, Duquesnoy B, Delcambre B. Joint Bone Spine. 2002;69(3):275-81.
1349. **Description of an initiation program to robotic in vivo gynecological surgery for junior surgeons.** Margueritte F, Sallee C, Legros M, Lacorre A, Piver P, Aubard Y, et al. Journal of gynecology obstetrics and human reproduction. 2020;49(3):101627. <http://dx.doi.org/10.1016/j.jogoh.2019.101627>. Epub 2019 Sep 6.
1350. **Inefficacy of Infliximab in Primary Sjögren's Syndrome: Results of the Randomized, Controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).** Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. Arthritis and Rheumatism. 2004;50(4):1270-6.
1351. **Use of Repository Corticotropin Gel (Acthar) in Progressive Nephrotic Syndrome Secondary to Transplant Glomerulopathy: A Report of Three Cases.** Markell M, Brar A, Bhela S, Patel A, Salifu M. Kidney Medicine. 2019;1(1):31-5.
1352. **Comparison of efficacy of chloroquine alone, azithromycin alone, and chloroquine azithromycin combination for the treatment of uncomplicated Plasmodium Falciparum Malaria.** Marko JL, Chourishi A, Pandey SP. International Journal of Pharmaceutical Sciences Review and Research. 2011;11(1):7-12.
1353. **A comparative study of efficacy of Azithromycin and chloroquin for the treatment of uncomplicated plasmodium falciparum malaria.** Marko JL, Pandey SP, Chourishi A. International Journal of Pharmacy and Pharmaceutical Sciences. 2011;3(3):221-4.
1354. **Chloroquine retinopathy: is there a safe daily dose?** Marks JS. Ann Rheum Dis. 1982;41(1):52-8. <http://dx.doi.org/10.1136/ard.41.1.52>.
1355. **Is chloroquine obsolete in treatment of rheumatic disease?** Marks JS, Power BJ. Lancet. 1979;1(8112):371-3. [http://dx.doi.org/10.1016/s0140-6736\(79\)92905-2](http://dx.doi.org/10.1016/s0140-6736(79)92905-2).
1356. **Long-term outcomes of patients with recent-onset rheumatoid arthritis after 10 years of tight controlled treatment: A randomized trial.** Markusse IM, Akdemir G, Dirven L, Goekoop-Ruiterman YPM, Van Groenendael JHLM, Han KH, et al. Annals of Internal Medicine. 2016;164(8):523-31.
1357. **Comparison of screening procedures in hydroxychloroquine toxicity.** Marmor MF. Archives of ophthalmology (Chicago, Ill : 1960). 2012;130(4):461-9. <http://dx.doi.org/10.1001/archophthalmol.2011.371>. Epub 2011 Dec 12.
1358. **Value of red targets and pattern deviation plots in visual field screening for hydroxychloroquine retinopathy.** Marmor MF, Chien FY, Johnson MW. JAMA Ophthalmology. 2013;131(4):476-80.
1359. **Effect of disease stage on progression of hydroxychloroquine retinopathy.** Marmor MF, Hu J. JAMA ophthalmology. 2014;132(9):1105-12. <http://dx.doi.org/10.1001/jamaophthalmol.2014.1099>.
1360. **Disparity between visual fields and optical coherence tomography in hydroxychloroquine retinopathy.** Marmor MF, Melles RB. Ophthalmology. 2014;121(6):1257-62. <http://dx.doi.org/10.1016/j.ophtha.2013.12.002>. Epub 2014 Jan 16.

1361. **The effectiveness and toxicity of cyclosporin a in rheumatoid arthritis: Longitudinal analysis of a population-based registry.** Marra CA, Esdaile JM, Guh D, Fisher JH, Chalmers A, Anis AH. *Arthritis Care and Research.* 2001;45(3):240-5.
1362. **Rheumatoid arthritis in the geriatric patient.** Marshall LL. *Journal of Geriatric Drug Therapy.* 1999;12(4):45-72.
1363. **New insights into Whipple's disease - A rare intestinal inflammatory disorder.** Marth T. *Digestive Diseases.* 2009;27(4):494-501.
1364. **Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine.** Martin D, Menschik D, Bryant-Genevier M, Ball R. *Drug Saf.* 2013;36(7):547-56. <http://dx.doi.org/10.1007/s40264-013-0051-9>.
1365. **Studies of D-penicillamine and hydroxychloroquine used in combination in the treatment of rheumatoid arthritis.** Martin MFR, Dixon JS, Sittton NG, Wright V. *Journal of Drug Development.* 1993;5(4):207-14.
1366. **Is routine ultrasound guidance for central line placement beneficial? A prospective analysis.** Martin MJ, Husain FA, Piesman M, Mullenix PS, Steele SR, Andersen CA, et al. *Current surgery.* 2004;61(1):71-4. <http://dx.doi.org/10.1016/j.cursur.2003.07.010>.
1367. **Cystic Lung Disease Among Patients With Sjögren Syndrome: Frequency, Natural History, and Associated Risk Factors.** Martínez-Balzano CD, Touray S, Kopec S. *Chest.* 2016;150(3):631-9.
1368. **Use of microperimetry to evaluate hydroxychloroquine and chloroquine retinal toxicity.** Martinez-Costa L, Victoria Ibanez M, Murcia-Bello C, Epifanio I, Verdejo-Gimeno C, Beltran-Catalan E, et al. *Canadian journal of ophthalmology Journal canadien d'ophtalmologie.* 2013;48(5):400-5. <http://dx.doi.org/10.1016/j.jcjo.2013.03.018>.
1369. **Durable clinical benefit in metastatic renal cell carcinoma patients who discontinue PD-1/PD-L1 therapy for immune-related adverse events.** Martini DJ, Hamieh L, McKay RR, Harshman LC, Brandao R, Norton CK, et al. *Cancer Immunology Research.* 2018;6(4):402-8.
1370. **Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosus.** Martin-Iglesias D, Artaraz J, Fonollosa A, Ugarte A, Arteagabeitia A, Ruiz-Irastorza G. *Lupus.* 2019;28(4):555-9. <http://dx.doi.org/10.1177/0961203319829826>. Epub 2019 Feb 12.
1371. **Drug-induced subacute cutaneous lupus erythematosus: Evidence for differences from its idiopathic counterpart.** Marzano AV, Lazzari R, Polloni I, Crosti C, Fabbri P, Cugno M. *British Journal of Dermatology.* 2011;165(2):335-41.
1372. **Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article.** Mascolo A, Berrino PM, Gareri P, Castagna A, Capuano A, Manzo C, et al. *Inflammopharmacology.* 2018;26(5):1141-9. <http://dx.doi.org/10.1007/s10787-018-0498-5>. Epub 2018 Jun 9.
1373. Mason S, O'Keeffe C, Carter A, O'Hara R, Stride C. *Health Services and Delivery Research.* An evaluation of foundation doctor training: a mixed-methods study of the impact on workforce well-being and patient care [the Evaluating the Impact of Doctors in Training (EDiT) study]. Southampton (UK): NIHR Journals Library Copyright (c) Queen's Printer and Controller of HMSO 2013. This work was produced by Mason et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of



advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.; 2013.

1374. **Indications for and complications of intestinal stomas in the children and adults at a tertiary care hospital in a resource-limited setting: a Tanzanian experience.** Massenga A, Chibwae A, Nuri AA, Bugimbi M, Munisi YK, Mfinanga R, et al. *BMC gastroenterology*. 2019;19(1):157. <http://dx.doi.org/10.1186/s12876-019-1070-5>.
1375. **Acute psychosis after ingestion of chloroquine.** Masson C, Chéron F, Gautier MS, Cambier J. *Presse médicale (Paris, France : 1983)*. 1990;19(7):334.
1376. **Associations between sleep habits and mental health status and suicidality in a longitudinal survey of monozygotic twin adolescents.** Matamura M, Tochigi M, Usami S, Yonehara H, Fukushima M, Nishida A, et al. *Journal of sleep research*. 2014;23(3):290-4. <http://dx.doi.org/10.1111/jsr.12127>. Epub 2014 Jan 24.
1377. **Malaria prevention in travelling children.** Mathijs S. *South African Family Practice*. 2012;54(6):482-4.
1378. **Trauma laparoscopy: A prospect of skills training (cohort study).** Matsevych OY, Koto MZ, Aldous C. *International journal of surgery (London, England)*. 2018;55:117-23. <http://dx.doi.org/10.1016/j.ijso.2018.05.033>. Epub 2018 May 26.
1379. **Efficacy of chloroquine-proguanil malaria prophylaxis in a non-immune population in Bangui, Central African Republic: A case-control study.** Matsika-Claquin MD, Ménard D, Fontanet AL, Ngwhotue A, Sarda J, Talarmin A. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2006;100(4):381-6.
1380. **Etanercept therapy for immune-mediated cochleovestibular disorders: A multi-center, open-label, pilot study.** Matteson EL, Choi HK, Poe DS, Wise C, Lowe VJ, McDonald TJ, et al. *Arthritis Care and Research*. 2005;53(3):337-42.
1381. **Multifocal electroretinographic evaluation of long-term hydroxychloroquine users.** Maturi RK, Yu M, Weleber RG. *Archives of ophthalmology (Chicago, Ill : 1960)*. 2004;122(7):973-81. <http://dx.doi.org/10.1001/archophth.122.7.973>.
1382. **The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal.** Mavrikakis I, Sfrikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, et al. *Ophthalmology*. 2003;110(7):1321-6. [http://dx.doi.org/10.1016/S0161-6420\(03\)00409-3](http://dx.doi.org/10.1016/S0161-6420(03)00409-3).
1383. **Mefloquine use, psychosis, and violence: A retinoid toxicity hypothesis.** Mawson AR. *Medical Science Monitor*. 2013;19(1):579-83.
1384. **Prolonged neuropsychiatric effects following management of chloroquine intoxication with psychotropic polypharmacy.** Maxwell NM, Nevin RL, Stahl S, Block J, Shugarts S, Wu AHB, et al. *Clinical Case Reports*. 2015;3(6):379-87.
1385. **The volume-mortality relation for radical cystectomy in England: retrospective analysis of hospital episode statistics.** Mayer EK, Bottle A, Darzi AW, Athanasiou T, Vale JA. *Bmj*. 2010;340:c1128. <http://dx.doi.org/10.1136/bmj.c1128>.
1386. **Efficacy of artemether-lumefantrine, the nationally-recommended artemisinin combination for the treatment of uncomplicated falciparum malaria, in southern Laos.** Mayxay M, Khanthavong M, Chanthongthip O, Imwong M, Pongvongsa T, Hongvanthong B, et al. *Malaria Journal*. 2012;11.
1387. **Thiamin supplementation does not reduce the frequency of adverse events after anti-malarial therapy among patients with falciparum malaria in southern Laos.** Mayxay M, Khanthavong M, Cox L, Sichanthongthip O,

Imwong M, Pongvongsa T, et al. *Malaria Journal*. 2014;13(1).

1388. **Dual inhibition of BDNF/TrkB and autophagy: a promising therapeutic approach for colorectal cancer.** Mazouffre C, Geyl S, Perraud A, Blondy S, Jauberteau MO, Mathonnet M, et al. *Journal of Cellular and Molecular Medicine*. 2017;21(10):2610-22.

1389. **Therapeutic adherence in patients with systemic lupus erythematosus: a cross-sectional study.** Mazur-Nicorici L, Sadovici-Bobeica V, Garabajiu M, Mazur M. *Romanian journal of internal medicine = Revue roumaine de medecine interne*. 2018;56(2):109-15.

1390. **Incident comorbidity among patients with rheumatoid arthritis treated or not with low-dose glucocorticoids: A retrospective study.** Mazzantini M, Talarico R, Doveri M, Consensi A, Cazzato M, Bazzichi L, et al. *Journal of Rheumatology*. 2010;37(11):2232-6.

1391. **The association between COMT rs4680 and 5-HTTLPR genotypes and concussion history in South African rugby union players.** Mc Fie S, Abrahams S, Patricios J, Suter J, Posthumus M, September AV. *Journal of sports sciences*. 2018;36(8):920-33. <http://dx.doi.org/10.1080/02640414.2017.1346274>. Epub 2017 Jun 30.

1392. **The association between harm avoidance personality traits and self-reported concussion history in South African rugby union players.** Mc Fie S, Abrahams S, Patricios J, Suter J, Posthumus M, September AV. *Journal of science and medicine in sport*. 2018;21(1):16-21. <http://dx.doi.org/10.1016/j.jsams.2017.07.014>. Epub 2017 Jul 20.

1393. **Rheumatic diseases in the elderly: Dealing with rheumatic pain in extended care facilities.** McCarberg BH. *Clinics in Geriatric Medicine*. 2005;21(3):543-61.

1394. **Malaria prevention, mefloquine neurotoxicity, neuropsychiatric illness, and risk-benefit analysis in the Australian defence force.** McCarthy S. *Journal of Parasitology Research*. 2015;2015.

1395. **Personal experience in the treatment of seropositive rheumatoid arthritis with drugs used in combination.** McCarty DJ. *Semin Arthritis Rheum*. 1993;23(2):42-9. [http://dx.doi.org/10.1016/s0049-0172\(10\)80006-x](http://dx.doi.org/10.1016/s0049-0172(10)80006-x).

1396. **Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis.** McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE, et al. *Clinical Infectious Diseases*. 2009;48(10):1364-71.

1397. **The dystonias.** McGeer EG, McGeer PL. *Canadian Journal of Neurological Sciences*. 1988;15(4):447-83.

1398. **Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus.** McGhie TK, Harvey P, Su J, Anderson N, Tomlinson G, Touma Z. *Clinical and experimental rheumatology*. 2018;36(4):545-51.

1399. **Low dose chloroquine decreases insulin resistance in human metabolic syndrome but does not reduce carotid intima-media thickness.** McGill JB, Johnson M, Hurst S, Cade WT, Yarasheski KE, Ostlund RE, et al. *Diabetology and Metabolic Syndrome*. 2019;11(1).

1400. **A pilot study of primary care physicians' attitude to weight loss surgery in England: are the young more prejudiced?** McGlone ER, Wingfield LR, Munasinghe A, Batterham RL, Reddy M, Khan OA. *Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery*. 2018;14(3):376-80. <http://dx.doi.org/10.1016/j.soard.2017.11.013>. Epub 2017 Nov 20.

1401. **Screening for ocular surface disease in the intensive care unit.** McHugh J, Alexander P, Kalhor A, Ionides A. *Eye (London, England)*. 2008;22(12):1465-8. <http://dx.doi.org/10.1038/sj.eye.6702930>. Epub 2007 Aug 24.

1402. **Progression of peripheral joint disease in psoriatic arthritis: A 5-yr prospective study.** McHugh NJ, Balachrishnan C, Jones SM. *Rheumatology*. 2003;42(6):778-83.

1403. **Understanding the patient perspective - Results of the rheumatoid arthritis: Insights, strategies & expectations (RAISE) patient needs survey.** McInnes IB, Combe B, Burmester G. *Clinical and Experimental Rheumatology*. 2013;31(3):350-7.
1404. **Bioavailability of hydroxychloroquine tablets in patients with rheumatoid arthritis.** McLachlan AJ, Tett SE, Cutler DJ, Day RO. *British journal of rheumatology*. 1994;33(3):235-9. <http://dx.doi.org/10.1093/rheumatology/33.3.235>.
1405. **Chemoprophylaxis of malaria in non-immune residents in Dar es Salaam, Tanzania.** McLarty DG, Webber RH, Jaatinen M, Kihamia CH, Murru M, Kumano M, et al. *Lancet*. 1984;2(8404):656-9. [http://dx.doi.org/10.1016/s0140-6736\(84\)91223-6](http://dx.doi.org/10.1016/s0140-6736(84)91223-6).
1406. **Toward earlier diagnosis of splenic injury?** McLaughlan CA, Maheson M, Sloan JP, Dove F. *Archives of emergency medicine*. 1988;5(1):34-7. <http://dx.doi.org/10.1136/emj.5.1.34>.
1407. **Predictors of cognitive dysfunction in patients with systemic lupus erythematosus.** McLaurin EY, Holliday SL, Williams P, Brey RL. *Neurology*. 2005;64(2):297-303. <http://dx.doi.org/10.1212/01.WNL.0000149640.78684.EA>.
1408. **Baseline factors predicting change from the initial DMARD treatment during the first 2 years of rheumatoid arthritis: Experience in the ERAN inception cohort.** McWilliams DF, Kiely PDW, Young A, Walsh DA. *BMC Musculoskeletal Disorders*. 2013;14.
1409. **Late-onset systemic lupus erythematosus: characteristics and outcome in comparison to juvenile- and adult-onset patients—a multicenter retrospective cohort.** Medhat BM, Behiry ME, Sobhy N, Farag Y, Marzouk H, Mostafa N, et al. *Clinical Rheumatology*. 2020;39(2):435-42.
1410. **A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors.** Mehnert JM, Kaveney AD, Malhotra J, Spencer K, Portal D, Goodin S, et al. *Cancer Chemotherapy and Pharmacology*. 2019;84(4):899-907.
1411. Mehta B, Salmon J, Ibrahim S, editors. *Potential Shortages of Hydroxychloroquine for Patients with Lupus During the Coronavirus Disease 2019 Pandemic* 2020: American Medical Association.
1412. **The Risk of Severe Depression, Psychosis or Panic Attacks with Prophylactic Antimalarials.** Meier CR, Wilcock K, Jick SS. *Drug Safety*. 2004;27(3):203-13.
1413. **Inflammatory arthritis in patients with myelodysplastic syndromes: A multicenter retrospective study and literature review of 68 cases.** Mekinian A, Braun T, Decaux O, Falgarone G, Toussirot E, Raffray L, et al. *Medicine (United States)*. 2014;93(1):1-10.
1414. **Treatment of the elderly rheumatoid arthritis patient.** Melikterminas E, Ranganath V, Furst DE. *Future Rheumatology*. 2008;3(3):235-8.
1415. **The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy.** Melles RB, Marmor MF. *JAMA ophthalmology*. 2014;132(12):1453-60. <http://dx.doi.org/10.1001/jamaophthalmol.2014.3459>.
1416. **Pericentral retinopathy and racial differences in hydroxychloroquine toxicity.** Melles RB, Marmor MF. *Ophthalmology*. 2015;122(1):110-6.
1417. **Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis.** Melsens K, Vandecasteele E, Deschepper E, Badot V, Blockmans D, Brusselle G, et al. *Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine*. 2018;73(2):119-25.

1418. **In vitro chloroquine resistance modulation study on fresh isolates of Brazilian Plasmodium falciparum: intrinsic antimalarial activity of phenothiazine drugs.** Menezes CM, Kirchgatter K, Di Santi SM, Savalli C, Monteiro FG, Paula GA, et al. *Memórias do Instituto Oswaldo Cruz*. 2002;97(7):1033-9.
1419. **Inappropriate prescribing of antimalarial therapy for the treatment of undifferentiated febrile illness among the elderly.** Menon VB, Ramesh M, Pereira P, Chilkunda Raviprakash V, Undela K. *Journal of Pharmacy Practice and Research*. 2018;48(6):530-6.
1420. **Maternal effects as drivers of sibling competition in a parent-offspring conflict context? An experimental test.** Merklings T, Perrot C, Helfenstein F, Ferdy JB, Gaillard L, Lefol E, et al. *Ecology and evolution*. 2016;6(11):3699-710. <http://dx.doi.org/10.1002/ece3.1777>. eCollection 2016 Jun.
1421. **Chloroquine-Primaquine Therapeutic Efficacy, Safety, and Plasma Levels in Patients with Uncomplicated Plasmodium vivax Malaria in a Colombian Pacific Region.** Mesa-Echeverry E, Niebles-Bolivar M, Tobon-Castano A. *The American journal of tropical medicine and hygiene*. 2019;100(1):72-7. <http://dx.doi.org/10.4269/ajtmh.18-0655>.
1422. **Minocycline hyperpigmentation.** Messner EJ, Finger DR, Crowe MA, Royer MC. *Journal of Clinical Rheumatology*. 1999;5(5):273-8.
1423. **[Photodermatosis induced by hydroxychloroquine: 4 cases].** Metayer I, Balguerie X, Courville P, Lauret P, Joly P. *Ann Dermatol Venereol*. 2001;128(6):729-31.
1424. **Nonendemic pemphigus foliaceus in children.** Metry DW, Hebert AA, Jordon RE. *Journal of the American Academy of Dermatology*. 2002;46(3):419-22.
1425. **Expandable proximal femoral nail versus gamma proximal femoral nail for the treatment of AO/OTA 31A1-3 fractures.** Michael D, Yaniv W, Tal FR, Kessler Evan G, Eyal A, Nimrod S, et al. *Injury*. 2016;47(2):419-23. <http://dx.doi.org/10.1016/j.injury.2015.10.013>. Epub 2015 Oct 28.
1426. **Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy.** Michaelides M, Stover NB, Francis PJ, Weleber RG. *Archives of ophthalmology (Chicago, Ill : 1960)*. 2011;129(1):30-9. <http://dx.doi.org/10.1001/archophthalmol.2010.321>.
1427. **Resident Identification of Significant Learning Experiences: A Qualitative Analysis.** Michel E, Meyerson SL. *The Annals of thoracic surgery*. 2016;102(5):1731-5. <http://dx.doi.org/10.1016/j.athoracsur.2016.05.045>. Epub 2016 Jul 25.
1428. **[Kapandji enlargement plasty of A1 pulley. Results in 15 primary trigger fingers with a 5 year (2-8 years) follow-up].** Migaud H, Fontaine C, Brazier J, Pierchon F, Duquenois A. *Annales de chirurgie de la main et du membre superieur : organe officiel des societes de chirurgie de la main = Annals of hand and upper limb surgery*. 1996;15(1):37-41; discussion 2. [http://dx.doi.org/10.1016/s0753-9053\(96\)80022-6](http://dx.doi.org/10.1016/s0753-9053(96)80022-6).
1429. **International travel patterns and travel risks of patients diagnosed with cancer.** Mikati T, Taur Y, Seo SK, Shah MK. *Journal of Travel Medicine*. 2013;20(2):71-7.
1430. **[Ocular complications after treatment with antimalarial agents in dermatology].** Mikkelsen J. *Ugeskrift for laeger*. 1979;141(34):2316-8.
1431. **Prospective study of survival outcomes in non-Hodgkin's lymphoma patients with rheumatoid arthritis.** Mikuls TR, Endo JO, Puumala SE, Aoun PA, Black NA, O'Dell JR, et al. *Journal of Clinical Oncology*. 2006;24(10):1597-602.
1432. **Associations of disease activity and treatments with mortality in men with rheumatoid arthritis:**

**Results from the VARA registry.** Mikuls TR, Fay BT, Michaud K, Sayles H, Thiele GM, Caplan L, et al. *Rheumatology*. 2011;50(1):101-9.

1433. **Morbidity of varicose vein surgery: auditing the benefit of changing clinical practice.** Miller GV, Lewis WG, Sainsbury JR, Macdonald RC. *Annals of the Royal College of Surgeons of England*. 1996;78(4):345-9.

1434. **Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis.** Miller KD, Lobel HO, Satriale RF, Kuritsky JN, Stern R, Campbell CC. *The American journal of tropical medicine and hygiene*. 1986;35(3):451-8. <http://dx.doi.org/10.4269/ajtmh.1986.35.451>.

1435. **Antiphospholipid Antibody Syndrome with Valvular Vegetations in Acute Q Fever.** Million M, Thuny F, Bardin N, Angelakis E, Edouard S, Bessis S, et al. *Clinical Infectious Diseases*. 2016;62(5):537-44.

1436. **Evolution from acute Q fever to endocarditis is associated with underlying valvulopathy and age and can be prevented by prolonged antibiotic treatment.** Million M, Walter G, Thuny F, Habib G, Raoult D. *Clinical Infectious Diseases*. 2013;57(6):836-44.

1437. **Clinical characteristics and outcome associated with pandemic (2009) H1N1 influenza infection in patients with hematologic malignancies: A retrospective cohort study.** Minnema BJ, Husain S, Mazzulli T, Hosseini-Mogaddam SM, Patel M, Brandwein J, et al. *Leukemia and Lymphoma*. 2013;54(6):1250-5.

1438. **Malaria chemoprophylaxis in traveling children.** Minodier P, Noël G, Blanc P, Tsaregorodtseva N, Retornaz K, Garnier JM. *Archives de Pédiatrie*. 2005;12(1):53-8.

1439. **Arthritis in primary Sjögren's syndrome: Characteristics, outcome and treatment from French multicenter retrospective study.** Mirouse A, Seror R, Vicaut E, Mariette X, Dougados M, Fauchais AL, et al. *Autoimmunity Reviews*. 2019;18(1):9-14.

1440. **Monitoring the efficacy of antimalarial medicines in India via sentinel sites: Outcomes and risk factors for treatment failure.** Mishra N, Srivastava B, Bharti RS, Rana R, Kaitholia K, Anvikar AR, et al. *J Vector Borne Dis*. 2016;53(2):168-78.

1441. **Effectiveness of  $\alpha$ ,  $\beta$ -arteether in acute falciparum malaria.** Mishra SK, Asthana OP, Mohanty S, Patnaik JK, Das BS, Srivastava JS, et al. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1995;89(3):299-301.

1442. **[Diagnosis and treatment of rheumatoid arthritis].** Misiuniene N, Baranauskaite A. *Medicina (Kaunas, Lithuania)*. 2002;38(1):110-6.

1443. **Poststroke delirium incidence and outcomes: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU).** Mitasova A, Kostalova M, Bednarik J, Michalcakova R, Kasperek T, Balabanova P, et al. *Critical care medicine*. 2012;40(2):484-90. <http://dx.doi.org/10.1097/CCM.0b013e318232da12>.

1444. **Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.** Mitchell EL, Lau PKH, Khoo C, Liew D, Leung J, Liu B, et al. *European Journal of Cancer*. 2018;105:88-102.

1445. **Progression of hydroxychloroquine toxic effects after drug therapy cessation: New evidence from multimodal imaging.** Mititelu M, Wong BJ, Brenner M, Bryar PJ, Jampol LM, Fawzi AA. *JAMA Ophthalmology*. 2013;131(9):1187-97.

1446. **The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis.** Mittal L, Werth VP. *Journal of the American Academy of Dermatology*. 2017;77(2):374-7.

1447. **Antimalarial drug toxicities in rheumatic skin disease patients.** Mittal L, Zhang L, Feng R, Werth V. *Arthritis and Rheumatology*. 2017;69.
1448. **Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.** Mittal L, Zhang L, Feng R, Werth VP. *Journal of the American Academy of Dermatology*. 2018;78(1):100-6.e1.
1449. **Treatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung disease.** Mittoo S, Jacob T, Craig A, Bshouty Z. *Canadian Respiratory Journal*. 2010;17(6):282-6.
1450. **Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas.** Miyamoto M, Takano M, Aoyama T, Soyama H, Yoshikawa T, Tsuda H, et al. *Journal of gynecologic oncology*. 2017;28(3):e33. <http://dx.doi.org/10.3802/jgo.2017.28.e33>. Epub 2017 Feb 13.
1451. **VOLUMETRIC SINGLE-LAYER INNER RETINAL ANALYSIS IN PATIENTS WITH HYDROXYCHLOROQUINE TOXICITY.** Modi YS, Au A, Parikh VS, Ehlers JP, Schachat AP, Singh RP. *Retina*. 2016;36(10):1941-50. <http://dx.doi.org/10.1097/IAE.0000000000001036>.
1452. **Acute mechanical circulatory support for fulminant myocarditis complicated by cardiogenic shock.** Mody KP, Takayama H, Landes E, Yuzefpolskaya M, Colombo PC, Naka Y, et al. *Journal of Cardiovascular Translational Research*. 2014;7(2):156-64.
1453. **Q fever endocarditis in Spain. Clinical characteristics and outcome.** Mogollón MV, Anguita MP, Aguado JM, Tornos P, Miró JM, Gálvez-Acebal J, et al. *Enfermedades Infecciosas y Microbiología Clínica*. 2011;29(2):109-16.
1454. **Chloroquine psychosis: A chemical psychosis?** Mohan D, Mohandas E, Rajat R. *Journal of the National Medical Association*. 1981;73(11):1073-6.
1455. **Adult onset dystonia of the foot as a presenting symptom of systemic lupus erythematosus.** Mohanna L, Cobo A, Jaraba S, Martínez Yélamos S, Bas J, Jaumà S, et al. *European Journal of Neurology*. 2011;18:591.
1456. **Adverse cutaneous drug reactions: Eight year assessment in hospitalized patients.** Mokhtari F, Nikyar Z, Naeini BA, Esfahani AA, Rahmani S. *Journal of Research in Medical Sciences*. 2014;19(8):720-5.
1457. **Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort.** Molad Y, Gorshtein A, Wysenbeek AJ, Guedj D, Majadla R, Weinberger A, et al. *Lupus*. 2002;11(6):356-61. <http://dx.doi.org/10.1191/0961203302lu203ra>.
1458. **Heart valve calcification in young patients with systemic lupus erythematosus: A window to premature atherosclerotic vascular morbidity and a risk factor for all-cause mortality.** Molad Y, Levin-Iaina N, Vaturi M, Sulkes J, Sagie A. *Atherosclerosis*. 2006;185(2):406-12.
1459. **Systemic lupus erythematosus: Current state of diagnosis and treatment.** Moldovan I. *Comprehensive Therapy*. 2006;32(3):158-62.
1460. **Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies.** Molloy ES, Calabrese LH. *Arthritis and Rheumatism*. 2012;64(9):3043-51.
1461. **A prospective intensive study of adverse drug reactions in rural medicine.** Montastruc P, Rey S, Rey C, M.-E LL, Montastruc JL. *Drug Investigation*. 1993;6(6):337-9.
1462. **Validation of national institutes of health global scoring system for chronic Graft-Versus-Host Disease (GVHD) according to overall and GVHD-specific survival.** Moon JH, Sohn SK, Lambie A, Ellis L, Hamad N, Uhm J, et

al. *Biology of Blood and Marrow Transplantation*. 2014;20(4):556-63.

1463. **Antiparasitic therapy in children.** Moon TD, Oberhelman RA. *Pediatric Clinics of North America*. 2005;52(3):917-48.

1464. **Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience.** Mooradian MJ, Nasrallah M, Gainor JF, Reynolds KL, Cohen JV, Lawrence DP, et al. *Seminars in Arthritis and Rheumatism*. 2019;48(6):1127-32.

1465. **The impact of the robotic platform on assistant variability in complex gastrointestinal surgery.** Moore MD, Afaneh C, Gray KD, Panjwani S, Fahey TJ, 3rd, Pomp A, et al. *The Journal of surgical research*. 2017;219:98-102. <http://dx.doi.org/10.1016/j.jss.2017.05.127>. Epub 2017 Jun 28.

1466. **Hepatic abscess and thoracic complications in Central Mexico.** Morales FM, Carmona RE, Garces JC, Vergara HF. *Revista del Instituto Nacional de Enfermedades Respiratorias*. 1997;10(3):168-74.

1467. **Junior versus senior physicians for informing families of intensive care unit patients.** Moreau D, Goldgran-Toledano D, Alberti C, Jourdain M, Adrie C, Annane D, et al. *Am J Respir Crit Care Med*. 2004;169(4):512-7. <http://dx.doi.org/10.1164/rccm.200305-645OC>. Epub 2003 Dec 4.

1468. **Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis.** Moreland LW, Bucy RP, Tilden A, Pratt PW, LoBuglio AF, Khzaeli M, et al. *Arthritis and Rheumatism*. 1993;36(3):307-18.

1469. **Nondepleting humanized anti-CD4 monoclonal antibody in patients with refractory rheumatoid arthritis.** Moreland LW, Haverty TP, Wacholtz MC, Knowles RW, Bucy RP, Heck Jr LW, et al. *Journal of Rheumatology*. 1998;25(2):221-8.

1470. **Etanercept treatment in adults with established rheumatoid arthritis: 7 Years of clinical experience.** Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, et al. *Journal of Rheumatology*. 2006;33(5):854-61.

1471. **Diagnosis, treatment and prevention of mania and hipomania within the bipolar disorder.** Moreno RA, Moreno DH, Ratzke R. *Revista de Psiquiatria Clinica*. 2005;32:39-48.

1472. **High prevalence of risk factors in elderly patients using drugs associated with acquired torsades de pointes chronically in Colombia.** Moreno-Gutiérrez PA, Gaviria-Mendoza A, Cañón MM, Machado-Alba JE. *British Journal of Clinical Pharmacology*. 2016:504-11.

1473. **Survey of junior hospital doctors' attitudes to cardiopulmonary resuscitation.** Morgan R, Westmoreland C. *Postgrad Med J*. 2002;78(921):413-5. <http://dx.doi.org/10.1136/pmj.78.921.413>.

1474. **The association between alcohol use and problematic internet use: A large-scale nationwide cross-sectional study of adolescents in Japan.** Morioka H, Itani O, Osaki Y, Higuchi S, Jike M, Kaneita Y, et al. *Journal of epidemiology*. 2017;27(3):107-11. <http://dx.doi.org/10.1016/j.je.2016.10.004>. Epub 2017 Jan 17.

1475. **Comparison of knowledge to antimicrobial stewardship institution policies targeting Staphylococcus aureus bacteremia and candidemia between medical doctors and pharmacists in an academic teaching hospital in Japan.** Moriyama Y, Ishikane M, Hayakawa K, Yamamoto K, Akazawa T, Sugiki Y, et al. *Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy*. 2019;25(5):396-9. <http://dx.doi.org/10.1016/j.jiac.2018.11.006>. Epub 2018 Dec 1.

1476. **Trabeculectomy as an introduction to intraocular surgery in an ophthalmic training program.** Morrell AJ, Searle AE, O'Neill EC. *Ophthalmic surgery*. 1989;20(8):557-60.

1477. **A dental risk management protocol for electroconvulsive therapy.** Morris AJ, Roche SA, Bentham P, Wright J. *The journal of ECT.* 2002;18(2):84-9. <http://dx.doi.org/10.1097/00124509-200206000-00004>.
1478. **Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients.** Morris SJ, Wasko MC, Antohe JL, Sartorius JA, Kirchner HL, Dancea S, et al. *Arthritis care & research.* 2011;63(4):530-4.
1479. **Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension.** Morrisroe K, Stevens W, Huq M, Prior D, Sahhar J, Ngian GS, et al. *Arthritis Research and Therapy.* 2017;19(1).
1480. **Abdominal radiograph requesting in the setting of acute abdominal pain: temporal trends and appropriateness of requesting.** Morris-Stiff G, Stiff RE, Morris-Stiff H. *Annals of the Royal College of Surgeons of England.* 2006;88(3):270-4. <http://dx.doi.org/10.1308/003588406X98586>.
1481. **Comparative Safety of Therapies in Systemic Lupus Erythematosus.** Mosak J, Furie R. *Rheumatic Disease Clinics of North America.* 2012;38(4):795-807.
1482. **The relationship between disease activity and depression in Egyptian patients with rheumatoid arthritis.** Mostafa H, Radwan A. *Egyptian Rheumatologist.* 2013;35(4):193-9.
1483. **Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.** Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. *Lancet.* 1999;353(9164):1568-73. [http://dx.doi.org/10.1016/s0140-6736\(98\)08513-4](http://dx.doi.org/10.1016/s0140-6736(98)08513-4).
1484. **Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial.** Möttönen T, Hannonen P, Leirisalo-Repo M, Nissilä M, Kautiainen H, Korpela M, et al. *Lancet.* 1999;353(9164):1568-73.
1485. **Drawing up the balance sheet after a year. Leflunomide for patients with rheumatoid arthritis.** Mourad L, Van Roon EN, Jansen TL, Baars WA, Tobi H, Brouwers JRB. *Pharmaceutisch Weekblad.* 2001;136(46):1716-20.
1486. **Effect of Resident Participation on Outcomes in High-Order Cesarean Deliveries.** Mourad M, Gupta S, Rebarber A, Saltzman DH, Fox NS. *Obstetrics and gynecology.* 2015;126:21s-6s. <http://dx.doi.org/10.1097/AOG.0000000000001009>.
1487. **Supervising the supervisors--procedural training and supervision in internal medicine residency.** Mourad M, Kohlwes J, Maselli J, Auerbach AD. *Journal of general internal medicine.* 2010;25(4):351-6. <http://dx.doi.org/10.1007/s11606-009-1226-z>.
1488. **Persistence of Imported Malaria into the United Kingdom: An Epidemiological Review of Risk Factors and At-risk Groups.** Moyo QM, Besser M, Lynn R, Lever AML. *Clinical Infectious Diseases.* 2019;69(7):1156-62.
1489. **A randomized multicenter clinical trial of 99Tc-methylene diphosphonate in treatment of rheumatoid arthritis.** Mu R, Liang J, Sun L, Zhang Z, Liu X, Huang C, et al. *International Journal of Rheumatic Diseases.* 2018;21(1):161-9.
1490. **A study of clinical profile of malaria in a tertiary referral centre in South Canara.** Muddaiah M, Prakash PS. *Journal of Vector Borne Diseases.* 2006;43(1):29-33.
1491. **Efficacy and safety of the six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in adolescents and adults: A pooled analysis of individual patient data from randomized clinical trials.** Mueller EA, van Vugt M, Kirch W, Andriano K, Hunt P, de Palacios PI. *Acta Tropica.* 2006;100(1):41-53.



1492. **Clinical need-directed blood tests: a step in saving the NHS?** Mughal Z, Narayanan A, Gupta V, Reay-Jones N. *Annals of clinical biochemistry*. 2016;53:568-74. <http://dx.doi.org/10.1177/0004563215617782>. Epub 2016 Jan 7.
1493. **Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial.** Mulenga V, Cook A, Walker AS, Kabamba D, Chijoka C, Ferrier A, et al. *Clin Infect Dis*. 2010;51(9):1081-9. <http://dx.doi.org/10.1086/656628>.
1494. **Chloroquine and nonconvulsive status epilepticus [4].** Mulhauser P, Allemann Y, Regamey C. *Annals of Internal Medicine*. 1995;123(1):76-7.
1495. **Resistance patterns of Plasmodium falciparum malaria to chloroquine in Kampala, Uganda.** Mulindwa HG, Mayanja-Kizza H, Freers J. *East African Medical Journal*. 2002;79(3):115-9.
1496. **Anterior minimally invasive approach for total hip replacement: five-year survivorship and learning curve.** Muller DA, Zingg PO, Dora C. *Hip international : the journal of clinical and experimental research on hip pathology and therapy*. 2014;24(3):277-83. <http://dx.doi.org/10.5301/hipint.5000108>. Epub 2014 Feb 3.
1497. **Evolution of malaria mortality and morbidity after the emergence of chloroquine resistance in Niakhar, Senegal.** Munier A, Diallo A, Marra A, Cot M, Arduin P, Ndiaye O, et al. *Malar J*. 2009;8:270. <http://dx.doi.org/10.1186/1475-2875-8-270>.
1498. **The prevalence and impact of voice problems in primary school teachers.** Munier C, Kinsella R. *Occupational medicine (Oxford, England)*. 2008;58(1):74-6. <http://dx.doi.org/10.1093/occmed/kqm104>. Epub 2007 Nov 21.
1499. **Randomized double blind trial of an extract from the pentacyclic alkaloid-chemotype of uncaria tomentosa for the treatment of rheumatoid arthritis.** Mur E, Hartig F, Eibl G, Schirmer M. *Journal of Rheumatology*. 2002;29(4):678-81.
1500. **Drug-induced cardiovascular disorders.** Murphy CA, Dargie HJ. *Drug Safety*. 2007;30(9):783-804.
1501. **Falciparum malaria.** Murphy GS, Oldfield EC. *Infectious Disease Clinics of North America*. 1996;10(4):747-75.
1502. **Ventricular assist device support as a bridge to heart transplantation in patients with giant cell myocarditis.** Murray LK, González-Costello J, Jonas SN, Sims DB, Morrison KA, Colombo PC, et al. *European Journal of Heart Failure*. 2012;14(3):312-8.
1503. **Fracture clinic redesign: improving standards in patient care and interprofessional education.** Murray O, Christen K, Marsh A, Bayer J. *Swiss medical weekly*. 2012;142:w13630. <http://dx.doi.org/10.4414/smw.2012.13630>. eCollection 2012.
1504. **Ureterovaginal fistula--etiological factors and outcome.** Murtaza B, Mahmood A, Niaz WA, Akmal M, Ahmad H, Saeed S. *JPMA The Journal of the Pakistan Medical Association*. 2012;62(10):999-1003.
1505. **Visual dysfunction in retinal and optic nerve disease.** Murtha T, Stasheff SF. *Neurologic Clinics*. 2003;21(2):445-81.
1506. **Chloroquine influences renal function in rural zimbabweans with acute transient fever.** Musabayane CT, Musvibe A, Wenyika J, Munjeri O, Osim EE. *Renal Failure*. 1999;21(2):189-97.
1507. **The Trauma of Sexual Harassment and its Mental Health Consequences Among Nurses.** Mushtaq M, Sultana S, Imtiaz I. *Journal of the College of Physicians and Surgeons--Pakistan : JCPSP*. 2015;25(9):675-9.

<http://dx.doi.org/09.2015/JCPSP.675679>.

1508. **Secondary myelodysplastic syndrome after hydroxychloroquine therapy.** Muslimani AA, Spiro TP, Chaudhry AA, Daw HA. *Annals of hematology*. 2007;86(7):531-4. <http://dx.doi.org/10.1007/s00277-006-0249-3>. Epub 2007 Jan 5.
1509. **Atovaquone/proguanil: A new drug combination to combat malaria.** Mustafa MS, Agrawal VK. *Medical Journal Armed Forces India*. 2008;64(2):167-8.
1510. **Toxic psychosis during chloroquine treatment.** Mustakallio KK, Pihkanen TA, Putkonen T. *Annales medicinae internae Fenniae*. 1962;51:223-8.
1511. **Chloroquine psychosis?** Mustakallio KK, Putkonen T, Pihkanen TA. *Lancet (London, England)*. 1962;2(7270):1387-8.
1512. **Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: A nationwide prospective study.** Mustonen P, Lehtonen KV, Javela K, Puurunen M. *Lupus*. 2014;23(14):1468-76.
1513. **Knowledge and occupational hazards of barbers in the transmission of hepatitis B and C was low in Kumasi, Ghana.** Mutocheluh M, Kwarteng K. *The Pan African medical journal*. 2015;20:260. <http://dx.doi.org/10.11604/pamj.2015.20.260.4138>. eCollection 2015.
1514. **Clinical, neuroimaging and immunological phenotype of South African neuropsychiatric systemic lupus erythematosus patients.** Mvambo N, Bhigjee AI, Mody GM. *Lupus*. 2019;28(5):685-94.
1515. **Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland.** Myllykangas-Luosujärvi R, Aho K, Kautiainen H, Hakala M. *Rheumatology*. 1999;38(6):499-503.
1516. **Current status of malaria chemotherapy and the role of pharmacology in antimalarial drug research and development.** Na-Bangchang K, Karbwang J. *Fundamental and Clinical Pharmacology*. 2009;23(4):387-409.
1517. **Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: A nested, case-control study.** Nadareishvili Z, Michaud K, Hallenbeck JM, Wolfe F. *Arthritis Care and Research*. 2008;59(8):1090-6.
1518. **Audit of deaths less than a week after admission through an emergency department: how accurate was the ED diagnosis and were any deaths preventable?** Nafsi T, Russell R, Reid CM, Rizvi SM. *Emergency medicine journal : EMJ*. 2007;24(10):691-5. <http://dx.doi.org/10.1136/emj.2006.044867>.
1519. **Usefulness of long-term ambulatory electrocardiography in heart disease screening system for school children and high school students.** Nagashima M, Matsushima M, Ogawa A, Yazaki T, Osuga A, Kaneko T, et al. *Japanese circulation journal*. 1985;49(12):1290-6. <http://dx.doi.org/10.1253/jcj.49.1290>.
1520. **The ability of disease modifying antirheumatic drugs to induce and maintain improvement in patients with rheumatoid arthritis. Epidemiology of DMARDs treatment in Japan.** Nagashima M, Shu G, Yamamoto K, Yamahatsu S, Yoshino S. *Clinical and Experimental Rheumatology*. 2005;23(1):27-35.
1521. **Liver stiffness measurement versus clinicians' prediction or both for the assessment of liver fibrosis in patients with chronic hepatitis C.** Nahon P, Thabut G, Ziol M, Htar MT, Cesaro F, Barget N, et al. *The American journal of gastroenterology*. 2006;101(12):2744-51. <http://dx.doi.org/10.1111/j.1572-0241.2006.00816.x>.
1522. **Effect of resident postgraduate year on outcomes after laparoscopic appendectomy for appendicitis in children.** Naiditch JA, Lautz TB, Raval MV, Madonna MB, Barsness KA. *Journal of laparoendoscopic & advanced*

surgical techniques Part A. 2012;22(7):715-9. <http://dx.doi.org/10.1089/lap.2012.0032>. Epub 2012 Jul 30.

1523. **Biowaiver monographs for immediate-release solid oral dosage forms: Primaquine phosphate.** Nair A, Abrahamsson B, Barends DM, Groot DW, Kopp S, Polli JE, et al. *Journal of Pharmaceutical Sciences*. 2012;101(3):936-45.

1524. **ERG and other discriminators between advanced hydroxychloroquine retinopathy and retinitis pigmentosa.** Nair AA, Marmor MF. *Documenta Ophthalmologica*. 2017;134(3):175-83.

1525. **Management of giardiasis in children.** Nair KPB. *INDIAN PRACT*. 1973;26(11):527-30.

1526. **Vitamin D insufficiency in Japanese female college students: a preliminary report.** Nakamura K, Nashimoto M, Tsuchiya Y, Obata A, Miyanishi K, Yamamoto M. *International journal for vitamin and nutrition research Internationale Zeitschrift für Vitamin- und Ernährungsforschung Journal international de vitaminologie et de nutrition*. 2001;71(5):302-5. <http://dx.doi.org/10.1024/0300-9831.71.5.302>.

1527. **[Factors relevant to long-term social prognosis of patients with spina bifida].** Nakamura M, Shimoizumi H. *No to hattatsu = Brain and development*. 1999;31(1):21-6.

1528. **Reproducibility of the Dorr classification and its quantitative indices on plain radiographs.** Nakaya R, Takao M, Hamada H, Sakai T, Sugano N. *Orthopaedics & traumatology, surgery & research : OTSR*. 2019;105(1):17-21. <http://dx.doi.org/10.1016/j.otsr.2018.11.008>. Epub 2018 Dec 26.

1529. **Clinical results of a randomized controlled trial on the effect of adjuvant immunochemotherapy using Esquinon and Krestin in patients with curatively resected gastric cancer. Cooperative Study Group of Cancer Immunochemotherapy, Tokai Gastrointestinal Oncology Group.** Nakazato H, Ichihashi H, Kondo T. *Gan to kagaku ryoho Cancer & chemotherapy*. 1986;13(2):308-18.

1530. **Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: A double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study).** Nam JL, Villeneuve E, Hensor EMA, Conaghan PG, Keen HI, Buch MH, et al. *Annals of the Rheumatic Diseases*. 2014;73(1):75-85.

1531. **Validation for a scoring system of the ALS cardiac arrest simulation test (CASTest).** Napier F, Davies RP, Baldock C, Stevens H, Lockett AS, Bullock I, et al. *Resuscitation*. 2009;80(9):1034-8. <http://dx.doi.org/10.1016/j.resuscitation.2009.04.043>. Epub 2009 Jun 13.

1532. **Outcome in severe acute renal failure associated with malaria.** Naqvi R, Ahmad E, Akhtar F, Naqvi A, Rizbi A. *Nephrology Dialysis Transplantation*. 2003;18(9):1820-3.

1533. **Biological Agents in the Management of Felty's Syndrome: A Systematic Review.** Narváez J, Domingo-Domenech E, Gómez-Vaquero C, López-Vives L, Estrada P, Aparicio M, et al. *Seminars in Arthritis and Rheumatism*. 2012;41(5):658-68.

1534. **Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy.** Narváez J, Juárez-López P, J LL, Narváez JA, Palmero R, García del Muro X, et al. *Autoimmunity Reviews*. 2018;17(10):1040-5.

1535. **Impact of Residents on Safety Outcomes in Laparoscopic Cholecystectomy.** Nasri B, Saxe J. *World J Surg*. 2019;43(12):3013-8. <http://dx.doi.org/10.1007/s00268-019-05141-5>.

1536. **National Clinical Guideline C. National Institute for Health and Clinical Excellence: Guidance. Intravenous Fluid Therapy: Intravenous Fluid Therapy in Adults in Hospital.** London: Royal College of Physicians (UK) National Clinical Guideline Centre.; 2013.

1537. **Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease.** Navajas EV, Krema H, Hammoudi DS, Lipton JH, Simpson ER, Boyd S, et al. Canadian journal of ophthalmology Journal canadien d'ophtalmologie. 2015;50(6):442-50. <http://dx.doi.org/10.1016/j.jcjo.2015.08.003>.
1538. **Clinical experience with infliximab among Filipino patients with rheumatic diseases.** Navarra SV, Raso AA, Lichauco JJ, Tan PP. APLAR Journal of Rheumatology. 2006;9(2):150-6.
1539. **Accuracy of abdominal ultrasound for the diagnosis of pneumoperitoneum in patients with acute abdominal pain: a pilot study.** Nazerian P, Tozzetti C, Vanni S, Bartolucci M, Gualtieri S, Trausi F, et al. Critical ultrasound journal. 2015;7(1):15. <http://dx.doi.org/10.1186/s13089-015-0032-6>. Epub 2015 Oct 6.
1540. **Updated cataract surgery complexity stratification score for trainee ophthalmic surgeons.** Nderitu P, Ursell P. Journal of cataract and refractive surgery. 2018;44(6):709-17. <http://dx.doi.org/10.1016/j.jcrs.2018.04.036>. Epub 2018 Jul 4.
1541. **Factors affecting cataract surgery operating time among trainees and consultants.** Nderitu P, Ursell P. Journal of cataract and refractive surgery. 2019;45(6):816-22. <http://dx.doi.org/10.1016/j.jcrs.2019.01.002>. Epub 2019 Mar 14.
1542. **Diagnosis and treatment of malaria in peripheral health facilities in Uganda: Findings from an area of low transmission in south-western Uganda.** Ndyomugenyi R, Magnussen P, Clarke S. Malaria Journal. 2007;6.
1543. **Profile of Patients Attending Psychogeriatric Clinic in a Tertiary Care Setting.** Neethu S, Indu PV, Anil P. Indian journal of psychological medicine. 2016;38(5):404-7. <http://dx.doi.org/10.4103/0253-7176.191373>.
1544. **Mixed-phenotype large granular lymphocytic leukemia: a rare subtype in the large granular lymphocytic leukemia spectrum.** Neff JL, Rangan A, Jevremovic D, Nguyen PL, Chiu A, Go RS, et al. Human Pathology. 2018;81:96-104.
1545. **DRUG REACTIONS IN ADOLESCENCE.** Neff L. GP. 1964;29:112-3.
1546. **Efficacy of chloroquine and primaquine for the treatment of uncomplicated plasmodium vivax malaria in Cruzeiro do Sul, Brazil.** Negreiros S, Farias S, Viana GMR, Okoth SA, Chenet SM, De Souza TMH, et al. American Journal of Tropical Medicine and Hygiene. 2016;95(5):1061-8.
1547. **Observational cadaveric study of emergency bystander cricothyroidotomy with a ballpoint pen by untrained junior doctors and medical students.** Neill A, Anderson P. Emergency medicine journal : EMJ. 2013;30(4):308-11. <http://dx.doi.org/10.1136/emmered-2012-201317>. Epub 2012 May 5.
1548. **Retinopathy induced by drugs and herbal medicines.** Nencini C, Barberi L, Runci FM, Micheli L. European Review for Medical and Pharmacological Sciences. 2008;12(5):293-8.
1549. **Malaria among patients and aid workers consulting a primary healthcare centre in Leogane, Haiti, November 2010 to February 2011 - a prospective observational study.** Neuberger A, Zaulan O, Tenenboim S, Vernet S, Pex R, Held K, et al. Eurosurveillance. 2011;16(13).
1550. **Identification of a Syndrome Class of Neuropsychiatric Adverse Reactions to Mefloquine from Latent Class Modeling of FDA Adverse Event Reporting System Data.** Nevin RL, Leoutsakos JM. Drugs in R and D. 2017;17(1):199-210.
1551. **Tell Me Straight: Teaching Residents to Disclose Adverse Events in Surgery.** Newcomb AB, Liu C, Trickey AW, Dort J. Journal of surgical education. 2018;75(6):e178-e91. <http://dx.doi.org/10.1016/j.jsurg.2018.08.006>. Epub 2018 Sep 21.

1552. **Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus.** Ng KP, Manson JJ, Rahman A, Isenberg DA. *Arthritis Care and Research.* 2006;55(6):900-4.
1553. **Severe Sensory Neuronopathy in Primary Sjogren Syndrome Resulting in Charcot Arthropathy.** Nguyen M, Peschken CA. *The Journal of rheumatology.* 2016;43(7):1449-51. <http://dx.doi.org/10.3899/jrheum.160137>.
1554. **Safety of endoscopic sinus surgery in a residency training program.** Nguyen QA, Cua DJ, Ng M, Rice DH. *Ear, nose, & throat journal.* 1999;78(12):898-902, 4.
1555. **The role of hydroxychloroquine in the treatment of lichen planopilaris: A retrospective case series and review.** Nic Dhonncha E, Foley CC, Markham T. *Dermatologic Therapy.* 2017;30(3).
1556. **Acute psychosis following treatment with chloroquine for a primo-invasion of Plasmodium vivax malaria [1].** Nicolas X, Granier H, Adam F, Laborde JP, Talarmin F, Klotz F. *Presse Medicale.* 2003;32(3):117.
1557. **Triage during the week of the Sichuan earthquake: a review of utilized patient triage, care, and disposition procedures.** Nie H, Tang SY, Lau WB, Zhang JC, Jiang YW, Lopez BL, et al. *Injury.* 2011;42(5):515-20. <http://dx.doi.org/10.1016/j.injury.2010.01.113>. Epub 2010 Feb 13.
1558. **Hydroxychloroquine Use in the United States and the Potential Impact of Critical Shortages from SARS-CoV-2.** Niforatos JD, Johansen ME. 2020.
1559. **Systematic lupus erythematosus prevalence in the U.K.: Methodological issues when using the General Practice Research Database to estimate frequency of chronic relapsing-remitting disease.** Nightingale AL, Farmer RDT, de Vries CS. *Pharmacoepidemiology and Drug Safety.* 2007;16(2):144-51.
1560. **Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users.** Nika M, Blachley TS, Edwards P, Lee PP, Stein JD. *JAMA ophthalmology.* 2014;132(10):1199-208. <http://dx.doi.org/10.1001/jamaophthalmol.2014.1720>.
1561. **Giant cell arteritis.** Ninan J, Lester S, Hill C. *Best Practice and Research: Clinical Rheumatology.* 2016;30(1):169-88.
1562. **Experience with low-dose methotrexate: Toxicity, tolerability and effect on conventional patterns of drug therapy for inflammatory arthritis.** Nisar M, Carlisle L, Amos R. *Clinical Rheumatology.* 1995;14(5):544-50.
1563. **Epidemiological characteristics of sudden cardiac arrest in schools.** Nishiuchi T, Hayashino Y, Iwami T, Kitamura T, Nishiyama C, Kajino K, et al. *Resuscitation.* 2014;85(8):1001-6. <http://dx.doi.org/10.1016/j.resuscitation.2014.04.027>. Epub 2014 May 10.
1564. **Clinical pilot study of roquinimex (Linomide®) in patients with autoimmune disease.** Nived O, Sturfelt G, Nilsson B, Termander B, Gunnarsson PO, Strandgarden K, et al. *International Journal of Immunotherapy.* 1994;10(2):49-59.
1565. **Knowledge of skin hazards and the use of gloves by Australian hairdressing students and practising hairdressers.** Nixon R, Roberts H, Frowen K, Sim M. *Contact dermatitis.* 2006;54(2):112-6. <http://dx.doi.org/10.1111/j.0105-1873.2006.00790.x>.
1566. **Fixed drug eruption in Nigeria.** Nnoruka EN, Ikeh VO, Mbah AU. *International Journal of Dermatology.* 2006;45(9):1062-5.
1567. **What are the risk factors for post-operative infection after hip hemiarthroplasty? Systematic review**

**of literature.** Noailles T, Brulefert K, Chalopin A, Longis PM, Gouin F. *Int Orthop.* 2016;40(9):1843-8. <http://dx.doi.org/10.1007/s00264-015-3033-y>. Epub 2015 Nov 27.

1568. **NSQIP Analysis of Axillary Lymph Node Dissection Rates for Breast Cancer: Implications for Resident and Fellow Participation.** Nocera NF, Pyfer BJ, De La Cruz LM, Chatterjee A, Thiruchelvam PT, Fisher CS. *Journal of surgical education.* 2018;75(5):1281-6. <http://dx.doi.org/10.1016/j.j Surg.2018.02.020>. Epub 2018 Mar 28.

1569. **Impact of anti-TNF therapy on NK cells function and on immunosurveillance against B-cell lymphomas.** Nocturne G, Boudaoud S, Ly B, Pascaud J, Paoletti A, Mariette X. *Journal of Autoimmunity.* 2017;80:56-64.

1570. **Azithromycin combination therapy with artesunate or quinine for the treatment of uncomplicated Plasmodium falciparum malaria in adults: A randomized, phase 2 clinical trial in Thailand.** Noedl H, Krudsood S, Chalermratana K, Silachamroon U, Leowattana W, Tangpukdee N, et al. *Clinical Infectious Diseases.* 2006;43(10):1264-71.

1571. **Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience.** Nordström DC, Konttinen L, Korpela M, Tiippana-Kinnunen T, Eklund K, Forsberg S, et al. *Rheumatology International.* 2006;26(8):741-8.

1572. **Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators.** Noseworthy JH, Wolinsky JS, Lublin FD, Whitaker JN, Linde A, Gjorstrup P, et al. *Neurology.* 2000;54(9):1726-33. <http://dx.doi.org/10.1212/wnl.54.9.1726>.

1573. **Other 4-methanolquinolines, amyl alcohols and phentathrenes: Mefloquine, lumefantrine and halofantrine.** Nosten F, Phillips-Howard PA, ter Kuile FO. *Journal.* 2012;41(Issue):95-111.

1574. **Neurosarcoidosis: Clinical manifestations, diagnosis and treatment.** Nozaki K, Judson MA. *Presse Medicale.* 2012;41(6):e331-e48.

1575. **Neurosarcoidosis.** Nozaki K, Judson MA. *Current Treatment Options in Neurology.* 2013;15(4):492-504.

1576. **Knowledge and practices relating to malaria in a semi-urban area of Cameroon: choices and sources of antimalarials, self-treatment and resistance.** Nsagha DS, Njunda AL, Kamga HL, Nsagha SM, Nguedia Assob JC, Wiysonge CS, et al. *The Pan African medical journal.* 2011;9:8. <http://dx.doi.org/10.4314/pamj.v9i1.71180>. Epub 2011 May 25.

1577. **Variable course of disease of rheumatoid arthritis-associated usual interstitial pneumonia compared to other subtypes.** Nurmi HM, Purokivi MK, Kärkkäinen MS, Kettunen HP, Selander TA, Kaarteenaho RL. *BMC Pulmonary Medicine.* 2016;16(1):1.

1578. **Cutaneous Lupus: A Brief Review of Old and New Medical Therapeutic Options.** Nutan F, Ortega-Loayza AG. *Journal of Investigative Dermatology Symposium Proceedings.* 2017;18(2):S64-S8.

1579. **A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine.** Nuver-Zwart IH, van Riel PL, van de Putte LB, Gribnau FW. *Ann Rheum Dis.* 1989;48(5):389-95. <http://dx.doi.org/10.1136/ard.48.5.389>.

1580. **Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.** Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, et al. *Journal of Clinical Oncology.* 2005;23(31):7785-93.

1581. **TOXIC PSYCHOSIS DUE TO QUINARCRINE AND CHLOROQUINE.** O.L Sr. *JAMA : the journal of the American Medical Association.* 1964;187:373-5.

1582. **Cerebral malaria: A diagnostic dilemma. A case report.** Oberfield RA, Burkes L, Feinberg SS. *General Hospital Psychiatry*. 1981;3(3):227-9.
1583. **Foot drop following primary total hip arthroplasty.** O'Brien S, Gallagher N, Spence D, Bennett D, Dennison J, Beverland DE. *Hip international : the journal of clinical and experimental research on hip pathology and therapy*. 2020;30(2):135-40. <http://dx.doi.org/10.1177/1120700019835454>. Epub 2019 Mar 26.
1584. **Simulation TRaining for Operative vaginal Birth Evaluation: study protocol for an observational stepped-wedge interrupted time-series study (STROBE).** O'Brien S, Lenguerrand E, Jordan S, Cornthwaite K, Burden C, Timlin L, et al. *BMC Pregnancy Childbirth*. 2019;19(1):109. <http://dx.doi.org/10.1186/s12884-019-2222-x>.
1585. **Use of antimalarials in dermatology.** Ochsendorf FR. *JDDG - Journal of the German Society of Dermatology*. 2010;8(10):829-45.
1586. **Chloroquine and hydroxychloroquine: Side-effect profile of important drugs.** Ochsendorf FR, Runne U. *Hautarzt*. 1991;42(3):140-6.
1587. **Tyrosine phosphorylation in psoriatic T cells is modulated by drugs that induce or improve psoriasis.** Ockenfels HM, Nussbaum G, Schultewolter T, Mertins K, Wagner SN, Goos M. *Dermatology*. 1995;191(3):217-25. <http://dx.doi.org/10.1159/000246549>.
1588. **The nontechnical causes of diving accidents: can U.S. Navy divers learn from other industries?** O'Connor PE. *Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc*. 2007;34(1):51-9.
1589. **Combination DMARD therapy with hydroxychloroquine, sulfasalazine, and methotrexate.** O'Dell JR. *Clinical and experimental rheumatology*. 1999;17(6):S53-8.
1590. **Treatment of early seropositive rheumatoid arthritis: A two-year, double-blind comparison of minocycline and hydroxychloroquine.** O'Dell JR, Blakely KW, Mallek JA, Eckhoff PJ, Leff RD, Wees SJ, et al. *Arthritis and Rheumatism*. 2001;44(10):2235-41.
1591. **Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.** O'Dell JR, Haire C, Erikson N, Drymalski W, Palmer W, Maloley P, et al. *The Journal of rheumatology Supplement*. 1996;44:72-4.
1592. **Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.** O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. *The New England journal of medicine*. 1996;334(20):1287-91. <http://dx.doi.org/10.1056/NEJM199605163342002>.
1593. **Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.** O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, et al. *Arthritis and rheumatism*. 2002;46(5):1164-70. <http://dx.doi.org/10.1002/art.10228>.
1594. **Therapies for active rheumatoid arthritis after methotrexate failure.** O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al. *The New England journal of medicine*. 2013;369(4):307-18. <http://dx.doi.org/10.1056/NEJMoa1303006>. Epub 2013 Jun 11.
1595. **Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis.** O'Dell JR, Petersen K, Leff R, Palmer W, Schned E, Blakely K, et al. *Journal of Rheumatology*. 2006;33(2):213-8.

1596. **Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis.** Odoherthy C, Schnabl M, Spargo L, Cleland LG, James M, Proudman SM, et al. *Pharmacogenomics*. 2012;13(12):1427-34.
1597. **Mixed connective tissue disease in children and adolescents.** Oetgen WJ, Boice JA, Lawless OJ. *Pediatrics*. 1981;67(3):333-7.
1598. **A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.** Ogar CK, Abiola A, Yuah D, Ibrahim A, Oreagba IA, Amadi EC, et al. *Pharmaceutical Medicine*. 2019;33(2):145-57.
1599. **Hypereosinophilic syndrome: A multicenter, retrospective analysis of clinical characteristics and response to therapy.** Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, et al. *Journal of Allergy and Clinical Immunology*. 2009;124(6):1319-25.e3.
1600. **Treatment of rheumatoid arthritis with ornidazole: A randomized, double-blind, placebo-controlled study.** Ogrenidik M. *Rheumatology International*. 2006;26(12):1132-7.
1601. **Clinical features of vivax malaria.** Oh MD, Shin H, Shin D, Kim U, Lee S, Kim N, et al. *American Journal of Tropical Medicine and Hygiene*. 2001;65(2):143-6.
1602. **Dysphagia in inflammatory myopathy: Clinical characteristics, treatment strategies, and outcome in 62 patients.** Oh TH, Brumfield KA, Hoskin TL, Stolp KA, Murray JA, Basford JR. *Mayo Clinic Proceedings*. 2007;82(4):441-7.
1603. **The social condition of a cohort of peasant farmers in rural community in southwest Nigeria.** Ohaeri JU, Asuzu MO, Odejide OA. *African journal of medicine and medical sciences*. 1997;26(1):35-8.
1604. **Factors associated with diagnostic stage of hip osteoarthritis due to acetabular dysplasia among Japanese female patients: a cross-sectional study.** Ohfuji S, Jingushi S, Kondo K, Sofue M, Itoman M, Matsumoto T, et al. *BMC Musculoskelet Disord*. 2016;17:320. <http://dx.doi.org/10.1186/s12891-016-1179-4>.
1605. **Effects of malaria volunteer training on coverage and timeliness of diagnosis: a cluster randomized controlled trial in Myanmar.** Ohnmar, Tun M, San S, Than W, Chongsuvivatwong V. *Malar J*. 2012;11:309. <http://dx.doi.org/10.1186/1475-2875-11-309>.
1606. **Hypertrophic obstructive cardiomyopathy due to a novel T-to-A transition at codon 624 in the beta-myosin heavy chain (beta-MHC) gene possibly related to the sudden death.** Ohsuzu F, Katsushika S, Akanuma M, Nakamura H, Harada H, Satoh M, et al. *Int J Cardiol*. 1997;62(3):203-9. [http://dx.doi.org/10.1016/s0167-5273\(97\)00256-8](http://dx.doi.org/10.1016/s0167-5273(97)00256-8).
1607. **Molecular surveillance of drug-resistant Plasmodium falciparum in two distinct geographical areas of Nigeria.** Ojurongbe O, Oyedeji SI, Oyibo WA, Fagbenro-Beyioku AF, Kun JF. *Wiener Klinische Wochenschrift*. 2010;122(23):681-5.
1608. **Cardiac sympathectomy for refractory ventricular arrhythmias in cardiac sarcoidosis.** Okada DR, Assis FR, Gilotra NA, Ha JS, Berger RD, Calkins H, et al. *Heart Rhythm*. 2019;16(9):1408-13.
1609. **Patient-level factors influencing hypertension control in adults in Accra, Ghana.** Okai DE, Manu A, Amoah EM, Laar A, Akamah J, Torpey K. *BMC Cardiovasc Disord*. 2020;20(1):123. <http://dx.doi.org/10.1186/s12872-020-01370-y>.
1610. **Cutaneous lupus erythematosus: Diagnosis and treatment.** Okon LG, Werth VP. *Best Practice and Research: Clinical Rheumatology*. 2013;27(3):391-404.



1611. **Adverse drug reactions in a developing country: Problems encountered in a surveillance programme in a Nigerian hospital.** Okonkwo PO, Egere JU, Ogbuokiri JE. Central African Journal of Medicine. 1980;26(11):239-42.
1612. **Challenging logics of complex intervention trials: Community perspectives of a health care improvement intervention in rural Uganda.** Okwaro FM, Chandler CIR, Hutchinson E, Nabirye C, Taaka L, Kayendeke M, et al. Social Science and Medicine. 2015;131:10-7.
1613. **Prevalence and factors associated with hypertension and obesity among civil servants in Kaduna, Kaduna State, June 2012.** Oladimeji AM, Fawole O, Nguku P, Nsubuga P. The Pan African medical journal. 2014;18:13. <http://dx.doi.org/10.11694/pamj.supp.2014.18.1.3260>. eCollection 2014.
1614. **Prevention of partner violence by focusing on behaviors of both young males and females.** O'Leary KD, Slep AM. Prevention science : the official journal of the Society for Prevention Research. 2012;13(4):329-39. <http://dx.doi.org/10.1007/s11121-011-0237-2>.
1615. **Introducing a post-operative proforma for elective lower limb arthroplasty patients - improving patient care and junior doctor confidence.** Olivier J, Stoddart M, Miller K, McLintock R, Dahill M. BMJ quality improvement reports. 2017;6(1):e000043. <http://dx.doi.org/10.1136/bmjquality-2017-000043>. eCollection 2017.
1616. **Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice: A study in a French emergency department.** Olivier P, Boulbés O, Tubery M, Lauque D, Montastruc JL, Lapeyre-Mestre M. Drug Safety. 2002;25(14):1035-44.
1617. **Treatment of chronic erosive oral lichen planus with low concentrations of topical tacrolimus: An open prospective study.** Olivier V, Lacour JP, Mousnier A, Garraffo R, Monteil RA, Ortonne JP. Archives of Dermatology. 2002;138(10):1335-8.
1618. **Late-onset rheumatoid arthritis and late-onset spondyloarthritis.** Olivieri I, Pipitone N, D'Angelo S, Padula A, Salvarani C. Clinical and Experimental Rheumatology. 2009;27(4):S139-S45.
1619. **The establishment of student needs: an important internal factor affecting course outcome.** Olmesdahl PJ. Medical teacher. 1999;21(2):174-9. <http://dx.doi.org/10.1080/01421599979824>.
1620. **Failure of simulation training to change residents' management of oesophageal intubation.** Olympio MA, Whelan R, Ford RP, Saunders IC. Br J Anaesth. 2003;91(3):312-8. <http://dx.doi.org/10.1093/bja/aeg183>.
1621. **Pharmacogenetics and mental disease.** Omenn GS, Motulsky AG. Psychological Medicine. 1974;4(2):125-9.
1622. **Polyarthritis as a complication of intravesical bacillus Calmette-Guerin immunotherapy for bladder cancer.** Onur O, Celiker R. Clin Rheumatol. 1999;18(1):74-6. <http://dx.doi.org/10.1007/s100670050059>.
1623. **Cannabis and amphetamine use and its psychosocial correlates among school-going adolescents in Ghana.** Opong Asante K. Child and adolescent psychiatry and mental health. 2019;13:33. <http://dx.doi.org/10.1186/s13034-019-0293-0>. eCollection 2019.
1624. **Attention! A good bedside test for delirium?** O'Regan NA, Ryan DJ, Boland E, Connolly W, McGlade C, Leonard M, et al. Journal of neurology, neurosurgery, and psychiatry. 2014;85(10):1122-31. <http://dx.doi.org/10.1136/jnnp-2013-307053>. Epub 2014 Feb 25.
1625. **Adolescent girls' understanding of tetanus infection and prevention: implications for the disease control in Western Nigeria.** Orimadegun AE, Adepoju AA, Akinyinka OO. Frontiers in public health. 2014;2:24. <http://dx.doi.org/10.3389/fpubh.2014.00024>. eCollection 2014.

1626. **The life-threatening complications of dermatologic therapies.** Orion E, Matz H, Wolf R. *Clinics in Dermatology*. 2005;23(2):182-92.
1627. **Gastric cancer: factors affecting survival.** Orman S, Cayci HM. *Acta chirurgica Belgica*. 2019;119(1):24-30. <http://dx.doi.org/10.1080/00015458.2018.1453437>. Epub 2018 Mar 21.
1628. **Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: Results from the nationwide Danish DANBIO registry.** Ørnbjerg LM, Østergaard M, Bøyesen P, Krogh NS, Thormann A, Tarp U, et al. *Annals of the Rheumatic Diseases*. 2013;72(1):57-63.
1629. **The antiphospholipid syndrome: What are we really measuring? How do we measure it? And how do we treat it?** Ortel TL. *Journal of Thrombosis and Thrombolysis*. 2006;21(1):79-83.
1630. **Dermatomyositis: Analysis of 109 patients surveyed at the Hospital das Clínicas (HCFMUSP), São Paulo, Brazil.** Ortigosa LCM, dos Reis VMS. *Anais Brasileiros de Dermatologia*. 2014;89(5):719-27.
1631. **Efficacy of tocilizumab in conventional treatment-refractory adult-onset still's disease: Multicenter retrospective open-label study of thirty-four patients.** Ortiz-Sanjuán F, Blanco R, Calvo-Rio V, Narvaez J, Rubio Romero E, Olivé A, et al. *Arthritis and Rheumatology*. 2014;66(6):1659-65.
1632. **Quality Metrics in Surgery Resident Performance of Screening Colonoscopy.** Ortolani JB, Zhong X, Tershak DR, Ferrara JJ, Paget CJ. *The American surgeon*. 2015;81(7):710-3.
1633. **Acute neuropharmacologic action of chloroquine on cortical neurons in vitro.** O'Shaughnessy TJ, Zim B, Ma W, Shaffer KM, Stenger DA, Zamani K, et al. *Brain Research*. 2003;959(2):280-6.
1634. **Morbidity rates on Vanguard Class submarines during nuclear deterrent patrol: a retrospective review over 13 years.** O'Shea MK, Scutt MJ. *Journal of the Royal Naval Medical Service*. 2009;95(3):127-35.
1635. **Substance use among secondary school students in an urban setting in Nigeria: Prevalence and associated factors.** Oshodi OY, Aina OF, Onajole AT. *African Journal of Psychiatry (South Africa)*. 2010;13(1):52-7.
1636. **The safety of bronchoscopy in a pulmonary fellowship program.** Ouellette DR. *Chest*. 2006;130(4):1185-90. <http://dx.doi.org/10.1378/chest.130.4.1185>.
1637. **Manic episode after malaria prophylaxis with mefloquine: Case report.** Oueriagli Nabih F, Touhami M, Abilkassem L. *International Journal of Neuropsychopharmacology*. 2012;15:244.
1638. **Drug-induced movement disorders.** Owen RT. *Pharmacy International*. 1980;1(9):181-3.
1639. **Severe morbidity among children in a trial malaria chemoprophylaxis with pyrimethamine or chloroquine in Ibarapa, Nigeria.** Oyediran AB, Topley E, Osunkoya BO, Bamgboye A, Williams AI, Ogunba EO, et al. *African journal of medicine and medical sciences*. 1993;22(1):55-63.
1640. **Views of emergency physicians working in university and state hospitals in Turkey regarding the use of analgesics in patients with acute abdominal pain.** Ozen O, Kiyani S. *Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES*. 2016;22(2):175-83. <http://dx.doi.org/10.5505/tjtes.2015.06706>.
1641. **Patient experiences, attitudes and expectations towards receiving information about anti-TNF medication: a quantitative study.** Packham J, Arkell P, Sheeran T, Brownfield A, Cadwgan A, Ryan S. *Clinical Rheumatology*. 2017;36(11):2595-600.
1642. **Safety of Abatacept in Rheumatoid Arthritis with Serologic Evidence of Past or Present Hepatitis B Virus Infection.** Padovan M, Filippini M, Tincani A, Lanciano E, Bruschi E, Epis O, et al. *Arthritis Care and Research*.

2016;68(6):738-43.

1643. **Repurposing the antipsychotic chlorpromazine for the treatment of glioblastoma multiforme.** Paggi MG, Abbruzzese C, Matteoni S, Matarrese P, Giannarelli D, Sperduti I, et al. *Neuro-Oncology*. 2019;21:iii55.

1644. **Factors associated with delay in giving thrombolytic therapy after arrival at hospital.** Palmer DJ, Cox KL, Dear K, Leitch JW. *The Medical journal of Australia*. 1998;168(3):111-4.

1645. **5th National Audit Project (NAP5) on accidental awareness during general anaesthesia: summary of main findings and risk factors.** Pandit JJ, Andrade J, Bogod DG, Hitchman JM, Jonker WR, Lucas N, et al. *Br J Anaesth*. 2014;113(4):549-59. <http://dx.doi.org/10.1093/bja/aeu313>. Epub 2014 Sep 9.

1646. **Methotrexate and hydroxychloroquine combination therapy in chronic chikungunya arthritis: A 16 week study.** Pandya S. *Indian Journal of Rheumatology*. 2008;3(3):93-7.

1647. **Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis.** Panoulas VF, Douglas KMJ, Milionis HJ, Stavropoulos-Kalinglou A, Nightingale P, Kita MD, et al. *Rheumatology*. 2007;46(9):1477-82.

1648. **Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis.** Panoulas VF, Douglas KMJ, Stavropoulos-Kalinoglou A, Metsios GS, Nightingale P, Kita MD, et al. *Rheumatology*. 2008;47(1):72-5.

1649. **Association of the TRAF1/C5 locus with increased mortality, particularly from malignancy or sepsis, in patients with rheumatoid arthritis.** Panoulas VF, Smith JP, Nightingale P, Kitas GD. *Arthritis and Rheumatism*. 2009;60(1):39-46.

1650. **Wet Lab-Based Cataract Surgery Training Curriculum for the PGY 2/PGY 3 Ophthalmology Resident.** Pantanelli SM, Papachristou G, Callahan C, Chen M, Khalifa Y. *MedEdPORTAL : the journal of teaching and learning resources*. 2018;14:10782. [http://dx.doi.org/10.15766/mep\\_2374-8265.10782](http://dx.doi.org/10.15766/mep_2374-8265.10782).

1651. **The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy.** Panthakalam S, Bhatnagar D, Klimiuk P. *Scottish Medical Journal*. 2004;49(4):139-41.

1652. **Sepsis in Haiti: Prevalence, treatment, and outcomes in a Port-au-Prince referral hospital.** Papali A, Verceles AC, Augustin ME, Colas LN, Jean-Francois CH, Patel DM, et al. *Journal of Critical Care*. 2017;38:35-40.

1653. **A guide to treatment of sarcoidosis.** Papanikolaou IC, Shigemitsu H, Sharma OP. *Current Drug Therapy*. 2010;5(2):122-31.

1654. **Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.** Papp KA, Miller B, Gordon KB, Caro I, Kwon P, Compton PG, et al. *Journal of the American Academy of Dermatology*. 2006;54(4):S164-S70.

1655. **Acute generalized exanthematous pustulosis induced by hydroxychloroquine: three cases and a review of the literature.** Paradisi A, Bugatti L, Sisto T, Filosa G, Amerio PL, Capizzi R. *Clinical therapeutics*. 2008;30(5):930-40. <http://dx.doi.org/10.1016/j.clinthera.2008.05.014>.

1656. **Interstitial lung disease in primary Sjögren syndrome.** Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH. *Chest*. 2006;130(5):1489-95.

1657. **Adverse Drug Reaction-Related Hospitalizations in Elderly Australians: A Prospective Cross-Sectional Study in Two Tasmanian Hospitals.** Parameswaran Nair N, Chalmers L, Bereznicki BJ, Curtain C, Peterson GM, Connolly M, et al. *Drug Safety*. 2017;40(7):597-606.

1658. **Lymphocytic colitis: Clinical features, treatment, and outcomes.** Pardi DS, Ramnath VR, Loftus Jr EV, Tremaine WJ, Sandborn WJ. *American Journal of Gastroenterology*. 2002;97(11):2829-33.
1659. **Cardiac manifestations other than valvulopathy in antiphospholipid syndrome: Long-time echocardiography follow-up study.** Pardos-Gea J, Avegliano G, Evangelista A, Vilardell M, Ordi-Ros J. *International Journal of Rheumatic Diseases*. 2015;18(1):76-83.
1660. **Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: A double blind, randomized comparison with pioglitazone.** Pareek A, Chandurkar N, Thomas N, Viswanathan V, Deshpande A, Gupta OP, et al. *Current Medical Research and Opinion*. 2014;30(7):1257-66.
1661. **Comparative study of efficacy and safety of hydroxychloroquine and chloroquine in polymorphic light eruption: a randomized, double-blind, multicentric study.** Pareek A, Khopkar U, Sacchidanand S, Chandurkar N, Naik GS. *Indian journal of dermatology, venereology and leprology*. 2008;74(1):18-22.  
<http://dx.doi.org/10.4103/0378-6323.38401>.
1662. **Can doctors identify older patients at risk of medication harm following hospital discharge? A multicentre prospective study in the UK.** Parekh N, Stevenson JM, Schiff R, Graham Davies J, Bremner S, Van der Cammen T, et al. *British journal of clinical pharmacology*. 2018;84(10):2344-51. <http://dx.doi.org/10.1111/bcp.13690>. Epub 2018 Jul 30.
1663. **Laparoscopic cholecystectomy performed by residents: a retrospective study on 569 patients.** Pariani D, Fontana S, Zetti G, Cortese F. *Surgery research and practice*. 2014;2014:912143.  
<http://dx.doi.org/10.1155/2014/912143>. Epub 2014 Jan 2.
1664. **Ocular manifestation in treated multibacillary Hansen's disease.** Parikh R, Thomas S, Muliylil J, Parikh S, Thomas R. *Ophthalmology*. 2009;116(11):2051-7.e1. <http://dx.doi.org/10.1016/j.ophtha.2009.04.021>. Epub 2009 Sep 19.
1665. **Impact of an Electronic Decision Support Tool on Hydroxychloroquine Screening.** Parikh VS, Au A, Modi YS, Schachat AP, Rodstrom T, Singh RP. *Ophthalmology*. 2016;123(11):2433-5.  
<http://dx.doi.org/10.1016/j.ophtha.2016.06.056>. Epub 2016 Aug 11.
1666. **Nonleaking Cystoid Macular Edema as a Presentation of Hydroxychloroquine Retinal Toxicity.** Parikh VS, Modi YS, Au A, Ehlers JP, Srivastava SK, Schachat AP, et al. *Ophthalmology*. 2016;123(3):664-6.  
<http://dx.doi.org/10.1016/j.ophtha.2015.09.011>. Epub 2015 Oct 14.
1667. **Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis.** Park JH, Park EK, Koo DW, Lee S, Lee SH, Kim GT, et al. *BMC Musculoskeletal Disorders*. 2017;18(1).
1668. **High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus.** Parker BJ, Bruce IN. *Lupus*. 2007;16(6):387-93.
1669. **Psychiatric effects of drugs for other disorders.** Parker C. *Medicine (United Kingdom)*. 2012;40(12):691-5.
1670. **Antipsychotics in the treatment of schizophrenia.** Parker C. *Progress in Neurology and Psychiatry*. 2013;17(3):6-18.
1671. **Outcome of emergency department patients with delayed admission to an intensive care unit.** Parkhe M, Myles PS, Leach DS, Maclean AV. *Emergency medicine (Fremantle, WA)*. 2002;14(1):50-7.  
<http://dx.doi.org/10.1046/j.1442-2026.2002.00286.x>.

1672. **Influence of volume of work on the outcome of treatment for patients with colorectal cancer.** Parry JM, Collins S, Mathers J, Scott NA, Woodman CB. *Br J Surg.* 1999;86(4):475-81. <http://dx.doi.org/10.1046/j.1365-2168.1999.01064.x>.
1673. **The impact of employee level and work stress on mental health and GP service use: an analysis of a sample of Australian government employees.** Parslow RA, Jorm AF, Christensen H, Broom DH, Strazdins L, Rm DS. *BMC Public Health.* 2004;4:41. <http://dx.doi.org/10.1186/1471-2458-4-41>.
1674. **Rationale and preliminary results of the GRISAR study.** Pasero G, Della Casa-Alberighi O. *Reumatismo.* 1992;44:51-65.
1675. **Prevalence and determinants of QT interval prolongation in medical inpatients.** Pasquier M, Pantet O, Hugli O, Pruvot E, Buclin T, Waeber G, et al. *Internal Medicine Journal.* 2012;42(8):933-40.
1676. **Nephron-sparing surgery for renal cell carcinoma: detailed analysis of complications over a 15-year period.** Pasticier G, Timsit MO, Badet L, De La Torre Abril L, Halila M, Fassi Fehri H, et al. *European urology.* 2006;49(3):485-90. <http://dx.doi.org/10.1016/j.eururo.2005.12.049>. Epub 2006 Jan 11.
1677. **Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19).** Pastick KA, Okafor EC, Wang F, Lofgren SM, Skipper CP, Nicol MR, et al. *Open Forum Infectious Diseases.* 2020.
1678. **An analysis of drug induced Stevens-Johnson syndrome.** Pate PP, Gandhi AM, Desai CK, Desai MK, Dikshit RK. *Indian Journal of Medical Research.* 2012;136(6):1051-3.
1679. **Neurosarcoidosis.** Patel AV, Stickler DE, Tyor WR. *Current Treatment Options in Neurology.* 2007;9(3):161-8.
1680. **Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: A prospective study.** Patel KJ, Kedia MS, Bajpai D, Mehta SS, Kshirsagar NA, Gogtay NJ. *BMC Clinical Pharmacology.* 2007;7.
1681. **Ionising radiation exposure in paediatric trauma.** Patel NG, Mohamed AM, Cooper G, McFadyen I. *Annals of the Royal College of Surgeons of England.* 2014;96(3):190-3. <http://dx.doi.org/10.1308/003588414X13814021677313>.
1682. **Clinical study of cutaneous drug eruptions in 200 patients.** Patel R, Marfatia Y. *Indian Journal of Dermatology, Venereology and Leprology.* 2008;74(4):430.
1683. **Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer.** Patel S, Hurez V, Nawrocki ST, Goros M, Michalek J, Sarantopoulos J, et al. *Oncotarget.* 2016;7(37):59087-97.
1684. **Polymyalgia rheumatica in older adults.** Patil P, Dasgupta B. *Aging Health.* 2013;9(5):483-95.
1685. **Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: A randomized controlled trial.** Paton NI, Goodall RL, Dunn DT, Franzen S, Collaco-Moraes Y, Gazzard BG, et al. *JAMA - Journal of the American Medical Association.* 2012;308(4):353-61.
1686. **Is juvenile dermatomyositis a different disease in children up to three years of age at onset than in children above three years at onset? A retrospective review of 23 years of a single center's experience.** Patwardhan A, Rennebohm R, Dvorchik I, Spencer CH. *Pediatric Rheumatology.* 2012;10.
1687. **Medications in pregnancy.** Paulus W. *MMW-Fortschritte der Medizin.* 2005;147(16):37-40.
1688. **Prolactin in systemic lupus erythematosus.** Puzner R, Urowitz MB, Gladman DD, Gough JM. *The Journal*

of rheumatology. 1994;21(11):2064-7.

1689. **Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.** Pavelka K, Akkoç N, Al-Maini M, Zerbini CAF, Karateev DE, Nasonov EL, et al. *Rheumatology International*. 2017;37(9):1469-79.
1690. **Shunt reversal due to deterioration of chloroquine-induced cardiomyopathy in a patient with primary Sjogren syndrome.** Pavsic N, Mraz J, Strazar ZD, Gabrijelcic J, Toplisek J, Kozelj M, et al. *Int J Cardiol*. 2016;215:145-6. <http://dx.doi.org/10.1016/j.ijcard.2016.04.112>. Epub 2016 Apr 14.
1691. **An EORTC phase II study of the efficacy and safety of linomide in the treatment of advanced renal cell carcinoma.** Pawinski A, Van Oosterom AT, De Wit R, Fosså S, Croles J, Svedberg A, et al. *European Journal of Cancer Part A*. 1997;33(3):496-9.
1692. **677C > T and 1298A > C MTHFR polymorphisms affect arechin treatment outcome in rheumatoid arthritis.** Pawlik A, Kurzawski M, Gornik W, Dabrowska-Zamojcin E, Drozdziak M. *Pharmacological reports : PR*. 2007;59(6):721-6.
1693. **A multicenter study of patients with adult-onset Still's disease compared with systemic juvenile idiopathic arthritis.** Pay S, Türkçapar N, Kalyoncu M, Şimşek I, Beyan E, Ertenli I, et al. *Clinical Rheumatology*. 2006;25(5):639-44.
1694. **Clinical characteristics of hydroxychloroquine retinopathy.** Payne JF, Hubbard GB, 3rd, Aaberg TM, Sr., Yan J. *The British journal of ophthalmology*. 2011;95(2):245-50. <http://dx.doi.org/10.1136/bjo.2009.172148>. Epub 2010 Aug 7.
1695. **[Long-term follow-up of nosocomial rotavirus infections at the Infectious Diseases Clinic of the Medical School Hospital in Plzen (1987-1994)].** Pazdiora P, Taborska J, Svecova M. *Epidemiologie, mikrobiologie, imunologie : casopis Spolecnosti pro epidemiologii a mikrobiologii Ceske lekarske spolecnosti JE Purkyne*. 1996;45(3):95-100.
1696. **Pharmacotherapy follow-up: Role in active malaria surveillance in a travel medicine centre outside the transmission area in Brazil.** Pedro RS, Brasil P, Pina-Costa A, Machado CR, Damasceno LS, Daniel-Ribeiro CT, et al. *Journal of Clinical Pharmacy and Therapeutics*. 2017;42(6):750-7.
1697. **Implementation of pretravel advice: Good for malaria, bad for diarrhoea.** Peetermans WE, Van Wijngaerden E. *Acta Clinica Belgica*. 2001;56(5):284-8.
1698. **Experiences with rituximab for the treatment of autoimmune diseases with ocular involvement.** Pelegrin L, Jakob E, Schmidt-Bacher A, Schwenger V, Becker M, Max R, et al. *Journal of Rheumatology*. 2014;41(1):84-90.
1699. **Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus.** Pelle MT, Callen JP, Bigby M. *Archives of Dermatology*. 2002;138(9):1231-3.
1700. **Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis.** Peltomaa R, Paimela L, Kautiainen H, Leirisalo-Repo M. *Annals of the Rheumatic Diseases*. 2002;61(10):889-94.
1701. **Adolescent marijuana use: a review.** Penning M, Barnes GE. *The International journal of the addictions*. 1982;17(5):749-91. <http://dx.doi.org/10.3109/10826088209056326>.
1702. **Multifocal electroretinography evaluation for early detection of retinal dysfunction in patients taking**

**hydroxychloroquine.** Penrose PJ, Tzekov RT, Sutter EE, Fu AD, Allen Jr AW, Fung WE, et al. *Retina*. 2003;23(4):503-12.

1703. **Clinical profile of 266 Filipino patients with rheumatoid arthritis included in the rheumatoid arthritis database and registry (RADAR) of the Philippine General Hospital.** Penserga EG, Natividad TAL, Salido ES, Salido E, Reyes H, Tee M, et al. *International Journal of Rheumatic Diseases*. 2015;18(4):433-8.

1704. **Rheumatoid Arthritis Treatment After Methotrexate: The Durability of Triple Therapy Versus Etanercept.** Peper SM, Lew R, Mikuls T, Brophy M, Rybin D, Wu H, et al. *Arthritis care & research*. 2017;69(10):1467-72. <http://dx.doi.org/10.1002/acr.23255>. Epub 2017 Sep 6.

1705. **Compliance and tolerability of mefloquine and chloroquine plus proguanil for long-term malaria chemoprophylaxis in groups at particular risk (the military).** Peragallo MS, Sabatinelli G, Sarnicola G. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1999;93(1):73-7.

1706. **Chloroquine: ophthalmological safety, and clinical assessment in rheumatoid arthritis.** Percival SP, Meanock I. *Br Med J*. 1968;3(5618):579-84. <http://dx.doi.org/10.1136/bmj.3.5618.579>.

1707. **Geropharmacology for the rheumatologist.** Percy LA, Fang MA. *Rheumatic Disease Clinics of North America*. 2000;26(3):433-54.

1708. **Safety, efficacy and pharmacokinetic evaluations of a new coated chloroquine tablet in a single-arm open-label non-comparative trial in Brazil: A step towards a user-friendly malaria vivax treatment.** Pereira D, Daher A, Zanini G, Maia I, Fonseca L, Pitta L, et al. *Malaria Journal*. 2016;15(1).

1709. **Sjogren Sensory Neuronopathy (Sjogren Ganglionopathy): Long-Term Outcome and Treatment Response in a Series of 13 Cases.** Pereira PR, Viala K, Maisonobe T, Haroche J, Mathian A, Hie M, et al. *Medicine (Baltimore)*. 2016;95(19):e3632. <http://dx.doi.org/10.1097/MD.0000000000003632>.

1710. **The role of community health workers in improving child health programmes in Mali.** Perez F, Ba H, Dastagire SG, Altmann M. *BMC International Health and Human Rights*. 2009;9(1).

1711. **Drug allergy and challenge protocols: A three-year follow-up in Reims university hospital.** Perrin F, Lavaud F, Rey JB, Gourdier B, Lebargy F. *Journal de Pharmacie Clinique*. 2004;23(2):63-8.

1712. **Beyond the Learning Curve: Comparison of Microscopic and Endoscopic Incidences of Internal Carotid Injury in a Series of Highly Experienced Operators.** Perry A, Graffeo CS, Meyer J, Carlstrom LP, Oushy S, Driscoll CLW, et al. *World Neurosurg*. 2019;131:e128-e35. <http://dx.doi.org/10.1016/j.wneu.2019.07.074>. Epub 2019 Jul 15.

1713. **CHLOROQUINE PSYCHOSES.** Persson G. *Svenska läkartidningen*. 1964;61:1537-41.

1714. **Morbidity of laparoscopic fundoplication for gastroesophageal reflux: a retrospective study about 1470 patients.** Pessaux P, Arnaud JP, Ghavami B, Flament JB, Trebuchet G, Meyer C, et al. *Hepato-gastroenterology*. 2002;49(44):447-50.

1715. **Malaria chemoprophylaxis: When should we use it and what are the options?** Petersen E. *Expert Review of Anti-Infective Therapy*. 2004;2(1):119-32.

1716. **Early warning score challenges and opportunities in the care of deteriorating patients.** Petersen JA. *Danish medical journal*. 2018;65(2).

1717. **Using the Health Belief Model to Assess the HIV Education Needs of Junior and Senior High School Students.** Petosa R, Wessinger J. *International quarterly of community health education*. 1989;10(2):135-43. <http://dx.doi.org/10.2190/2M88-72L9-Q7XY-XE92>.

1718. **An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life.** Pettersson S, Lövgren M, Eriksson LE, Moberg C, Svenungsson E, Gunnarsson I, et al. *Scandinavian Journal of Rheumatology*. 2012;41(5):383-90.
1719. **Clinical diagnosis of malaria and the risk of chloroquine self-medication in rural health centres in Burkina Faso.** Pfeiffer K, Some F, Muller O, Sie A, Kouyate B, Haefeli WE, et al. *Tropical medicine & international health : TM & IH*. 2008;13(3):418-26. <http://dx.doi.org/10.1111/j.1365-3156.2008.02017.x>.
1720. **Orphans' perspectives on grief and loss in Botswana.** Phaladze NA, Ngwenya BN, Gabaitiri L. *AIDS care*. 2018;30(4):506-10. <http://dx.doi.org/10.1080/09540121.2017.1382677>. Epub 2017 Oct 4.
1721. **SEQUENTIAL CHANGES in HYDROXYCHLOROQUINE RETINOPATHY up to 20 YEARS after STOPPING the DRUG: Implications for Mild Versus Severe Toxicity.** Pham BH, Marmor MF. *Retina*. 2019;39(3):492-501.
1722. **Remission of proteinuria in primary glomerulonephritis: We know the goal but do we know the price?** Philibert D, Cattran D. *Nature Clinical Practice Nephrology*. 2008;4(10):550-9.
1723. **It's okay to talk: suicide awareness simulation.** Phillips EC, Neagle G, Cameron B, Moneypenny M. *The clinical teacher*. 2019;16(4):373-7. <http://dx.doi.org/10.1111/tct.13044>. Epub 2019 Jun 18.
1724. **Experience with etanercept in an academic medical center: Are infection rates increased?** Phillips K, Husni ME, Karlson EW, Coblyn JS. *Arthritis Care and Research*. 2002;47(1):17-21.
1725. **CNS adverse events associated with antimalarial agents: Fact or fiction?** Phillips-Howard PA, Ter Kuile FO. *Drug Safety*. 1995;12(6):370-83.
1726. **Dihydroartemisinin-piperazine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial.** Phyo AP, Lwin KM, Price RN, Ashley EA, Russell B, Sriprawatt K, et al. *Clin Infect Dis*. 2011;53(10):977-84. <http://dx.doi.org/10.1093/cid/cir631>.
1727. **Prospective evaluation of drug-induced lung toxicity with high-resolution CT and transbronchial biopsy.** Piciocchi S, Romagnoli M, Chilosi M, Bigliuzzi C, Dubini A, Beomonte Zobel B, et al. *La Radiologia medica*. 2011;116(2):246-63. <http://dx.doi.org/10.1007/s11547-010-0608-y>. Epub 2010 Dec 3.
1728. **RABBIT risk score and ICU admission due to infection in patients with rheumatoid arthritis.** Pieringer H, Hintenberger R, Pohanka E, Steinwender C, Meier J, Gruber F, et al. *Clinical Rheumatology*. 2017;36(11):2439-45.
1729. **Experiences in the outpatient care of patients with rheumatoid arthritis and ankylosing spondylarthritis with chloroquine diphosphate and indometacin as longterm therapy.** Pietruschka WD, Beenken O, Otto W. *Zeitschrift fur Arztliche Fortbildung*. 1973;67(24):1242-4.
1730. **Rituximab treatment in patients with primary Sjögren's syndrome: An open-label phase II study.** Pijpe J, Van Imhoff GW, Spijkervet FKL, Roodenburg JLN, Wolbink GJ, Mansour K, et al. *Arthritis and Rheumatism*. 2005;52(9):2740-50.
1731. **Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs.** Pinho de Oliveira Ribeiro N, Rafael de Mello Schier A, Ornelas AC, Pinho de Oliveira CM, Nardi AE, Silva AC. *Comprehensive psychiatry*. 2013;54(8):1185-9. <http://dx.doi.org/10.1016/j.comppsy.2013.05.010>. Epub 2013 Jul 3.
1732. **IS THE PHYSICIAN EXPERTISE IN DIGITAL RECTAL EXAMINATION OF VALUE IN DETECTING ANAL TONE IN COMPARISON TO ANORECTAL MANOMETRY?** Pinto RA, Correa Neto IJF, Nahas SC, Froehner Junior I, Soares DFM, Ceconello I. *Arq Gastroenterol*. 2019;56(1):79-83. <http://dx.doi.org/10.1590/S0004-2803.201900000-04>. Epub 2019 Mar 18.



1733. **Two challenge and rechallenge episodes of chloroquine-induced psychotic mania in a patient with rheumatoid arthritis.** Plesnicar BK, Velikonja I, Plesnicar A, Vitorovic S. *Aktuelle Rheumatologie*. 2013;38(3):177-9.
1734. **Malaria: What's New in the Management of Malaria?** Plewes K, Leopold SJ, Kingston HWF, Dondorp AM. *Infectious Disease Clinics of North America*. 2019;33(1):39-60.
1735. **Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study.** Pokroy-Shapira E, Gelernter I, Molad Y. *Clin Rheumatol*. 2014;33(5):649-57. <http://dx.doi.org/10.1007/s10067-014-2527-0>. Epub 2014 Feb 19.
1736. **Evaluation of adverse events triggered by the use of chloroquine diphosphate, emphasis on retina toxicity, in 350 patients with lupus erythematosus.** Ponchet MRNC, Vilela MAC, Suni Sinahara KK, De Freitas Dotto P. *Anais Brasileiros de Dermatologia*. 2005;80:S275-S82.
1737. **The GLADEL Multinational Latin American Prospective Inception Cohort of 1,214 Patients with Systemic Lupus Erythematosus: Ethnic and Disease Heterogeneity among "Hispanics".** Pons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, et al. *Medicine*. 2004;83(1):1-17.
1738. **IgG4-related disease in a multi-ethnic community: Clinical characteristics and association with malignancy.** Poo SX, Tham CSW, Smith C, Lee J, Cairns T, Galliford J, et al. *QJM*. 2019;112(10):763-9.
1739. **Training surgeons and the informed consent process: routine disclosure of trainee participation and its effect on patient willingness and consent rates.** Porta CR, Sebesta JA, Brown TA, Steele SR, Martin MJ. *Archives of surgery (Chicago, Ill : 1960)*. 2012;147(1):57-62. <http://dx.doi.org/10.1001/archsurg.2011.235>. Epub 2011 Sep 19.
1740. **Combination therapy in rheumatoid arthritis - No benefit of addition of hydroxychloroquine to patients with a suboptimal response to intramuscular gold therapy.** Porter DR, Capell HA, Hunter J. *Journal of Rheumatology*. 1993;20(4):645-9.
1741. **Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 years.** Posalski JD, Ishimori ML, Wallace DJ, Weisman MH. *Lupus*. 2009;18(6):516-21.
1742. **Are two (inexperienced) heads better than one (experienced) head? Averaging house officers' prognostic judgments for critically ill patients.** Poses RM, Bekes C, Winkler RL, Scott WE, Copare FJ. *Arch Intern Med*. 1990;150(9):1874-8.
1743. **Resurgence of malaria and drug resistance in plasmodium falciparum and plasmodium vivax species in Bombay.** Potkar CN, Kshirsagar NA, Kathuria R. *The Journal of the Association of Physicians of India*. 1995;43(5):336-8.
1744. **The role of the assistant during robot-assisted partial nephrectomy: does experience matter?** Potretzke AM, Knight BA, Brockman JA, Vetter J, Figenshau RS, Bhayani SB, et al. *Journal of robotic surgery*. 2016;10(2):129-34. <http://dx.doi.org/10.1007/s11701-016-0582-z>. Epub 2016 Apr 2.
1745. **Occupational factors for mood and anxiety disorders among junior medical doctors.** Pougnet R, Di Costanzo LP, Kerrien M, Jousset D, Lodde B, Dewitte JD, et al. *La Medicina del lavoro*. 2015;106(5):386-93.
1746. **Gender differences in the association between substance use and elevated depressive symptoms in a general adolescent population.** Poulin C, Hand D, Boudreau B, Santor D. *Addiction (Abingdon, England)*. 2005;100(4):525-35. <http://dx.doi.org/10.1111/j.1360-0443.2005.01033.x>.
1747. **Screening for correctable visual acuity deficits in school-age children and adolescents.** Powell C,

Wedner S, Richardson S. The Cochrane database of systematic reviews. 2005(1):Cd005023.  
<http://dx.doi.org/10.1002/14651858.CD005023.pub2>.

1748. **The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: A nested case-control study of inception patients.** Prasad R, Ibanez D, Gladman D, Urowitz MB. *Lupus*. 2007;16(3):157-62.

1749. **Phacoemulsification learning curve: experience of two junior trainee ophthalmologists.** Prasad S. *Journal of cataract and refractive surgery*. 1998;24(1):73-7. [http://dx.doi.org/10.1016/s0886-3350\(98\)80077-1](http://dx.doi.org/10.1016/s0886-3350(98)80077-1).

1750. **Resistance to changing practice from pro re nata prescriptions to patient group directions in acute mental health settings.** Price O, Baker JA. *Journal of psychiatric and mental health nursing*. 2013;20(7):623-30. <http://dx.doi.org/10.1111/j.1365-2850.2012.01960.x>. Epub 2012 Sep 10.

1751. **Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use.** Proudman SM, James MJ, Spargo LD, Metcalf RG, Sullivan TR, Rischmueller M, et al. *Ann Rheum Dis*. 2015;74(1):89-95. <http://dx.doi.org/10.1136/annrheumdis-2013-204145>. Epub 2013 Sep 30.

1752. **Response-Driven Combination Therapy with Conventional Disease-Modifying Antirheumatic Drugs Can Achieve High Response Rates in Early Rheumatoid Arthritis with Minimal Glucocorticoid and Nonsteroidal Anti-Inflammatory Drug Use.** Proudman SM, Keen HI, Stamp LK, Lee ATY, Goldblatt F, Ayres OC, et al. *Seminars in Arthritis and Rheumatism*. 2007;37(2):99-111.

1753. **Ocular toxicity of chloroquine among Thai patients.** Puavilai S, Kunavisarut S, Vatanasuk M, Timpatanapong P, Sriwong ST, Janwitayanujit S, et al. *International Journal of Dermatology*. 1999;38(12):934-7.

1754. **Low-dose methotrexate treatment of rheumatoid arthritis.** Puchner R, Steglegger-Friede B, Roithinger FX, Knoflach P. *Acta Medica Austriaca*. 1994;21(4):107-10.

1755. **Comprehensive care of travelers.** Pust RE, Peate WF, Cordes DH. *Journal of Family Practice*. 1986;23(6):572-7.

1756. **Comparison of Complications and Surgical Outcomes of Adolescent Idiopathic Scoliosis Between Junior Attending Surgeons and Senior Attending Surgeons.** Qiao J, Xiao L, Xu L, Shi B, Qian B, Zhu Z, et al. *World Neurosurg*. 2018;115:e580-e4. <http://dx.doi.org/10.1016/j.wneu.2018.04.103>. Epub 2018 Apr 24.

1757. **Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events.** Quach LT, Chang BH, Brophy MT, Soe Thwin S, Hannagan K, O'Dell JR. *Rheumatology (Oxford, England)*. 2017;56(3):378-83. <http://dx.doi.org/10.1093/rheumatology/kew412>.

1758. **Prospective audit of upper gastrointestinal endoscopy in two regions of England: safety, staffing, and sedation methods.** Quine MA, Bell GD, McCloy RF, Charlton JE, Devlin HB, Hopkins A. *Gut*. 1995;36(3):462-7. <http://dx.doi.org/10.1136/gut.36.3.462>.

1759. **Complex Membrane Channel Blockade: A Unifying Hypothesis for the Prodromal and Acute Neuropsychiatric Sequelae Resulting from Exposure to the Antimalarial Drug Mefloquine.** Quinn JC. *Journal of Parasitology Research*. 2015;2015.

1760. **Two cases of chloroquine psychosis.** Rab SM. *British medical journal*. 1963;1(5340):1275.

1761. **[Disagreement between physicians' medication records and information given by patients].** Rabol R, Arroe GR, Folke F, Madsen KR, Langergaard MT, Larsen AH, et al. *Ugeskrift for laeger*. 2006;168(13):1307-10.

1762. **Rational Clinical Pathology Assessment in the Intensive Care Unit.** Rachakonda KS, Parr M, Aneman A,

Bhonagiri S, Micallef S. Anaesthesia and intensive care. 2017;45(4):503-10.  
<http://dx.doi.org/10.1177/0310057X1704500415>.

1763. **Risk and spectrum of diseases in travelers to popular tourist destinations.** Rack J, Wichmann O, Kamara B, Günther M, Cramer J, Schönfeld C, et al. *Journal of Travel Medicine*. 2005;12(5):248-53.

1764. **Malaria prophylaxis for short journeys.** Raeber PA, Braendli B, Darioli R, Holdener F, Loutan L, Markwalder K, et al. *Medecine et Hygiene*. 1991;49(1900):2321-5.

1765. **Psychotic symptoms in volunteers serving overseas.** Ragan E, Wilson R, Li F. *Lancet*. 1985;2(8445):37.

1766. **Prostaglandins and schizophrenia: a review.** Ragheb M, Ban TA. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 1982;6(2):87-93.

1767. **Mental health in the tropics.** Rahman A, Prince M. *Annals of Tropical Medicine and Parasitology*. 2009;103(2):95-110.

1768. **Efficacy of combined chloroquine and sulfadoxine - Pyrimethamine in uncomplicated Plasmodium falciparum malaria in Bangladesh.** Rahman M, Rahman R, Bangali M, Das S, Talukder MR, Ringwald P. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2004;98(7):438-41.

1769. **Percutaneous treatment of liver abscesses: Needle aspiration versus catheter drainage.** Rajak CL, Gupta S, Jain S, Chawla Y, Gulati M, Suri S. *American Journal of Roentgenology*. 1998;170(4):1035-9.

1770. **Neuroleptic malignant syndrome masked by cerebral malaria.** Rajesh KM, Sinnathamby V, Sakthi AN. *BMJ Case Reports*. 2013.

1771. **Diagnostic omission errors in acute paediatric practice: impact of a reminder system on decision-making.** Ramnarayan P, Winrow A, Coren M, Nanduri V, Buchdahl R, Jacobs B, et al. *BMC Med Inform Decis Mak*. 2006;6:37. <http://dx.doi.org/10.1186/1472-6947-6-37>.

1772. **Beyond the joints: Neurological involvement in rheumatoid arthritis.** Ramos-Remus C, Duran-Barragan S, Castillo-Ortiz JD. *Clinical Rheumatology*. 2012;31(1):1-12.

1773. **Three hundred robotic-assisted mitral valve repairs: the Cedars-Sinai experience.** Ramzy D, Trento A, Cheng W, De Robertis MA, Mirocha J, Ruzza A, et al. *J Thorac Cardiovasc Surg*. 2014;147(1):228-35.  
<http://dx.doi.org/10.1016/j.jtcvs.2013.09.035>. Epub 2013 Nov 4.

1774. **Suicidal behaviour and related risk factors among school-aged youth in the Republic of Benin.** Randall JR, Doku D, Wilson ML, Peltzer K. *PLoS One*. 2014;9(2):e88233. <http://dx.doi.org/10.1371/journal.pone.0088233>. eCollection 2014.

1775. **The older rheumatoid arthritis patients: Who are they and how should they be treated?** Ranganath VK, Amjadi S, Melikterminas E, Furst DE. *Aging Health*. 2010;6(5):533-49.

1776. **Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.** Ranganath VK, Furst DE. *Clinics in Geriatric Medicine*. 2005;21(3):649-69.

1777. **Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis.** Ranganath VK, Maranian P, Elashoff DA, Woodworth T, Khanna D, Hahn T, et al. *Rheumatology (United Kingdom)*. 2013;52(10):1809-17.

1778. **Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.** Rangwala R, Chang YC, Hu J, Algazy KM, Evans TL, Fecher LA,

et al. *Autophagy*. 2014;10(8):1391-402.

1779. **Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.** Rangwala R, Leone R, Chang YC, Fecher LA, Schuchter LM, Kramer A, et al. *Autophagy*. 2014;10(8):1369-79. <http://dx.doi.org/10.4161/auto.29118>. Epub 2014 May 20.

1780. **The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: The eleven-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial.** Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Järvenpää S, Leirisalo-Repo M, et al. *Arthritis and Rheumatism*. 2009;60(5):1222-31.

1781. **Evaluation of a novel risk assessment method for self-harm associated with Borderline Personality Disorder.** Rao S, Broadbear JH, Thompson K, Correia A, Preston M, Katz P, et al. *Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists*. 2017;25(5):460-5. <http://dx.doi.org/10.1177/1039856217707390>. Epub 2017 May 10.

1782. **Chloroquine Is Effective for Maintenance of Remission in Autoimmune Hepatitis: Controlled, Double-Blind, Randomized Trial.** Raquel Benedita Terrabuio D, Augusto Diniz M, Teofilo de Moraes Falcão L, Luiza Vilar Guedes A, Akeme Nakano L, Silva Evangelista A, et al. *Hepatology Communications*. 2019;3(1):116-28.

1783. **Course and prognosis of early rheumatoid arthritis.** Rasker JJ, Cosh JA. *Scandinavian Journal of Rheumatology, Supplement*. 1989;18(79):45-56.

1784. **Chronic graft-versus-host disease: Clinical manifestation and therapy.** Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP. *Bone Marrow Transplantation*. 2001;28(2):121-9.

1785. **Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia.** Ratcliff A, Siswantoro H, Kenangalem E, Wuwung M, Brockman A, Edstein MD, et al. *Trans R Soc Trop Med Hyg*. 2007;101(4):351-9. <http://dx.doi.org/10.1016/j.trstmh.2006.06.008>. Epub 2006 Oct 9.

1786. **Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): A double blind, placebo controlled dose-finding study in rheumatoid arthritis.** Rau R, Sander O, Van Riel P, Van de Putte L, Hasler F, Zaugg M, et al. *Journal of Rheumatology*. 2003;30(4):680-90.

1787. **Longterm treatment of destructive rheumatoid arthritis with methotrexate.** Rau R, Schleusser B, Herborn G, Karger T. *Journal of Rheumatology*. 1997;24(10):1881-9.

1788. **Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.** Rau R, Schleusser B, Herborn G, Karger T. *Journal of Rheumatology*. 1998;25(8):1485-92.

1789. **Brief communication: Characteristics of spontaneous cases of tuberculosis associated with infliximab.** Raval A, Akhavan-Toyserkani G, Brinker A, Avigan M. *Annals of Internal Medicine*. 2007;147(10):699-702.

1790. **Epidemiological review of malaria with reference to causality analysis, treatment monitoring and outcome.** Ravindra K, Shinde RR, Mayur G, Pawan G, Mahendra G, Dnyanda K, et al. *International Journal of Research in Ayurveda and Pharmacy*. 2013;4(5):754-8.

1791. **Systemic lupus erythematosus presenting as morbid jealousy.** Ravindran A, Carney MWP, Denman AM. *Postgraduate Medical Journal*. 1980;56(656):419-20.

1792. **A study on leflunomide-induced liver injury in rheumatoid arthritis patients.** Razak SA, Islahudin F, Shamsuddin AF, Shahri NS. *Research Journal of Pharmacy and Technology*. 2013;6(5):556-61.

1793. **Impact of the national prevention policy and scrum law changes on the incidence of rugby-related catastrophic cervical spine injuries in French Rugby Union.** Reboursiere E, Bohu Y, Retiere D, Sesboue B, Pineau V, Colonna JP, et al. *British journal of sports medicine*. 2018;52(10):674-7. <http://dx.doi.org/10.1136/bjsports-2016-096122>. Epub 2016 Jul 25.
1794. **Psychotic episode in a patient coming home from Africa: Possible role of mefloquine.** Recasens C, Zittoun C, Feline A. *Annales de Psychiatrie*. 1993;8(2):100-3.
1795. **Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long-Term Effects on Serum Immunoglobulins.** Reddy V, Martinez L, Isenberg DA, Leandro MJ, Cambridge G. *Arthritis Care and Research*. 2017;69(6):857-66.
1796. **Doctors' emotional reactions to recent death of a patient: cross sectional study of hospital doctors.** Redinbaugh EM, Sullivan AM, Block SD, Gadmer NM, Lakoma M, Mitchell AM, et al. *Bmj*. 2003;327(7408):185. <http://dx.doi.org/10.1136/bmj.327.7408.185>.
1797. **Opportunistic infections in patients with idiopathic inflammatory myopathies.** Redondo-Benito A, Curran A, Villar-Gomez A, Trallero-Araguas E, Fernández-Codina A, Pinal-Fernandez I, et al. *International Journal of Rheumatic Diseases*. 2018;21(2):487-96.
1798. **Operational feasibility of rapid diagnostic kits & blister packs use for malaria control in high transmission areas of Orissa & Chhattisgarh.** Reetha AM, Sharma SK, Tyagi PK, Valecha N, Nagpal BN, Dash AP. *Indian Journal of Medical Research*. 2007;125(1):65-72.
1799. **Characterization of resident surgeon participation during carotid endarterectomy and impact on perioperative outcomes.** Reeves JG, Kasirajan K, Veeraswamy RK, Ricotta JJ, 2nd, Salam AA, Dodson TF, et al. *J Vasc Surg*. 2012;55(1):268-73. <http://dx.doi.org/10.1016/j.jvs.2011.08.039>. Epub 2011 Nov 1.
1800. **Do trainee surgeons have an adverse effect on the outcome after total hip arthroplasty?: a ten-year review.** Reidy MJ, Faulkner A, Shitole B, Clift B. *The bone & joint journal*. 2016;98(3):301-6. <http://dx.doi.org/10.1302/0301-620X.98B3.35997>.
1801. **Barriers to prompt and effective treatment of malaria in northern Sri Lanka.** Reilley B, Abeyasinghe R, Pakianathar MV. *Tropical Medicine and International Health*. 2002;7(9):744-9.
1802. **Etiology and management of chronic pelvic pain syndromes.** Reisner LA. *Journal of Pharmaceutical Care in Pain and Symptom Control*. 1997;5(4):31-48.
1803. **Clinically important ocular reactions to systemic drug therapy.** Rennie IG. *Drug Safety*. 1993;9(3):196-211.
1804. **Resident postgraduate year does not influence rate of complications following inguinal herniorrhaphy.** Renteria O, Mokdad AA, Imran J, Huerta S. *The Journal of surgical research*. 2017;219:61-5. <http://dx.doi.org/10.1016/j.jss.2017.05.122>. Epub 2017 Jun 23.
1805. **International multicenter randomized, placebo-controlled phase III clinical trial of  $\beta$ -d-mannuronic acid in rheumatoid arthritis patients.** Rezaieyazdi Z, Farooqi A, Soleymani-Salehabadi H, Ahmadzadeh A, Aslani M, Omidian S, et al. *Inflammopharmacology*. 2019;27(5):911-21.
1806. **A patient-centered approach to the burden of symptoms in patients with scleroderma treated with Bosentan: A prospective single-center observational study.** Rezus E, Burlui AM, Gafton B, Stratulat TA, Zota GR, Cardoneanu A, et al. *Experimental and Therapeutic Medicine*. 2020;19(3):1739-46.

1807. **Case 2/2014 - 51-year old patient with systemic lupus erythematosus and fever after valve replacement.** Ribeiro WN, Yamada AT, Gutierrez PS. *Arquivos Brasileiros de Cardiologia*. 2014;102(5):e44-e51.
1808. **Test anxiety. Relationship to academic and clinical performance in dental hygiene students.** Rich SK. *Journal of dental hygiene* : JDH. 1991;65(8):390-5.
1809. **Efficacy and safety of neuromodulators in inflammatory arthritis: A Cochrane systematic review.** Richards BL, Whittle SL, Van Der Heijde DM, Buchbinder R. *Journal of Rheumatology*. 2012;39:28-33.
1810. **Cost and Outcome of Behavioural Activation versus Cognitive Behavioural Therapy for Depression (COBRA): a randomised, controlled, non-inferiority trial.** Richards DA, Ekers D, McMillan D, Taylor RS, Byford S, Warren FC, et al. *Lancet*. 2016;388(10047):871-80. [http://dx.doi.org/10.1016/S0140-6736\(16\)31140-0](http://dx.doi.org/10.1016/S0140-6736(16)31140-0). Epub 2016 Jul 23.
1811. **A central role for the polyamines in the aetiology of schizophrenia.** Richardson Andrews RC. *Medical Hypotheses*. 1983;11(2):157-66.
1812. **Is body mass index a risk factor for sport injury in adolescents?** Richmond SA, Kang J, Emery CA. *Journal of science and medicine in sport*. 2013;16(5):401-5. <http://dx.doi.org/10.1016/j.jsams.2012.11.898>. Epub 2012 Dec 28.
1813. **Comparison of Biologic Discontinuation in Patients With Elderly-Onset Versus Younger-Onset Rheumatoid Arthritis.** Richter MD, Matteson EL, Davis JM, Achenbach SJ, Crowson CS. *ACR Open Rheumatology*. 2019;1(10):627-31.
1814. **Permanent health impairment after staying in malaria areas.** Rieke B, Fleischer K. *Versicherungsmedizin*. 1993;45(6):197-202.
1815. **Up-dated ophthalmological screening and follow-up management for long-term antimalarial treatment.** Rigaudière F, Ingster-Moati I, Hache JC, Leid J, Verdet R, Haymann P, et al. *Journal Francais d'Ophthalmologie*. 2004;27(2):191-9.
1816. **Chemoresistance of Plasmodium falciparum in the urban area of Yaounde, Cameroon. Part 2: Evaluation of the efficacy of amodiaquine and sulfadoxine-pyrimethamine for the treatment of Plasmodium falciparum malaria in Yaounde, Cameroon.** Ringwald P, Keundjian A, Same Ekobo A, Basco LK. *Tropical Medicine and International Health*. 2000;5(9):620-7.
1817. **Leflunomide/chloroquin combination therapy in rheumatoid arthritis: A pilot study.** Rintelen B, Andel I, Sautner J, Leeb BF. *Clinical Rheumatology*. 2006;25(4):557-9.
1818. **Effectiveness of quinacrine (mepacrine) in photosensitive autoimmune diseases, lupus erythematosus, and dermatomyositis: Report on 38 cases and literature review.** Rios-Fernández R, Callejas-Rubio JL, Ortego-Centeno N. *Archives of Rheumatology*. 2019;34(1):34-43.
1819. **Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in southwestern India.** Rishikesh K, Kamath A, Hande MH, Vidyasagar S, Acharya RV, Acharya V, et al. *Malar J*. 2015;14:310. <http://dx.doi.org/10.1186/s12936-015-0824-y>.
1820. **Thymic epithelial tumor-Associated Cytopenia: A 10-year observational study in France.** Rivoisy C, Besse B, Girard N, Lioger B, Viillard JF, Lega JC, et al. *Journal of Thoracic Oncology*. 2016;11(3):391-9.
1821. **Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis.** Roberts J, Smylie M, Walker J, Basappa NS, Chu Q, Kolinsky M, et al. *Clin Rheumatol*. 2019;38(5):1513-9. <http://dx.doi.org/10.1007/s10067-019-04451-2>. Epub 2019 Jan 30.

1822. **Mortality following acute pancreatitis: social deprivation, hospital size and time of admission: record linkage study.** Roberts SE, Thorne K, Evans PA, Akbari A, Samuel DG, Williams JG. BMC gastroenterology. 2014;14:153. <http://dx.doi.org/10.1186/1471-230X-14-153>.
1823. **Giardiasis - why do the symptoms sometimes never stop?** Robertson LJ, Hanevik K, Escobedo AA, Mørch K, Langeland N. Trends in Parasitology. 2010;26(2):75-82.
1824. **Current prescribing patterns of elastic compression stockings post-deep venous thrombosis.** Roche-Nagle G, Ward F, Barry M. Phlebology. 2010;25(2):72-8. <http://dx.doi.org/10.1258/phleb.2009.009002>.
1825. **Casualties from a junior-senior high school during the Persian Gulf War: toxic poisoning or mass hysteria?** Rockney RM, Lemke T. Journal of developmental and behavioral pediatrics : JDBP. 1992;13(5):339-42.
1826. **Psychiatric complications with chloroquine and quinacrine.** Rockwell DA. The American journal of psychiatry. 1968;124(9):1257-60.
1827. **[Diagnostic methods for chloroquine diphosphate induced retinopathy in systemic lupus erythematosus].** Rodrigues LD, Shinjo SK, Oyamada MK, Serracarbassa PD, Takahashi WY, Borba EF, et al. Arquivos brasileiros de oftalmologia. 2009;72(3):313-20. <http://dx.doi.org/10.1590/s0004-27492009000300007>.
1828. **The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial.** Rodríguez PC, Prada DM, Moreno E, Aira LE, Molinero C, López AM, et al. Clinical and Experimental Immunology. 2018;191(2):229-39.
1829. **Recent advances in the treatment of systemic lupus erythematosus.** Rodriguez-Garcia V, Sapeta Dias S, Isenberg D. International Journal of Clinical Rheumatology. 2014;9(1):89-100.
1830. **High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy.** Rodriguez-Padilla JA, Hedges ITR, Monson B, Srinivasan V, Wojtkowski M, Reichel E, et al. Archives of Ophthalmology. 2007;125(6):775-80.
1831. **Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: A survival analysis.** Rodriguez-Rodríguez L, Jover-Jover JA, Fontsero O, Peña-Blanco RC, León L, Fernández-Gutierrez B, et al. Scandinavian Journal of Rheumatology. 2013;42(6):433-6.
1832. **Current Use of Domperidone and Co-prescribing of Medications that Increase Its Arrhythmogenic Potential Among Older Adults: A Population-Based Cohort Study in Ontario, Canada.** Rojas-Fernandez C, Stephenson AL, Fischer HD, Wang X, Mestre T, Hutson JR, et al. Drugs and Aging. 2014;31(11):805-13.
1833. **Phase II randomized, double-blind, placebo-controlled study of whole-brain irradiation with concomitant chloroquine for brain metastases.** Rojas-Puentes LL, Gonzalez-Pinedo M, Crismatt A, Ortega-Gomez A, Gamboa-Vignolle C, Nunez-Gomez R, et al. Radiation oncology (London, England). 2013;8:209. <http://dx.doi.org/10.1186/1748-717X-8-209>.
1834. **Lupus patients in an emergency unit. Causes of consultation, hospitalization and outcome. A cohort study.** Rojas-Serrano J, Cardiel MH. Lupus. 2000;9(8):601-6.
1835. **Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis.** Rolain JM, Boulous A, Mallet MN, Raoult D. Antimicrobial Agents and Chemotherapy. 2005;49(7):2673-6.
1836. **Correlation between Serum Doxycycline Concentrations and Serologic Evolution in Patients with Coxiella burnetii Endocarditis.** Rolain JM, Mallet MN, Raoult D. Journal of Infectious Diseases. 2003;188(9):1322-5.

1837. **Physiotherapists' participation in peer review in New Zealand: implications for the profession.** Rolland TM, Hocking C, Jones M. *Physiotherapy research international : the journal for researchers and clinicians in physical therapy.* 2010;15(2):118-22. <http://dx.doi.org/10.1002/pri.467>.
1838. **Rural-urban differences in household treatment-seeking behaviour for suspected malaria in children at Bata District, Equatorial Guinea.** Romay-Barja M, Jarrin I, Ncogo P, Nseng G, Sagrado MJ, Santana-Morales MA, et al. *PLoS ONE.* 2015;10(8).
1839. **Who needs drug prophylaxis against malaria? My personal view.** Rombo L. *Journal of Travel Medicine.* 2005;12(4):217-21.
1840. **A Risk Index for Geriatric Acute Medical Admissions (RIGAMA).** Romero-Ortuno R, O'Dwyer C, Byrne D, O'Riordan D, Silke B. *Acute medicine.* 2014;13(1):6-11.
1841. **Scleromyxedema: A multicenter study of characteristics, comorbidities, course, and therapy in 30 patients.** Rongioletti F, Merlo G, Cinotti E, Fausti V, Cozzani E, Cribier B, et al. *Journal of the American Academy of Dermatology.* 2013;69(1):66-72.
1842. **Reticular erythematous mucinosis: a review of patients' characteristics, associated conditions, therapy and outcome in 25 cases.** Rongioletti F, Merlo V, Riva S, Cozzani E, Cinotti E, Ghigliotti G, et al. *The British journal of dermatology.* 2013;169(6):1207-11. <http://dx.doi.org/10.1111/bjd.12577>.
1843. **Cervical spine surgery in patients with rheumatoid arthritis: Longterm mortality and its determinants.** Ronkainen A, Niskanen M, Auvinen A, Aalto J, Luosujärvi R. *Journal of Rheumatology.* 2006;33(3):517-22.
1844. **Neuropsychiatric manifestations after mefloquine therapy for plasmodium falciparum malaria: Comparing a retrospective and a prospective study.** Rønn AM, Rønne-Rasmussen J, Gøtzsche PC, Bygbjerg IC. *Tropical Medicine and International Health.* 1998;3(2):83-8.
1845. **Chloroquine cardiotoxicity: clinicopathologic features in three patients and comparison with three patients with Fabry disease.** Roos JM, Aubry MC, Edwards WD. *Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.* 2002;11(5):277-83. [http://dx.doi.org/10.1016/s1054-8807\(02\)00118-7](http://dx.doi.org/10.1016/s1054-8807(02)00118-7).
1846. **The effect of the grade of surgeon on blood loss in fractured neck-of-femur surgery.** Rose B, Sindali K, Soueid H, Jeer PJ. *European journal of orthopaedic surgery & traumatology : orthopedie traumatologie.* 2013;23(4):449-56. <http://dx.doi.org/10.1007/s00590-012-1015-y>. Epub 2012 Jun 5.
1847. **Do benzodiazepines modify the incidence of neuroleptic-induced dystonia? [14].** Rosebush PI, Mazurek MF, Khanna K. *American Journal of Psychiatry.* 1993;150(3):528-9.
1848. **The Hunter pulmonary angiography catheter for a brachiocephalic vein approach.** Rosen G, Kowalik KJ, Ganguli S, Hunter DW. *Cardiovascular and interventional radiology.* 2006;29(6):997-1002. <http://dx.doi.org/10.1007/s00270-003-0093-y>.
1849. **Phase II study of roquinimex in myelodysplastic syndrome.** Rosenfeld CS, Zeigler ZR, Shadduck RK, Nilsson B. *American journal of clinical oncology.* 1997;20(2):189-92. <http://dx.doi.org/10.1097/00000421-199704000-00018>.
1850. **A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.** Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, et al. *Autophagy.* 2014;10(8):1359-68. <http://dx.doi.org/10.4161/auto.28984>. Epub 2014 May 20.
1851. **Views of older people on cataract surgery options: an assessment of preferences by conjoint analysis.**



- Ross MA, Avery AJ, Foss AJ. Quality & safety in health care. 2003;12(1):13-7. <http://dx.doi.org/10.1136/qhc.12.1.13>.
1852. **Porphyria cutanea tarda: Effects and risk factors for hepatotoxicity from high-dose chloroquine treatment.** Rossmann-Ringdahl I, Olsson R. *Acta Dermato-Venereologica*. 2007;87(5):401-5.
1853. **Effects of prosorba® Column apheresis in patients with chronic refractory rheumatoid arthritis.** Roth S. *Journal of Rheumatology*. 2004;31(11):2131-5.
1854. **Birdshot chorioretinopathy: Long-term manifestations and visual prognosis.** Rothova A, Berendschot TTJM, Probst K, Van Kooij B, Baarsma GS. *Ophthalmology*. 2004;111(5):954-9.
1855. **Lymphocyte 3H-spiroperidol binding in schizophrenia: Preliminary findings.** Rotstein E, Mishra RK, Singal DP, Barone D. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 1983;7(4):729-32.
1856. **Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review.** Roubille C, Haraoui B. *Seminars in Arthritis and Rheumatism*. 2014;43(5):613-26.
1857. **Prescriptions for chronic high-dose cyclooxygenase-2 inhibitors are often inappropriate and potentially dangerous.** Roumie CL, Arbogast PG, Mitchel Jr EF, Griffin MR. *Journal of General Internal Medicine*. 2005;20(10):879-83.
1858. **Ocular involvement in epidermolysis bullosa acquisita with long-term follow-up.** Rousseau A, Prost-Squarcioni C, Doan S, Leroux-Villet C, Caux F, Hoang-Xuan T, et al. *British Journal of Ophthalmology*. 2020;104(2):235-40.
1859. **Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy.** Routy JP, Angel JB, Patel M, Kanagaratham C, Radzioch D, Kema I, et al. *HIV medicine*. 2015;16(1):48-56. <http://dx.doi.org/10.1111/hiv.12171>. Epub 2014 Jun 2.
1860. **Pharmaco-economic relations and social problems in the basal treatment of rheumatoid arthritis resistant forms.** Rovensky J, Foltan V, Urbankova L, Rybar I, Orlovská M, Greguskova K, et al. *Rheumatologia*. 1998;12(4):161-70.
1861. **Polyarthritis flare complicating rheumatoid arthritis infliximab therapy: A paradoxical adverse reaction.** Rozenbaum M, Boulman N, Slobodin G, Ayubkhanov E, Rosner I. *Journal of Clinical Rheumatology*. 2006;12(6):269-71.
1862. **Essential mixed cryoglobulinemia type II.** Rozin AP, Lewin M, Braun-Moscovici Y, Itzhak OB, Bergman R, Balbir-Gurman A. *Clinical and experimental rheumatology*. 2006;24(3):329-32.
1863. **Topical tacrolimus in the treatment of symptomatic oral lichen planus: A series of 13 patients.** Rozycki TW, Rogers IRS, Pittelkow MR, McEvoy MT, El-Azhary RA, Bruce AJ, et al. *Journal of the American Academy of Dermatology*. 2002;46(1):27-34.
1864. **[Comparative evaluation of various methods of immunosuppressive therapy in severe bronchial asthma].** Rudyk BI. *Terapevticheskii arkhiv*. 1985;57(5):36-9.
1865. **The impact of resident involvement in minimally-invasive urologic oncology procedures.** Ruhotina N, Dagenais J, Gandaglia G, Sood A, Abdollah F, Chang SL, et al. *Canadian Urological Association journal = Journal de l'Association des urologues du Canada*. 2014;8(9):334-40. <http://dx.doi.org/10.5489/cuaj.2170>.
1866. **Exploring the impact of consultants' experience on hospital mortality by day of the week: a retrospective analysis of hospital episode statistics.** Ruiz M, Bottle A, Aylin PP. *BMJ quality & safety*. 2016;25(5):337-44. <http://dx.doi.org/10.1136/bmjqs-2015-004105>. Epub 2015 Jul 22.

1867. **Current Trends in Training in the Surgical Management of Acute Appendicitis at a Veteran Affairs Hospital.** Ruiz M, Shahid Z, Renteria O, Huerta S. *Journal of surgical education*. 2019;76(2):506-11. <http://dx.doi.org/10.1016/j.j Surg.2018.07.029>. Epub 2018 Sep 21.
1868. **Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib.** Runger TM, Adami S, Benhamou CL, Czerwiński E, Farrerons J, Kendler DL, et al. *Journal of the American Academy of Dermatology*. 2012;66(3):e89-e96.
1869. **A retrospective analysis of adverse events in the elderly in a tertiary referral center in Mumbai (Bombay), India.** Rupawala A, Kshirsagar N, Gogtay N. *Indian Journal of Medical Sciences*. 2009;63(5):167-73.
1870. **Effects of bioaerosol exposure on work-related symptoms among Swiss sawmill workers.** Rusca S, Charriere N, Droz PO, Oppliger A. *International archives of occupational and environmental health*. 2008;81(4):415-21. <http://dx.doi.org/10.1007/s00420-007-0228-6>. Epub 2007 Aug 4.
1871. **Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy.** Russell E, Luk F, Manocha S, Ho T, O'Connor C, Hussain H. *Seminars in Arthritis and Rheumatism*. 2013;43(1):119-24.
1872. **[Chloroquine/hydroxychloroquine: variability of retinotoxic cumulative doses].** Ruther K, Foerster J, Berndt S, Schroeter J. *Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft*. 2007;104(10):875-9. <http://dx.doi.org/10.1007/s00347-007-1560-7>.
1873. **Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine.** Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H. *The British journal of dermatology*. 1992;127(5):513-8. <http://dx.doi.org/10.1111/j.1365-2133.1992.tb14851.x>.
1874. **Delirium in an adult acute hospital population: predictors, prevalence and detection.** Ryan DJ, O'Regan NA, Caoimh RO, Clare J, O'Connor M, Leonard M, et al. *BMJ Open*. 2013;3(1). <http://dx.doi.org/10.1136/bmjopen-2012-001772>.
1875. **Corticosteroids and systemic lupus erythematosus pancreatitis: A case series.** Saab S, Corr MP, Weisman MH. *Journal of Rheumatology*. 1998;25(4):801-6.
1876. **Left ventricle functional assessment by three-dimensional echocardiography in patients with systemic lupus erythematosus.** Saad AK, Cintora FM, Pinasco DS, Villalba CN, Vinicki JP, Paniego F, et al. *Revista Argentina de Cardiologia*. 2017;85(6):477-83.
1877. **Pattern of drugs use and association with anti-mutated citrullinated vimentin antibody in rheumatoid arthritis.** Safi MAA, Fathaldin OA. *Saudi Medical Journal*. 2015;36(3):316-23.
1878. **Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults.** Sagara I, Oduro AR, Mulenga M, Dieng Y, Ogutu B, Tiono AB, et al. *Malaria Journal*. 2014;13(1).
1879. **Chloroquine-induced recurrent psychosis.** Sahoo S, Kumar M, Sinha VK. *American Journal of Therapeutics*. 2007;14(4):406-7.
1880. **Comparison of the efficacy & safety of minocycline versus hydroxychloroquine as an add-on therapy to methotrexate in treatment of rheumatoid arthritis.** Saini R, Kaushal J, Singh H. *Indo Global Journal of Pharmaceutical Sciences*. 2013;3(1):27-32.
1881. **Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: A**

**randomized comparative study.** Sairanen J, Tammela TLJ, Leppilahti M, Multanen M, Paananen I, Lehtoranta K, et al. *Journal of Urology*. 2005;174(6):2235-8.

1882. **Systemic lupus erythematosus-associated acute transverse myelitis: manifestations, treatments, outcomes, and prognostic factors in 20 patients.** Saison J, Costedoat-Chalumeau N, Maucourt-Boulch D, Iwaz J, Marignier R, Cacoub P, et al. *Lupus*. 2015;24(1):74-81. <http://dx.doi.org/10.1177/0961203314547795>. Epub 2014 Aug 12.

1883. **[Drugs associated with acute generalized exanthematic pustulosis].** Saissi EH, Beau-Salinas F, Jonville-Bera AP, Lorette G, Autret-Leca E. *Ann Dermatol Venereol*. 2003;130(6):612-8.

1884. **Antimalarial drugs for treating and preventing malaria in pregnant and lactating women.** Saito M, Gilder ME, McGready R, Nosten F. *Expert Opinion on Drug Safety*. 2018;17(11):1129-44.

1885. **Effectiveness of infliximab in treating selected patients with sarcoidosis.** Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP. *Respiratory Medicine*. 2006;100(11):2053-9.

1886. **Efficacy of chloroquine for the treatment of Plasmodium vivax in the Saharan zone in Mauritania.** Salem MSOA, Lemine YOM, Deida JM, Lemrabott MAO, Ouldabdallahi M, Ba MDD, et al. *Malaria Journal*. 2015;14(1).

1887. **Efficacy of vitamin D in patients with active rheumatoid arthritis receiving methotrexate therapy.** Salesi M, Farajzadegan Z. *Rheumatology international*. 2012;32(7):2129-33. <http://dx.doi.org/10.1007/s00296-011-1944-5>. Epub 2011 Apr 27.

1888. **Prevalence and correlates of metabolic syndrome in patients with rheumatoid arthritis in Argentina.** Salinas MJH, Bertoli AM, Lema L, Saucedo C, Rosa J, Quintana R, et al. *Journal of Clinical Rheumatology*. 2013;19(8):439-43.

1889. **How do trainee doctors introduce themselves to patients?** Salman M, Tingas A, Yentis SM. *Postgrad Med J*. 2018;94(1114):432-5. <http://dx.doi.org/10.1136/postgradmedj-2017-135219>. Epub 2018 Aug 10.

1890. **Leprosy in a rheumatology setting: A challenging mimic to expose.** Salvi S, Chopra A. *Clinical Rheumatology*. 2013;32(10):1557-63.

1891. **Phase I study of a chloroquine-gemcitabine combination in patients with metastatic or unresectable pancreatic cancer.** Samaras P, Tusup M, Nguyen-Kim TDL, Seifert B, Bachmann H, von Moos R, et al. *Cancer Chemotherapy and Pharmacology*. 2017;80(5):1005-12.

1892. **Frontal fibrosing alopecia: a clinical review of 36 patients.** Samrao A, Chew AL, Price V. *The British journal of dermatology*. 2010;163(6):1296-300. <http://dx.doi.org/10.1111/j.1365-2133.2010.09965.x>.

1893. **Thalidomide in the treatment of discoid lupus erythematosus (D.L.E.).** Samsoen M, Grosshans E, Basset A. *Annales de Dermatologie et de Venereologie*. 1980;107(6):515-23.

1894. **Adverse drug reactions in internal medicine units and associated risk factors.** Sánchez Muñoz-Torrero JF, Barquilla P, Velasco R, Fernández Capitan MDC, Pacheco N, Vicente L, et al. *European Journal of Clinical Pharmacology*. 2010;66(12):1257-64.

1895. **Factors associated with a poor treatment outcome among children treated for malaria in Ibadan, Southwest Nigeria.** Sangowawa AO, Amodu OK, Olaniyan SA, Amodu FA, Olumese PE, Omotade OO. *Epidemiology Research International*. 2014;2014.

1896. **Prognostic factors of radiographic progression in early rheumatoid arthritis: A two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids.** Sanmartí R,

- Gómez-Centeno A, Ercilla G, Larrosa M, Viñas O, Vazquez I, et al. *Clinical Rheumatology*. 2007;26(7):1111-8.
1897. **Adsorptive granulocyte/monocyte apheresis for the treatment of refractory rheumatoid arthritis: An open pilot multicentre trial.** Sanmartí R, Marsal S, Valverde J, Casado E, Lafuente R, Kashiwagi N, et al. *Rheumatology*. 2005;44(9):1140-4.
1898. **Selenium and clinical trials: New therapeutic evidence for multiple diseases.** Sanmartín C, Plano D, Font M, Palop JA. *Current Medicinal Chemistry*. 2011;18(30):4635-50.
1899. **Ocular adverse effects associated with systemic medications: Recognition and management.** Santaella RM, Fraunfelder FW. *Drugs*. 2007;67(1):75-93.
1900. **LVIS Jr. stent for treatment of intracranial aneurysms with parent vessel diameter of 2.5 mm or less.** Santillan A, Boddu S, Schwarz J, Lin N, Gobin YP, Knopman J, et al. *Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences*. 2018;24(3):246-53. <http://dx.doi.org/10.1177/1591019918759307>. Epub 2018 Feb 20.
1901. **Prescription pattern of anti-malarial drugs in a tertiary care hospital.** Santoshkumar RJ, Manjunath S, Sharanabasappa MA. *Asian Pacific Journal of Tropical Medicine*. 2010;3(5):379-81.
1902. **Direct comparative effectiveness among 3 anti-tumor necrosis factor biologics in a real-life cohort of patients with rheumatoid arthritis.** Santos-Moreno P, Sánchez G, Gómez D, Bello-Gualtero J, Castro C. *Journal of Clinical Rheumatology*. 2016;22(2):57-62.
1903. **Comparison of the history obtained by patient-completed questionnaires with doctors' standard notes for patients with acute abdominal pain.** Saravanan B, Muhammad R, Geach R, Jenkinson LR. *Postgrad Med J*. 2009;85(1010):634-6. <http://dx.doi.org/10.1136/pgmj.2007.066902>.
1904. **Bipolar hemiarthroplasty in the treatment of hip fracture: are special centres necessary for the optimal outcome?** Sarvilinna R, Pajamaki J, Sovelius R, Puolakka T, Huhtala H, Jarvinen M. *Scand J Surg*. 2002;91(2):182-5. <http://dx.doi.org/10.1177/145749690209100209>.
1905. **A dual-team approach benefits standard-volume surgeons, but has minimal impact on outcomes for a high-volume surgeon in AIS patients.** Sarwahi V, Galina J, Wendolowski S, Dimauro JP, Moguevich M, Katyal C, et al. *Spine deformity*. 2020. <http://dx.doi.org/10.1007/s43390-020-00049-w>.
1906. **Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.** Sauer BC, Teng CC, Tang D, Leng J, Curtis JR, Mikuls TR, et al. *Arthritis care & research*. 2017;69(3):313-22. <http://dx.doi.org/10.1002/acr.22944>.
1907. **Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: A 12-month open randomized pilot study.** Saviola G, Abdi Ali L, Shams ES, Coppini A, Cavalieri F, Campostrini L, et al. *Rheumatology*. 2007;46(6):994-8.
1908. **Clodronate and hydroxychloroquine in erosive osteoarthritis: a 24-month open randomized pilot study.** Saviola G, Abdi-Ali L, Campostrini L, Sacco S, Baiardi P, Manfredi M, et al. *Mod Rheumatol*. 2012;22(2):256-63. <http://dx.doi.org/10.1007/s10165-011-0506-8>. Epub 2011 Aug 19.
1909. **Excellent short- and long-term outcomes after concomitant aortic valve replacement and coronary artery bypass grafting performed by surgeons in training.** Saxena A, Dinh D, Smith JA, Reid CM, Shardey GC, Newcomb AE. *J Thorac Cardiovasc Surg*. 2013;145(2):334-40. <http://dx.doi.org/10.1016/j.jtcvs.2012.09.073>. Epub 2012 Oct 27.
1910. **Rapid and deep control of inflammation in rheumatoid arthritis with infliximab and its correlation**

**with acute-phase reactants.** Scali JJ, Visentini S, Salomón J, Sevilla D, Ju YC, Morales E, et al. *Journal*. 2007;1110(Issue):389-401.

1911. **Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study).** Scarpato S, Antivalle M, Favalli EG, Nacci F, Frigelli S, Bartoli F, et al. *Rheumatology*. 2010;49(2):289-94.

1912. **Diagnostic Performance of Ultra-Low-Dose Computed Tomography for Detecting Asbestos-Related Pleuropulmonary Diseases: Prospective Study in a Screening Setting.** Schaal M, Severac F, Labani A, Jeung MY, Roy C, Ohana M. *PLoS One*. 2016;11(12):e0168979. <http://dx.doi.org/10.1371/journal.pone.0168979>. eCollection 2016.

1913. **Co-prescription of QT-interval prolonging drugs: An analysis in a large cohort of geriatric patients.** Schächtele S, Tümena T, Gaßmann KG, Fromm MF, Maas R. *PLoS ONE*. 2016;11(5).

1914. **Juvenile rheumatoid arthritis.** Schaller J. *Postgraduate medicine*. 1977;61(1):177-84. <http://dx.doi.org/10.1080/00325481.1977.11714517>.

1915. **Intox, detox, antidotes – Evidence based diagnosis and treatment of acute intoxications.** Schaper A, Ebbecke M. *European Journal of Internal Medicine*. 2017;45:66-70.

1916. **Intoxication-related fatalities in northern Germany.** Schaper A, Renneberg B, Desel H, Langer C. *European Journal of Internal Medicine*. 2006;17(7):474-8.

1917. **The effect of laparoscopic cholecystectomy on resident training.** Schauer PR, Page CP, Stewart RM, Schwesinger WH, Sirinek KR. *American journal of surgery*. 1994;168(6):566-9; discussion 9-70. [http://dx.doi.org/10.1016/s0002-9610\(05\)80123-0](http://dx.doi.org/10.1016/s0002-9610(05)80123-0).

1918. **Depression increases risk of incident myocardial infarction among Veterans Administration patients with rheumatoid arthritis.** Scherrer JF, Virgo KS, Zeringue A, Bucholz KK, Jacob T, Johnson RG, et al. *General Hospital Psychiatry*. 2009;31(4):353-9.

1919. **Critical illness and changes in sensory perception.** Schiffman SS. *Proceedings of the Nutrition Society*. 2007;66(3):331-45.

1920. **Particularities of treatment with conventional synthetic disease-modifying antirheumatic drugs (DMARDs) in a group of patients with rheumatoid arthritis.** Schiotis RE, Goşa D, Bocşan C, Suciú Ş, Buzoianu AD. *Farmacia*. 2017;65(3):479-84.

1921. **The position of mefloquine as a 21st century malaria chemoprophylaxis.** Schlagenhauf P, Adamcova M, Regep L, Schaerer MT, Rhein HG. *Malaria Journal*. 2010;9(1).

1922. **Stand-by treatment of malaria in travellers: A review.** Schlagenhauf P, Steffen R. *Journal of Tropical Medicine and Hygiene*. 1994;97(3):151-60.

1923. **Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: Multicentre, randomised, double blind, four arm study.** Schlagenhauf P, Tschopp A, Johnson R, Nothdurft HD, Beck B, Schwartz E, et al. *British Medical Journal*. 2003;327(7423):1078-81.

1924. **[Bipolar hemiarthroplasty in femoral neck fractures--impact of duration of surgery, time of day and the surgeon's experience on the complication rate].** Schliemann B, Seybold D, Gessmann J, Fehmer T, Schildhauer TA, Muhr G. *Z Orthop Unfall*. 2009;147(6):689-93. <http://dx.doi.org/10.1055/s-0029-1186204>. Epub 2009 Dec 8.

1925. **Folic acid supplementation is suboptimal in a national cohort of older veterans receiving low dose oral methotrexate.** Schmajuk G, Tonner C, Miao Y, Yazdany J, Gannon J, Boscardin WJ, et al. *PLoS ONE*. 2016;11(12).

1926. **[Clinical observations on lichen planus of the oral cavity]**. Schmidt CR, Tiede D. *Deutsche Stomatologie*. 1972;22(10):820-4.
1927. **Anti-malarial chemoprophylaxis and the risk of developing neuropsychiatric disorders**. Schneider C, Adamcova M, Jick SS, Miller MK, Schlagenhauf P, Rhein HG, et al. *Pharmacoepidemiology and Drug Safety*. 2013;22:65.
1928. **Antimalarial chemoprophylaxis and the risk of neuropsychiatric disorders**. Schneider C, Adamcova M, Jick SS, Schlagenhauf P, Miller MK, Rhein HG, et al. *Travel Medicine and Infectious Disease*. 2013;11(2):71-80.
1929. **Insurance status does not affect short-term outcomes after oncological colorectal surgery in Europe, but influences the use of minimally invasive techniques: a propensity score-matched analysis**. Schneider MA, Rickenbacher A, Frick L, Cabalzar-Wondberg D, Kaser S, Clavien PA, et al. *Langenbecks Arch Surg*. 2018;403(7):863-72. <http://dx.doi.org/10.1007/s00423-018-1716-8>. Epub 2018 Oct 25.
1930. **Postureteroscopic lesion scale: a new management modified organ injury scale--evaluation in 435 ureteroscopic patients**. Schoenthaler M, Wilhelm K, Kuehhas FE, Farin E, Bach C, Buchholz N, et al. *J Endourol*. 2012;26(11):1425-30. <http://dx.doi.org/10.1089/end.2012.0227>. Epub 2012 Aug 27.
1931. **Prophylaxis of malaria**. Schwartz E. *Mediterranean Journal of Hematology and Infectious Diseases*. 2012;4(1).
1932. **Serious adverse events of mefloquine in relation to blood level and gender**. Schwartz E, Potasman I, Rotenberg M, Almog S, Sadetzki S. *American Journal of Tropical Medicine and Hygiene*. 2001;65(3):189-92.
1933. **Primaquine as prophylaxis for malaria for nonimmune travelers: A comparison with mefloquine and doxycycline**. Schwartz E, Regev-Yochay G. *Clin Infect Dis*. 1999;29(6):1502-6. <http://dx.doi.org/10.1086/313527>.
1934. **The addition of chloroquine and metformine to metabloc induces a rapid drop of tumor markers in advanced carcinoma**. Schwartz L, Gabillet J, Buhler L, Steyaert JM. *Cancer Therapy*. 2015;10:20-7.
1935. **Senior residents as teaching assistants during laparoscopic cholecystectomy in the 80-hour workweek era: effect on biliary injury and overall complication rates**. Schwartz SI, Yaghoubian AT, Andacheh ID, Green SH, Falor AE, Kaji AH, et al. *Journal of surgical education*. 2013;70(6):796-9. <http://dx.doi.org/10.1016/j.jsurg.2013.09.011>.
1936. **Toxic myopathies: Muscle biopsy features**. Scola RH, Pereira ER, Lorenzoni PJ, Werneck LC. *Arquivos de Neuro-Psiquiatria*. 2007;65(1):82-6.
1937. **Audit of 200 consecutive aortic aneurysm repairs carried out by a single surgeon in a district hospital: results of surgery and factors affecting outcome**. Scott A, Baillie CT, Sutton GL, Smith A, Bowyer RC. *Annals of the Royal College of Surgeons of England*. 1992;74(3):205-10; discussion 10-1.
1938. **Retrospective evaluation of continuation rates following a switch to subcutaneous methotrexate in rheumatoid arthritis patients failing to respond to or tolerate oral methotrexate: The MENTOR study**. Scott DGI, Claydon P, Ellis C. *Scandinavian Journal of Rheumatology*. 2014;43(6):470-6.
1939. **Patient-based outcomes and quality of life after salvageable wartime extremity vascular injury**. Scott DJ, Arthurs ZM, Stannard A, Monroe HM, Clouse WD, Rasmussen TE. *J Vasc Surg*. 2014;59(1):173-9.e1. <http://dx.doi.org/10.1016/j.jvs.2013.07.103>. Epub 2013 Sep 13.
1940. **Q fever endocarditis: The mayo clinic experience**. Scott JW, Baddour LM, Tleyjeh IM, Moustafa S, Sun YG, Mookadam F. *American Journal of the Medical Sciences*. 2008;336(1):53-7.

1941. **Open trial of thalidomide in the treatment of rheumatoid arthritis.** Scoville CD, Reading JC. *Journal of Clinical Rheumatology*. 1999;5(5):261-7.
1942. **Epidemiology, preventive services, and illnesses of international travelers.** Scoville SL, Bryan JP, Tribble D, Paparello SF, Malone JL, Ohl CA, et al. *Military Medicine*. 1997;162(3):172-8.
1943. **Improving patient safety using clinical needs assessments in IV therapy.** Scroggs J. *British journal of nursing* (Mark Allen Publishing). 2008;17(19):S22-8. <http://dx.doi.org/10.12968/bjon.2008.17.Sup8.31471>.
1944. **Epidemic visceral leishmaniasis in Sudan: A randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone.** Seaman J, Pryce D, Sondorp HE, Moody A, Bryceson ADM, Davidson RN. *Journal of Infectious Diseases*. 1993;168(3):715-20.
1945. **Chest HRCT findings in patients with primary Sjögren's syndrome.** Sebastian A, Misterska-Skóra M, Silicki J, Sebastian M, Wiland P. *Advances in Clinical and Experimental Medicine*. 2017;26(7):1101-6.
1946. **Can junior emergency physicians use E-point septal separation to accurately estimate left ventricular function in acutely dyspneic patients? Secko MA, Lazar JM, Saliccioli LA, Stone MB. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2011;18(11):1223-6. <http://dx.doi.org/10.1111/j.1553-2712.2011.01196.x>. Epub 2011 Nov 1.**
1947. **Oral diseases and diabetes: Nigerian medical and dental caregivers' perspective.** Sede MA, Ehizele AO. *Annals of African medicine*. 2015;14(4):193-9. <http://dx.doi.org/10.4103/1596-3519.158525>.
1948. **Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: A randomized control trial.** Sedhain A, Hada R, Agrawal RK, Bhattarai GR, Baral A. *BMC Nephrology*. 2018;19(1).
1949. **Leg ulceration in rheumatoid arthritis - An underreported multicausal complication with considerable morbidity: Analysis of thirty-six patients and review of the literature.** Seitz CS, Berens N, Bröcker EB, Trautmann A. *Dermatology*. 2010;220(3):268-73.
1950. **Object relations in adolescence: a comparison of normal and inpatient adolescents.** Sekiya H, Sato A, Sakai Y, Naka Y, Suzuki K, Kashima H, et al. *Psychiatry and clinical neurosciences*. 2012;66(4):270-5. <http://dx.doi.org/10.1111/j.1440-1819.2012.02353.x>.
1951. **Spatial and space-time clustering of mortality due to malaria in rural Tanzania: Evidence from Ifakara and Rufiji Health and Demographic Surveillance System sites.** Selemani M, Mrema S, Shamte A, Shabani J, Mahande MJ, Yeates K, et al. *Malaria Journal*. 2015;14(1).
1952. **Hydroxychloroquine retinopathy screening.** Semmer AE, Lee MS, Harrison AR, Olsen TW. *The British journal of ophthalmology*. 2008;92(12):1653-5. <http://dx.doi.org/10.1136/bjo.2008.144402>. Epub 2008 Oct 1.
1953. **Hypergammaglobulinemic purpura in systemic autoimmune rheumatic diseases: predictive value of anti-Ro(SSA) and anti-La(SSB) antibodies and treatment with indomethacin and hydroxychloroquine.** Senecal JL, Chartier S, Rothfield N. *The Journal of rheumatology*. 1995;22(5):868-75.
1954. **The efficacy and safety of etanercept in patients with rheumatoid arthritis and spondyloarthropathy on hemodialysis.** Senel S, Kisacik B, Ugan Y, Kasifoglu T, Tunc E, Cobankara V. *Clinical Rheumatology*. 2011;30(10):1369-72.
1955. **Survey of consent practices for inpatient colonoscopy and endoscopic retrograde cholangiopancreatography at a tertiary referral center.** Seow CH, Leber JM, Ee HC, Yusoff IF. *J Gastroenterol Hepatol*. 2006;21(8):1340-5. <http://dx.doi.org/10.1111/j.1440-1746.2006.04152.x>.

1956. **MIP Improves Detection of Brain Metastases.** Sepulveda F, Yanez P, Carnevale MD, Romero C, Castillo M. *Journal of computer assisted tomography*. 2016;40(6):997-1000. <http://dx.doi.org/10.1097/RCT.0000000000000466>.
1957. **[A comparison of characteristics of pathologic hobbies in schizophrenic patients of different age].** Sergeev, Il, Deych RV, Malinochka SA. *Zhurnal nevrologii i psikiatrii imeni SS Korsakova*. 2016;116(1):29-33. <http://dx.doi.org/10.17116/jnevro20161161129-33>.
1958. **Combined basic therapy of rheumatoid arthritis with methotrexate and plaquenil.** Sergiets NA, Erova NK. *Terapevticheskiĭ arkhiv*. 2009;81(6):34-7.
1959. **Severe imported plasmodium falciparum malaria, France, 1996-2003.** Seringe E, Thellier M, Fontanet A, Legros F, Bouchaud O, Ancelle T, et al. *Emerging Infectious Diseases*. 2011;17(5):807-13.
1960. **Switching between TNF $\alpha$  antagonists in rheumatoid arthritis: Personal experience and review of the literature.** Serivo R, Conti F, Spinelli FR, Truglia S, Magrini L, Di Franco M, et al. *Reumatismo*. 2009;61(2):107-17.
1961. **Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).** Seror R, Bootsma H, Saraux A, Bowman SJ, Theander E, Brun JG, et al. *Annals of the Rheumatic Diseases*. 2016;75(2):382-9.
1962. **Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial.** Sessler DI, Pei L, Huang Y, Fleischmann E, Marhofer P, Kurz A, et al. *Lancet*. 2019;394(10211):1807-15. [http://dx.doi.org/10.1016/S0140-6736\(19\)32313-X](http://dx.doi.org/10.1016/S0140-6736(19)32313-X). Epub 2019 Oct 20.
1963. **The Comparative Safety of Multiple Alternative Agents in Refractory Chronic Urticaria Patients.** Seth S, Khan DA. *Journal of Allergy and Clinical Immunology: In Practice*. 2017;5(1):165-70.e2.
1964. **Biologic treatment for rheumatic disease: Real-world big data analysis from the Greek country-wide prescription database.** Sfrikakis PP, Bournia VK, Sidiropoulos P, Boumpas DT, Drosos AA, Kitis GD, et al. *Clinical and Experimental Rheumatology*. 2017;35(4):579-85.
1965. **MonitorNet: The Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.** Sfriso P, Salaffi F, Montecucco CM, Bombardieri S, Todesco S. *Reumatismo*. 2009;61(2):132-9.
1966. **Evaluation of FDG PET combined with cardiac MRI for the diagnosis and therapeutic monitoring of cardiac sarcoidosis.** Sgard B, Brilliet PY, Bouvry D, Djelbani S, Nunes H, Meune C, et al. *Clinical Radiology*. 2019;74(1):81.e9-.e18.
1967. **Stress and burnout in colorectal and vascular surgical consultants working in the UK National Health Service.** Sharma A, Sharp DM, Walker LG, Monson JR. *Psycho-oncology*. 2008;17(6):570-6. <http://dx.doi.org/10.1002/pon.1269>.
1968. **Neurosarcoidosis: a personal perspective based on the study of 37 patients.** Sharma OP. *Chest*. 1997;112(1):220-8. <http://dx.doi.org/10.1378/chest.112.1.220>.
1969. **A malaria outbreak in Naxalbari, Darjeeling district, West Bengal, India, 2005: Weaknesses in disease control, important risk factors.** Sharma PK, Ramachandran R, Hutin YJ, Sharma R, Gupte MD. *Malaria Journal*. 2009;8(1).
1970. **Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients.** Sharma TS, Wasko MC, Tang X, Vedamurthy D, Yan X, Cote J, et al. *Journal of the American Heart Association*.



Association. 2016;5(1). <http://dx.doi.org/10.1161/JAHA.115.002867>.

1971. **Evaluation of efficacy of combination of methotrexate and hydroxychloroquine with leflunomide in active rheumatoid arthritis.** Shashikumar NS, Shivamurthy MC, Chandrashekara S. Indian Journal of Pharmacology. 2010;42(6):358-61.

1972. **The ethical decisions UK doctors make regarding advanced cancer patients at the end of life--the perceived (in) appropriateness of anticoagulation for venous thromboembolism: a qualitative study.** Sheard L, Prout H, Dowding D, Noble S, Watt I, Maraveyas A, et al. BMC medical ethics. 2012;13:22. <http://dx.doi.org/10.1186/1472-6939-13-22>.

1973. **Barriers to the diagnosis and treatment of venous thromboembolism in advanced cancer patients: a qualitative study.** Sheard L, Prout H, Dowding D, Noble S, Watt I, Maraveyas A, et al. Palliative medicine. 2013;27(4):339-48. <http://dx.doi.org/10.1177/0269216312461678>. Epub 2012 Oct 23.

1974. **Quinine and the ABCs of Long QT: A Patient's Misfortune with Arthritis, (Alcoholic) Beverages, and Cramps.** Sheehan ET, Frizzell JD, Gabaldon J, West MB. Journal of general internal medicine. 2016;31(10):1254-7. <http://dx.doi.org/10.1007/s11606-016-3738-7>. Epub 2016 May 12.

1975. **Ileum-targeted steroid therapy in rheumatoid arthritis: Double-blind, placebo-controlled trial of controlled-release budesonide.** Sheldon P. Rheumatology International. 2003;23(4):154-8.

1976. **Thalidomide in the treatment of lepra reactions.** Sheskin J. Clinical Pharmacology and Therapeutics. 1965;6(3):303-6.

1977. **The impact of the improvement in internal medicine consultation process on ED length of stay.** Shin S, Lee SH, Kim DH, Kim SC, Kim TY, Kang C, et al. The American journal of emergency medicine. 2018;36(4):620-4. <http://dx.doi.org/10.1016/j.ajem.2017.09.041>. Epub 2017 Sep 28.

1978. **Systemic lupus erythematosus in the elderly: Antimalarials in disease remission.** Shinjo SK. Rheumatology International. 2009;29(9):1087-90.

1979. **Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: Related to disease duration?** Shinjo SK, Maia Júnior OO, Tizziani VAP, Morita C, Kochen JAL, Takahashi WY, et al. Clinical Rheumatology. 2007;26(8):1248-53.

1980. **Assessment of Outcome After Pancreaticoduodenectomy by Junior Surgeons.** Shirai Y, Shiba H, Horiuchi T, Saito N, Furukawa K, Sakamoto T, et al. Anticancer research. 2016;36(7):3505-10.

1981. **Integrating human factors research and surgery: a review.** Shouhed D, Gewertz B, Wiegmann D, Catchpole K. Archives of surgery (Chicago, Ill : 1960). 2012;147(12):1141-6. <http://dx.doi.org/10.1001/jamasurg.2013.596>.

1982. **Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease?** Shroyer NF, Lewis RA, Lupski JR. American journal of ophthalmology. 2001;131(6):761-6. [http://dx.doi.org/10.1016/s0002-9394\(01\)00838-8](http://dx.doi.org/10.1016/s0002-9394(01)00838-8).

1983. **ISMP adverse drug reactions-Rosuvastatin-induced thrombocytopenia; Lisinopril-induced nightmares; Valproate sodium-associated hypotension; Gabapentin-induced delusions of parasitosis; Piperacillin/tazobactam-induced petechial rash; Adverse events associated with testosterone; Chloroquine-induced hair hypopigmentation; Scoring system to assess adr risk among In-hospital elderly patients.** Shuster J. Hospital Pharmacy. 2010;45(10):758-61.

1984. **Validation of memorial delirium assessment scale.** Shyamsundar G, Raghuthaman G, Rajkumar AP, Jacob

- KS. J Crit Care. 2009;24(4):530-4. <http://dx.doi.org/10.1016/j.jcrrc.2008.12.016>. Epub 2009 Mar 27.
1985. **Psychiatric morbidity among physically ill persons in eastern Nepal.** Shyangwa PM, Joshi D, Sherchan S, Thapa KB. Nepal Medical College journal : NMCJ. 2009;11(2):118-22.
1986. **Tropical medicine and travel medicine: Medical advice for aviation medical examiners concerning flight operations in tropical areas.** Siedenburg J, Perry I, Stüben U. Aviation Space and Environmental Medicine. 2005;76(3):A1-A30.
1987. **Sarilumab for the treatment of ankylosing spondylitis: Results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN).** Sieper J, Braun J, Kay J, Badalamenti S, Radin AR, Jiao L, et al. Annals of the Rheumatic Diseases. 2015;74(6):1051-7.
1988. **Chemotherapeutic immunosuppression in the rat.** Siering H. Clujul Medical. 1973;46(2):371-2.
1989. **Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study.** Sihvonen S, Korpela M, Mustonen J, Huhtala H, Karstila K, Pasternack A. Journal of Rheumatology. 2006;33(9):1740-6.
1990. **Evaluation of Readministration of Immune Checkpoint Inhibitors after Immune-Related Adverse Events in Patients with Cancer.** Simonaggio A, Michot JM, Voisin AL, Le Pavec J, Collins M, Lallart A, et al. JAMA Oncology. 2019;5(9):1310-7.
1991. **Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantation.** Simonsson B, Totterman T, Hokland P, Lauria F, Carella AM, Fernandez MN, et al. Bone marrow transplantation. 2000;25(11):1121-7. <http://dx.doi.org/10.1038/sj.bmt.1702411>.
1992. **Real-life experience of managing vulval erosive lichen planus: A case-based review and U.K. multicentre case note audit.** Simpson RC, Littlewood SM, Cooper SM, Cruickshank ME, Green CM, Derrick E, et al. British Journal of Dermatology. 2012;167(1):85-91.
1993. **CT-generated radiographs in obese patients with acetabular fractures: can they be used in lieu of plain radiographs?** Sinatra PM, Moed BR. Clin Orthop Relat Res. 2014;472(11):3362-9. <http://dx.doi.org/10.1007/s11999-014-3697-4>.
1994. **Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda.** Singal AK, Kormos-Hallberg C, Lee C, Sadagoparamanujam VM, Grady JJ, Freeman DH, Jr., et al. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2012;10(12):1402-9. <http://dx.doi.org/10.1016/j.cgh.2012.08.038>. Epub 2012 Sep 14.
1995. **Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis.** Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Journal of Rheumatology. 1991;18(2):188-94.
1996. **Ovarian Insufficiency is Major Short-term Toxicity in Systemic Lupus Erythematosus Patients Treated with Cyclophosphamide.** Singh G, Misra R, Aggarwal A. The Journal of the Association of Physicians of India. 2016;64(2):28-31.
1997. **Middle ear microsurgery in india: a retrospective audit study.** Singh M, Rai A, Bandyopadhyay S. Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India. 2006;58(2):133-6. <http://dx.doi.org/10.1007/BF03050767>.
1998. **Safety assessment of resident grade and supervision level during emergency appendectomy: analysis of a multicenter, prospective study.** Singh P, Turner EJ, Cornish J, Bhangu A. Surgery. 2014;156(1):28-38. <http://dx.doi.org/10.1016/j.surg.2014.04.007>. Epub 2014 Jun 2.

1999. **Hospital management of diabetic ketoacidosis: are clinical guidelines implemented effectively?** Singh RK, Perros P, Frier BM. *Diabetic medicine : a journal of the British Diabetic Association*. 1997;14(6):482-6. [http://dx.doi.org/10.1002/\(SICI\)1096-9136\(199706\)14:6<482::AID-DIA371>3.0.CO;2-A](http://dx.doi.org/10.1002/(SICI)1096-9136(199706)14:6<482::AID-DIA371>3.0.CO;2-A).
2000. **Neuropsychiatric problems in systemic lupus erythematosus.** Singh RPN, Singh SN, Sinha AKN. *Journal of the Indian Medical Association*. 1979;73(11):196-8.
2001. **Neuropsychiatric toxicity of chloroquine.** Singh RPN, Sinha AKN. *Journal of the Indian Medical Association*. 1981;77(8):133-4.
2002. **Hydroxychloroquine and covid-19.** Sinha N, Balayla G. *Postgraduate Medical Journal*. 2020;postgradmedj-2020-137785.
2003. **A simple measure to improve the rates of thromboprophylaxis prescription post surgical fixation of neck of femur fractures in a district general hospital.** Sinha P, Najefi AA, Hambidge J. *BMJ quality improvement reports*. 2014;3(1). <http://dx.doi.org/10.1136/bmjquality.u202991.w1956>. eCollection 2014.
2004. **Fixed-Dose Artesunate-Amodiaquine Combination vs Chloroquine for Treatment of Uncomplicated Blood Stage P. vivax Infection in the Brazilian Amazon: An Open-Label Randomized, Controlled Trial.** Siqueira AM, Alencar AC, Melo GC, Magalhaes BL, Machado K, Alencar Filho AC, et al. *Clin Infect Dis*. 2017;64(2):166-74. <http://dx.doi.org/10.1093/cid/ciw706>. Epub 2016 Oct 20.
2005. **Lupus damage and waist circumference as the independent risk factors for cardiovascular disease in SLE patients from Phramongkutklo hospital.** Siricheepchaiyan W, Narongroeknawin P, Pakchotanon R, Asavatanabodee P, Chaiamnuay S. *Journal of the Medical Association of Thailand*. 2016;99(3):290-300.
2006. **Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival.** Siso A, Ramos-Casals M, Bove A, Brito-Zeron P, Soria N, Munoz S, et al. *Lupus*. 2008;17(4):281-8. <http://dx.doi.org/10.1177/0961203307086503>.
2007. **The spectrum of ocular involvement in systemic lupus erythematosus in a tertiary eye care center in Nepal.** Sitaula R, Narayan Shah D, Singh D. *Ocular Immunology and Inflammation*. 2011;19(6):422-5.
2008. **Leflunomide Use during the First 33 Months after Food and Drug Administration Approval: Experience with a National Cohort of 3,325 Patients.** Siva C, Eisen SA, Shepherd R, Cunningham F, Fang MA, Finch W, et al. *Arthritis Care and Research*. 2003;49(6):745-51.
2009. **Experience with FRED junior flow diverter in treatment of cerebral aneurysms at or distal to the circle of Willis.** Sivasankar R, Shrivastava M, Limaye US. *Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia*. 2019;69:166-9. <http://dx.doi.org/10.1016/j.jocn.2019.07.079>. Epub 2019 Aug 23.
2010. **Improvement of internal jugular vein cannulation using an ultrasound-guided technique.** Slama M, Novara A, Safavian A, Ossart M, Safar M, Fagon JY. *Intensive Care Med*. 1997;23(8):916-9. <http://dx.doi.org/10.1007/s001340050432>.
2011. **Outcomes of minimally invasive abdominal sacrocolpopexy with resident operative involvement.** Slopnick EA, Hijaz AK, Henderson JW, Mahajan ST, Nguyen CT, Kim SP. *International urogynecology journal*. 2018;29(10):1537-42. <http://dx.doi.org/10.1007/s00192-018-3578-6>. Epub 2018 Feb 20.
2012. **Diagnostic dilemmas in Fabry disease: A case series study on GLA mutations of unknown clinical significance.** Smid BE, Hollak CEM, Poorthuis BJHM, van den Bergh Weerman MA, Florquin S, Kok WEM, et al. *Clinical Genetics*. 2015;88(2):161-6.

2013. **Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response.** Smith MH, Bass AR. *Arthritis Care and Research.* 2019;71(3):362-6.
2014. **Thromboembolism after surgical treatment of hip fractures.** Snook GA, Chrisman OD, Wilson TC. *Clin Orthop Relat Res.* 1981(155):21-4.
2015. **Evaluation of hydroxychloroquine retinopathy with multifocal electroretinography.** So SC, Hedges TR, Schuman JS, Quireza ML. *Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.* 2003;34(3):251-8.
2016. **In vivo chemosensitivity tests of Plasmodium falciparum to chloroquine in Senegal: the development of resistance and the assessment of therapeutic efficacy.** Sokhna CS, Molez JF, Ndiaye P, Sane B, Trape JF. *Bulletin de la Société de pathologie exotique (1990).* 1997;90(2):83-9.
2017. **Utility of disease modifying antirheumatic drugs in 'sawtooth' strategy. A prospective study of early rheumatoid arthritis patients up to 15 years.** Sokka T, Hannonen P. *Annals of the Rheumatic Diseases.* 1999;58(10):618-22.
2018. **Mortality in early 'sawtooth' treated rheumatoid arthritis patients during the first 8-14 years.** Sokka T, Möttönen T, Hannonen P. *Scandinavian Journal of Rheumatology.* 1999;28(5):282-7.
2019. **A retrospective study of treating RA patients with various combinations of slow-acting antirheumatic drugs in a County hospital.** Sokka TM, Kautiainen HJ, Hannonen PJ. *Scandinavian Journal of Rheumatology.* 1997;26(6):440-3.
2020. **Fluorescence lifetimes in patients with hydroxychloroquine retinopathy.** Solberg Y, Dysli C, Möller B, Wolf S, Zinkernagel MS. *Investigative Ophthalmology and Visual Science.* 2019;60(6):2165-72.
2021. **Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis.** Solomon DH, Avorn J, Katz JN, Weinblatt ME, Setoguchi S, Levin R, et al. *Arthritis and Rheumatism.* 2006;54(12):3790-8.
2022. **Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.** Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. *Jama.* 2011;305(24):2525-31. <http://dx.doi.org/10.1001/jama.2011.878>.
2023. **Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist.** Solomon DH, Rassen JA, Kuriya B, Chen L, Harrold LR, Graham DJ, et al. *Annals of the Rheumatic Diseases.* 2013;72(11):1813-8.
2024. **Systemic lupus erythematosus and pemphigus vulgaris preceded by depressive psychosis.** Somorin AO, Agbakwu SN, Nwaefuna A. *Central African Journal of Medicine.* 1981;27(1):12-4.
2025. **Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria.** Song CH, Stern S, Giruparajah M, Berlin N, Sussman GL. *Annals of Allergy, Asthma and Immunology.* 2013;110(2):113-7.
2026. **Profiling of the bacteria responsible for pyogenic liver abscess by 16S rRNA gene pyrosequencing.** Song YG, Shim SG, Kim KM, Lee DH, Kim DS, Choi SH, et al. *Journal of microbiology (Seoul, Korea).* 2014;52(6):504-9. <http://dx.doi.org/10.1007/s12275-014-4241-7>. Epub 2014 May 29.
2027. **Severe and complicated malaria in KwaZulu-Natal.** Soni PN, Gouws E. *South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.* 1996;86(6):653-6.
2028. **Cutaneous Adverse Drug Reactions with Antimalarials and Allergological Skin Tests.** Soria A, Barbaud

- A, Assier H, Avenel-Audran M, Tétart F, Raison-Peyron N, et al. *Dermatology*. 2015;231(4):353-9.
2029. **Impact of seniority on operative time and short-term outcome in laparoscopic cholecystectomy: Experience of an academic Surgical Department in a developing country.** Souadka A, Naya MS, Serji B, El Malki HO, Mohsine R, Ifrine L, et al. *Journal of minimal access surgery*. 2017;13(2):131-4.  
<http://dx.doi.org/10.4103/0972-9941.186687>.
2030. **Elderly-onset rheumatoid arthritis.** Soubrier M, Mathieu S, Payet S, Dubost JJ, Ristori JM. *Joint Bone Spine*. 2010;77(4):290-6.
2031. **Indications for lowering LDL cholesterol in rheumatoid arthritis: An unrecognized problem.** Soubrier M, Zerkak D, Dougados M. *Journal of Rheumatology*. 2006;33(9):1766-9.
2032. **The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients.** Soukup T, Dosedel M, Pavek P, Nekvindova J, Barvik I, Bubancova I, et al. *Rheumatology International*. 2015;35(7):1149-61.
2033. **[Epidemiological, clinical and therapeutic aspects of severe malaria in adults in the infectious disease department of Central University Hospital of Dakar].** Soumare M, Diop BM, Ndour CT, Dieng Y, Ndiaye FS, Badiane S. *Dakar medical*. 1999;44(1):8-11.
2034. **Acute psychosis after mefloquine: A case report.** Sowunmi A. *East African Medical Journal*. 1994;71(12):818-20.
2035. **Hydroxychloroquine, dosage parameters and retinopathy.** Spalton DJ, Verdon Roe GM, Hughes GR. *Lupus*. 1993;2(6):355-8. <http://dx.doi.org/10.1177/096120339300200604>.
2036. **[Conversion in laparoscopic cholecystectomy for acute cholecystitis].** Spatariu A, Nicolau AE, Beuran M, Tudor C, Oprescu C. *Chirurgia (Bucharest, Romania : 1990)*. 2010;105(4):469-72.
2037. **The presence of psychological trauma symptoms in resuscitation providers and an exploration of debriefing practices.** Spencer SA, Nolan JP, Osborn M, Georgiou A. *Resuscitation*. 2019;142:175-81.  
<http://dx.doi.org/10.1016/j.resuscitation.2019.06.280>. Epub 2019 Jun 25.
2038. **Recognition of the deteriorating patient.** Spiers L, Singh Mohal J, Pearson-Stuttard J, Greenlee H, Carmichael J, Busher R. *BMJ quality improvement reports*. 2015;4(1).  
<http://dx.doi.org/10.1136/bmjquality.u206777.w2734>. eCollection 2015.
2039. **Vitamin D levels are associated with expression of SLE, but not flare frequency.** Squance ML, Reeves GEM, Tran HA. *International Journal of Rheumatology*. 2014;2014.
2040. **Malaria surveillance: Cases reported in Italy in the period 1993-1996.** Squarcione S, Troiano T, D'Amato S. *Mediterranean Journal of Infectious and Parasitic Diseases*. 1998;13(1):41-6.
2041. **Single crossclamp: Safe training tool for coronary artery bypass grafting.** Srivastava V, Purohit M, Bose A, Bittar MN, Rogers S, Zacharias J. *Asian cardiovascular & thoracic annals*. 2016;24(7):633-7.  
<http://dx.doi.org/10.1177/0218492316657242>. Epub 2016 Jul 6.
2042. **The treatment of lupus pernio results of 116 treatment courses in 54 patients.** Stagaki E, Mountford WK, Lackland DT, Judson MA. *Chest*. 2009;135(2):468-76.
2043. **Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis.** Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, et al. *Journal of Rheumatology*. 2011;38(12):2540-7.

2044. **Improving analgesia prescription for trauma inpatients.** Stanger S, Dahill M, Hillary C, Whitham R, Tasker A. *BMJ open quality*. 2018;7(4):e000397. <http://dx.doi.org/10.1136/bmjopen-2018-000397>. eCollection 2018.
2045. **Clinical prognostic indices of fatality in elderly patients admitted to hospital with acute pneumonia.** Starczewski AR, Allen SC, Vargas E, Lye M. *Age and ageing*. 1988;17(3):181-6. <http://dx.doi.org/10.1093/ageing/17.3.181>.
2046. **Traveling with infants and children. Part IV: Insect avoidance and malaria prevention.** Stauffer WM, Kamat D, Magill AJ. *Journal of Travel Medicine*. 2003;10(4):225-40.
2047. **Travellers' malaria.** Steffen R, Behrens RH. *Parasitology Today*. 1992;8(2):61-6.
2048. **Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa.** Steffen R, Fuchs E, Schildknecht J, Naef U, Funk M, Schlagenhauf P, et al. *Lancet*. 1993;341(8856):1299-303.
2049. **Macronutrient Intake in Soccer Players-A Meta-Analysis.** Steffl M, Kinkorova I, Kokstejn J, Petr M. *Nutrients*. 2019;11(6). <http://dx.doi.org/10.3390/nu11061305>.
2050. **Hydroxychloroquine neuromyotoxicity.** Stein M, Bell MJ, Ang LC. *Journal of Rheumatology*. 2000;27(12):2927-31.
2051. **Infliximab in patients with primary Sjögren's syndrome: A pilot study.** Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. *Arthritis and Rheumatism*. 2001;44(10):2371-5.
2052. **Hydrochloroquine retinopathy: characteristic presentation with review of screening.** Stelton CR, Connors DB, Walia SS, Walia HS. *Clin Rheumatol*. 2013;32(6):895-8. <http://dx.doi.org/10.1007/s10067-013-2226-2>. Epub 2013 Mar 21.
2053. **Anti-BlyS treatment of 36 israeli systemic lupus erythematosus patients.** Sthoeger Z, Lorber M, Tal Y, Toubi E, Amital H, Kivity S, et al. *Israel Medical Association Journal*. 2017;19(1):44-8.
2054. **Vincristine efficacy and safety in treating immune thrombocytopenia: A retrospective study of 35 patients.** Stirnemann J, Kaddouri N, Khellaf M, Morin AS, Prendki V, Michel M, et al. *European Journal of Haematology*. 2016;96(3):269-75.
2055. **Psychotropic Pharmacotherapy Associated With QT Prolongation Among Veterans With Posttraumatic Stress Disorder.** Stock EM, Zeber JE, McNeal CJ, Banchs JE, Copeland LA. *Annals of Pharmacotherapy*. 2018;52(9):838-48.
2056. **Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): Results from randomized, double-blind phase 1a and phase 1b trials.** Stohl W, Merrill JT, Looney RJ, Buyon J, Wallace DJ, Weisman MH, et al. *Arthritis Research and Therapy*. 2015;17(1).
2057. **Therapeutic efficacy of artemether-lumefantrine and artesunate-mefloquine for treatment of uncomplicated Plasmodium falciparum malaria in Luang Namtha Province, Lao People's Democratic Republic.** Stohrer JM, Dittrich S, Thongpaseuth V, Vanisaveth V, Phetsouvanh R, Phompida S, et al. *Tropical Medicine and International Health*. 2004;9(11):1175-83.
2058. **Implementation of an Intraoperative Instructional Timeout Just Prior to Stapler Use Improves Proficiency of Surgical Stapler Usage by Surgery Residents.** Stolarski AE, Kim NE, O'Neal P, Sanchez V, Whang E, Kristo G. *Journal of surgical education*. 2019;76(6):1622-8. <http://dx.doi.org/10.1016/j.jsurg.2019.05.005>. Epub 2019 Jun 22.

2059. **Malaria prevention strategies: Adherence among Boston area travelers visiting malaria-endemic countries.** Stoney RJ, Chen LH, Jentes ES, Wilson ME, Han PV, Benoit CM, et al. *American Journal of Tropical Medicine and Hygiene*. 2016;94(1):136-42.
2060. **Does Orthopaedic Training Compromise the Outcome in Knee Joint Arthroplasty?** Storey R, Frampton C, Kieser D, Ailabouni R, Hooper G. *Journal of surgical education*. 2018;75(5):1292-8. <http://dx.doi.org/10.1016/j.jsurg.2018.02.011>. Epub 2018 Mar 21.
2061. **Detection and evaluation of a drug safety signal concerning pancreatic cancer: Lessons from a joint approach of three European biologics registers.** Strangfeld A, Hyrich K, Askling J, Arkema E, Davies R, Listing J, et al. *Rheumatology*. 2011;50(1):146-51.
2062. **Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death.** Straus SMJM, Sturkenboom MCJM, Bleumink GS, Dieleman JP, Van Der Lei J, De Graeff PA, et al. *European Heart Journal*. 2005;26(19):2007-12.
2063. **Association of the drug of abuse in road traffic collision death in hospital Kuala Lumpur.** Subramaniam K, Fadzlee FF, Soon LP, Madon NF, Saidin MH, Mahmood MS. *Medical Journal of Malaysia*. 2018;73(5):272-5.
2064. **Malaria.** Suh KN, Kain KC, Keystone JS. *Canadian Medical Association Journal*. 2004;170(11):1693-702.
2065. **Safe re-administration of tumor necrosis factor-alpha (TNFalpha) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFalpha therapy.** Suh YS, Kwok SK, Ju JH, Park KS, Park SH, Yoon CH. *Journal of Korean medical science*. 2014;29(1):38-42. <http://dx.doi.org/10.3346/jkms.2014.29.1.38>. Epub 2013 Dec 26.
2066. **An audit of current practice and management of metastatic spinal cord compression at a regional cancer centre.** Sui J, Fleming JS, Kehoe M. *Ir Med J*. 2011;104(4):111-4.
2067. **Antirheumatic drug use and the risk of acute myocardial infarction.** Suissa S, Bernatsky S, Hudson M. *Arthritis Care and Research*. 2006;55(4):531-6.
2068. **TNF- $\alpha$  antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease.** Suissa S, Ernst P, Hudson M. *Pulmonary Pharmacology and Therapeutics*. 2008;21(1):234-8.
2069. **Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis.** Suissa S, Ernst P, Hudson M, Bitton A, Kezouh A. *American Journal of Medicine*. 2004;117(2):87-92.
2070. **Mechanisms of neurotransmitter release by amphetamines: A review.** Sulzer D, Sonders MS, Poulsen NW, Galli A. *Progress in Neurobiology*. 2005;75(6):406-33.
2071. **Pediatric malaria in the developing world.** Summer AP, Stauffer WM, Fischer PR. *Seminars in Pediatric Infectious Diseases*. 2005;16(2):105-15.
2072. **Coincidence of apical ballooning syndrome (tako-tsubo/stress cardiomyopathy) and posterior reversible encephalopathy syndrome: Potential common substrate and pathophysiology?** Summers MR, Madhavan M, Chokka RG, Rabinstein AA, Prasad A. *Journal of Cardiac Failure*. 2012;18(2):120-5.
2073. **Evidence for risk of cardiomyopathy with hydroxychloroquine.** Sumpter MD, Tatro LS, Stoecker WV, Rader RK. *Lupus*. 2012;21(14):1594-6. <http://dx.doi.org/10.1177/0961203312462757>. Epub 2012 Oct 4.
2074. **[Surveillance data on notifiable infectious diseases among students aged 6-22 years in China, 2011-2016].** Sun J, Yang WW, Zeng LJ, Geng MJ, Dong YH, Xing Y, et al. *Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi*. 2018;39(12):1589-95. <http://dx.doi.org/10.3760/cma.j.issn.0254-6450.2018.12.010>.

2075. **The mediating effects of stress and coping on depression among adolescents in China.** Sun Y, Tao F, Hao J, Wan Y. *Journal of child and adolescent psychiatric nursing : official publication of the Association of Child and Adolescent Psychiatric Nurses, Inc.* 2010;23(3):173-80. <http://dx.doi.org/10.1111/j.1744-6171.2010.00238.x>.
2076. **A pilot study of the utility of a laboratory-based spinal fixation training program for neurosurgical residents.** Sundar SJ, Healy AT, Kshetry VR, Mroz TE, Schlenk R, Benzel EC. *Journal of neurosurgery Spine.* 2016;24(5):850-6. <http://dx.doi.org/10.3171/2015.8.SPINE15119>. Epub 2016 Jan 15.
2077. **Clinical profile of chikungunya fever in patients in a tertiary care centre in Maharashtra, India.** Suryawanshi SD, Dube AH, Khadse RK, Jalgaonkar SV, Sathe PS, Zavar SD, et al. *Indian Journal of Medical Research.* 2009;129(4):438-41.
2078. **A prospective controlled trial of the efficacy of isopropyl alcohol wipes before venesection in surgical patients.** Sutton CD, White SA, Edwards R, Lewis MH. *Annals of the Royal College of Surgeons of England.* 1999;81(3):183-6.
2079. **The Systemic Lupus International Collaborating Clinics (SLICC) damage index: A systematic literature review.** Sutton EJ, Davidson JE, Bruce IN. *Seminars in Arthritis and Rheumatism.* 2013;43(3):352-61.
2080. **[Drinking behaviors of Japanese adolescents' problem drinker--report of 1996 national survey].** Suzuki K, Minowa M, Osaki Y, Wada K. *Nihon Arukoru Yakubutsu Igakkai zasshi = Japanese journal of alcohol studies & drug dependence.* 2001;36(1):39-52.
2081. **[Development of a New Scholastic Program for Medication Counseling Practice in Preclinical Training, Constructed for Junior Students by Senior Students Based on Their Experiences of On-site Practice].** Suzuki S, Aono I, Imai N, Kuwabara A, Kenda Y, Matsumoto M, et al. *Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.* 2017;137(11):1391-408. <http://dx.doi.org/10.1248/yakushi.17-00092>.
2082. **Porphyria cutanea tarda: clinical and laboratory features.** Sweeney GD, Jones KG. *Can Med Assoc J.* 1979;120(7):803-7.
2083. **Side effects of methotrexate treatment in patients with rheumatoid arthritis.** Świerkot J, Szechiński J. *Advances in Clinical and Experimental Medicine.* 2008;17(4):387-94.
2084. **Mania, severe psychotic episode, and stroupper (PTSD) symptoms after prophylactic doses of chloroquine.** Swift B. *Journal of Pharmacy Practice.* 2012;25(2):298-9.
2085. **Organ donation knowledge and attitudes among health science students in Greece: emerging interprofessional needs.** Symvoulakis EK, Rachiotis G, Papagiannis D, Markaki A, Dimitroglou Y, Morgan M, et al. *International journal of medical sciences.* 2014;11(6):634-40. <http://dx.doi.org/10.7150/ijms.8686>. eCollection 2014.
2086. **Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base.** Taccone FS, Gorham J, Vincent J-L. *The Lancet Respiratory Medicine.* 2020.
2087. **The association of level of practical experience in transrectal ultrasonography guided prostate biopsy with its diagnostic outcome.** Tadtayev S, Hussein A, Carpenter L, Vasdev N, Boustead G. *Annals of the Royal College of Surgeons of England.* 2017;99(3):218-23. <http://dx.doi.org/10.1308/rcsann.2016.0308>. Epub 2016 Sep 23.
2088. **Electronic prescribing increases uptake of clinical pharmacologists' recommendations in the hospital setting.** Taegtmeier AB, Curkovic I, Rufibach K, Corti N, Battegay E, Kullak-Ublick GA. *British journal of clinical pharmacology.* 2011;72(6):958-64. <http://dx.doi.org/10.1111/j.1365-2125.2011.04032.x>.
2089. **Intrinsic risk factors and athletic injuries.** Taimela S, Kujala UM, Osterman K. *Sports medicine (Auckland,*



NZ). 1990;9(4):205-15. <http://dx.doi.org/10.2165/00007256-199009040-00002>.

2090. **[Evaluation of indices indicating elderly long-term care need in municipalities]**. Takeda S, Tamura K. [Nihon koshu eisei zasshi] Japanese journal of public health. 2004;51(5):335-46.
2091. **Human Leukocyte Antigen Shared Epitope and Inflammation, Cardiovascular Disease, Cancer, and Mortality among Postmenopausal Women in the Women's Health Initiative Rheumatoid Arthritis Study**. Talabi MB, MacKey RH, Kuller LH, Dorman JS, Deane KD, Robinson WH, et al. American Journal of Epidemiology. 2017;186(2):245-54.
2092. **Intensity of transmission and spread of gene mutations linked to chloroquine and sulphadoxine-pyrimethamine resistance in falciparum malaria**. Talisuna AO, Langi P, Mutabingwa TK, Van Marck E, Speybroeck N, Egwang TG, et al. International Journal for Parasitology. 2003;33(10):1051-8.
2093. **Efficacy of artesunate plus amodiaquine, artesunate plus sulfadoxine-pyrimethamine, and chloroquine plus sulfadoxine-pyrimethamine in patients with uncomplicated Plasmodium falciparum in the Comoros Union**. Tall A, Rabarijaona LP, Robert V, Bedja SA, Arie F, Randrianariveolosia M. Acta Tropica. 2007;102(3):176-81.
2094. **Erysipelothrix rhusiopathiae bloodstream infection – A 22-year experience at Mayo Clinic, Minnesota**. Tan EM, Marcelin JR, Adeel N, Lewis RJ, Enzler MJ, Tosh PK. Zoonoses and Public Health. 2017;64(7):e65-e72.
2095. **Kielland's forceps delivery: is it a dying art?** Tan KH, Sim R, Yam KL. Singapore Med J. 1992;33(4):380-2.
2096. **Relationships between Sleep Behaviors and Unintentional Injury in Southern Chinese School-Aged Children: A Population-Based Study**. Tan Y, Ma D, Chen Y, Cheng F, Liu X, Li L. International journal of environmental research and public health. 2015;12(10):12999-3015. <http://dx.doi.org/10.3390/ijerph121012999>.
2097. **Vascular endothelial growth factor, lipoprotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erithematosus**. Tanaseanu C, Tudor S, Tamsulea I, Marta D, Manea G, Moldoveanu E. European Journal of Medical Research. 2007;12(4):145-51.
2098. **Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial**. Tang LQ, Chen DP, Guo L, Mo HY, Huang Y, Guo SS, et al. The Lancet Oncology. 2018;19(4):461-73. [http://dx.doi.org/10.1016/S1470-2045\(18\)30104-9](http://dx.doi.org/10.1016/S1470-2045(18)30104-9). Epub 2018 Feb 28.
2099. **Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial**. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. medRxiv. 2020:2020.04.10.20060558.
2100. **Retinal functional changes measured by frequency-doubling technology in patients treated with hydroxychloroquine**. Tanga L, Centofanti M, Oddone F, Parravano M, Parisi V, Ziccardi L, et al. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2011;249(5):715-21. <http://dx.doi.org/10.1007/s00417-010-1612-6>. Epub 2011 Jan 21.
2101. **Genetic polymorphisms of thiopurine S-methyltransferase in a cohort of patients with systemic autoimmune diseases**. Tani C, Mosca M, Colucci R, Gori G, D'Ascanio A, Ghisu N, et al. Clinical and Experimental Rheumatology. 2009;27(2):321-4.
2102. **Unhealthy lifestyle, poor mental health, and its correlation among adolescents: a nationwide cross-sectional survey**. Tanihata T, Kanda H, Osaki Y, Ohida T, Minowa M, Wada K, et al. Asia Pac J Public Health. 2015;27(2):Np1557-65. <http://dx.doi.org/10.1177/1010539512452753>. Epub 2012 Jul 18.

2103. **Rheumatoid arthritis in older people.** Tantram B, Richards S, Thomas M. *CME Journal Geriatric Medicine*. 2005;7(2):70-5.
2104. **Physical activity might not be the protective factor for health risk behaviours and psychopathological symptoms in adolescents.** Tao FB, Xu ML, Kim SD, Sun Y, Su PY, Huang K. *J Paediatr Child Health*. 2007;43(11):762-7. <http://dx.doi.org/10.1111/j.1440-1754.2007.01217.x>.
2105. **Prevalence and risk factors for cervical neoplasia: a cervical cancer screening program in Beijing.** Tao L, Han L, Li X, Gao Q, Pan L, Wu L, et al. *BMC Public Health*. 2014;14:1185. <http://dx.doi.org/10.1186/1471-2458-14-1185>.
2106. **Diastolic dysfunction in rheumatoid arthritis patients with low disease activity.** Targońska-Stępnik B, Biskup M, Biskup W, Majdan M. *Clinical Rheumatology*. 2019;38(4):1131-7.
2107. **Serum amyloid a as a marker of persistent inflammation and an indicator of cardiovascular and renal involvement in patients with rheumatoid arthritis.** Targońska-Stępnik B, Majdan M. *Mediators of Inflammation*. 2014;2014.
2108. **Associations between parameters of nutritional status and disease activity in patients with rheumatoid arthritis.** Targońska-Stępnik B, Majdan M. *Polskie Archiwum Medycyny Wewnętrznej*. 2011;121(4):122-8.
2109. **Amino-terminal pro-brain natriuretic peptide as a prognostic marker in patients with rheumatoid arthritis.** Targońska-Stępnik B, Majdan M. *Clinical Rheumatology*. 2011;30(1):61-9.
2110. **Prospective assessment of cardiovascular risk parameters in patients with rheumatoid arthritis.** Targońska-Stępnik B, Piotrowski M, Zwolak R, Drelich-Zbroja A, Majdan M. *Cardiovascular Ultrasound*. 2018;16(1).
2111. **Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus: Results from a single center.** Tarr T, Gyorfy B, Szekaneč É, Bhattoa HP, Zeher M, Szegedi G, et al. *Journal*. 2007;1108(Issue):76-82.
2112. **Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus.** Tarr T, Papp G, Nagy N, Cserép E, Zeher M. *Clinical Rheumatology*. 2017;36(2):327-33.
2113. **Active disease is independently associated with more severe anxiety rather than depressive symptoms in patients with systemic lupus erythematosus.** Tay SH, Cheung PPM, Mak A. *Lupus*. 2015;24(13):1392-9.
2114. **Acetaminophen overdose in the Military Health System.** Taylor LG, Xie S, Meyer TE, Coster TS. *Pharmacoepidemiol Drug Saf*. 2012;21(4):375-83. <http://dx.doi.org/10.1002/pds.3206>. Epub 2012 Feb 23.
2115. **Antimalarial Drug Toxicity: A Review.** Taylor WRJ, White NJ. *Drug Safety*. 2004;27(1):25-61.
2116. **Infliximab therapy for hepatic and intestinal sarcoidosis.** Te HS, Campbell L, Chohan S. *Gastroenterology and Hepatology*. 2007;3(6):447-52.
2117. **A case of acute psychosis due to Chloroquine.** Tedeschi M. *Information Psychiatrique*. 1983;59(9):1191-7.
2118. **The incidence of cardiovascular manifestations detected by echocardiography in systemic lupus erythematosus.** Tegzová D, Jansa P, Ambrož D, Paleček T, Dušek L. *Ceska Revmatologie*. 2007;15(2):64-71.
2119. **Polymyositis and dermatomyositis in Sarawak: a profile of patients treated in the Sarawak General Hospital.** Teh CL, Wong JS, Soo HH. *Rheumatology international*. 2012;32(1):265-8. <http://dx.doi.org/10.1007/s00296-010-1745-2>. Epub 2011 Jan 18.

2120. **Evidence for cardiac safety and antiarrhythmic potential of chloroquine in systemic lupus erythematosus.** Teixeira RA, Borba EF, Pedrosa A, Nishioka S, Viana VST, Ramires JA, et al. *Europace*. 2014;16(6):887-92.
2121. **Retinal toxicity related to hydroxychloroquine in patients with systemic lupus erythematosus and rheumatoid arthritis.** Telek HH, Yesilirmak N, Sungur G, Ozdemir Y, Yesil NK, Ornek F. *Documenta ophthalmologica Advances in ophthalmology*. 2017;135(3):187-94. <http://dx.doi.org/10.1007/s10633-017-9607-9>. Epub 2017 Aug 29.
2122. **Serious psychiatric symptoms after chloroquine treatment following experimental malaria infection.** Telgt DS, Van Der Yen AJ, Schimmer B, Droogleever-Fortuyn HA, Sauerwein RW. *Annals of Pharmacotherapy*. 2005;39(3):551-4.
2123. **Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis.** Ten Wolde S, Breedveld FC, Hermans J, Vandenbroucke JP, Van De Laar MAFJ, Markusse HM, et al. *Lancet*. 1996;347(8998):347-52.
2124. **Accuracy of ProSeal laryngeal mask airway intracuff pressure estimation using finger palpation technique - a prospective, observational study.** Teoh PF, Seet E, Macachor J, Chia N. *Anaesthesia and intensive care*. 2012;40(3):467-71. <http://dx.doi.org/10.1177/0310057X1204000312>.
2125. **Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry.** Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, et al. *Arthritis and Rheumatism*. 2010;62(8):2458-66.
2126. **Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sjögren's syndrome-related neuropathy.** Terrier B, Lacroix C, Guillevin L, Hatron PY, Dhote R, Maillot F, et al. *Arthritis Care and Research*. 2007;57(8):1520-9.
2127. **Neurosarcoidosis: Presentations and management.** Terushkin V, Stern BJ, Judson MA, Hagiwara M, Pramanik B, Sanchez M, et al. *Neurologist*. 2010;16(1):2-15.
2128. **Insights from pharmacokinetic and pharmacodynamic studies of hydroxychloroquine.** Tett S, McLachlan A, Day R, Cutler D. *Agents and actions Supplements*. 1993;44:145-90.
2129. **Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis--a prospective, dose ranging study.** Tett SE, Cutler DJ, Beck C, Day RO. *The Journal of rheumatology*. 2000;27(7):1656-60.
2130. **Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis--a cross sectional study.** Tett SE, Day RO, Cutler DJ. *The Journal of rheumatology*. 1993;20(11):1874-9.
2131. **Prevalence of hydroxychloroquine-induced side-effects in dermatology patients: A retrospective survey of 102 patients.** Tétu P, Hamelin A, Lebrun-Vignes B, Soria A, Barbaud A, Francès C, et al. *Annales de Dermatologie et de Venereologie*. 2018;145(6):395-404.
2132. **Itch in ethnic populations.** Tey HL, Yosipovitch G. *Acta Dermato-Venereologica*. 2010;90(3):227-34.
2133. **High disease activity may increase fear-avoidance beliefs in rheumatoid arthritis.** Tezcan ME, Cinkit Doğan B, Şen N, Sargin M. *Archives of Rheumatology*. 2017;32(4):325-32.
2134. **Cutaneous adverse drug reactions in a tertiary care teaching hospital in India: An intensive monitoring study.** Thakkar S, Patel TK, Vahora R, Bhabhor P, Patel R. *Indian Journal of Dermatology*. 2017;62(6):510-7.

2135. **Outcome of patients with sarcoidosis refractory to TNF antagonists: A case series.** Thery-Casari C, Jamilloux Y, Bouvry D, Chapelon-Abrie C, Marquet A, Bielefeld P, et al. *Sarcoidosis Vasculitis and Diffuse Lung Diseases*. 2018;35(4):371-5.
2136. **Chikungunya Fever: A Clinical and Virological Investigation of Outpatients on Reunion Island, South-West Indian Ocean.** Thiberville SD, Boisson V, Gaudart J, Simon F, Flahault A, de Lamballerie X. *PLoS Neglected Tropical Diseases*. 2013;7(1).
2137. **Malaria prophylaxis.** Thomas JEP. *Central African Journal of Medicine*. 1991;37(10):339-40.
2138. **Prevention of malaria in travellers - A summary of current guidelines.** Thomson E, Bannister B. *CPD Infection*. 2002;3(3):80-4.
2139. **Low-dose thalidomide is an effective second-line treatment in cutaneous lupus erythematosus.** Thomson KF, Goodfield MJD. *Journal of Dermatological Treatment*. 2001;12(3):145-7.
2140. **Outcomes of chronic hepatitis B infection in oriental patients with rheumatic diseases.** Thong BYH, Ee TK, Hiok HC, Wan CC. *Annals of the Academy of Medicine Singapore*. 2007;36(2):100-5.
2141. **Undergraduate nursing students' attitudes toward mental health nursing.** Thongpriwan V, Leuck SE, Powell RL, Young S, Schuler SG, Hughes RG. *Nurse education today*. 2015;35(8):948-53. <http://dx.doi.org/10.1016/j.nedt.2015.03.011>. Epub 2015 Mar 25.
2142. **[Epidemiological characteristics of echinococcosis death cases in China from 2008 to 2016].** Tian T, Chun-Li C, Wei-Ping W, Tie-Wu J, Men-Bao Q, Yu-Wan H, et al. *Zhongguo xue xi chong bing fang zhi za zhi = Chinese journal of schistosomiasis control*. 2018;30(3):282-8. <http://dx.doi.org/10.16250/j.32.1374.2018064>.
2143. **Adverse events in a paediatric intensive care unit: relationship to workload, skill mix and staff supervision.** Tibby SM, Correa-West J, Durward A, Ferguson L, Murdoch IA. *Intensive Care Med*. 2004;30(6):1160-6. <http://dx.doi.org/10.1007/s00134-004-2256-y>. Epub 2004 Apr 6.
2144. **Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up.** Tiippana-Kinnunen T, Paimela L, Kautiainen H, Laasonen L, Leirisalo-Repo M. *Scandinavian Journal of Rheumatology*. 2010;39(1):12-8.
2145. **Autoantibodies in black South Africans with systemic lupus erythematosus: Spectrum and clinical associations.** Tikly M, Burgin S, Mohanlal P, Bellingan A, George J. *Clinical Rheumatology*. 1996;15(2):143-7.
2146. **A case of vivax malaria presenting with psychosis.** Tilluckdharry CC, Chadee DD, Doon R, Nehall J. *The West Indian medical journal*. 1996;45(1):39-40.
2147. **Development of a health care utilisation data-based index for rheumatoid arthritis severity: A preliminary study.** Ting G, Schneeweiss S, Scranton R, Katz JN, Weinblatt ME, Young M, et al. *Arthritis Research and Therapy*. 2008;10(4).
2148. **Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature.** Tinti MG, Carnevale V, Inglese M, Molinaro F, Bernal M, Migliore A, et al. *Clinical and Experimental Medicine*. 2019;19(3):281-8.
2149. **Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.** Tison A, Quéré G, Misery L, Funck-Brentano E, Danlos FX, Routier E, et al. *Arthritis and Rheumatology*. 2019;71(12):2100-11.

2150. **Efficacy of chloroquine, chloroquine plus sulphadoxine-pyrimethamine, and amodiaquine for treatment of vivax malaria in Bangka island, Indonesia: A randomized trial.** Tjitra E, Maladi, Prasetyorini B, Suprianto S, Harun S, Nurhayati, et al. *Medical Journal of Indonesia*. 2008;17(2):96-106.
2151. **Randomized comparative study of chloroquine and halofantrine in vivax malaria patients.** Tjitra E, Oemijati S, Pribadi W, Arbani PR, Harianto PN, Kawulur P, et al. *Medical Journal of Indonesia*. 1995;4(1):30-6.
2152. **[Rational therapeutic approach in rheumatoid arthritis].** Tlustochowicz W. *Annales Academiae Medicae Stetinensis*. 2006;52:5-10.
2153. **Hydroxychloroquine. Seven-year experience.** Tobin DR, Krohel G, Rynes RI. *Archives of ophthalmology (Chicago, Ill : 1960)*. 1982;100(1):81-3. <http://dx.doi.org/10.1001/archophth.1982.01030030083006>.
2154. **Leukogram Profile and Clinical Status in vivax and falciparum Malaria Patients from Colombia.** Tobón-Castaño A, Mesa-Echeverry E, Miranda-Arboleda AF. *Journal of Tropical Medicine*. 2015;2015.
2155. **Annual longitudinal survey at up to five time points reveals reciprocal effects of bedtime delay and depression/anxiety in adolescents.** Tochigi M, Usami S, Matamura M, Kitagawa Y, Fukushima M, Yonehara H, et al. *Sleep medicine*. 2016;17:81-6. <http://dx.doi.org/10.1016/j.sleep.2015.08.024>. Epub 2015 Oct 22.
2156. **Oxidative stress plays an important role in the pathogenesis of drug-induced retinopathy.** Toler SM. *Experimental Biology and Medicine*. 2004;229(7):607-15.
2157. **Frontal fibrosing alopecia among men: A clinicopathologic study of 7 cases.** Tolkachjov SN, Chaudhry HM, Camilleri MJ, Torgerson RR. *J Am Acad Dermatol*. 2017;77(4):683-90.e2. <http://dx.doi.org/10.1016/j.jaad.2017.05.045>. Epub 2017 Jul 14.
2158. **Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIII. Baseline predictors of vascular events.** Toloza SMA, Uribe AG, McGwin Jr G, Alarcón GS, Fessler BJ, Bastian HM, et al. *Arthritis and Rheumatism*. 2004;50(12):3947-57.
2159. **Dilated examination of patients referred with minor lid complaints--is it necessary?** Tomlins PJ, Benskin S, Tahhan M, Tyagi AK. *Eye (London, England)*. 2007;21(7):941-2. <http://dx.doi.org/10.1038/sj.eye.6702348>. Epub 2006 Apr 28.
2160. **Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: A cross-sectional study.** Toms TE, Panoulas VF, Douglas KMJ, Griffiths HR, Kitis GD. *Arthritis Research and Therapy*. 2008;10(6).
2161. **Lipid profile changes in rheumatoid arthritis patients: Investigation of different affecting factors.** Toosi TD, Rostamiyan A, Moharrami K, Movassaghi S, Nakhjavani M, Norooznezhad AH. *Acta Medica Iranica*. 2018;56(10):665-70.
2162. **Mefloquine neurotoxicity: A literature review.** Toovey S. *Travel Medicine and Infectious Disease*. 2009;7(1):2-6.
2163. **Systemic lupus erythematosus vasculitis: A current therapeutic overview.** Toubi E, Kessel A, Bamberger E, Golan TD. *Current Treatment Options in Cardiovascular Medicine*. 2004;6(2):87-97.
2164. **Serum adipokines and adipose tissue distribution in rheumatoid arthritis and ankylosing spondylitis. A comparative study.** Toussirot É, Grandclément É, Gaugler B, Michel F, Wendling D, Saas P, et al. *Frontiers in Immunology*. 2013;4.
2165. **Bacterial extract (OM-89) specific and non specific immunomodulation in rheumatoid arthritis**

- patients.** Toussirot É, Robinet É, Saas P, Chabod J, Augé B, Cozma G, et al. *Autoimmunity*. 2006;39(4):299-306.
2166. **Instrumentality as a life-stress moderator for early versus middle adolescents.** Towbes LC, Cohen LH, Glyshaw K. *J Pers Soc Psychol*. 1989;57(1):109-19. <http://dx.doi.org/10.1037//0022-3514.57.1.109>.
2167. **Routine examination of the newborn: the EMREN study. Evaluation of an extension of the midwife role including a randomised controlled trial of appropriately trained midwives and paediatric senior house officers.** Townsend J, Wolke D, Hayes J, Dave S, Rogers C, Bloomfield L, et al. *Health Technol Assess*. 2004;8(14):iii-iv, ix-xi, 1-100. <http://dx.doi.org/10.3310/hta8140>.
2168. **Chloroquine potentiation of thioridazine effects in rats and drug-resistant schizophrenic patients: A preliminary report.** Traficante LJ, Hine B, Gershon S, Sakalis G. *Communications in Psychopharmacology*. 1977;1(4):407-19.
2169. **Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients.** Tragulpiankit P, Chulavatnatol S, Rerkpattanapipat T, Janwityanujit S, Somjarit S, Sirikhedgon U. *International Journal of Rheumatic Diseases*. 2012;15(3):315-21.
2170. **Modelling Outcomes of Complex Treatment Strategies Following a Clinical Guideline for Treatment Decisions in Patients with Rheumatoid Arthritis.** Tran-Duy A, Boonen A, Kievit W, van Riel PLCM, van de Laar MAFJ, Severens JL. *Pharmacoeconomics*. 2014;32(10):1015-28.
2171. **The rise and fall of malaria in a west African rural community, Dielmo, Senegal, from 1990 to 2012: A 22 year longitudinal study.** Trape JF, Tall A, Sokhna C, Ly AB, Diagne N, Ndiath O, et al. *The Lancet Infectious Diseases*. 2014;14(6):476-88.
2172. **Parasitosis, dopaminergic modulation and metabolic disturbances in schizophrenia: Evolution of a hypothesis.** Treuer T, Martenyi F, Karagianis J. *Neuroendocrinology Letters*. 2007;28(5):535-40.
2173. **Osteoarthritis.** Trevisani VFM, De Alencar Fidelix TS. *Revista Brasileira de Medicina*. 2009;66:51-9.
2174. **Combination therapy with hydroxychloroquine and methotrexate in rheumatoid arthritis.** Trnavsky K, Gatterova J, Linduskova M, Peliskova Z. *Zeitschrift fur Rheumatologie*. 1993;52(5):292-6.
2175. **Vasectomy under local anaesthesia performed free of charge as a family planning service: complications and results.** Trollip GS, Fisher M, Naidoo A, Theron PD, Heyns CF. *South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde*. 2009;99(4):238-42.
2176. **Outcomes of the patients in the respiratory care center are not associated with the seniority of the caring resident.** Tsai MJ, Huang JY, Wei PJ, Wang CY, Yang CJ, Wang TH, et al. *The Kaohsiung journal of medical sciences*. 2013;29(1):43-9. <http://dx.doi.org/10.1016/j.kjms.2012.08.007>. Epub 2012 Oct 10.
2177. **The Diagnostic Utility of Multifocal Electroretinography in Detecting Chloroquine and Hydroxychloroquine Retinal Toxicity.** Tsang AC, Ahmadi S, Hamilton J, Gao J, Virgili G, Coupland SG, et al. *American journal of ophthalmology*. 2019;206:132-9. <http://dx.doi.org/10.1016/j.ajo.2019.04.025>. Epub 2019 May 10.
2178. **Long-term evaluation of antimalarials in a Dutch SLE cohort: Intolerance and other reasons for non-use.** Tsang ASMWP, Bultink IEM, Voskuyl AE. *Clinical and Experimental Rheumatology*. 2014;32(1):95-100.
2179. **Comparative evaluation of drug prescription appropriateness in public and private health institutions of south west ethiopia: The case of Wolkite town.** Tsega B, Makonnen E. *International Journal of Pharmaceutical Sciences and Research*. 2012;3(12):4922-8.
2180. **Chloroquine in the treatment of porphyria cutanea tarda.** Tsega E, Besrat A, Damtew B, Seyoum E,

- Landells JW. *Trans R Soc Trop Med Hyg.* 1981;75(3):401-4. [http://dx.doi.org/10.1016/0035-9203\(81\)90104-8](http://dx.doi.org/10.1016/0035-9203(81)90104-8).
2181. **Antimalarial-induced cardiomyopathy in systemic lupus erythematosus: As rare as considered?** Tselios K, Deeb M, Gladman DD, Harvey P, Akhtari S, Mak S, et al. *Journal of Rheumatology.* 2019;46(4):391-6.
2182. **Abnormal cardiac biomarkers in patients with systemic lupus erythematosus and no prior heart disease: A consequence of antimalarials?** Tselios K, Gladman DD, Harvey P, Akhtari S, Su J, Urowitz MB. *Journal of Rheumatology.* 2019;46(1):64-9.
2183. **[The prognosis of encephaloceles (author's transl)].** Tsuchida T, Okada K, Ueki K. *No shinkei geka Neurological surgery.* 1981;9(2):143-50.
2184. **Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis.** Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. *New England Journal of Medicine.* 1995;333(3):137-41.
2185. **Adverse drug reactions in patients admitted on Internal Medicine wards in a district and Regional Hospital in Uganda.** Tumwikirize WA, Ogwal-Okeng JW, Vernby A, Anokbonggo WW, Gustafsson LL, Lundborg SC. *African Health Sciences.* 2011;11(1):72-8.
2186. **Fluid resuscitation of hypotensive emergency patients with and without an algorithm.** Tunturi T, Kaukinen S, Kaukinen L, Gronlund A, Eerola R. *Resuscitation.* 1986;13(3):175-84. [http://dx.doi.org/10.1016/0300-9572\(86\)90099-7](http://dx.doi.org/10.1016/0300-9572(86)90099-7).
2187. **Partial amputations of the foot for diabetic gangrene.** Turnbull AR, Chester JF. *Annals of the Royal College of Surgeons of England.* 1988;70(5):329-31.
2188. **Drug-induced Proarrhythmia and Torsade de Pointes: A Primer for Students and Practitioners of Medicine and Pharmacy.** Turner JR, Rodriguez I, Mantovani E, Gintant G, Kowey PR, Klotzbaugh RJ, et al. *Journal of Clinical Pharmacology.* 2018;58(8):997-1012.
2189. **Treatment of elderly rheumatoid arthritis.** Tutuncu Z, Kavanaugh A. *Future Rheumatology.* 2007;2(3):313-9.
2190. **Rheumatic Disease in the Elderly: Rheumatoid Arthritis.** Tutuncu Z, Kavanaugh A. *Rheumatic Disease Clinics of North America.* 2007;33(1):57-70.
2191. **Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: A multi-centre Australian study.** Tymms K, Kelly A, Bird P, Griffiths H, de Jager J, Littlejohn G, et al. *International Journal of Rheumatic Diseases.* 2018;21(2):510-6.
2192. **[Dermatomyositis treatment. About sixteen cases (author's transl)].** Typhagne F, Revuz J, Touraine R. *Ann Dermatol Venereol.* 1978;105(6):593-8.
2193. **Is there an effective treatment for late-onset systemic lupus erythematosus?** Ugarte-Gil MF, Alarcón GS. *Aging Health.* 2013;9(4):437-50.
2194. **Evaluation of Maculopathy in Patients Using Hydroxychloroquine.** Ugurlu A, Aslanova M, Cebeci Z, Kir Mercul N. *Turkish journal of ophthalmology.* 2019;49(3):149-53. <http://dx.doi.org/10.4274/tjo.galenos.2018.67864>.
2195. **Intra-operative cardiac arrest--a tropical experience.** Ugwu BT, Isamade ES, Isamade EI. *West African journal of medicine.* 2000;19(4):277-80.
2196. **Quantitative assessment of outer retinal layers and ellipsoid zone mapping in hydroxychloroquine retinopathy.** Ugwuegbu O, Uchida A, Singh RP, Beven L, Hu M, Kaiser S, et al. *The British journal of ophthalmology.*

2019;103(1):3-7. <http://dx.doi.org/10.1136/bjophthalmol-2018-312363>. Epub 2018 Sep 6.

2197. **Spectral domain optical coherence tomography for early detection of retinal alterations in patients using hydroxychloroquine.** Ulviye Y, Betul T, Nur T, Selda C. *Indian Journal of Ophthalmology*. 2013;61(4):168-71.

2198. **Evaluation of the cognitive effect of newborn resuscitation training on health-care workers in selected states in Northern Nigeria.** Umar LW, Ahmad HR, Isah A, Idris HW, Hassan L, Abdullahi FL, et al. *Annals of African medicine*. 2018;17(1):33-9. [http://dx.doi.org/10.4103/aam.aam\\_47\\_17](http://dx.doi.org/10.4103/aam.aam_47_17).

2199. **Neurosarcoidosis.** Ungprasert P, Matteson EL. *Rheumatic Disease Clinics of North America*. 2017;43(4):593-606.

2200. **[Risky eating behaviors in student population in Mexico City: trends 1997-2003].** Unikel-Santoncini C, Bojorquez-Chapela I, Villatoro-Velazquez J, Fleiz-Bautista C, Medina-Mora Icaza ME. *Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion*. 2006;58(1):15-27.

2201. **Antiphospholipid syndrome: Recent advances.** Uppal SS, Bammigatti C. *Indian Journal of Rheumatology*. 2007;2(3):105-13.

2202. **Initial academic experience and learning curve with robotic spine instrumentation.** Urakov TM, Chang KH, Burks SS, Wang MY. *Neurosurgical focus*. 2017;42(5):E4. <http://dx.doi.org/10.3171/2017.2.FOCUS175>.

2203. **Survival analysis of turkish patients with systemic lupus erythematosus: Older age at diagnosis affects mortality.** Üsküdar Cansu D, Üsküdar Teke H, Korkmaz C. *Archives of Rheumatology*. 2017;32(2):141-8.

2204. **Consenting practice for laparoscopic cholecystectomy - are we doing enough to warn patients about their operation?** Uzzaman MM, Tayeh S, Sinha S, Ratnasingham K, Stoker DL. *International journal of surgery (London, England)*. 2011;9(8):643-7. <http://dx.doi.org/10.1016/j.ijssu.2011.08.004>. Epub 2011 Sep 16.

2205. **Primaquine revisited six decades after its discovery.** Vale N, Moreira R, Gomes P. *European Journal of Medicinal Chemistry*. 2009;44(3):937-53.

2206. **Low efficacy of chloroquine: time to switchover to artemisinin-based combination therapy for falciparum malaria in India.** Valecha N, Joshi H, Mallick PK, Sharma SK, Kumar A, Tyagi PK, et al. *Acta tropica*. 2009;111(1):21-8. <http://dx.doi.org/10.1016/j.actatropica.2009.01.013>. Epub 2009 Feb 7.

2207. **Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperazine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study.** Valecha N, Savargaonkar D, Srivastava B, Rao BH, Tripathi SK, Gogtay N, et al. *Malar J*. 2016;15:42. <http://dx.doi.org/10.1186/s12936-016-1084-1>.

2208. **Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: Real-life experience in Finnish patients.** Valleala H, Korpela M, Möttönen T, Hienonen-Kempas T, Kauppi M, Hannonen P, et al. *Scandinavian Journal of Rheumatology*. 2009;38(5):323-7.

2209. **Mental disturbances induced by drugs.** Vallejo Ruiloba J. *Archivos de Neurobiologia*. 1979;42(5):389-414.

2210. **Low-dose oral chloroquine in patients with porphyria cutanea tarda and low-moderate iron overload.** Valls V, Ena J, Enriquez-De-Salamanca R. *Journal of Dermatological Science*. 1994;7(3):169-75.

2211. **Anxiety and depression in patients with primary Sjogren's syndrome.** Valtýsdóttir ST, Guðbjörnsson B, Lindqvist U, Hällgren R, Hetta J. *Journal of Rheumatology*. 2000;27(1):165-9.

2212. **Antimalarials.** Van Beek MJ, Piette WW. *Dermatologic Therapy*. 2001;14(2):143-53.



2213. **Factors influencing standard pretravel health advice - A study in Belgium.** Van De Winkel K, Van Den Daele A, Van Gompel A, Van Den Ende J. *Journal of Travel Medicine.* 2007;14(5):288-96.
2214. **Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine.** van den Borne BE, Landewe RB, Goei The HS, Rietveld JH, Zwinderman AH, Bruyn GA, et al. *The Journal of rheumatology.* 1998;25(8):1493-8.
2215. **Chloroquine therapy in patients with recent-onset rheumatoid arthritis: the clinical response can be predicted by the low level of acute-phase reaction at baseline.** van den Borne BE, Landewe RB, Rietveld JH, Goei The HS, Griep EN, Breedveld FC, et al. *Clin Rheumatol.* 1999;18(5):369-72. <http://dx.doi.org/10.1007/s100670050121>.
2216. **Hyperreactive malaria in expatriates returning from sub-Saharan Africa.** Van den Ende J, van Gompel A, van den Enden E, Taelman H, Vanham G, Vervoort T. *Tropical medicine & international health : TM & IH.* 2000;5(9):607-11. <http://dx.doi.org/10.1046/j.1365-3156.2000.00619.x>.
2217. **The effectiveness of early treatment with 'second-line' antirheumatic drugs. A randomized, controlled trial.** Van der Heide A, Jacobs JWJ, Bijlsma JWJ, Heurkens AHM, Van Booma- Frankfort C, Van der Veen MJ, et al. *Annals of Internal Medicine.* 1996;124(8):699-707.
2218. **Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.** Van Der Heijde D, Da Silva JC, Dougados M, Geher P, Van Der Horst-Bruinsma I, Juanola X, et al. *Annals of the Rheumatic Diseases.* 2006;65(12):1572-7.
2219. **Sensitivity of a Dutch Health Assessment Questionnaire in a trial comparing hydroxychloroquine vs. sulphasalazine.** van der Heijde DM, van Riel PL, van de Putte LB. *Scand J Rheumatol.* 1990;19(6):407-12. <http://dx.doi.org/10.3109/03009749009097629>.
2220. **Follow-up of 686 patients with acute Q fever and detection of chronic infection.** Van Der Hoek W, Versteeg B, Meekelenkamp JCE, Renders NHM, Leenders ACAP, Weers-Pothoff I, et al. *Clinical Infectious Diseases.* 2011;52(12):1431-6.
2221. **Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis.** Van Der Kooij SM, De Vries-Bouwstra JK, Goekoop-Ruiterman YPM, Ewals JAPM, Han KH, Hazes JMW, et al. *Arthritis Care and Research.* 2009;61(1):4-12.
2222. **Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate.** Van der Veen MJ, Van der Heide A, Kruize AA, Bijlsma JWJ. *Annals of the Rheumatic Diseases.* 1994;53(4):224-8.
2223. **Overdiagnosis of malaria in hospitalized patients in Namibia.** Van Dillen J, De Jager AJ, De Jong I, Wendte JF. *Tropical Doctor.* 2007;37(3):185-6.
2224. **A prospective study of the feasibility of continuous spinal anesthesia in a university hospital.** Van Gessel E, Forster A, Gamulin Z. *Anesthesia and analgesia.* 1995;80(5):880-5. <http://dx.doi.org/10.1097/00000539-199505000-00005>.
2225. **Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.** van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. *Arthritis and rheumatism.* 1996;39(1):34-40. <http://dx.doi.org/10.1002/art.1780390105>.
2226. **Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study.** Van Gool WA, Weinstein HC, Scheltens P, Walstra GJ. *Lancet.*

2001;358(9280):455-60. [http://dx.doi.org/10.1016/s0140-6736\(01\)05623-9](http://dx.doi.org/10.1016/s0140-6736(01)05623-9).

2227. **QT interval prolongation in users of selective serotonin reuptake inhibitors in an elderly surgical population: A cross-sectional study.** Van Haelst IMM, Van Klei WA, Doodeman HJ, Warnier MJ, De Bruin ML, Kalkman CJ, et al. *Journal of Clinical Psychiatry*. 2014;75(1):15-21.

2228. **Acute dystonia.** Van Harten PN. *Nederlands Tijdschrift voor Geneeskunde*. 1997;141(30):1471-4.

2229. **Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis.** van Jaarsveld CH, Jahangier ZN, Jacobs JW, Blaauw AA, van Albada-Kuipers GA, ter Borg EJ, et al. *Rheumatology (Oxford, England)*. 2000;39(12):1374-82. <http://dx.doi.org/10.1093/rheumatology/39.12.1374>.

2230. **Long-term usage and side-effect profile of sulphasalazine in rheumatoid arthritis.** Van Riel PLCM, Van Gestel AM, Van de Putte LBA. *British Journal of Rheumatology*. 1995;34:40-2.

2231. **Treatment of chronic Q fever: Clinical efficacy and toxicity of antibiotic regimens.** Van Roeden SE, Bleeker-Rovers CP, De Regt MJA, Kampschreur LM, Hoepelman AIM, Wever PC, et al. *Clinical Infectious Diseases*. 2018;66(5):719-26.

2232. **The effect of measuring serum doxycycline concentrations on clinical outcomes during treatment of chronic Q fever.** van Roeden SE, Bleeker-Rovers CP, Kampschreur LM, de Regt MJA, Windsant AV, Hoepelman AIM, et al. *Journal of Antimicrobial Chemotherapy*. 2018;73(4):1068-76.

2233. **Leflunomide in active rheumatoid arthritis: A prospective study in daily practice.** Van Roon EN, Jansen TLTA, Mourad L, Houtman PM, Bruyn GAW, Griep EN, et al. *British Journal of Clinical Pharmacology*. 2004;58(2):201-8.

2234. **Outcome of rheumatoid arthritis in relation to age and rheumatoid factor at diagnosis.** Van Schaardenburg D, Hazes JMW, De Boer A, Zwinderman AH, Meijers KAE, Breedveld FC. *Journal of Rheumatology*. 1993;20(1):45-52.

2235. **Prednisone treatment of elderly-onset rheumatoid arthritis. Disease activity and bone mass in comparison with chloroquine treatment.** van Schaardenburg D, Valkema R, Dijkmans BA, Papapoulos S, Zwinderman AH, Han KH, et al. *Arthritis and rheumatism*. 1995;38(3):334-42. <http://dx.doi.org/10.1002/art.1780380307>.

2236. **Subclinical renal dysfunction is independently associated with cardiovascular events in rheumatoid arthritis: The CARRÉ study.** Van Sijl AM, Van Den Oever IAM, Peters MJL, Boers M, Dijkmans BAC, Van Halm VP, et al. *Annals of the Rheumatic Diseases*. 2012;71(3):341-4.

2237. **Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial.** Van Tuyl LHD, Lems WF, Voskuyl AE, Kerstens PJSM, Garnerio P, Dijkmans BAC, et al. *Annals of the Rheumatic Diseases*. 2008;67(11):1574-7.

2238. **Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.** van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L, Waltbrand E, et al. *Lancet*. 2009;374(9688):459-66. [http://dx.doi.org/10.1016/S0140-6736\(09\)60944-2](http://dx.doi.org/10.1016/S0140-6736(09)60944-2).

2239. **Hydroxychloroquine (HCQ): an observational cohort study in primary and secondary prevention of pneumonia in an at-risk population.** Vanasse A, Courteau J, Chiu Y, Cantin A, Leduc R. *medRxiv*. 2020:2020.04.08.20057893.

2240. **New trends in early diagnosis of hydroxychloroquine toxic retinopathy.** Vanderzee G, Tassi D. *Optometry (St Louis, Mo)*. 2012;83(5):200-7.

2241. **Does Personality Predict Depression and Use of an Internet-Based Intervention for Depression among Adolescents?** Vangberg HC, Lillevoll KR, Waterloo K, Eisemann M. *Depression research and treatment*. 2012;2012:593068. <http://dx.doi.org/10.1155/2012/593068>. Epub 2012 Aug 15.
2242. **The trypanosome lytic factor of human serum and the molecular basis of sleeping sickness.** Vanhamme L, Pays E. *International Journal for Parasitology*. 2004;34(8):887-98.
2243. **[Retinal pigment epithelium--the point about safety of antimalarial agents].** Vanheesbeke A. *Bulletin de la Societe belge d'ophtalmologie*. 2007(304):47-58.
2244. **Methotrexate: Long-term safety and efficacy in an Australian consultant rheumatology practice.** Varatharajan N, Lim IGS, Anandacoomarasamy A, Russo R, Byth K, Spencer DG, et al. *Internal Medicine Journal*. 2009;39(4):228-36.
2245. **Late-onset sarcoidosis: A comparative study.** Varron L, Cottin V, Schott AM, Broussolle C, Sève P. *Medicine*. 2012;91(3):137-43.
2246. **The McGill simulator for endoscopic sinus surgery (MSESS): a validation study.** Varshney R, Frenkiel S, Nguyen LH, Young M, Del Maestro R, Zeitouni A, et al. *Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale*. 2014;43:40. <http://dx.doi.org/10.1186/s40463-014-0040-8>.
2247. **Acute generalized exanthematous pustulosis: Report of five cases and systematic review of clinical and histopathological findings.** Vassallo C, Derlino F, Brazzelli V, D'Ospina RM, Borroni G. *Giornale Italiano di Dermatologia e Venereologia*. 2014;149(3):281-90.
2248. **Course of asymptomatic liver involvement in sarcoidosis: role of therapy in selected cases.** Vatti R, Sharma OP. *Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG*. 1997;14(1):73-6.
2249. **Evaluation of lipid profile, macular toxicity and clinical manifestations according to APO E genotype in systemic lupus erythematosus and rheumatoid arthritis patients treated with chloroquine.** Vazquez-Del Mercado M, Munoz-Valle JF, Santos A, Bernard-Medina AG, Martinez-Bonilla G, Paczka JA, et al. *Scand J Rheumatol*. 2002;31(1):32-7. <http://dx.doi.org/10.1080/030097402317255345>.
2250. **A randomised controlled trial comparing StarClose and AngioSeal vascular closure devices in a district general hospital--the SCOAST study.** Veasey RA, Large JK, Silberbauer J, Paul G, Taggu W, Ellery S, et al. *Int J Clin Pract*. 2008;62(6):912-8. <http://dx.doi.org/10.1111/j.1742-1241.2008.01761.x>.
2251. **Incidence and time trends of herpes zoster in rheumatoid arthritis: A population-based cohort study.** Veetil BMA, Myasoedova E, Matteson EL, Gabriel SE, Green AB, Crowson CS. *Arthritis Care and Research*. 2013;65(6):854-61.
2252. **Learning curve using the second-generation cryoballoon ablation.** Velagic V, de Asmundis C, Mugnai G, Hunuk B, Hacıoglu E, Stroker E, et al. *Journal of cardiovascular medicine (Hagerstown, Md)*. 2017;18(7):518-27. <http://dx.doi.org/10.2459/JCM.0000000000000493>.
2253. **Patterns of care: burr-hole cover application for chronic subdural hematoma trepanation.** Velz J, Vasella F, Akeret K, Dias SF, Jehli E, Bozinov O, et al. *Neurosurgical focus*. 2019;47(5):E14. <http://dx.doi.org/10.3171/2019.8.FOCUS19245>.
2254. **Proposal of a new classification of postoperative ileus based on its clinical impact--results of a global survey and preliminary evaluation in colorectal surgery.** Venara A, Slim K, Regimbeau JM, Ortega-Deballon P, Vielle B, Lermite E, et al. *International journal of colorectal disease*. 2017;32(6):797-803. <http://dx.doi.org/10.1007/s00384-017-2788-6>. Epub 2017 Mar 10.

2255. **Resident participation and postoperative outcomes in adrenal surgery.** Venkat R, Valdivia PL, Guerrero MA. *The Journal of surgical research*. 2014;190(2):559-64. <http://dx.doi.org/10.1016/j.jss.2014.05.025>. Epub 2014 May 20.
2256. **Case 11-2010: A 69-year-old woman with lethargy, confusion, and abnormalities on brain imaging.** Venna N, Gonzalez RG, Camelo-Piragua SI. *New England Journal of Medicine*. 2010;362(15):1431-7+362.
2257. **Clinical outcome of experimental human malaria induced by Plasmodium falciparum-infected mosquitoes.** Verhage DF, Telgt DSC, Bousema JT, Hermsen CC, van Gemert GJ A, van der Meer JWM, et al. *Netherlands Journal of Medicine*. 2005;63(2):52-8.
2258. **Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis.** Verschuere P, Esselens G, Westhovens R. *Rheumatology*. 2008;47(1):59-64.
2259. **The Utrecht experience with different treatment strategies in early rheumatoid arthritis.** Verstappen SM, Jacobs JW, Bijlsma JW. *Clinical and experimental rheumatology*. 2003;21(5):S165-8.
2260. **Functional Health Assessment Questionnaire (HAQ) and psychological HAQ are associated with and predicted by different factors in rheumatoid arthritis.** Verstappen SMM, Jacobs JWG, Huisman AM, Van Rijthoven AWAM, Sokka T, Bijlsma JWJ. *Journal of Rheumatology*. 2007;34(9):1837-40.
2261. **Prevalence and follow-up analysis of evolution of severe and moderate neuropsychiatric manifestations in hospitalized systemic lupus erythematosus in the rheumatology service of the Hospital General de Fortaleza.** Vieira WP, Pinheiro MNA, Sampaio AXC, Callado CM, Vieira RMRdA, Callado MRM. *Revista Brasileira de Reumatologia*. 2008;48(3):141-50.
2262. **Emerging clinical issues related to management of multiorgan comorbidities and polypharmacy.** Vigouroux C, Bastard JP, Capeau J. *Current Opinion in HIV and AIDS*. 2014;9(4):371-8.
2263. **Elderly onset rheumatoid arthritis: Differential diagnosis and choice of first-line and subsequent therapy.** Villa-Blanco JI, Calvo-Alén J. *Drugs and Aging*. 2009;26(9):739-50.
2264. **In-vivo sensitivity of Plasmodium vivax isolates from Rondônia (western Amazon region, Brazil) to regimens including chloroquine and primaquine.** Villalobos-Salcedo JM, Tada MS, Kimura E, Menezes MJ, Pereira da Silva LH. *Ann Trop Med Parasitol*. 2000;94(8):749-58. <http://dx.doi.org/10.1080/00034980020027960>.
2265. **Reasons for not reporting adverse incidents: an empirical study.** Vincent C, Stanhope N, Crowley-Murphy M. *Journal of evaluation in clinical practice*. 1999;5(1):13-21. <http://dx.doi.org/10.1046/j.1365-2753.1999.00147.x>.
2266. **Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis.** Vis M, Nurmohamed MT, Wolbink G, Voskuyl AE, De Koning MHMT, Van De Stadt RJ, et al. *Journal of Rheumatology*. 2005;32(2):252-5.
2267. **Combined autophagy and proteasome inhibition a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.** Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L, et al. *Autophagy*. 2014;10(8):1380-90.
2268. **Amyotrophic lateral sclerosis (ALS), a novel rare cause of elevated plasma troponin T levels.** Von Lueder TG, Melsom MN, Atar D, Agewall S. *Clinical laboratory*. 2011;57(7):615-8.
2269. **The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: A double-blind, community-randomized, placebo-controlled trial in the Gambia.** von

Seidlein L, Walraven G, Milligan PJM, Alexander N, Manneh F, Deen JL, et al. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2003;97(2):217-25.

2270. **Adverse drug reactions in inpatients of internal medicine wards at a tertiary care hospital: A prospective cohort study.** Vora MB, Trivedi HR, Shah BK, Tripathi CB. Journal of Pharmacology and Pharmacotherapeutics. 2011;2(1):21-5.

2271. **Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis.** Vorselaars ADM, Verwoerd A, Van Moorsel CHM, Keijsers RGM, Rijkers GT, Grutters JC. European Respiratory Journal. 2014;43(2):602-9.

2272. **Detection of color vision defects in chloroquine retinopathy.** Vu BL, Easterbrook M, Hovis JK. Ophthalmology. 1999;106(9):1799-803; discussion 804. [http://dx.doi.org/10.1016/S0161-6420\(99\)90338-X](http://dx.doi.org/10.1016/S0161-6420(99)90338-X).

2273. **Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: The first three years.** Wabe N, Sorich MJ, Wechalekar MD, Cleland LG, McWilliams L, Lee A, et al. Arthritis Research and Therapy. 2015;17(1):1.

2274. **Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years: association with persistence to therapy.** Wabe N, Wojciechowski J, Wechalekar MD, Cleland LG, McWilliams L, Lee A, et al. International journal of rheumatic diseases. 2017;20(10):1447-56. <http://dx.doi.org/10.1111/1756-185X.13184>. Epub 2017 Sep 26.

2275. **Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort.** Wabe NT, Sorich MJ, Wechalekar MD, Cleland LG, McWilliams L, Lee AT, et al. The Journal of rheumatology. 2016;43(9):1643-9. <http://dx.doi.org/10.3899/jrheum.151392>. Epub 2016 Jul 15.

2276. **Psychosocial correlates of suicide attempts among junior and senior high school youth.** Wagner BM, Cole RE, Schwartzman P. Suicide & life-threatening behavior. 1995;25(3):358-72.

2277. **Direct and indirect costs of rheumatoid arthritis and the socio-emotional effects of this disease - An Austrian study.** Wagner E, Lackerbauer E, Siegmeth W. Wiener Medizinische Wochenschrift. 2005;155(9):217-26.

2278. **Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: A retrospective cohort study.** Wahie S, Daly AK, Cordell HJ, Goodfield MJ, Jones SK, Lovell CR, et al. Journal of Investigative Dermatology. 2011;131(10):1981-6.

2279. **Self-resolution of Epstein-Barr virus-associated B-cell lymphoma in a patient with dermatomyositis following withdrawal of mycophenolate mofetil and methotrexate.** Waldman MA, Callen JP. Journal of the American Academy of Dermatology. 2004;51(2):S124-S30.

2280. **The Mortality Associated with Erythema Nodosum Leprosum in Ethiopia: A Retrospective Hospital-Based Study.** Walker SL, Lebas E, Doni SN, Lockwood DNJ, Lambert SM. PLoS Neglected Tropical Diseases. 2014;8(3).

2281. **New insights into mechanisms of therapeutic effects of antimalarial agents in SLE.** Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturupalli SR. Nature Reviews Rheumatology. 2012;8(9):522-33.

2282. **Cutaneous lupus erythematosus without systemic lupus erythematosus: Clinical and laboratory features.** Wallace DJ, Pistiner M, Nessim S, Metzger AL, Klinenberg JR. Seminars in Arthritis and Rheumatism. 1992;21(4):221-6.

2283. **Bullous pemphigoid: From bench to bedside.** Walsh SRA, Hogg D, Mydlarski PR. Drugs. 2005;65(7):905-26.

2284. **Impact of Childhood Abuse on the Risk of Non-Suicidal Self-Injury in Mainland Chinese Adolescents.** Wan Y, Chen J, Sun Y, Tao F. PLoS One. 2015;10(6):e0131239. <http://dx.doi.org/10.1371/journal.pone.0131239>. eCollection 2015.
2285. **[Relationships between various forms of childhood abuse and suicidal behaviors among middle school students].** Wan Y, Liu W, Sun Y, Hao J, Tao F. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2016;37(4):506-11. <http://dx.doi.org/10.3760/cma.j.issn.0254-6450.2016.04.013>.
2286. **Malaria protection measures used by in-flight travelers to South African game parks.** Waner S, Durrhiem D, Braack LEO, Gammon S. Journal of Travel Medicine. 1999;6(4):254-7.
2287. **Computer-assisted preoperative planning improves the learning curve of PFNA-II in the treatment of intertrochanteric femoral fractures.** Wang D, Zhang K, Qiang M, Jia X, Chen Y. BMC Musculoskelet Disord. 2020;21(1):34. <http://dx.doi.org/10.1186/s12891-020-3048-4>.
2288. **Treatment of chloroquine-resistant malaria using pyrimethamine in combination with berberine, tetracycline or cotrimoxazole.** Wang Don S, Jiddawi MS, Xie Qiu H, Abdulla SM. East African Medical Journal. 1997;74(5):283-4.
2289. **Listeriosis at a Tertiary Care Hospital in Beijing, China: High prevalence of nonclustered healthcare-associated cases among adult patients.** Wang HL, Ghanem KG, Wang P, Yang S, Li TS. Clinical Infectious Diseases. 2013;56(5):666-76.
2290. **Analysis of Unplanned Return to the Operating Room Within 30 Days of Initial Neurosurgery: A 3-Year Experience at a Single Center.** Wang J, Xu Y, Liu R, Huang M, Yan X, Lu J, et al. World Neurosurg. 2018;118:e766-e71. <http://dx.doi.org/10.1016/j.wneu.2018.07.047>. Epub 2018 Jul 17.
2291. **Benefits and Risks of Chloroquine and Hydroxychloroquine in The Treatment of Viral Diseases: A Meta-Analysis of Placebo Randomized Controlled Trials.** Wang J, Yu L, Li K. medRxiv. 2020:2020.04.13.20064295.
2292. **[Survival time and influencing factors in multidrug-resistant tuberculosis patients in Wuhan, 2006-2014].** Wang JJ, Zhou ML, Chen C, Wu G, Zuo YP, Ren X, et al. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2019;40(11):1409-13. <http://dx.doi.org/10.3760/cma.j.issn.0254-6450.2019.11.013>.
2293. **Confirmed False Positive Proteinuria in Patients with Systemic Lupus Erythematosus Taking Hydroxychloroquine: a Spot Sample Measurement.** Wang JM, Li JY, Huang WC, Wen CY, Lee CH, Yang CY, et al. Clinical laboratory. 2015;61(5):581-6. <http://dx.doi.org/10.7754/clin.lab.2014.140706>.
2294. **Hemostatic effects of heat probe thermocoagulation for patients with peptic ulcer bleeding: an experience of 329 patients.** Wang K, Lin HJ, Chua RT, Perng CL, Lee SD, Lee CH. Zhonghua yi xue za zhi = Chinese medical journal; Free China ed. 1995;55(1):25-30.
2295. **[An epidemiological study of the adolescent nonfatal unintentional injuries in Taiwan].** Wang KC. The Kaohsiung journal of medical sciences. 1998;14(6):348-56.
2296. **[Prevalence and risk factors for anxiety among inhabitants in the relief centers after the 5 \*12 Sichuan earthquake].** Wang M, Yuan J, Li TG, Wang DD, Hu ZG, Liu JP, et al. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2008;29(9):887-90.
2297. **Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study.** Wang N, Guo Y, Yang L, Fu W, Xu Y, Hou L, et al. Neural Regeneration Research. 2012;7(11):862-6.
2298. **Proximal third humeral shaft fractures fixed with long helical PHILOS plates in elderly patients: benefit of pre-contouring plates on a 3D-printed model-a retrospective study.** Wang Q, Hu J, Guan J, Chen Y,

- Wang L. *J Orthop Surg Res.* 2018;13(1):203. <http://dx.doi.org/10.1186/s13018-018-0908-9>.
2299. **Open bedside tracheotomy in the intensive care unit.** Wang SJ, Sercarz JA, Blackwell KE, Aghamohammadi M, Wang MB. *The Laryngoscope.* 1999;109(6):891-3. <http://dx.doi.org/10.1097/00005537-199906000-00009>.
2300. **Intestinal autophagy links psychosocial stress with gut microbiota to promote inflammatory bowel disease.** Wang SL, Shao BZ, Zhao SB, Chang X, Wang P, Miao CY, et al. *Cell Death and Disease.* 2019;10(6).
2301. **Sensitivity of Plasmodium falciparum to antimalarial drugs in Hainan Island, China.** Wang SQ, Wang GZ, Li YC, Meng F, Lin SG, Zhu ZH, et al. *Korean Journal of Parasitology.* 2015;53(1):35-41.
2302. **Management guidelines and outcome measures in giant cell arteritis (PMR).** Warrington KJ, Matteson EL. *Clinical and Experimental Rheumatology.* 2007;25(6):S137-S41.
2303. **Smoking activates cytotoxic CD8+ T cells and causes survivin release in rheumatoid arthritis.** Wasén C, Turkkila M, Bossios A, Erlandsson M, Andersson KM, Ekerljung L, et al. *Journal of Autoimmunity.* 2017;78:101-10.
2304. **Brief mindfulness-based stress management program for a better mental state in working populations - Happy Nurse Project: A randomized controlled trial().** Watanabe N, Horikoshi M, Shinmei I, Oe Y, Narisawa T, Kumachi M, et al. *J Affect Disord.* 2019;251:186-94. <http://dx.doi.org/10.1016/j.jad.2019.03.067>. Epub 2019 Mar 22.
2305. **Deliberate self-harm in adolescents aged 12-18: a cross-sectional survey of 18,104 students.** Watanabe N, Nishida A, Shimodera S, Inoue K, Oshima N, Sasaki T, et al. *Suicide & life-threatening behavior.* 2012;42(5):550-60. <http://dx.doi.org/10.1111/j.1943-278X.2012.00111.x>. Epub 2012 Aug 13.
2306. **Help-seeking behavior among Japanese school students who self-harm: results from a self-report survey of 18,104 adolescents.** Watanabe N, Nishida A, Shimodera S, Inoue K, Oshima N, Sasaki T, et al. *Neuropsychiatr Dis Treat.* 2012;8:561-9. <http://dx.doi.org/10.2147/NDT.S37543>. Epub 2012 Nov 22.
2307. **Vascular access: a role for a renal nurse clinician.** Waterhouse D. *EDTNA/ERCA journal (English ed).* 2002;28(2):64-6, 9. <http://dx.doi.org/10.1111/j.1755-6686.2002.tb00203.x>.
2308. **Improved gastrointestinal tolerance and patient preference of enteric- coated sulfasalazine versus uncoated sulfasalazine tablets in patients with rheumatoid arthritis.** Weaver A, Chatwell R, Churchill M, Kastanek L, Beyene J, Garceau R, et al. *Journal of Clinical Rheumatology.* 1999;5(4):193-200.
2309. **Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: Results from the RADIUS observational registry.** Weaver AL, Lautzenheiser RL, Schiff MH, Gibofsky A, Perruquet JL, Luetkemeyer J, et al. *Current Medical Research and Opinion.* 2006;22(1):185-98.
2310. **Vascular complications of Q-fever infections.** Wegdam-Blans MCA, Vainas T, Van Sambeek MR, Cuyper PW, Tjhie HTJ, Van Straten AHM, et al. *European Journal of Vascular and Endovascular Surgery.* 2011;42(3):384-92.
2311. **[Psychiatric disorders in patients with chronic rhinosinusitis and its associated factor analysis].** Wei L, Wang Z. *Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery.* 2014;49(12):969-74.
2312. **Outpatient management of patients with immune thrombocytopenia (ITP) by hematologists 1995-2014.** Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, et al. *Oncology Research and Treatment.* 2016;39(1):41-4.
2313. **Treatment of rheumatoid arthritis with a Syk kinase inhibitor: A twelve-week, randomized,**

- placebo-controlled trial.** Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, et al. *Arthritis and Rheumatism*. 2008;58(11):3309-18.
2314. **Malaria therapy in 452 patients, with special reference to the use of quinine.** Weinke T, Held T, Trautmann M, Rogler G, Mravak S, Alexander M, et al. *Journal of Infection*. 1992;25(2):173-80.
2315. **Geriatric hearing loss: Myths, realities, resources for physicians.** Weinstein BE. *Geriatrics*. 1989;44(4):42-8+58.
2316. **Bicycle helmet use by children.** Weiss BD. *Pediatrics*. 1986;77(5):677-9.
2317. **Parasitic diseases and psychiatric illness.** Weiss MG. *Canadian Journal of Psychiatry*. 1994;39(10):623-8.
2318. **Treatment of lupus in the elderly.** Weitzel KW, Small RE. *Drug Topics*. 2004;148(3):105.
2319. **How does computer-aided diagnosis improve the management of acute abdominal pain?** Wellwood J, Johannessen S, Spiegelhalter DJ. *Annals of the Royal College of Surgeons of England*. 1992;74(1):40-6.
2320. **Acute pustular psoriasis complicated by leukocytoclastic vasculitis.** Welsch MJ. *Journal of drugs in dermatology : JDD*. 2003;2(2):193-7.
2321. **Rituximab treatment for spondyloarthritis. A nationwide series: Data from the AIR registry of the French Society of Rheumatology.** Wendling D, Dougados M, Berenbaum F, Brocq O, Schaevebeke T, Mazieres B, et al. *Journal of Rheumatology*. 2012;39(12):2327-31.
2322. **Chloroquine in treatment of porphyria cutanea tarda. Long-term efficacy of combined phlebotomy and high-dose chloroquine therapy.** Wennersten G, Ros AM. *Acta dermato-venereologica Supplementum*. 1982;100:119-23.
2323. **Current treatment of cutaneous lupus erythematosus.** Werth V. *Dermatology Online Journal*. 2001;7(1):37-48.
2324. **Atherogenic lipid profiles in rheumatoid arthritis.** White D, Fayez S, Doube A. *New Zealand Medical Journal*. 2006;119(1240).
2325. **Leflunomide use in New Zealand. A national prospective post-marketing study.** White DHN, Lynskey NV, Jones PBB. *Internal Medicine Journal*. 2009;39(2):95-102.
2326. **Mefloquine in the prophylaxis and treatment of falciparum malaria.** White NJ. *British Medical Journal*. 1994;308(6924):286-7.
2327. **Neurological dysfunction following malaria: Disease- or drug-related? [1].** White NJ. *Clinical Infectious Diseases*. 2000;30(5):836.
2328. **Combined hormonal and radiation therapy for lymph node-positive prostate cancer.** Whittington R, Malkowicz SB, Barnes MM, Broderick GA, Van Arsdalen K, Dougherty MJ, et al. *Urology*. 1995;46(2):213-9.
2329. **Associations between methotrexate use and the risk of cardiovascular events in patients with elderly-onset rheumatoid arthritis.** Widdifield J, Abrahamowicz M, Paterson JM, Huang A, Thorne JC, Pope JE, et al. *Journal of Rheumatology*. 2019;46(5):467-74.
2330. **Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.** Wiese MD, Schnabl M, O'Doherty C, Spargo LD, Sorich MJ, Cleland LG, et al. *Arthritis Research and Therapy*. 2012;14(4).



2331. **Treatment of patients with refractory rheumatoid arthritis with extracorporeal protein a immunoadsorption columns: A pilot trial.** Wiesenhutter CW, Irish BL, Bertram JH. *Journal of Rheumatology*. 1994;21(5):804-12.
2332. **Anti-influenza vaccination in systemic lupus erythematosus patients: An analysis of specific humoral response and vaccination safety.** Więsik-Szewczyk E, Romanowska M, Mielnik P, Chwalińska-Sadowska H, Brydak LB, Olesińska M, et al. *Clinical Rheumatology*. 2010;29(6):605-13.
2333. **Improving the safety of remote site emergency airway management.** Wijesuriya J, Brand J. *BMJ quality improvement reports*. 2014;2(2). <http://dx.doi.org/10.1136/bmjquality.u202785.w1275>. eCollection 2014.
2334. **Does resident post graduate year influence the outcomes of inguinal hernia repair?** Wilkiemeyer M, Pappas TN, Giobbie-Hurder A, Itani KM, Jonasson O, Neumayer LA. *Annals of surgery*. 2005;241(6):879-82; discussion 82-4. <http://dx.doi.org/10.1097/01.sla.0000164076.82559.72>.
2335. **Critical illness in systemic lupus erythematosus and the antiphospholipid syndrome.** Williams FMK, Chinn S, Hughes GRV, Leach RM. *Annals of the Rheumatic Diseases*. 2002;61(5):414-21.
2336. **In-hospital fellow coverage reduces communication errors in the surgical intensive care unit.** Williams M, Alban RF, Hardy JP, Oxman DA, Garcia ER, Hevelone N, et al. *J Crit Care*. 2014;29(3):445-9. <http://dx.doi.org/10.1016/j.jcrc.2014.01.004>. Epub 2014 Jan 13.
2337. **Autoimmune syndromes presenting as a paraneoplastic manifestation of myelodysplastic syndromes: Clinical features, course, treatment and outcome.** Williamson BT, Foltz L, Leitch HA. *Hematology Reports*. 2016;8(2):23-6.
2338. **Keeping score on psychiatric drug effects: Is mefloquine safe for malaria chemoprophylaxis?** Willmore CB, Ayesu LW. *Journal of Pharmacy Technology*. 2006;22(1):32-41.
2339. **Inverting the therapeutic pyramid: observations and recommendations on new directions in rheumatoid arthritis therapy based on the author's experience.** Wilske KR. *Semin Arthritis Rheum*. 1993;23(2):11-8. [http://dx.doi.org/10.1016/s0049-0172\(10\)80003-4](http://dx.doi.org/10.1016/s0049-0172(10)80003-4).
2340. **Five year review of the Rotaglide total knee arthroplasty.** Wilson CJ, Fitzgerald B, Tait GR. *The Knee*. 2003;10(2):167-71. [http://dx.doi.org/10.1016/s0968-0160\(02\)00107-2](http://dx.doi.org/10.1016/s0968-0160(02)00107-2).
2341. **Experience-based learning: junior medical students' reflections on end-of-life care.** Wilson H, Warmington S, Johansen ML. *Medical education*. 2019;53(7):687-97. <http://dx.doi.org/10.1111/medu.13907>. Epub 2019 May 20.
2342. **The assessment of patient life-expectancy: how accurate are urologists and oncologists?** Wilson JR, Clarke MG, Ewings P, Graham JD, MacDonagh R. *BJU international*. 2005;95(6):794-8. <http://dx.doi.org/10.1111/j.1464-410X.2005.05403.x>.
2343. **Impact of surgical experience on outcomes in total joint arthroplasties.** Wilson MD, Dowsey MM, Spelman T, Choong PF. *ANZ J Surg*. 2016;86(12):967-72. <http://dx.doi.org/10.1111/ans.13513>. Epub 2016 Sep 6.
2344. **Benefits and risks of malaria prophylaxis - an update.** Winstanley P. *Adverse Drug Reaction Bulletin*. 1994(164):619-22.
2345. **Malaria prophylaxis with mefloquine: Neurological and psychiatric adverse drug reactions.** Winstanley P, Behrens R. *Prescribers' Journal*. 1999;39(3):161-5.

2346. **Hydroxychloroquine as a glucose lowering drug.** Winter EM, Schrandt-van der Meer A, Eustatia-Rutten C, Janssen M. *BMJ Case Rep.* 2011;2011. <http://dx.doi.org/10.1136/bcr.06.2011.4393>.
2347. **Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.** Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K, Valdez H, et al. *Arthritis & rheumatology (Hoboken, NJ).* 2017;69(10):1960-8. <http://dx.doi.org/10.1002/art.40189>. Epub 2017 Sep 6.
2348. **A two-year experience of an integrated simulation residency curriculum.** Wittels KA, Takayesu JK, Nadel ES. *The Journal of emergency medicine.* 2012;43(1):134-8. <http://dx.doi.org/10.1016/j.jemermed.2011.05.086>. Epub 2012 Jan 4.
2349. **[Mid-term results of Wallaby I posterior cruciate retaining total knee arthroplasty: a prospective study of the first 425 cases].** Witvoet J, Hutten D, Masse Y, Nordin JY, Nizard R, Pidhorz L, et al. *Revue de chirurgie orthopedique et reparatrice de l'appareil moteur.* 2005;91(8):746-57. [http://dx.doi.org/10.1016/s0035-1040\(05\)84486-1](http://dx.doi.org/10.1016/s0035-1040(05)84486-1).
2350. **Do iatrogenic factors bias the placement of external ventricular catheters?--a single institute experience and review of the literature.** Woernle CM, Burkhardt JK, Bellut D, Krayenbuehl N, Bertalanffy H. *Neurologia medico-chirurgica.* 2011;51(3):180-6. <http://dx.doi.org/10.2176/nmc.51.180>.
2351. **Aggressive colorectal carcinoma phenotypes of invasion can be assessed reproducibly and effectively predict poor survival: interobserver study and multivariate survival analysis of a prospectively collected series of 299 patients after potentially curative resections with long-term follow-up.** Wohlke M, Schiffmann L, Prall F. *Histopathology.* 2011;59(5):857-66. <http://dx.doi.org/10.1111/j.1365-2559.2011.04027.x>.
2352. **Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases.** Wöhrer S, Troch M, Zwerina J, Schett G, Skrabas C, Gaiger A, et al. *Annals of Oncology.* 2007;18(4):647-51.
2353. **The Resident-Run Minor Surgery Clinic: A Pilot Study to Safely Increase Operative Autonomy.** Wojcik BM, Fong ZV, Patel MS, Chang DC, Petrusa E, Mullen JT, et al. *Journal of surgical education.* 2016;73(6):e142-e9. <http://dx.doi.org/10.1016/j.j Surg.2016.08.016>.
2354. **Do Not Blame the Resident: the Impact of Surgeon and Surgical Trainee Experience on the Occurrence of Intraoperative Adverse Events (iAEs) in Abdominal Surgery.** Wojcik BM, Lee JM, Peponis T, Amari N, Mendoza AE, Rosenthal MG, et al. *Journal of surgical education.* 2018;75(6):e156-e67. <http://dx.doi.org/10.1016/j.j Surg.2018.07.020>. Epub 2018 Sep 6.
2355. **Cefpodoxime for antimicrobial prophylaxis in neutropenia: A retrospective case series.** Wojenski DJ, Barreto JN, Wolf RC, Tosh PK. *Clinical Therapeutics.* 2014;36(6):976-81.
2356. **Monitoring risk behaviour in adolescent pupils regarding consumption of psychoactive substances.** Wojtyła-Buciora P, Klimberg A, Kapka-Skrzypczak L, Diatczyk J, Urbaniak M, Ulatowska-Szostak E, et al. *Annals of agricultural and environmental medicine : AAEM.* 2017;24(2):350-5. <http://dx.doi.org/10.26444/aaem/74449>. Epub 2017 Feb 6.
2357. **Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: Associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.** Wolfe F, Caplan L, Michaud K. *Arthritis and Rheumatism.* 2006;54(2):628-34.
2358. **Rheumatoid arthritis treatment and the risk of severe interstitial lung disease.** Wolfe F, Caplan L, Michaud K. *Scandinavian Journal of Rheumatology.* 2007;36(3):172-8.
2359. **Termination of slow acting antirheumatic therapy in rheumatoid arthritis: A 14-year prospective**

- evaluation of 1017 consecutive starts.** Wolfe F, Hawley DJ, Cathey MA. *Journal of Rheumatology*. 1990;17(8):994-1002.
2360. **Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus.** Wolfe F, Marmor MF. *Arthritis care & research*. 2010;62(6):775-84. <http://dx.doi.org/10.1002/acr.20133>.
2361. **The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: A cohort and nested case-control analysis.** Wolfe F, Michaud K. *Arthritis and Rheumatism*. 2008;58(9):2612-21.
2362. **Toward a definition and method of assessment of treatment failure and treatment effectiveness: The case of leflunomide versus methotrexate.** Wolfe F, Michaud K, Stephenson B, Doyle J. *Journal of Rheumatology*. 2003;30(8):1725-32.
2363. **Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis.** Wolfe F, Rasker JJ, Boers M, Wells GA, Michaud K. *Arthritis Care and Research*. 2007;57(6):935-42.
2364. **Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators.** Wolinsky JS, Narayana PA, Noseworthy JH, Lublin FD, Whitaker JN, Linde A, et al. *Neurology*. 2000;54(9):1734-41. <http://dx.doi.org/10.1212/wnl.54.9.1734>.
2365. **Clinical experience in the use of intravenous lipid emulsion in hydroxychloroquine and chloroquine overdose with refractory shock.** Wong OF, Chan YC, Lam SK, Fung HT, Ho JKY. *Hong Kong Journal of Emergency Medicine*. 2011;18(4):243-8.
2366. **Efficacy of transabdominal ultrasound examination in the diagnosis of early pregnancy complications in an emergency department.** Wong TW, Lau CC, Yeung A, Lo L, Tai CM. *Journal of accident & emergency medicine*. 1998;15(3):155-8. <http://dx.doi.org/10.1136/emj.15.3.155>.
2367. **Six-year retrospective review of drug reaction with eosinophilia and systemic symptoms.** Wongkitisophon P, Chanprapaph K, Rattanakaemakorn P, Vachiramom V. *Acta Dermato-Venereologica*. 2012;92(2):200-5.
2368. **Is cocaine use recognised as a risk factor for acute coronary syndrome by doctors in the UK?** Wood DM, Hill D, Gunasekera A, Greene SL, Jones AL, Dargan PI. *Postgrad Med J*. 2007;83(979):325-8. <http://dx.doi.org/10.1136/pgmj.2006.053850>.
2369. **Mefloquine: Contraindicated in patients with mood, psychotic or seizure disorders.** Woollorton E. *Canadian Medical Association Journal*. 2002;167(10):1147.
2370. **An audit of the use of hydroxychloroquine in rheumatology clinics.** Worth C, Yusuf IH, Turner B, Gourier H, Brooks EE, Mort DO, et al. *Rheumatology Advances in Practice*. 2018;2(1):1-7.
2371. **Optimal use of antimalarials in treating cutaneous lupus erythematosus.** Wozniacka A, McCauliffe DP. *American Journal of Clinical Dermatology*. 2005;6(1):1-11.
2372. **Perception and practices of Lagos state residents on the prevention and control of malaria in Lagos, Nigeria.** Wright K, Tayo F, Odusanya O, Kuyinu Y, Odugbemi B, Arowolo T, et al. *Annals of Tropical Medicine and Public Health*. 2013;6(5):503-7.
2373. **Novice training: The time course for developing competence in single port video-assisted thoracoscopic lobectomy.** Wu CF, Paradela M, Wu CY, Mercedes T, Fernandez R, Delgado M, et al. *Medicine*

(Baltimore). 2020;99(12):e19459. <http://dx.doi.org/10.1097/MD.00000000000019459>.

2374. **Hydroxychloroquine Use and Risk of CKD in Patients with Rheumatoid Arthritis.** Wu CL, Chang CC, Kor CT, Yang TH, Chiu PF, Tarng DC, et al. *Clinical journal of the American Society of Nephrology : CJASN*. 2018;13(5):702-9. <http://dx.doi.org/10.2215/CJN.11781017>. Epub 2018 Apr 16.

2375. **The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study.** Wu CY, Chen DY, Shen JL, Ho HJ, Chen CC, Kuo KN, et al. *Arthritis research & therapy*. 2014;16(5):449. <http://dx.doi.org/10.1186/s13075-014-0449-5>.

2376. **Which implant is better for beginners to learn to treat geriatric intertrochanteric femur fractures: A randomised controlled trial of surgeons, metalwork, and patients.** Wu K, Xu Y, Zhang L, Zhang Y, Xu W, Chu J, et al. *J Orthop Translat*. 2020;21:18-23. <http://dx.doi.org/10.1016/j.jot.2019.11.003>. eCollection 2020 Mar.

2377. **Epidemiological profile and risk factors of HIV and HBV/HCV co-infection in Fujian Province, southeastern China.** Wu S, Yan P, Yang T, Wang Z, Yan Y. *J Med Virol*. 2017;89(3):443-9. <http://dx.doi.org/10.1002/jmv.24666>. Epub 2016 Sep 2.

2378. **[The coverage rate and obstructive factors of influenza vaccine inoculation among residents aged above 18 years in Beijing from 2007 to 2010].** Wu SS, Yang P, Li HY, Ma CN, Zhang Y, Wang QY. *Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]*. 2011;45(12):1077-81.

2379. **Prophylaxis of deep venous thrombosis by hydroxychloroquine sulfate and heparin.** Wu TK, Tsapogas MJ, Jordan FR. *Surgery, gynecology & obstetrics*. 1977;145(5):714-8.

2380. **Behçet's disease complicated with thrombosis: A report of 93 Chinese cases.** Wu X, Li G, Huang X, Wang L, Liu W, Zhao Y, et al. *Medicine (United States)*. 2014;93(28):e263.

2381. **The Relationship Between Resilience and Mental Health in Chinese College Students: A Longitudinal Cross-Lagged Analysis.** Wu Y, Sang ZQ, Zhang XC, Margraf J. *Front Psychol*. 2020;11:108. <http://dx.doi.org/10.3389/fpsyg.2020.00108>. eCollection 2020.

2382. **The association between seniority of Accident and Emergency doctor and outcome following trauma.** Wyatt JP, Henry J, Beard D. *Injury*. 1999;30(3):165-8. [http://dx.doi.org/10.1016/s0020-1383\(98\)00252-6](http://dx.doi.org/10.1016/s0020-1383(98)00252-6).

2383. **Acceptability and factors associated with willingness to receive short messages for improving antiretroviral therapy adherence in China.** Xiao Y, Ji G, Tian C, Li H, Biao W, Hu Z. *AIDS care*. 2014;26(8):952-8. <http://dx.doi.org/10.1080/09540121.2013.869540>. Epub 2013 Dec 20.

2384. **Metformin Triggers Autophagy to Attenuate Drug-Induced Apoptosis in NSCLC Cells, with Minor Effects on Tumors of Diabetic Patients.** Xiao Z, Gaertner S, Morresi-Hauf A, Genzel R, Duell T, Ullrich A, et al. *Neoplasia (United States)*. 2017;19(5):385-95.

2385. **Assessing chloroquine toxicity in RA patients using retinal nerve fibre layer thickness, multifocal electroretinography and visual field test.** Xiaoyun MA, Dongyi HE, Linping HE. *The British journal of ophthalmology*. 2010;94(12):1632-6. <http://dx.doi.org/10.1136/bjo.2009.171082>. Epub 2010 Oct 8.

2386. **Mortality differential for various levels of education in China.** Xie W. *Chinese journal of population science*. 1996;8(1):41-9.

2387. **[Clinical analysis for patients with diabetic foot among multiple centers in China].** Xu J, Wang Y, Chen Y, Cai Y, Liu M, Zhou Q. *Zhong nan da xue xue bao Yi xue ban = Journal of Central South University Medical sciences*. 2019;44(8):898-904. <http://dx.doi.org/10.11817/j.issn.1672-7347.2019.180746>.

2388. **Self-rated health of Chinese adolescents: distribution and its associated factors.** Xu Z, Su H, Zou Y, Chen J, Wu J, Chang W. *Scand J Caring Sci.* 2011;25(4):780-6. <http://dx.doi.org/10.1111/j.1471-6712.2011.00893.x>. Epub 2011 May 13.
2389. **Sleep quality of Chinese adolescents: distribution and its associated factors.** Xu Z, Su H, Zou Y, Chen J, Wu J, Chang W. *J Paediatr Child Health.* 2012;48(2):138-45. <http://dx.doi.org/10.1111/j.1440-1754.2011.02065.x>. Epub 2011 Apr 7.
2390. **Antiphospholipid antibodies-associated diffuse alveolar hemorrhage.** Yachoui R, Sehgal R, Amlani B, Goldberg JW. *Semin Arthritis Rheum.* 2015;44(6):652-7. <http://dx.doi.org/10.1016/j.semarthrit.2014.10.013>. Epub 2014 Oct 31.
2391. **Association between lifestyle, parental smoke, socioeconomic status, and academic performance in Japanese elementary school children: the Super Diet Education Project.** Yamada M, Sekine M, Tatsuse T, Asaka Y. *Environmental health and preventive medicine.* 2019;24(1):22. <http://dx.doi.org/10.1186/s12199-019-0776-x>.
2392. **Irritable bowel syndrome among Japanese adolescents: A nationally representative survey.** Yamamoto R, Kaneita Y, Osaki Y, Kanda H, Suzuki K, Higuchi S, et al. *J Gastroenterol Hepatol.* 2015;30(9):1354-60. <http://dx.doi.org/10.1111/jgh.12974>.
2393. **p62 aggregates mediated Caspase 8 activation is responsible for progression of ovarian cancer.** Yan XY, Zhong XR, Yu SH, Zhang LC, Liu YN, Zhang Y, et al. *Journal of Cellular and Molecular Medicine.* 2019;23(6):4030-42.
2394. **Lupus pernio in sarcoidosis: Clinical features and treatment outcomes of 14 patients.** Yanardağ H, Pamuk Ö N, Pamuk GE. *Journal of Clinical Rheumatology.* 2003;9(2):72-6.
2395. **New Continuous Barbed Suture Device with Stratafix for the Vaginal Stump in Laparoscopic Hysterectomy.** Yanazume S, Togami S, Fukuda M, Kawamura T, Kamio M, Ota S, et al. *Gynecology and minimally invasive therapy.* 2018;7(4):167-71. [http://dx.doi.org/10.4103/GMIT.GMIT\\_34\\_18](http://dx.doi.org/10.4103/GMIT.GMIT_34_18). Epub 2018 Sep 26.
2396. **Tofacitinib for the treatment of lichen planopilaris: A case series.** Yang CC, Khanna T, Sallee B, Christiano AM, Bordone LA. *Dermatologic Therapy.* 2018;31(6).
2397. **Efficacy of omalizumab treatment for patients with chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) in Taiwan.** Yang CW, Cho YT, Chu CY. *Dermatologica Sinica.* 2017;35(4):182-6.
2398. **The study of personal constructs of death and fear of death among Taiwanese adolescents.** Yang SC, Chen SF. *Death studies.* 2009;33(10):913-40. <http://dx.doi.org/10.1080/07481180903251687>.
2399. **Prevention and prophylaxis of malaria in older travelers.** Yax JA, Collins CD, Malani PN. *Clinical Geriatrics.* 2007;15(8):36-45.
2400. **Chloroquine and hydroxychloroquine retinopathy-related risk factors in a Turkish cohort.** Yaylali SA, Sadigov F, Erbil H, Ekinci A, Akcakaya AA. *International ophthalmology.* 2013;33(6):627-34. <http://dx.doi.org/10.1007/s10792-013-9748-0>. Epub 2013 Mar 2.
2401. **Mania induced by mefloquine prophylaxis: Case description and literature review.** Yelmo S, Morera A, Henry M, Renshaw A, Gracia R. *European Psychiatry.* 2010;25.
2402. **Current screening practice in patients under long-term hydroxychloroquine medication in Taiwan: A nationwide population-based cohort study.** Yen CY, Lee PH, Yen JC, Chen CC, Hu HY, Tseng PC. *Medicine.* 2019;98(14):e15122.

2403. **Skin surgery in children: Local anaesthesia and sedation techniques.** Yeo LF, Eichenfield LF, Chan YC. *Expert Opinion on Pharmacotherapy*. 2007;8(3):317-27.
2404. **Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia.** Yeshiwondim AK, Tekle AH, Dengela DO, Yohannes AM, Teklehaimanot A. *Acta tropica*. 2010;113(2):105-13. <http://dx.doi.org/10.1016/j.actatropica.2009.10.001>. Epub 2009 Oct 14.
2405. **Relationship between cardiac valvular and arterial calcification in patients with rheumatoid arthritis and systemic lupus erythematosus.** Yiu KH, Wang S, Mok MY, Ooi GC, Khong PL, Lau CS, et al. *Journal of Rheumatology*. 2011;38(4):621-7.
2406. **Imported malaria in a tertiary hospital in Belgium: Epidemiological and clinical analysis.** Yomb JC, Jonckheere S, Colin G, Van Gompel F, Bigare E, Belkhir L, et al. *Acta Clinica Belgica*. 2013;68(2):101-6.
2407. **Effect of Hydroxychloroquine Treatment on Dry Eyes in Subjects with Primary Sjögren's Syndrome: a Double-Blind Randomized Control Study.** Yoon CH, Lee HJ, Lee EY, Lee EB, Lee WW, Kim MK, et al. *J Korean Med Sci*. 2016;31(7):1127-35.
2408. **Impact of specialty and level of training on CT measurement of femoral version: an interobserver agreement analysis.** Yoon RS, Koerner JD, Patel NM, Sirkin MS, Reilly MC, Liporace FA. *Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology*. 2013;14(4):277-81. <http://dx.doi.org/10.1007/s10195-013-0263-x>. Epub 2013 Aug 29.
2409. **Effect of an education program on improving help-seeking among parents of junior and senior high school students in Japan.** Yoshii H, Watanabe Y, Kitamura H, Nan Z, Akazawa K. *Global journal of health science*. 2011;4(1):33-41. <http://dx.doi.org/10.5539/gjhs.v4n1p33>.
2410. **A comparative study of clinical characteristics, work-up, treatment, and association to malignancy in dermatomyositis between two tertiary skin centers in the USA and Singapore.** Yosipovitch G, Tan A, LoSicco K, Manabat CG, Kannagra A, Carroll C, et al. *Int J Dermatol*. 2013;52(7):813-9. <http://dx.doi.org/10.1111/j.1365-4632.2011.05449.x>. Epub 2012 Jul 27.
2411. **Headaches and vasculitis.** Younger DS. *Neurologic Clinics*. 2004;22(1):207-28.
2412. **Interferon-stimulated gene 15 expression in systemic lupus erythematosus: Diagnostic value and association with lymphocytopenia.** Yuan Y, Ma H, Ye Z, Jing W, Jiang Z. *Zeitschrift fur Rheumatologie*. 2018;77(3):256-62.
2413. **Complication rates of external ventricular drain insertion by surgeons of different experience.** Yuen J, Selbi W, Muquit S, Berei T. *Annals of the Royal College of Surgeons of England*. 2018;100(3):221-5. <http://dx.doi.org/10.1308/rcsann.2017.0221>. Epub 2018 Jan 24.
2414. **An easy method to reduce anterior shoulder dislocation: the Spaso technique.** Yuen MC, Yap PG, Chan YT, Tung WK. *Emergency medicine journal : EMJ*. 2001;18(5):370-2. <http://dx.doi.org/10.1136/emj.18.5.370>.
2415. **PSYCHOTROPIC EFFECTS OF A SYNTHETIC ANTIMALARIAL.** Yvonneau M, Feldman N. *La Presse médicale*. 1965;73:705-8.
2416. **Toxic psychosis due to chloroquine overdose - A case report.** Zaki SA, Mauskar A, Shanbag P. *Journal of Vector Borne Diseases*. 2009;46(1):81-2.
2417. **The Victorian major trauma transfer study.** Zalstein S, Danne P, Taylor D, Cameron P, McLellan S, Fitzgerald M, et al. *Injury*. 2010;41(1):102-9. <http://dx.doi.org/10.1016/j.injury.2009.06.020>.

2418. **Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease.** Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. *Clinical Rheumatology*. 2016;35(10):2585-9.
2419. **Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence.** Zandi PP, Breitner JCS. *Neurobiology of Aging*. 2001;22(6):811-7.
2420. **Impact of risk factors for prolonged operative time in laparoscopic cholecystectomy.** Zdichavsky M, Bashin YA, Blumenstock G, Zieker D, Meile T, Konigsrainer A. *European journal of gastroenterology & hepatology*. 2012;24(9):1033-8. <http://dx.doi.org/10.1097/MEG.0b013e328354ad6e>.
2421. **[Survival analysis of people living with HIV/AIDS in Sichuan province, 1991-2017].** Zeng YL, Tang HL, Li JM, Wang QS, Yu H, Su L, et al. *Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi*. 2019;40(3):309-14. <http://dx.doi.org/10.3760/cma.j.issn.0254-6450.2019.03.010>.
2422. **Stevens-Johnson syndrome and toxic epidermal necrolysis: retrospective review of 10-year experience.** Zhang AJ, Nygaard RM, Endorf FW, Hylwa SA. *International Journal of Dermatology*. 2019;58(9):1069-77.
2423. **High Serum HDGF Levels Are Predictive of Bone Metastasis and Unfavorable Prognosis in Non-Small Cell Lung Cancer.** Zhang G, Liu Z, Chen Y, Zhang Y. *The Tohoku journal of experimental medicine*. 2017;242(2):101-8. <http://dx.doi.org/10.1620/tjem.242.101>.
2424. **Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program.** Zhang J, Xie F, Delzell E, Chen L, Kilgore ML, Yun H, et al. *Arthritis Care and Research*. 2013;65(11):1743-51.
2425. **The association between health literacy and psychosomatic symptoms of adolescents in China: a cross-sectional study.** Zhang SC, Li DL, Yang R, Wan YH, Tao FB, Fang J. *BMC Public Health*. 2019;19(1):1259. <http://dx.doi.org/10.1186/s12889-019-7589-0>.
2426. **Association of health literacy and sleep problems with mental health of Chinese students in combined junior and senior high school.** Zhang SC, Yang R, Li DL, Wan YH, Tao FB, Fang J. *PLoS One*. 2019;14(6):e0217685. <http://dx.doi.org/10.1371/journal.pone.0217685>. eCollection 2019.
2427. **Risk factors of severe imported malaria in Anhui province, China.** Zhang T, Xu X, Jiang J, Yu C, Tian C, Xie Q, et al. *Acta Tropica*. 2019;197.
2428. **A clinical analysis of prognostic factors for dermatomyositis-associated interstitial lung disease.** Zhang T, Zhang J, Liu X, Zhang L, Zhao D, Wu X, et al. *International Journal of Clinical and Experimental Medicine*. 2018;11(6):5903-11.
2429. **Prevalence and associated factors of overweight and obesity in a Chinese rural population.** Zhang X, Sun Z, Zhang X, Zheng L, Liu S, Xu C, et al. *Obesity (Silver Spring, Md)*. 2008;16(1):168-71. <http://dx.doi.org/10.1038/oby.2007.43>.
2430. **Gender differences in suicidal ideation and health-risk behaviors among high school students in Beijing, China.** Zhang YY, Lei YT, Song Y, Lu RR, Duan JL, Prochaska JJ. *Journal of global health*. 2019;9(1):010604. <http://dx.doi.org/10.7189/jogh.09.010604>.
2431. **Symptomatic knee osteonecrosis in patients with systemic lupus erythematosus: a case-control study.** Zhao L, Wu X, Wu H, Su J, Zhang W, Zhao Y, et al. *Rheumatology International*. 2016;36(8):1105-11.
2432. **Predictors of survival in Chinese patients with lupus nephritis.** Zheng ZH, Zhang LJ, Liu WX, Lei YS, Xing GL, Zhang JJ, et al. *Lupus*. 2012;21(10):1049-56. <http://dx.doi.org/10.1177/0961203312445230>. Epub 2012 Apr 18.
2433. **Functional gastrointestinal disorders among adolescents with poor sleep: a school-based study in**

- Shanghai, China.** Zhou HQ, Yao M, Chen GY, Ding XD, Chen YP, Li DG. Sleep & breathing = Schlaf & Atmung. 2012;16(4):1211-8. <http://dx.doi.org/10.1007/s11325-011-0635-5>. Epub 2011 Dec 22.
2434. **Cardiac Sarcoidosis: The Impact of Age and Implanted Devices on Survival.** Zhou Y, Lower EE, Li HP, Costea A, Attari M, Baughman RP. Chest. 2017;151(1):139-48.
2435. **Characteristics of pregnancy complications and treatment in obstetric antiphospholipid syndrome in China.** Zhou Z, Teng J, Sun Y, Liu H, Cheng X, Su Y, et al. Clinical Rheumatology. 2019;38(11):3161-8.
2436. **Liver abnormalities in adult onset still's disease: A retrospective study of 77 chinese patients.** Zhu G, Liu G, Liu Y, Xie Q, Shi G. Journal of Clinical Rheumatology. 2009;15(6):284-8.
2437. **Remission assessment of rheumatoid arthritis in daily practice in China: a cross-sectional observational study.** Zhu H, Li R, Da Z, Bi L, Li X, Li Y, et al. Clinical Rheumatology. 2018;37(3):597-605.
2438. **Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: A descriptive study of 17 cases from a national registry and review of the literature.** Ziemer M, Kardaun SH, Liss Y, Mockenhaupt M. British Journal of Dermatology. 2012;166(3):575-600.
2439. **Silver ring splints improve dexterity in patients with rheumatoid arthritis.** Zijlstra TR, Heijnsdijk-Rouwenhorst L, Rasker JJ. Arthritis Care and Research. 2004;51(6):947-51.
2440. **Changes in adolescents' knowledge and attitudes about AIDS over the course of the AIDS epidemic.** Zimet GD, DiClemente RJ, Lazebnik R, Anglin TM, Ellick EM, Williams P. The Journal of adolescent health : official publication of the Society for Adolescent Medicine. 1993;14(2):85-90. [http://dx.doi.org/10.1016/1054-139x\(93\)90090-c](http://dx.doi.org/10.1016/1054-139x(93)90090-c).
2441. **Treatment of periprosthetic joint infection of the elbow: 15-year experience at a single institution.** Zmistowski B, Pourjafari A, Padegimas EM, Sheth M, Cox RM, Ramsey ML, et al. Journal of Shoulder and Elbow Surgery. 2018;27(9):1636-41.
2442. **Damage in systemic lupus erythematosus and its association with corticosteroids.** Zonana-Nacach A, Barr SG, Magder LS, Petri M, Farnell J, Rosenburg R, et al. Arthritis and Rheumatism. 2000;43(8):1801-8.
2443. **Factors associated with burnout among residents in a developing country.** Zubairi AJ, Noordin S. Annals of medicine and surgery (2012). 2016;6:60-3. <http://dx.doi.org/10.1016/j.amsu.2016.01.090>. eCollection 2016 Mar.
2444. **Antimalarial therapy for lupus erythematosus: an apparent advantage of quinacrine.** Zuehlke RL, Lillis PJ, Tice A. Int J Dermatol. 1981;20(1):57-61. <http://dx.doi.org/10.1111/j.1365-4362.1981.tb05295.x>.
2445. **Peer-Led, Postanatomy Reflection Exercise in Dissection Teams: Curriculum and Training Materials.** Zuo SW, Cichowitz C, Shochet R, Venkatesan A. MedEdPORTAL : the journal of teaching and learning resources. 2017;13:10565. [http://dx.doi.org/10.15766/mep\\_2374-8265.10565](http://dx.doi.org/10.15766/mep_2374-8265.10565).
2446. **Assessment of a Risk Index for Suicide Attempts Among US Army Soldiers With Suicide Ideation: Analysis of Data From the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS).** Zuromski KL, Bernecker SL, Gutierrez PM, Joiner TE, King AJ, Liu H, et al. JAMA network open. 2019;2(3):e190766. <http://dx.doi.org/10.1001/jamanetworkopen.2019.0766>.